US20230416747A1 - Safe harbor loci - Google Patents

Safe harbor loci Download PDF

Info

Publication number
US20230416747A1
US20230416747A1 US18/453,801 US202318453801A US2023416747A1 US 20230416747 A1 US20230416747 A1 US 20230416747A1 US 202318453801 A US202318453801 A US 202318453801A US 2023416747 A1 US2023416747 A1 US 2023416747A1
Authority
US
United States
Prior art keywords
cell
seq
cells
sgrna
safe harbor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/453,801
Inventor
Xinying Zheng
Brendan Galvin
Somya Khare
Aaron Cooper
Michelle Nguyen
Anzhi Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arsenal Biosciences Inc
Original Assignee
Arsenal Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsenal Biosciences Inc filed Critical Arsenal Biosciences Inc
Priority to US18/453,801 priority Critical patent/US20230416747A1/en
Publication of US20230416747A1 publication Critical patent/US20230416747A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54Pancreas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411Immunoglobulin superfamily
    • A61K39/464412CD19 or B4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464466Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468Mesothelin [MSLN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Definitions

  • Cancer continues to present a significant clinical burdSen despite the substantial research efforts and scientific advances in cancer therapies.
  • Blood and bone marrow cancers are frequently diagnosed cancer types, including multiple myelomas, leukemia, and lymphomas.
  • Current treatment options for these cancers are not effective for all patients and/or can have substantial adverse side effects.
  • Other types of cancer also remain challenging to treat using existing therapeutic options.
  • Cancer immunotherapies are a promising solution because they can be highly specific, allowing for increased therapeutic effectiveness and the mitigation of side effects.
  • SHS safe harbor sites
  • the present disclosure is directed, inter alia, to safe harbor loci that exhibit high knock-in efficiency and stable expression of their transgenes. These safe harbor loci can be used to alter T cells for immunotherapy. These safe harbor loci are useful for the treatment of various diseases, including cancer.
  • the present disclosure provides an engineered cell, comprising at least one sequence encoding a transgene, wherein the at least one sequence is inserted within a safe harbor locus, the safe harbor locus is at any one or more of the sgRNA target loci provided in Table 4; and wherein expression of the at least one sequence encoding the transgene is operatively linked to an endogenous promoter.
  • the present disclosure provides an engineered cell, comprising at least one sequence encoding a transgene, wherein the at least one sequence is inserted within a safe harbor locus, the safe harbor locus is at any one or more of the sgRNA target loci provided in Table 4; and wherein expression of the at least one sequence encoding the transgene is operatively linked to an exogenous promoter.
  • the target locus is selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, and chr9:7970000-7980000.
  • the target locus is selected from: chr10:72290000-72300000, chr11:128340000-128350000, chr15:92830000-92840000, and chr16:11220000-11230000. In some embodiments, the target locus is chr11:128340000-128350000. In some embodiments, the target locus is chr15:92830000-92840000.
  • the target locus is a gene selected from: APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, GS120.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, and GS93.
  • the exogenous promoter is an EF1a promoter.
  • the engineered cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or a T cell progenitor.
  • the transgene encodes a recombinant protein, optionally a therapeutic agent.
  • the transgene encodes a chimeric antigen receptor (CAR).
  • the present disclosure provides a composition comprising the engineered cell as described herein and a pharmaceutical excipient.
  • the present disclosure provides a guide ribonucleic acids (gRNA) for editing a cell at a safe harbor locus, wherein gRNA comprises any one of the sgRNA sequences in Table 4.
  • gRNA guide ribonucleic acids
  • the gRNA comprises any one of SEQ ID NOS:1-120. In some embodiments, the gRNA comprises any one of SEQ ID NOS: 91-96 and 100-105. In some embodiments, the gRNA comprises SEQ ID NO:94 or SEQ ID NO:102. In some embodiments, the gRNA comprises SEQ ID NO:94. In some embodiments, the gRNA comprises SEQ ID NO:102. In some embodiments, the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or a T cell progenitor.
  • the present disclosure provides a method of editing a cell having chromosomal DNA, comprising inserting at least one sequence encoding a transgene within a safe harbor locus in the chromosomal DNA of the cell, wherein the safe harbor locus is any one or more of the sgRNA target loci provided in Table 4.
  • the target locus is selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, and chr9:7970000-7980000.
  • the target locus is selected from: chr10:72290000-72300000, chr11:128340000-128350000, chr15:92830000-92840000, and chr16:11220000-11230000. In some embodiments, the target locus is chr11:128340000-128350000. In some embodiments, the target locus is chr15:92830000-92840000.
  • the target locus is a gene selected from: APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, GS120.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, and GS93.
  • the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR).
  • the at least one sequence comprises an exogenous promoter and the exogenous promoter is operably linked to the transgene. In some embodiments, the exogenous promoter is an EF1a promoter.
  • the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or T cell progenitor. In some embodiments, the at least one sequence is inserted using a homology-directed repair.
  • the at least one sequence is inserted using a homology independent targeted insertion. In some embodiments, the at least one sequence is inserted using one or more guide ribonucleic acids (gRNAs) and one or more Cas9 endonucleases.
  • gRNAs guide ribonucleic acids
  • the one or more gRNAs comprises any one of SEQ ID NOS: 1-120. In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 91-96 and 100-105. In some embodiments, the gRNA comprises SEQ ID NO:94 or SEQ ID NO:102. In some embodiments, the gRNA comprises SEQ ID NO:94. In some embodiments, the gRNA comprises SEQ ID NO:102.
  • the present disclosure provides a method of editing a T cell, comprising contacting a T cell with one or more guide ribonucleic acids (gRNAs), at least one sequence encoding a transgene, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of the at least one sequence into chromosomal DNA within a safe harbor locus, wherein the safe harbor locus is selected from any one or more of the sgRNA target loci in Table 4.
  • gRNAs guide ribonucleic acids
  • Cas9 endonucleases facilitate the insertion of the at least one sequence into chromosomal DNA within a safe harbor locus, wherein the safe harbor locus is selected from any one or more of the sgRNA target loci in Table 4.
  • the one or more gRNAs comprises a sequence selected from any one of the sgRNA sequences in Table 4. In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 1-120. In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 91-96 and 100-105. In some embodiments, the gRNA comprises SEQ ID NO:94 or SEQ ID NO:102. In some embodiments, the gRNA comprises SEQ ID NO:94. In some embodiments, the gRNA comprises SEQ ID NO:102.
  • the target locus is selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, and chr9:7970000-7980000.
  • the target locus is selected from: chr10:72290000-72300000, chr11:128340000-128350000, chr15:92830000-92840000, and chr16:11220000-11230000. In some embodiments, the target locus is chr11:128340000-128350000. In some embodiments, the target locus is chr15:92830000-92840000.
  • the target locus is a gene selected from: APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, GS120.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4.
  • the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, and GS93
  • the present disclosure provides an ex vivo method of obtaining an engineered cell or population thereof, comprising (a) obtaining a cell; and (b) genetically modifying the cell by inserting at least one sequence encoding a transgene within a safe harbor locus, wherein the safe harbor locus is selected from any one of the sgRNA target loci in Table 4.
  • obtaining the cell comprises: (i) collecting a tissue sample from a subject, (ii) isolating the cells from the tissue samples, and (iii) culturing the cells in vitro.
  • the tissue sample is a blood sample.
  • the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or T cell precursor.
  • the at least one sequence is inserted using a homology-directed repair. In some embodiments, the at least one sequence is inserted using a homology independent targeted insertion.
  • the genetically modifying in step (b) comprises contacting the cell with one or more guide ribonucleic acids (gRNAs), the at least one sequence, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of the at least one sequence into chromosomal DNA within the safe harbor locus.
  • the one or more gRNAs comprises a sequence selected from any one of the sgRNA sequences in Table 4.
  • the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR). In some embodiments, the at least one sequence comprises an exogenous promoter and the exogenous promoter is operably linked to the transgene. In some embodiments, the exogenous promoter is an EF1a promoter.
  • the present disclosure provides a method of treating a subject having or at risk of having a disease, comprising administering to the subject an effective amount of an engineered cell as described herein, a population thereof, or a composition as described herein.
  • the cell, the population thereof, or the composition is administered to the subject by infusion.
  • the present disclosure provides a method of treating a subject having or at risk of having a disease, comprising (a) conducting any one of the methods described supra; and (b) administering to the subject an effective amount of a composition comprising the cell or a population thereof.
  • the composition is administered to the subject by infusion.
  • the disease is cancer.
  • the disease is blood cancer.
  • the present disclosure provides a method of identifying a safe harbor locus, comprising: (a) identifying genes or non-coding regions in a chromosome that are above a threshold level for expression across developmental cell states and/or a threshold level for accessibility of chromatin; (b) generating a linear model that correlates the gene or non-coding region from step (a) with knock-in (KI) efficiency and estimates the KI efficiency of any gene or coding region on the chromosome; and (c) selecting the safe harbor locus based on threshold parameters; wherein the safe harbor locus is selected for insertion of at least one sequence encoding a transgene within a cell.
  • KI knock-in
  • the threshold parameters include one or more of: stable expression of a transgene, knockout of the gene confers benefit to the function of the cell, no known function within the cell, stable transgene expression in vitro with or without CD3/CD28 stimulation, negligible off-target cleavage as detected by iGuide-Seq or CRISPR-Seq, less off-target cleavage relative to other loci as detected by iGuide-Seq or CRISPR-Seq, negligible transgene-independent cytotoxicity, negligible transgene-independent cytokine expression, negligible transgene-independent chimeric antigen receptor expression, negligible deregulation or silencing of nearby genes, and positioned outside of a cancer-related gene.
  • the stable expression of a transgene at the safe harbor locus is less than or equal to 2-fold expression change over the course of at least 1, 2, 3, 4, 5, 6, or 7 days, and wherein expression change is measured by mean fluorescence intensity of a reporter gene encoded by the at least one sequence.
  • the accessibility of chromatin is measured using an assay for transposase-accessible chromatin using sequencing (ATAC-seq).
  • the level of expression across developmental cell states is measured using RNA sequencing (RNA-seq).
  • the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or T cell precursor.
  • the linear model has a coefficient of determination (R 2 value) of at least 30%.
  • the present disclosure provides an engineered cell, composition, gRNA or method as described herein, wherein insertion within the safe harbor locus increase cell cytotoxicity of diseased cells.
  • the present disclosure provides an engineered cell, composition, gRNA or method as described herein, wherein knock-in efficiency at the safe harbor locus is increased relative to other locations along the chromosome.
  • FIG. 1 includes a schematic depicting the methodology used to identify safe harbor loci in the present disclosure, in some embodiments.
  • FIGS. 2 A- 2 C include schematic depicting 3 top safe harbor loci known in the art: AAVS1 ( FIG. 2 A ), CCR5 ( FIG. 2 B ), and Rosa26 ( FIG. 2 C ).
  • the figures were retrieved from Sadelain, M., et al. (2012). Safe harbours for the integration of new DNA in the human genome. Nature reviews Cancer, 12(1), 51-58, the relevant disclosures of which are herein incorporated by reference in their entirety.
  • FIG. 3 includes a schematic outlining the data provided in Roth, T. L., et al. 2019. Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561, the relevant disclosures of which are herein incorporated by reference in their entirety.
  • FIGS. 4 A- 4 B include heatmaps with samples clustered based on activation status and cell type, generated with processed RNA-seq data.
  • FIG. 4 A includes a heatmap of samples generated with processed RNA-seq data.
  • FIG. 4 B includes a heatmap sample generated with processed RNA-seq data, showing the clustering of ⁇ 20 k genes.
  • FIGS. 5 A- 5 B include plots generated using processed RNA-seq data.
  • FIG. 5 A includes a plot showing direct correlation between transcript expression data from Roth, T. L., et al. 2019 and transcript expression data generated by the inventors of the present disclosure.
  • FIG. 5 B includes a heatmap showing clusters of the top 10% expressed genes.
  • FIG. 6 includes a heatmap of samples generated with processed ATAC-seq data.
  • FIGS. 7 A- 7 B includes plots depicting the signal enrichment at transcription start sites (TSS) ( FIG. 7 A ) and peak size distribution ( FIG. 7 B ), generated with processed ATAC-seq data for coding regions.
  • TSS transcription start sites
  • FIG. 7 B peak size distribution
  • FIG. 8 includes a plot depicting the open chromatin regions around the TRAC locus.
  • FIG. 9 includes a plot depicting KI (knock-in) efficiency for coding regions/genes with GFP as a reporter.
  • FIG. 10 includes a plot depicting KI efficiency for coding regions/genes with tNGFR as a reporter.
  • FIG. 11 includes plots showing scaled KI efficiency for 90 genes vs d2 (day-2) RNA-seq data, d4 (day-4) RNA-seq data and ATAC-seq data, utilized for the predictive linear model.
  • FIG. 12 includes a plot showing chromatin accessibility for a top candidate non-coding region, measured using ATAQ sequencing.
  • FIG. 13 A includes plots showing the cell counts for GFP controls used for the evaluation of candidate KI loci.
  • FIG. 13 B includes pmax (GFP_high) readings for GFP controls used for the evaluation of candidate KI loci.
  • FIG. 14 A includes plots showing the maximum episomal GFP expression (GFP_high) readings for non-targeting controls.
  • FIG. 14 B includes the cell count for non-targeting controls from donors 1, 2, and 3.
  • FIG. 15 includes the cell count and maximum GFP expression (GFP_high) readings for WT controls.
  • FIG. 16 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA5, which targets a B2M safe harbor locus, and the construct expression was driven by an endogenous promoter.
  • FIG. 17 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA5, which targets a B2M safe harbor locus, and the construct expression was driven by an EF1a promoter.
  • FIG. 18 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA79 to target a TRAC safe harbor locus, and the construct expression was driven by an endogenous promoter.
  • FIG. 19 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA79, which targets a TRAC safe harbor locus, and the construct expression was driven by an exogenous promoter.
  • FIG. 20 includes plots showing TCR (T cell receptor) vs. GFP among all donors and time points when using sgRNA79, and the construct is driven by an endogenous promoter.
  • FIG. 21 includes plots showing TCR vs. GFP among all donors and time points when using sgRNA79 and the construct is driven by an exogenous promoter.
  • FIG. 22 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA83, which targets a TRAC safe harbor locus, and the construct expression was driven by an endogenous promoter.
  • FIG. 23 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA83, which targets a TRAC safe harbor locus, and the construct expression was driven by an exogenous promoter.
  • FIG. 24 includes plots showing TCR vs. GFP among all donors and time points when using sgRNA83 and the construct is driven by an endogenous promoter.
  • FIG. 25 includes plots showing TCR vs. GFP among all donors and time points when using sgRNA83 and the construct is driven by an exogenous promoter.
  • FIG. 26 includes plots illustrating potential sources of variation (e.g., edge effects and electroporation errors) observed between replicates and donors.
  • potential sources of variation e.g., edge effects and electroporation errors
  • FIG. 27 includes plots illustrating potential sources of variation observed between replicates and donors, e.g., relating to inherent differences between donors.
  • FIG. 28 includes plots illustrating potential sources of variation observed between replicates and donors, e.g., relating to gating errors.
  • FIG. 29 includes plots showing the GFP mean fluorescence intensity (GFP MFI) and KI efficiency for top KI loci evaluated with endogenous promoters.
  • FIG. 30 includes plots showing the GFP mean fluorescence intensity (GFP MFI) and KI efficiency for top KI loci evaluated with the EF1a promoter.
  • FIGS. 31 A- 31 C include plots showing all the significant KI loci (top KI loci) as evaluated with endogenous and EF1a promoters.
  • FIG. 31 A includes a plot showing that the expression from the EF1a promoter was approximately 10 times higher than expression from an endogenous promoter.
  • FIG. 31 B shows the top KI loci ranked by GFP MFI at week 3.
  • FIG. 31 C shows the top integration loci ranked by GFP MFI (at weeks 3 and 4; donors 1-3).
  • FIG. 32 A includes a plot showing some target loci and their measured transgene expression levels.
  • FIG. 32 B includes plots showing the transgene (Prime Receptor (PrimeR)) and TCR expression for the control and insertion at GS94, GS102 and TRAC loci.
  • Primary Receptor Primary Receptor
  • FIG. 33 A includes a plot showing the PrimeR levels measured for the indicated integration sites.
  • FIG. 33 B includes a schematic showing the GS94 integration site on Chromosome 11.
  • FIG. 34 A includes plots showing CAR induction and primeR expression of engineered T cells after 48 hours of coculturing with K562-CD19 cells.
  • FIG. 34 B includes plots showing the cytotoxity and cytokine secretion levels for engineered T cells 48 hours of coculturing with K562-CD19/MSLN cells.
  • FIG. 35 A includes a schematic showing the experimental overview for evaluating the effect of integration site on cytotoxicity.
  • FIG. 35 B includes plots showing the measured cytotoxicity for engineered T cells cocultured for 48 hours with the K562 CD19+/MSLN+ or K562 CD19 ⁇ /MSLN+ cells.
  • FIG. 36 A includes a schematic showing the experimental overview for evaluating the effect of integration site on cytokine secretion.
  • FIG. 36 B includes plots showing the measured cytokine levels for engineered T cells cocultured for 48 hours with K562 CD19+/MSLN+ cells.
  • FIG. 37 includes a schematic showing the in vitro experiment conducted to determin the effect of integration site on primeR-independent CAR expression.
  • Flow refers to flow cytometry and “restim” refers to repetitive CD3/CD28 stimulation of the engineered T cells.
  • EP refers to electroporation.
  • FIGS. 38 A and 38 B include plots showing the stability of PrimeR expression over time when using the indicated integration sites.
  • Flow refers to flow cytometry and “restim” refers to repetitive CD3/CD28 stimualation of the engineered T cells.
  • EP refers to electroporation.
  • the PrimeR expression is normalized to the expression from using the TRAC integration site.
  • FIG. 39 A includes a schematic showing the iGuide-Seq assay technique.
  • FIG. 39 B includes a plot showing the on-target efficiency, using iGuide Seq assay, for the indicated integration sites.
  • FIG. 39 C includes schematics from the iGuide-Seq analysis showing that GS94 had no reproducible putatitve off-targets across two donors
  • FIG. 39 C discloses SEQ ID NOS 312-322, 312-313, and 323-331, respectively, in order of appearance.
  • FIG. 40 includes a schematic showing the iGuide-Seq workflow and data.
  • FIG. 41 includes a plot showing rhAmp-segTM analysis of putative off-target sites identified by iGUIDE-seq and Elevation prediction.
  • FIG. 42 includes plots showing RNA-seq analysis of cells with GS94, GS102 and TRAC knock-in of CD19/MSLN circuits. Scatterplot of gene expression in cells with integration at the GS94 locus (y-axis) vs cells with integration at either the TRAC or the GS102 locus (x-axis) in two donors. The yellow dots correspond to ETS1 and FLI1. In blue are the genes that were found to be differentially expressed using edgeR (fold-change >0, FDR-corrected p-value ⁇ 0.01, average counts-per-million across compared conditions at least 2).
  • FIG. 43 includes plots showing the absence of cytokine-independent growth in cells with CD19/MSLN circuit KI at GS94.
  • the present disclosure provides safe harbor loci and methods for identifying safe harbor loci that exhibit high integration efficiency (e.g., high knock-in (KI) efficiency), high and constant levels of transgene expression, and such benefits independent of T cell activation/differentiation state.
  • the safe harbor loci also exhibit minimal to no disruption to T cell function and/or capacity for product manufacturing.
  • these loci are useful for effective and safe integration and expression of transgenes in T cells (e.g. in CAR T therapies).
  • the methods described herein can be used for the identification of safe harbor loci for insertion of transgenes in other types of cells.
  • FIG. 1 illustrates the overall approach that the inventors of the present disclosure used to identify safe harbor loci.
  • the present disclosure provides a method comprising the identification of genes within a genome and non-coding regions with sustained expression in a treatment cell (e.g. T cell) and using a predictive model of KI efficiency as a function of T cell chromatic state and computational analysis to predict candidate integration sites. The method further comprises evaluating the candidate integration sites for actual KI efficiency, sustained levels of transgene expression of a transgene, and minimal disruption to the treatment cell phenotype (e.g., T cell function and/or capacity for treatment product expansion and manufacturing).
  • the safe harbor loci allow for integration of a transgene driven by an endogenous promoter.
  • the safe harbor loci allow for integration of a transgene driven by an exogenous promoter (e.g. EF1a promoter).
  • the term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ⁇ 10%, ⁇ 5%, or ⁇ 1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s) ⁇ one standard deviation of that value(s).
  • the term “gene” refers to the basic unit of heredity, consisting of a segment of DNA arranged along a chromosome, which codes for a specific protein or segment of protein.
  • a gene typically includes a promoter, a 5′ untranslated region, one or more coding sequences (exons), optionally introns, a 3′ untranslated region.
  • the gene may further comprise a terminator, enhancers and/or silencers.
  • locus refers to a specific, fixed physical location on a chromosome where a gene or genetic marker is located.
  • target locus refers to a locus on a chromosome within which a safe harbor locus can be used for the insertion of a sequence.
  • a target locus can consist of multiple potential safe harbor loci (integration sites). Examples of target loci are provided in Table 4, as sgRNA target loci.
  • the notation used for the sgRNA target loci in Table 4 refers to the genomic region of the target locus, defined by the chromosome of the target locus and the coordinate range for that target locus.
  • chr10:33130000-33140000 refers to a target locus on Chr10 (chromosome 10) starting from coordinate 33130000 and ending with coordinate 33140000.
  • safe harbor locus refers to a locus at which genes or genetic elements can be incorporated without disruption to expression or regulation of adjacent genes. These safe harbor loci are also referred to as safe harbor sites (SHS).
  • SHS safe harbor sites
  • a safe harbor locus refers to an “integration site” or “knock-in site” at which a sequence encoding a transgene, as defined herein, can be inserted. In some embodiments the insertion occurs with replacement of a sequence that is located at the integration site. In some embodiments, the insertion occurs without replacement of a sequence at the integration site. Examples of integration sites contemplated are provided in Table 4.
  • the term “insert” refers to a nucleotide sequence that is integrated (inserted) at a safe harbor site.
  • the insert can be used to refer to the genes or genetic elements that are incorporated at the safe harbor site using, for example, homology-directed repair (HDR) CRISPR/Cas9 genome-editing or other methods for inserting nucleotide sequences into a genomic region known to those of ordinary skill in the art.
  • HDR homology-directed repair
  • CRISPR/Cas refers to a widespread class of bacterial systems for defense against foreign nucleic acid.
  • CRISPR/Cas systems are found in a wide range of eubacterial and archaeal organisms.
  • CRISPR/Cas systems include type I, II, and III sub-types. Wild-type type II CRISPR/Cas systems utilize an RNA-mediated nuclease, Cas9 in complex with guide and activating RNA to recognize and cleave foreign nucleic acid.
  • Guide RNAs having the activity of both a guide RNA and an activating RNA are also known in the art. In some cases, such dual activity guide RNAs are referred to as a small guide RNA (sgRNA).
  • sgRNA small guide RNA
  • Cas9 homologs are found in a wide variety of eubacteria, including, but not limited to bacteria of the following taxonomic groups: Actinobacteria, Aquificae, Bacteroidetes-Chlorobi, Chlamydiae-Verrucomicrobia, Chlroflexi, Cyanobacteria, Firmicutes, Proteobacteria, Spirochaetes, and Thermotogae.
  • An exemplary Cas9 protein is the Streptococcus pyogenes Cas9 protein. Additional Cas9 proteins and homologs thereof are described in, e.g., Chylinksi, et al., RNA Biol. 2013 May 1; 10(5): 726-737; Nat.
  • the Cas9 nuclease domain can be optimized for efficient activity or enhanced stability in the host cell.
  • RNA-mediated nuclease e.g., of bacterial or archeal orgin, or derived therefrom.
  • RNA-mediated nuclases include the foregoing Cas9 proteins and homologs thereof, and include but are not limited to, CPF1 (See, e.g., Zetsche et al., Cell, Volume 163, Issue 3, p 759-771, 22 Oct. 2015).
  • Cas9 ribonucleoprotein complex and the like refers to a complex between the Cas9 protein, and a crRNA (e.g., guide RNA or small guide RNA), the Cas9 protein and a trans-activating crRNA (tracrRNA), the Cas9 protein and a small guide RNA, or a combination thereof (e.g., a complex containing the Cas9 protein, a tracrRNA, and a crRNA guide RNA).
  • a crRNA e.g., guide RNA or small guide RNA
  • tracrRNA trans-activating crRNA
  • Cas9 protein and a small guide RNA e.g., a complex containing the Cas9 protein, a tracrRNA, and a crRNA guide RNA
  • T lymphocyte and “T cell” are used interchangeably and refer to cells that have completed maturation in the thymus, and identify certain foreign antigens in the body. The terms also refer to the major leukocyte types that have various roles in the immune system, including activation and deactivation of other immune cells.
  • the T cell can be any T cell such as a cultured T cell, e.g., a primary T cell, or a T cell derived from a cultured T cell line, e.g., a Jurkat, SupT1, etc., or a T cell obtained from a mammal.
  • the T cell can be a CD3+ cell.
  • the T cell can be any type of T cell, CD4+/CD8+ double positive T cells, CD4+ helper T cells (e.g. Th1 and Th2 cells), CD8+ T cells (e.g. cytotoxic T cells), peripheral Including but not limited to blood mononuclear cells (PBMC), peripheral blood leukocytes (PBL), tumor infiltrating lymphocytes (TIL), memory T cells, naive T cells, regulatory T cells, ⁇ T cells, etc. It can be any T cell at any stage of development. Additional types of helper T cells include Th3 (Treg) cells, Th17 cells, Th9 cells, or Tfh cells.
  • helper T cells include Th3 (Treg) cells, Th17 cells, Th9 cells, or Tfh cells.
  • T cells such as central memory T cells (Tcm cells), effector memory T cells (Tem cells and TEMRA cells).
  • a T cell can also refer to a genetically modified T cell, such as a T cell that has been modified to express a T cell receptor (TCR) or a chimeric antigen receptor (CAR). T cells can also be differentiated from stem cells or progenitor cells.
  • TCR T cell receptor
  • CAR chimeric antigen receptor
  • CD4+ T cells refers to a subset of T cells that express CD4 on their surface and are associated with a cellular immune response.
  • CD4+ T cells are characterized by a post-stimulation secretion profile that can include secretion of cytokines such as IFN- ⁇ , TNF- ⁇ , IL-2, IL-4 and IL-10.
  • CD4 is a 55 kD glycoprotein originally defined as a differentiation antigen on T lymphocytes, but was also found on other cells including monocytes/macrophages.
  • the CD4 antigen is a member of the immunoglobulin superfamily and has been implicated as an associative recognition element in MHC (major histocompatibility complex) class II restricted immune responses.
  • MHC major histocompatibility complex
  • CD8+ T cells refers to a subset of T cells that express CD8 on their surface, are MHC class I restricted, and function as cytotoxic T cells.
  • the “CD8” molecule is a differentiation antigen present on thymocytes, as well as on cytotoxic and suppressor T lymphocytes.
  • the CD8 antigen is a member of the immunoglobulin superfamily and is an associative recognition element in major histocompatibility complex class I restriction interactions.
  • ex vivo generally includes experiments or measurements made in or on living tissue, preferably in an artificial environment outside the organism, preferably with minimal differences from natural conditions.
  • construct refers to a complex of molecules, including macromolecules or polynucleotides.
  • the term “integration” refers to the process of stably inserting one or more nucleotides of a construct into the cell genome, i.e., covalently linking to a nucleic acid sequence in the chromosomal DNA of the cell. It may also refer to nucleotide deletions at a site of integration. Where there is a deletion at the insertion site, “integration” may further include substitution of the endogenous sequence or nucleotide deleted with one or more inserted nucleotides.
  • the term “exogenous” refers to a molecule or activity that has been introduced into a host cell and is not native to that cell.
  • the molecule can be introduced, for example, by introduction of the encoding nucleic acid into host genetic material, such as by integration into a host chromosome, or as non-chromosomal genetic material, such as a plasmid.
  • the term, when used in connection with expression of an encoding nucleic acid refers to the introduction of the encoding nucleic acid into a cell in an expressible form.
  • the term “endogenous” refers to a molecule or activity that is present in a host cell under natural, unedited conditions.
  • the term, when used in connection with expression of the encoding nucleic acid refers to expression of the encoding nucleic acid that is contained within the cell and not introduced exogenously.
  • a “polynucleotide donor construct” refers to a nucleotide sequence (e.g. DNA sequence) that is genetically inserted into a polynucleotide and is exogenous to that polynucleotide.
  • the polynucleotide donor construct is transcribed into RNA and optionally translated into a polypeptide.
  • the polynucleotide donor construct can include prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and synthetic DNA sequences.
  • the polynucleotide donor construct can be a miRNA, shRNA, natural polypeptide (i.e., a naturally occurring polypeptide) or fragment thereof or a variant polypeptide (e.g. a natural polypeptide having less than 100% sequence identity with the natural polypeptide) or fragments thereof.
  • natural polypeptide i.e., a naturally occurring polypeptide
  • variant polypeptide e.g. a natural polypeptide having less than 100% sequence identity with the natural polypeptide
  • transgene refers to a polynucleotide that has been transferred naturally, or by any of a number of genetic engineering techniques from one organism to another. It is optionally translated into a polypeptide. It is optionally translated into a recombinant protein.
  • a “recombinant protein” is a protein encoded by a gene—recombinant DNA—that has been cloned in a system that supports expression of the gene and translation of messenger RNA (see expression system).
  • the recombinant protein can be a therapeutic agent, e.g. a protein that treats a disease or disorder disclosed herein.
  • transgene can refer to a polynucleotide that encodes a polypeptide.
  • a transgene can also refer to a non-encoding sequence, such as, but not limited to shRNAs, miRNAs, and miRs.
  • protein protein
  • polypeptide peptide
  • operably linked refers to the binding of a nucleic acid sequence to a single nucleic acid fragment such that one function is affected by the other.
  • a promoter is capable of affecting the expression of a coding sequence or functional RNA (i.e., the coding sequence or functional RNA is under transcriptional control by the promoter)
  • the promoter is operably linked thereto.
  • Coding sequences can be operably linked to control sequences in both sense and antisense orientation.
  • developmental cell states refers to, for example, states when the cell is inactive, actively expressing, differentiating, senescent, etc.
  • developmental cell state may also refer to a cell in a precursor state (e.g., a T cell precursor).
  • the term “encoding” refers to a sequence of nucleic acids which codes for a protein or polypeptide of interest.
  • the nucleic acid sequence may be either a molecule of DNA or RNA.
  • the molecule is a DNA molecule.
  • the molecule is a RNA molecule.
  • When present as a RNA molecule it will comprise sequences which direct the ribosomes of the host cell to start translation (e.g., a start codon, ATG) and direct the ribosomes to end translation (e.g., a stop codon). Between the start codon and stop codon is an open reading frame (ORF).
  • ORF open reading frame
  • inserting refers to a manipulation of a nucleotide sequence to introduce a non-native sequence. This is done, for example, via the use of restriction enzymes and ligases whereby the DNA sequence of interest, usually encoding the gene of interest, can be incorporated into another nucleic acid molecule by digesting both molecules with appropriate restriction enzymes in order to create compatible overlaps and then using a ligase to join the molecules together.
  • restriction enzymes and ligases whereby the DNA sequence of interest, usually encoding the gene of interest, can be incorporated into another nucleic acid molecule by digesting both molecules with appropriate restriction enzymes in order to create compatible overlaps and then using a ligase to join the molecules together.
  • ligase to join the molecules together.
  • the term “subject” refers to a mammalian subject. Exemplary subjects include humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, goats, rabbits, pigs and sheep. In certain embodiments, the subject is a human. In some embodiments the subject has a disease or condition that can be treated with an engineered cell provided herein or population thereof. In some aspects, the disease or condition is a cancer.
  • promoter refers to a nucleotide sequence (e.g. DNA sequence) capable of controlling the expression of a coding sequence or functional RNA.
  • the promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers.
  • a promoter can be derived from natural genes in its entirety, can be composed of different elements from different promoters found in nature, and/or may comprise synthetic DNA segments.
  • a promoter, as contemplated herein, can be endogenous to the cell of interest or exogenous to the cell of interest. It is appreciated by those skilled in the art that different promoters can induce gene expression in different tissue or cell types, or at different developmental stages, or in response to different environmental conditions.
  • a promoter can be selected according to the strength of the promoter and/or the conditions under which the promoter is active, e.g., constitutive promoter, strong promoter, weak promoter, inducible/repressible promoter, tissue specific Or developmentally regulated promoters, cell cycle-dependent promoters, and the like.
  • a promoter can be an inducible promoter (e.g., a heat shock promoter, tetracycline-regulated promoter, steroid-regulated promoter, metal-regulated promoter, estrogen receptor-regulated promoter, etc.).
  • the promoter can be a constitutive promoter (e.g., CMV promoter, UBC promoter).
  • the promoter can be a spatially restricted and/or temporally restricted promoter (e.g., a tissue specific promoter, a cell type specific promoter, etc.). See for example U.S. application Ser. No. 15/715,068, the disclosures of which are herein incorporated by reference in their entirety.
  • Gene editing may involve a gene (or nucleotide sequence) knock-in or knock-out.
  • knock-in refers to an addition of a DNA sequence, or fragment thereof into a genome.
  • DNA sequences to be knocked-in may include an entire gene or genes, may include regulatory sequences associated with a gene or any portion or fragment of the foregoing.
  • a polynucleotide donor construct encoding a recombinant protein may be inserted into the genome of a cell carrying a mutant gene.
  • a knock-in strategy involves substitution of an existing sequence with the provided sequence, e.g., substitution of a mutant allele with a wild-type copy.
  • knock-out refers to the elimination of a gene or the expression of a gene.
  • a gene can be knocked out by either a deletion or an addition of a nucleotide sequence that leads to a disruption of the reading frame.
  • a gene may be knocked out by replacing a part of the gene with an irrelevant (e.g., non-coding) sequence.
  • non-homologous end joining refers to a cellular process in which cut or nicked ends of a DNA strand are directly ligated without the need for a homologous template nucleic acid. NHEJ can lead to the addition, the deletion, substitution, or a combination thereof, of one or more nucleotides at the repair site.
  • the term “homology directed repair” or HDR refers to a cellular process in which cut or nicked ends of a DNA strand are repaired by polymerization from a homologous template nucleic acid.
  • the homologous template nucleic acid can be provided by homologous sequences elsewhere in the genome (sister chromatids, homologous chromosomes, or repeated regions on the same or different chromosomes).
  • an exogenous template nucleic acid can be introduced to obtain a specific HDR-induced change of the sequence at the target site. In this way, specific mutations can be introduced at the cut site.
  • Vectors can be linear or circular. Vectors can integrate into a target genome of a host cell or replicate independently in a host cell. Vectors can comprise, for example, an origin of replication, a multicloning site, and/or a selectable marker.
  • An expression vector typically comprises an expression cassette.
  • Vectors and plasmids include, but are not limited to, integrating vectors, prokaryotic plasmids, eukaryotic plasmids, plant synthetic chromosomes, episomes, viral vectors, cosmids, and artificial chromosomes.
  • expression cassette is a polynucleotide construct, generated recombinantly or synthetically, comprising regulatory sequences operably linked to a selected polynucleotide to facilitate expression of the selected polynucleotide in a host cell.
  • the regulatory sequences can facilitate transcription of the selected polynucleotide in a host cell, or transcription and translation of the selected polynucleotide in a host cell.
  • An expression cassette can, for example, be integrated in the genome of a host cell or be present in an expression vector.
  • the phrase “subject in need thereof” refers to a subject that exhibits and/or is diagnosed with one or more symptoms or signs of a disease or disorder as described herein.
  • chemotherapeutic agent refers to a chemical compound useful in the treatment of cancer.
  • Chemotherapeutic agents include “anti-hormonal agents” or “endocrine therapeutics” which act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer.
  • composition refers to a mixture that contains, e.g., an engineered cell or protein contemplated herein.
  • the composition may contain additional components, such as adjuvants, stabilizers, excipients, and the like.
  • composition or “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective in treating a subject, and which contains no additional components which are unacceptably toxic to the subject in the amounts provided in the pharmaceutical composition.
  • the term “effective amount” refers to the amount of a compound (e.g., a compositions described herein, cells described herein) sufficient to effect beneficial or desired results.
  • An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
  • the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
  • modulate and “modulation” refer to reducing or inhibiting or, alternatively, activating or increasing, a recited variable.
  • increase and activate refer to an increase of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 50-fold, 100-fold, or greater in a recited variable.
  • reduce and “inhibit” refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 100-fold, or greater in a recited variable.
  • Gene editing therapies include, for example, viral vector integration and site specific integration.
  • Site-specific integration is a promising alternative to random integration of viral vectors, as it mitigates the risks of insertional mutagenesis or insertional oncogenesis (Kolb et al. Trends Biotechnol. 2005 23:399-406; Porteus et al. Nat Biotechnol. 2005 23:967-973; Paques et al. Curr Gen Ther. 2007 7:49-66).
  • site specific integration continues to face challenges such as poor knock-in efficiency, risk of insertional oncogenesis, unstable and/or anomalous expression of adjacent genes or the transgene, low accessibility (e.g. within kB of adjacent genes), etc.
  • SHS safe harbor loci or safe harbor sites
  • the most widely used of the putative human safe harbor sites is the AAVS1 site on chromosome 19q, which was initially identified as a site for recurrent adenoassociated virus insertion.
  • Other potential SHS have been identified on the basis of homology, with sites first identified in other species (e.g., the human homolog of the permissive murine Rosa26 locus) or among the growing number of human genes that appear non-essential under some circumstances.
  • One putative SHS of this type is the CCR5 chemokine receptor gene, which, when disrupted, confers resistance to human immunodeficiency virus infection.
  • Additional potential genomic SHS have been identified in human and other cell types on the basis of viral integration site mapping or gene-trap analyses, as was the original murine Rosa26 locus.
  • the AAVS1 (also known as the PPP 1R12C locus) on human chromosome 19 is a known SHS for hosting transgenes (e.g. DNA transgenes) with expected function. It is at position 19q13.42. It has an open chromatin structure and is transcription-competent.
  • the canonical SHS locus for AAVS1 is chr19: 55,625,241-55,629,351. See Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference.
  • An exemplary AAVS1 target gRNA and target sequence are provided below:
  • AAVS1-gRNA sequence (SEQ ID NO: 121) ggggccactagggacaggatGTTTTAGAGCTAGAA ATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC TTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTTT AAVS1 target sequence: (SEQ ID NO: 122) ggggccactagggacaggat
  • CCR5 which is located on chromosome 3 at position 3p21.31, encodes the major co-receptor for HIV-1. Disruption at this site in the CCR5 gene has been beneficial in HIV/AIDS therapy and prompted the development of zinc-finger nucleases that target its third exon.
  • the canonical SHS locus for CCR5 is chr3: 46,414,443-46,414,942. See Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference.
  • the mouse Rosa26 locus is particularly useful for genetic modification as it can be targeted with high efficiency and is expressed in most cell types tested.
  • Irion et al. 2007 (“Identification and targeting of the ROSA26 locus in human embryonic stem cells.” Nature biotechnology 25.12 (2007): 1477-1482, the relevant disclosure of which are herein incorporated by reference) identified the human homolog, human ROSA26, in chromosome 3 (position 3p25.3).
  • the canonical SHS locus for human Rosa26 (hRosa26) is chr3: 9,415,082-9,414,043. See Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference.
  • the present disclosure is directed to methods for identifying safe harbor loci with benefits including, but not limited to, high knock-in efficiency and high expression of transgene.
  • An example of applications of the presently disclosed methods is the identification of safe harbor loci for insertion of transgenes (e.g., chimeric antigen receptors (CAR)) into T-cells.
  • the safe harbor loci of the present disclosure are useful for the insertion of a sequence encoding a transgene.
  • the safe harbor sites allow for high transgene expression (sufficient to allow for transgene functionality or treatment of a disease of interest) and stable expression of the transgene over several days, weeks or months.
  • knockout of the gene at the safe harbor locus confers benefit to the function of the cell, or the gene at the safe harbor locus has no known function within the cell.
  • the safe harbor locus results in stable transgene expression in vitro with or without CD3/CD28 stimulation, negligible off-target cleavage as detected by iGuide-Seq or CRISPR-Seq, less off-target cleavage relative to other loci as detected by iGuide-Seq or CRISPR-Seq, negligible transgene-independent cytotoxicity, negligible transgene-independent cytokine expression, negligible transgene-independent chimeric antigen receptor expression, negligible deregulation or silencing of nearby genes, and positioned outside of a cancer-related gene.
  • a “nearby gene” can refer to a gene that is within about 100 kB, about 125 kB, about 150 kB, about 175 kB, about 200 kB, about 225 kB, about 250 kB, about 275 kB, about 300 kB, about 325 kB, about 350 kB, about 375 kB, about 400 kB, about 425 kB, about 450 kB, about 475 kB, about 500 kB, about 525 kB, about 550 kB away from the safe harbor locus (integration site).
  • the present disclosure contemplates inserts that comprise one or more transgenes.
  • the transgene can encode a therapeutic protein, an antibody, a peptide, a suicide gene, an apoptosis gene or any other gene of interest.
  • the safe harbor loci identified using the method described herein allow for transgene integration that results in, for example, enhanced therapeutic properties.
  • These enhanced therapeutic properties refer to an enhanced therapeutic property of a cell when compared to a typical immune cell of the same normal cell type.
  • an NK cell having “enhanced therapeutic properties” has an enhanced, improved, and/or increased treatment outcome when compared to a typical, unmodified and/or naturally occurring NK cell.
  • the therapeutic properties of immune cells can include, but are not limited to, cell transplantation, transport, homing, viability, self-renewal, persistence, immune response control and regulation, survival, and cytotoxicity.
  • the therapeutic properties of immune cells are also manifested by: antigen-targeted receptor expression; HLA presentation or lack thereof; tolerance to the intratumoral microenvironment; induction of bystander immune cells and immune regulation; improved target specificity with reduction; resistance to treatments such as chemotherapy.
  • the term “insert size” refers to the length of the nucleotide sequence being integrated (inserted) at the safe harbor site.
  • the insert size comprises at least about 100, 200, 300, 400 or 500 basepairs.
  • the insert size comprises about 500 nucleotides or basepairs.
  • the insert size comprises up to 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 kbp (kilo basepairs) or the sizes in between.
  • the insert size is greater than 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 kbp or the sizes in between. In some embodiments, the insert size is within the range of 3-15 kbp or is any number in that range. In some embodiments, the insert size is within the range of 1.5-8.3 kbp or is any number in that range. In some embodiments, the insert size is within the range of 1.5-15 kbp or is any number in that range. In some embodiments, the insert size is within the range of 0.5-20 kbp or is any number in that range.
  • the insert size is 0.5-10, 0.6-10, 0.7-10, 0.8-10, 0.9-10, 1-10, 2-10, 3-10, 4-10, 5-10, 6-10, 7-10, 8-10, 9-10 kbp. In some embodiments, the insert size is 0.5-11, 0.6-11, 0.7-11, 0.8-11, 0.9-11, 1-11, 2-11, 3-11, 4-11, 5-11, 6-11, 7-11, 8-11, 9-11, or 10-11 kbp. In some embodiments, the insert size is 0.5-12, 0.6-12, 0.7-12, 0.8-12, 0.9-12, 1-12, 2-12, 3-12, 4-12, 5-12, 6-12, 7-12, 8-12, 9-12, 10-12, or 11-12 kbp.
  • the insert size is 0.5-13, 0.6-13, 0.7-13, 0.8-13, 0.9-13, 1-13, 2-13, 3-13, 4-13, 5-13, 6-13, 7-13, 8-13, 9-13, 10-13, 11-13, or 12-13 kbp. In some embodiments, the insert size is 0.5-14, 0.6-14, 0.7-14, 0.8-14, 0.9-14, 1-14, 2-14, 3-14, 4-14, 5-14, 6-14, 7-14, 8-14, 9-14, 10-14, 11-14, 12-14 or 13-14 kbp.
  • the insert size is 0.5-15, 0.6-15, 0.7-15, 0.8-15, 0.9-15, 2-15, 3-15, 4-15, 5-15, 6-15, 7-15, 8-15, 9-15, 10-15, 11-15, 12-15, 13-15, or 14-15 kbp. In some embodiments, the insert size is 0.5-16, 0.6-16, 0.7-16, 0.8-16, 0.9-16, 1-16, 2-16, 3-16, 4-16, 5-16, 6-16, 7-16, 8-16, 9-16, 10-16, 11-16, 12-16, 13-16, 14-16 or 15-16 kbp.
  • the insert size is 0.5-17, 0.6-17, 0.7-17, 0.8-17, 0.9-17, 1-17, 2-17, 3-17, 4-17, 5-17, 6-17, 7-17, 8-17, 9-17, 10-17, 11-17, 12-17, 13-17, or 14-17, 15-17 or 16-17 kbp. In some embodiments, the insert size is 0.5-18, 0.6-18, 0.7-18, 0.8-18, 0.9-18, 1-18, 2-18, 3-18, 4-18, 5-18, 6-18, 7-18, 8-18, 9-18, 10-18, 11-18, 12-18, 13-18, 14-18, 15-18, 16-18 or 17-18 kbp.
  • the insert size is 0.5-19, 0.6-19, 0.7-19, 0.8-19, 0.9-19, 1-19, 2-19, 3-19, 4-19, 5-19, 6-19, 7-19, 8-19, 9-19, 10-19, 11-19, 12-19, 13-19, 14-0.7-20, 19, 15-19, 16-19, 17-19, or 18-19 kbp.
  • the insert size is 0.5-20, 0.6-20, 0.7-20, 0.8-20, 0.9-20, 1-20, 2-20, 3-20, 4-20, 5-20, 6-20, 7-20, 8-20, 9-20, 10-20, 11-20, 12-20, 13-20, 14-20, 15-20, 16-20, 17-20, 18-20, or 19-20 kbp.
  • the inserts of the present disclosure refer to nucleic acid molecules or polynucleotide inserted at a safe harbor site.
  • the nucleotide sequence is a DNA molecule, e.g., genomic DNA, or comprises deoxy-ribonucleotides.
  • the insert comprises a smaller fragment of DNA, such as a plastid DNA, mitochondrial DNA, or DNA isolated in the form of a plasmid, a fosmid, a cosmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), and/or any other sub-genome segment of DNA.
  • the insert is an RNA molecule or comprises ribonucleotides.
  • nucleotides in the insert are contemplated as naturally occurring nucleotides, non-naturally occurring, and modified nucleotides.
  • Nucleotides may be modified chemically or biochemically, or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications.
  • the polynucleotides can be in any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular conformations, and other three-dimension conformations contemplated in the art.
  • the inserts can have coding and/or non-coding regions.
  • the insert can comprises a non-coding sequence (e.g., control elements, e.g., a promoter sequence).
  • the insert encodes transcription factors.
  • the insert encodes an antigen binding receptors such as single receptors, T-cell receptors (TCRs), syn-notch, CARs, mAbs, etc.
  • the inserts are RNAi molecules, including, but not limited to, miRNAs, siRNA, shRNAs, etc.
  • the insert is a human sequence.
  • the insert is chimeric.
  • the insert is a multi-gene/multi-module therapeutic cassette.
  • a multi-gene/multi-module therapeutic cassette referst to an insert or cassette having one or more than one receptor (e.g., synthetic receptors), other exogenous protein coding sequences, non-coding RNAs, transcriptional regulatory elements, and/or insulator sequences, etc.
  • receptor e.g., synthetic receptors
  • other exogenous protein coding sequences e.g., non-coding RNAs, transcriptional regulatory elements, and/or insulator sequences, etc.
  • a cell comprising a safe harbor site and/or a cell comprising an insert at a safe harbor site as described in the present disclosure can be referred to as an engineered cell.
  • the cells can include, but are not limited to, eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells and the like.
  • the cell is a mammalian cell, for example, a human cell.
  • that engineered cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or a T cell progenitor.
  • Non-limiting examples of immune cells that are contemplated in the present disclosure include T cell, B cell, natural killer (NK) cell, NKT/iNKT cell, macrophage, myeloid cell, and dendritic cells.
  • Non-limiting examples of stem cells that are contemplated in the present disclosure include pluripotent stem cells (PSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), embryo-derived embryonic stem cells obtained by nuclear transfer (ntES; nuclear transfer ES), male germline stem cells (GS cells), embryonic germ cells (EG cells), hematopoietic stem/progenitor stem cells (HSPCs), somatic stem cells (adult stem cells), hemangioblasts, neural stem cells, mesenchymal stem cells and stem cells of other cells (including osteocyte, chondrocyte, myocyte, cardiac myocyte, neuron, tendon cell, adipocyte, pancreocyte, hepatocyte, nephrocyte and follicle cells and so on
  • the engineered cells is a T cell, NK cells, iPSC, and HSPC.
  • the engineered cells used in the present disclosure are human cell lines grown in vitro (e.g. deliberately immortalized cell lines, cancer cell lines, etc.).
  • the methods for integrating the inserts at the safe harbor sites can be viral or non-viral delivery techniques.
  • the nucleic acid sequence is inserted into the genome of the engineered cell by introducing a vector, for example, a viral vector, comprising the nucleic acid.
  • a viral vector for example, a viral vector
  • examples of viral vectors include, but are not limited to, adeno-associated viral (AAV) vectors, retroviral vectors or lentiviral vectors.
  • the lentiviral vector is an integrase-deficient lentiviral vector.
  • the nucleic acid sequence is inserted into the genome of the T cell via non-viral delivery.
  • the nucleic acid can be naked DNA, or in a non-viral plasmid or vector.
  • Non-viral delivery techniques can be site-specific integration techniques, as described herein or known to those of ordinary skill in the art. Examples of site-specific techniques for integration into the safe harbor loci include, without limitation, homology-dependent engineering using nucleases and homology independent targeted insertion using Cas9.
  • the insert is integrated at a safe harbor site by introducing into the engineered cell, (a) a targeted nuclease that cleaves a target region in the safe harbor site to create the insertion site; and (b) the nucleic acid sequence (insert), wherein the insert is incorporated at the insertion site by, e.g., HDR.
  • a targeted nuclease that cleaves a target region in the safe harbor site to create the insertion site
  • the nucleic acid sequence (insert) wherein the insert is incorporated at the insertion site by, e.g., HDR.
  • Chimeric antigen receptor (CAR) T cells are T cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy. Chimeric antigen receptors are receptor proteins that have been engineered to confer T cells with the ability to target a specific protein.
  • the genetic modification of lymphocytes (e.g. T cells) by incorporation of, for example, CARs, and administration of the engineered cells to a subject is an example of “adoptive cell therapy”.
  • the term “adoptive cell therapy” refers to cell-based immunotherapy for transfusion of autologous or allogeneic lymphocytes, referred to as T cells or B cells. In this CAR therapy approach, cells are expanded and cultured ex vivo and genetically modified, prior to transfusion.
  • T-cells are harvested from a subject—they can be autologous T-cells from the subject own blood or from a donor that will not be receiving the CAR therapy. Once isolated, the T-cells are genetically modified with a CAR, expanded ex vivo, and administered to the subject (i.e. patient) by, e.g. infusion.
  • the CARs may be introduced into the T-cells using, for example, a viral technique (e.g., retroviral integration) or site-specific technique.
  • a viral technique e.g., retroviral integration
  • site-specific technique e.g. CARs
  • the transgenes may be targeted to a safe harbor locus.
  • site-specific techniques for integration into the safe harbor loci include, without limitation, homology-dependent engineering using nucleases and homology independent targeted insertion using Cas9.
  • the engineered CAR T cells have applications to immune-oncology.
  • the CAR for example, can be selected to target a specific tumor antigen.
  • Examples of cancers that can be effectively targeted using CAR T cells are blood cancers.
  • CAR T cell therapy can be used to treat solid tumors.
  • gene editing or “genome editing”, as used herein, refer to a type of genetic manipulation in which DNA is inserted, replaced, or removed from the genome using artificially manipulated nucleases or “molecular scissors”. It is a useful tool for elucidating the function and effect of sequence-specific genes or proteins or altering cell behavior (e.g. for therapeutic purposes).
  • TALENs transcription activator-like effector nucleases
  • safe harbor loci e.g. the adeno-associated virus integration site 1 (AAVS1) safe harbor locus.
  • AAVS1 adeno-associated virus integration site 1
  • CRISPR/Cas9 clustered regularly interspaced short palindromic repeat/Cas9
  • Site specific gene editing approaches can include homology dependent mechanisms or homology independent mechanisms.
  • Crisp-Cas approach e.g. Crispr-Cas9
  • This approach incorporates the use of a guide polynucleotide (e.g. guide ribonucleic acid or gRNA) and a cas endonuclease (e.g. Cas9 endonuclease).
  • a guide polynucleotide e.g. guide ribonucleic acid or gRNA
  • a cas endonuclease e.g. Cas9 endonuclease
  • a polypeptide referred to as a “Cas endonuclease” or having “Cas endonuclease activity” refers to a CRISPR-related (Cas) polypeptide encoded by a Cas gene, wherein a Cas polypeptide is a target DNA sequence that can be cleaved when operably linked to one or more guide polynucleotides (see, e.g., U.S. Pat. No. 8,697,359). Also included in this definition are variants of Cas endonuclease that retain guide polynucleotide-dependent endonuclease activity.
  • the Cas endonuclease used in the donor DNA insertion method detailed herein is an endonuclease that introduces double-strand breaks into DNA at the target site (e.g., within the target locus or at the safe harbor site).
  • guide polynucleotide relates to a polynucleotide sequence capable of complexing with a Cas endonuclease and allowing the Cas endonuclease to recognize and cleave a DNA target site.
  • the guide polynucleotide can be a single molecule or a double molecule.
  • the guide polynucleotide sequence can be an RNA sequence, a DNA sequence, or a combination thereof (RNA-DNA combination sequence).
  • a guide polynucleotide comprising only ribonucleic acid is also referred to as “guide RNA”.
  • a polynucleotide donor construct is inserted at a safe harbor locus using a guide RNA (gRNA) in combination with a cas endonuclease (e.g. Cas9 endonuclease).
  • gRNA guide RNA
  • cas endonuclease e.g. Cas9 endonuclease
  • the guide polynucleotide includes a first nucleotide sequence domain (also referred to as a variable targeting domain or VT domain) that is complementary to a nucleotide sequence in the target DNA, and a second nucleotide that interacts with a Cas endonuclease polypeptide.
  • It can be a double molecule (also referred to as a double-stranded guide polynucleotide) comprising a sequence domain (referred to as a Cas endonuclease recognition domain or CER domain).
  • the CER domain of this double molecule guide polynucleotide comprises two separate molecules that hybridize along the complementary region.
  • the two separate molecules can be RNA sequences, DNA sequences and/or RNA-DNA combination sequences.
  • Genome editing using CRISPR-Cas approaches relies on the repair of site-specific DNA double-strand breaks (DSBs) induced by the RNA-guided Cas endonuclease (e.g. Cas 9 endonuclease). Homology-directed repair (HDR) of these DSBs enables precise editing of the genome by introducing defined genomic changes, including base substitutions, sequence insertions, and deletions.
  • HDR-based CRISPR/Cas9 genome-editing involves transfecting cells with Cas9, gRNA and donor DNA containing homologous arms matching the genomic locus of interest.
  • HITI non-homologous end joining
  • NHEJ non-homologous end joining
  • gRNAs Guide RNAs
  • donor plasmids lack homology arms and DSB repair does not occur through the HDR pathway.
  • the donor polynucleotide construct can be engineered to include Cas9 cleavage site(s) flanking the gene or sequence to be inserted. This results in Cas9 cleavage at both the donor plasmid and the genomic target sequence. Both target and donor have blunt ends and the linearized donor DNA plasmid is used by the NHEJ pathway resulting integration into the genomic DSB site.
  • the guide RNAs and/or mRNA (or DNA) encoding an endonuclease can be chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.
  • Non-limiting examples of such moieties include lipid moieties such as a cholesterol moiety, cholic acid, a thioether, a thiocholesterol, an aliphatic chain (e.g., dodecandiol or undecyl residues), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, adamantane acetic acid, a palmityl moiety and an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety. See for example U.S. application Ser. No. 15/715,068, the disclosures of which are herein incorporated by reference in their entirety.
  • the engineered cells, populations thereof, or compositions thereof are administered to a subject, generally a mammal, generally a human, in an effective amount.
  • the engineered cells may be administered to a subject by infusion (e.g., continuous infusion over a period of time) or other modes of administration known to those of ordinary skill in the art.
  • infusion e.g., continuous infusion over a period of time
  • other modes of administration known to those of ordinary skill in the art.
  • the engineered cells provided herein can be administered as part of a pharmaceutical compositions.
  • the present disclosure provides compositions comprising a guide RNA of the present disclosure.
  • the pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients , Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
  • the engineered cells provided herein not only find use in gene therapy but also in non-pharmaceutical uses such as, e.g., production of animal models and production of recombinant cell lines expressing a protein of interest.
  • the engineered cells of the present disclosure can be any cell, generally a mammalian cell, generally a human cell that has been modified by integrating a transgene at a safe harbor locus described herein.
  • the engineered cells are immune cells.
  • the engineered cells are lymphocytes.
  • the engineered cells are T cells or T cell precursors.
  • the engineered cells, compositions and methods of the present disclosure are useful for therapeutic applications such as CAR T cell therapy and TCR T cell therapy.
  • the insertion of a sequence encoding a transgene within a safe harbor locus maintains the TCR expression relative to instances when there is no insertion and enables transgene expression while maintaining TCR function.
  • Non-limiting examples of such diseases include alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, cancer, dermatomyositis, diabetes (type 1), certain juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain Valley Syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, certain myocarditis, multiple sclerosis, pemphigus/pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary bile With cirrhosis, psoriasis, rheumatoid arthritis, scleroderma/systemic sclerosis, Sjogren's syndrome, systemic lupus erythematosus, certain thyroiditis, certain uveitis, vitiligo, multiple va
  • Cancers that can be treated with the engineered cells (e.g., CAR T-cells) of the present disclosure, populations thereof, or compositions thereof include blood cancers.
  • the cancer treated using the engineered cells (e.g., CAR T-cells) described herein, populations thereof, or compositions thereof is a hematologic malignancy or leukemia.
  • the engineered cells (e.g., CAR T-cells) described herein, populations thereof, or compositions thereof are used for the treatment of acute lymphoblastic leukemia (ALL) or diffuse large B-cell lymphoma (DLBCL).
  • ALL acute lymphoblastic leukemia
  • DLBCL diffuse large B-cell lymphoma
  • the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplasia, myelodysplastic syndromes, acute T-lymphoblastic leukemia, or acute promyelocytic leukemia, chronic myelomonocytic leukemia, or myeloid blast crisis of chronic myeloid leukemia.
  • AML acute myeloid leukemia
  • ALL acute lymphoblastic leukemia
  • myelodysplasia myelodysplasia
  • myelodysplastic syndromes myelodysplastic syndromes
  • acute T-lymphoblastic leukemia or acute promyelocytic leukemia
  • chronic myelomonocytic leukemia chronic myelomonocytic leukemia
  • myeloid blast crisis of chronic myeloid leukemia.
  • cancers treatable using the engineered cells (e.g., CAR T-cells) described herein include, without limitation, breast cancer, ovarian cancer, esophageal cancer, bladder or gastric cancer, salivary duct carcinoma, salivary duct carcinomas, adenocarcinoma of the lung or aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
  • the cancer is brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
  • the cancer is a squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, neuroblastoma, sarcoma (e.g., an angiosarcoma or chondrosarcoma), larynx cancer, parotid cancer, biliary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondrosarcoma, choroid
  • the present disclosure provides methods of treating a subject in need of treatment by administering to the subject a composition comprising any of the engineered cells described herein.
  • the terms “treat,” “treatment,” and the like refer generally to obtaining a desired pharmacological and/or physiological effect. That effect is preventive in terms of complete or partial prevention of the disease and/or therapeutic in terms of partial or complete cure of the disease and/or adverse effects resulting from the disease.
  • treatment encompasses any treatment of a disease in a subject (e.g., mammal, e.g., human).
  • Treatment may also refer to the administration of the engineered cells provided herein to a subject that is susceptible to the disease but has not yet been diagnosed as suffering from it, including preventing the disease from occurring; inhibiting disease progression; or reducing the disease (i.e., causing a regression of the disease). Further, treatment may stabilize or reduce undesirable clinical symptoms in subjects (e.g., patients).
  • the cells provided herein populations thereof, or compositions thereof may be administered before, during or after the occurrence of the disease or injury.
  • the subject has a disease, condition, and/or injury that can be treated and/or ameliorated by cell therapy.
  • the subject in need of cell therapy is a subject having an injury, disease, or condition, thereby causing cell therapy (e.g., therapy in which cellular material is administered to the subject).
  • cell therapy e.g., therapy in which cellular material is administered to the subject.
  • a subject in need of cell therapy includes, but is not limited to, a bone marrow transplant or stem cell transplant candidate, a subject who has received chemotherapy or radiation therapy, a hyperproliferative disease or cancer (e.g., a hematopoietic system), a subject having or at risk of developing a hyperproliferative disease or cancer), a subject having or at risk of developing a tumor (e.g., solid tumor), viral infection or virus. It is also intended to encompass subjects suffering from or at risk of suffering from a disease associated with an infection.
  • a hyperproliferative disease or cancer e.g., a hematopoietic system
  • a subject having or at risk of developing a hyperproliferative disease or cancer e.g., solid tumor
  • a tumor e.g., solid tumor
  • the present disclosure provides a composition of the present disclosure along with instructions for use.
  • the instructions for use can be present in the kits as a package insert, in the labeling of the container of the kit or components thereof, or can be in digital form (e.g. on a CD-ROM, via a link on the internet).
  • a kit can include one or more of a genome-targeting nucleic acid, a polynucleotide encoding a genome-targeting nucleic acid, a site-directed polypeptide, and/or a polynucleotide encoding a site-directed polypeptide. Additional components within the kits are also contemplated, for example, buffer (such as reconstituting buffer, stabilizing buffer, diluting buffer), and/or one or more control vectors.
  • an engineered cells of the present disclosure or composition thereof is administered with at least one additional therapeutic agent.
  • Any suitable additional therapeutic agent may be administered with an engineered cell provided herein, populations thereof, or compositions thereof.
  • the additional therapeutic agent is selected from radiation, an ophthalmologic agent, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof.
  • an engineered cell of the present disclosure or composition thereof is administered with a steroid.
  • the administration of a steroid can prevent or mitigate the risk of a subject receiving the engineered cell(s) or composition thereof having an autoimmune reaction.
  • the additional therapeutic agent may be administered by any suitable means.
  • the engineered cells described herein, populations thereof, or compositions thereof and the additional therapeutic agent is administered in the same pharmaceutical composition, e.g. by infusion.
  • the engineered cells described herein and additional therapeutic agent are included in different pharmaceutical compositions.
  • the pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients , Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
  • the additional therapeutic agent is administered by any suitable mode of administration.
  • modes of administration include, without limitation, intravitreal, subretinal, suprachoroidal, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, topical, pulmonary, and subcutaneous routes.
  • administering can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent.
  • the objective of the experiments in this set of examples was to identify T-cell knock-in (KI) loci in coding regions outside of the T Cell Receptor Alpha Constant (TRAC) locus.
  • KI T-cell knock-in loci
  • T Cell Receptor Alpha Constant T Cell Receptor Alpha Constant
  • CAR T chimeric antigen receptor therapy
  • FIG. 4 A and FIG. 4 B show the processed RNA-seq data, showing that samples cluster based on activation status and by cell type. Donor 4 (AKI4) was identified as an outlier, as it clustered differently than the others, and was removed from remaining analysis.
  • the transcript expression data from RNA-seq experiments on the 90 genes cited in the Roth, T. L. et al. paper was correlated to transcript expression data in Roth, T. L. et al. paper. (See FIG. 5 A and FIG. 5 B ).
  • FIG. 6 shows the process ATAC-seq data, which focused on the 10 kb area around the transcription start site (TSS). Again, donor 4 (AK14) was identified as an outlier, based on expression profile in both CD4 and CD8 cells, and was removed from remaining analysis. The results of the remaining ATAC-seq analysis are shown in FIGS. 7 A- 8 . The data in FIG. 7 A for TSS enrichment scores also indicated that all libraries were high quality. The data on open chromatin regions around the TRAC locus revealed the highest signal near exon 3 rather than exon 1 ( FIG. 8 ).
  • the K1 efficiency results (obtained using the model described infra) based on the 5 donors, 2 gRNA, and 2 replicates/gRNAs from the Roth, T. L. et al. paper are shown in FIG. 9 and FIG. 10 .
  • FIG. 11 shows KI efficiency versus day 2 (d2) RNA-seq data, day 4 (d4) RNA seq data, and d2 ATAC data.
  • the linear model was applied to remaining candidate genes to estimate their KI efficiency.
  • the candidate coding loci were selected by first ranking all genes in the pooled data sets by predicted KI efficiency, using RNA-seq expression data from d2 (day 2).
  • the candidate loci also had to be accessible based on ATAC-seq data.
  • 16 well-characterized coding genes were selected as candidate genes. The knockout of these 16 would confer a benefit to the function of CART cells (e.g. B2M, CD5, SMAD2, PTPRC, CD3E).
  • An additional 12 coding genes with high predicted KI efficiency and no apparent essential function were selected as candidate genes. (See Table 2).
  • the inventors here started by looking in highly accessible regions of the genome (10 kb windows). The most accessible region overlapped with (i) annotated protein coding genes (>50% accessible regions), (ii) pseudogenes and noncoding RNAs ( ⁇ 20% accessible regions), and (iii) enhancer/regulatory regions ( ⁇ 20% accessible regions).
  • the candidate genes were required to be ⁇ 10 kb from the coding regions.
  • a few regions that overlapped with long intergenic noncoding RNAs (lincRNAs) but did not have apparent function in T cells were also considered.
  • FIG. 12 is a plot showing the normalized ATAQ SEQ data for a top candidate non-coding region.
  • FACS panel GFP, TCR, Zombie
  • RNA-seq data at d0, d2, and d4 (to determine stable expression)
  • ATAC-seq data at d2 (to identify activated cells).
  • the methods used for conducting the RNA-seq and ATAC-seq experiments are in Roth, T. L., et al. 2019. (Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561), which is herein incorporated by reference in its entirety.
  • Loci significance was calculated using robust rank aggregation, which was the methodology used for consistent ranking of loci among donors and time points.
  • Methods for conducting robust rank aggregation are known in the art. (See, for example, Kolde, R., et al. (2012). Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics (Oxford, England), 28(4), 573-580, the disclosure of which is herein incorporated by reference in its entirety).
  • FIGS. 13 A- 25 The results from the analysis of controls and experimental groups is shown in FIGS. 13 A- 25 .
  • the loci were ranked based on mean florescence intensity (MFI) of reporter gene, GFP, and KI efficiency.
  • FIG. 29 shows GFP MFI and KI efficiency for all significant loci having endogenous promoters.
  • the B2M locus reported the highest GFP MFI.
  • the TRAC locus was among the top 10 MFI.
  • the highest GFP MFI readings were reported in week 1 and reduced slightly in weeks 3 and 4.
  • the results also showed most top loci have more than 1 sgRNA.
  • the SOCS1 locus reported the highest KI efficiency. Overall, KI efficiency showed greater variation among donors than GFP MFI.
  • FIG. 30 shows GFP MFI and KI efficiency for all significant loci having exogenous promoters (e.g. EF1a promoters).
  • the TRAC locus reported the highest GFP MFI. There was comparable expression between weeks 3 and 4. The results also showed most top loci have more than 1 sgRNA.
  • the SOCS1 locus reported the highest KI efficiency. Overall, KI efficiency showed less variation when driven by the exogenous promoters than when driven by endogenous promoters.
  • FIGS. 31 A, 31 B, and 31 C show GFP MFI and KI efficiency for all significant loci having endogenous and exogenous (e.g., EF1a) promoters.
  • endogenous and exogenous (e.g., EF1a) promoters The results showed that expression driven by EF1a promoters is about 10 ⁇ higher than endogenous promoters ( FIG. 31 A ).
  • KI efficiency the SOCS1 locus reported the highest KI efficiency. At weeks 3 and 4, KI efficiency was higher when driven by the exogenous promoters than when driven by endogenous promoters.
  • TCR expression was measured following circuit cassette knock in of PrimeR (Prime Receptor (Myc)).
  • Myc denotes an N-terminal Myc epitope tag to facilate detection of surface expressed primer receptor.
  • CD3-CD28 Dynabead-activated T cells were electroporated with sgRNA/Cas9 RNPs targeting the indicated sites (see FIGS. 32 B and 33 A ), as well as HDRTs with homology arms directing HDR-mediated integration into the indicated sites.
  • sgRNA/Cas9 RNPs targeting the indicated sites (see FIGS. 32 B and 33 A ), as well as HDRTs with homology arms directing HDR-mediated integration into the indicated sites.
  • At day 6 post-electroporation cells were stained with anti-TCRalpha/beta and anti-myc antibodies and analyzed on an Attune NxT flow cytometer. As shown in FIG.
  • the TCR expression was maintained at GS94 and GS102 candidate integration (knock-in) sites. Only 2 ⁇ 3 of the cells that had circuit cassette knock in of PrimeR at GS79 (TRAC) locus maintained TCR expression. These results indicated that the GS94 and GS102 sites showed better potential for TCR stimulation.
  • the percentage of cells showing effective knock-in was 36% ⁇ 4% when using the GS94 integration site, as compared to 32% ⁇ 5% when using the TRAC integration site.
  • GS94 is a candidate integration site located on chromosome 11's distal q arm. It is within 180-350 kb of the promoters for ETS1 and FLI1 ( FIG. 33 B ), however that is considered low-risk for integration vector gene therapy. The circuit expression and function potential of the GS94 gene was evaluated.
  • T cells underwent circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site.
  • the cells were cocultured with K562 C19 cells for 48 hours and then the PrimeR induced CAR MFI was compared to the PrimeR MFI.
  • T cells generated as described in the Example above were cocultured with K562 CD19+/MSLN ⁇ cells at day 7 post-electroporation.
  • MSLN (mesothelin) is a gene that is overexpressed in human pancreatic cancer.
  • Cells were then stained with anti-FLAG antibody 48 h post initiation of coculture and analyzed on an Attune NxT flow cytometer.
  • GS94 resulted in prime antigen-dependent CAR expression that was approximately two-fold higher than the expression in several other candidate integration sites as well as the TRAC integration site. Additionally, on average, the prime receptor surface expression level was no less than 50% of expression level when using the TRAC integration site.
  • T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site were cocultured with K562 C19/MSLN cells for 48 hours.
  • MSLN is a gene that is overexpressed in human pancreatic cancer.
  • the cells were treated at a 1:1 effector:target cell ratio (1:1 E:T)).
  • T cells generated as described above were cocultured with K562 CD19+/MSLN+ cells at day 7 post-electroporation. 48 h post initiation of coculture, supernatants were collected and analyzed via Luminex® for cytokine levels.
  • the cytokines measure were IL-2, INFg, and TNF. Cytotoxicity was analyzed by measuring luciferase activity of remaining target cells after 48 h. Each of the data points in FIG. 34 B represent two replicates and the lines represent the range of cytotoxicity for the replicates. As shown in FIG. 34 B , the GS94 integration sites resulted in superior cycotoxic ability and cytokine secretion following the 48-hour coculture with K562 C19/MSLN cells.
  • T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site were cocultured with K562 CD19+/MSLN+ cells or K562 CD19 ⁇ /MSLN+ cells (“K562 MSLN”) at day 7 post-electroporation for 48 hours. 0.3, 1.0, and 3.0 E:T cell ratios were tested. See FIG. 35 A and FIG. 35 B .
  • cytotoxicity was analyzed by measuring luciferase activity of remaining target cells
  • the GS94 integration site resulted in equivalent cytotoxic potential to the TRAC integration site and there was no prime-independent cytotoxicity.
  • a group that had target cells only (E:T 0; Targets only) was compared to a group with an E:T cell ratio of 1.
  • supernatant was collected and analyzed via Luminex® for cytokine levels to measure secretion of IL-2, INFg and TNF cytokines. See FIG. 36 A and FIG. 36 B .
  • the GS94 integration site resulted in equivalent cytokine secretion to the TRAC integration site and there was no prime-independent secretion of IL-2, INFg or TNF.
  • T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site, GS94 integration site, and GS102 integration site were cultured in vitro for 32 days.
  • the cells were treated with repetitive CD3/CD28 stimulation at days 5, 12, 19 and 28 of the experiment.
  • the cells were evaluated for CAR expression using a flow cytometry assay.
  • T cell activation through TCR did not result in prime R-independent CAR expression from circuit cassette integration at the candidate integration sites.
  • T cells generated as described above were cultured in 96-well plates, with T cell growth medium being exchanged every 2 days. At days 5, 12, 19 and 28, T cells were stimulated with 1:1 CD3/CD28 Dynabeads. Cells were analyzed for PrimeR expression by myc epitope tag staining, and for CAR expression by FLAG epitope tag staining at the indicated time points. Flow analysis was performed on an Attune NxT flow cytometer.
  • T cells that had undergone circuit cassette integration with PrimeR at the integration sites indicated in FIG. 38 were cultured in vitro for 32 days. Briefly, T cells generated as described above were cultured in 96-well plates, with T cell growth medium being exchanged every 2 days. At days 5, 12, 19 and 28, T cells were stimulated with 1:1 CD3/CD28 Dynabeads repetitive stimulation. Flow cytometry assays were run on days 16 and 32 using an Attune NxT flow cytometer. The cells were analyzed for PrimeR expression by myc epitope tag staining. As shown in FIGS. 38 A and 38 B , the GS94 integration site resulted in stable PrimeR expression over at least a 4-week period.
  • iGUIDE-Seq assay was used.
  • the methods used for conducting the iGUIDE-Seq assay are illustrated in FIG. 39 A and provided in Nobles et al., Genome Biology (2019), which is hereby incorporated by reference in its entirety.
  • FIG. 39 B the GS94 integration site had the highest on-target editing efficiency of the evaluated candidate integration sites.
  • FIG. 39 C GS94 resulted in no putative off-target editing as observed with two donors.
  • Elevation prediction Computational predictions of potential off-target sites from (gs94) were performed using Elevation-search (algorithm described in Listberg et al. 2018. Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nat Biomed Engr 2, 37-48; software obtained from github.com/Microsoft/Elevation). All sites identified by Elevation-search were subjected to analysis using rhAmp-segTM.
  • rhAmpSegTM 49 candidate off-target sites for GS94 identified by iGUIDE or the Elevation prediction algorithm and the GS94 target site were characterized by rhAmpSegTM (Integrated DNA Technologies, Inc.). This targeted amplification enables NGS-based quantification of the editing occurring at numerous sites simultaneously. Genomic DNA from T cells from at least 2 donors that had been treated singly with each of the following 7 guides: GS84, GS94, GS95, GS96, GS102, GS108, and GS138 was isolated with the GenFind® V3 DNA purification system (Beckman Coulter).
  • rhAmpSegTM amplification pools Two separate rhAmpSegTM amplification pools were used to cover the 50 loci, the procedure was performed as recommended by Integrated DNA Technologies for each of the samples.
  • the rhAmpSegTM libraries were sequenced on a MiniSegTM with a Mid Output Kit (300-cycles) (Illumina).
  • the CRISPResso2 algorithm (github.com/pinellolab/CRISPResso2) was used to determine the percentage of insertions and deletions at each of the amplified loci.
  • Statistical significance FDR-adjusted p-value ⁇ 0.001 using a chi-squared test was only observed at the GS94 site.
  • RNA-seq To evaluate changes induced by GS94 integration at the transcriptional level, a CD19/MSLN circuit was integrated at the GS79 (TRAC), GS94, and GS102 integration sites. On day 6 post-integration, 1e6 edited cells were sorted using a BD FACSAria based on transgene expression. RNA was isolated from sorted T cells with the RNeasy kit (Qiagen). Purified RNA was converted into an NGS library using the TruSeqTM RNA Library Prep Kit v2 (Illumina). Libraries were sequenced on either the NovaSeqTM 6000 or NextSeqTM 550 instruments (Illumina). The STAR 2.7.3a aligner (Dobin A. et al.
  • Cytokine-independent growth assay To evaluate the safety of the primary T cells with GS94 locus KI, cytokine-independent growth assay was performed to evaluate the potential for oncogenic transformation. Briefly, primary human T cells that had undergone CD19/MSLN circuit cassette integration at GS94 locus were thawed and recovered overnight. 1 ⁇ 10 6 cells were then seeded in one well of a 24 well-GRex plate, culturing for 5 days in the medium with or without cytokines. Cell number and viability were recorded at days 0, 3 and 5. As a positive control, 1 ⁇ 10 6 Jurkat cells were cultured in the medium without cytokines in parallel. As shown in FIG.
  • CRISPR reagents e.g. SpCas9 complexed with sgRNA
  • GS94-targeting CRISPR RNP showed the highest percentage of iGUIDE-seq oligo cassette trapping events of all candidates evaluated, and the control sgRNA sequences from the iGUIDE-seq paper showed similar specificities to what was reported in the original publication, suggesting that the assay performed as expected.
  • Putative off-target sites were taken from the iGUIDE-seq output, which already suggested that the putative sites were spurious. Additional target sites were predicted by a computational approach (Elevation software package). rhAmp-segTM was used to prepare high-throughput sequencing libraries for each of the putative off-target sites, and the method was applied to DNA samples from T cells electroporated with CRISPR RNPs targeting the candidate target sites. The resulting NGS data were processed with CRISPResso2 software, and the frequency of insertions and deletions (indels) was taken as indication of CRISPR cleavage activity, as is common in the field.
  • indels frequency of insertions and deletions
  • T cells electroporated with GS94-targeting CRISPR RNP showed no greater frequency of indels at the set of putative off-target sites than T cells treated with CRISPR RNP targeting other sites, consistent with the GS94-targeting CRISPR RNP having no consequential or detectable off-target activity, and therefore being the most specific out of the set evaluated ( FIG. 41 ).
  • RNA-seq libraries were prepared and sequenced, and analysis of the resulting Illumina sequencing data revealed no biologically or statistically significant differences in expression of any genes within 300 kb of the GS94 site in cells with integrations at GS94 compared to cells with integration at TRAC or the GS102 sites ( FIG. 42 ). Furthermore, other gene expression differences that reached statistical significance were minimal in number and in effect size, consistent with them being noise in the comparison.
  • transgene integration at GS94 could confer a transformed phenotype
  • cells with integrations at the GS94 site were cultured with and without cytokines in vitro. Cells remained alive and viable with cytokine addition, but died without cytokine supplementation and lost their viability ( FIG. 43 ). The positive control Jurkat cells remained viable and proliferated. Overall, this indicates that integration of a transgene at GS94 does not confer capacity for cytokine-independent growth, which is a hallmark of T cell transformation.
  • T cells In vivo efficacy of T cells with a transgene cassette expressing a CAR recognizing a tumor antigen, or a CAR recognizing a tumor antigen under control of a priming receptor recognizing an antigen in the anatomical vicinity of the tumor, is assessed against human tumor cells such as K562 engineered to express the CAR antigen or to express antigens recognized by both the priming receptor and the CAR.
  • Tumor cells e.g. 1e6
  • Tumor growth is assessed by dimensional measurement by calipers every 2-4 days.
  • mice are intravenously injected with 5e6 T cells with a CAR or prime-CAR circuit cassette integrated at a specific site by CRISPR-mediated insertion, or with T cells engineered with CRISPR RNP alone, or with PBS alone as a sham injection. Tumor growth is monitored and mice are euthanized when tumor volume reaches 2000 cubic mm. Peripheral blood is bled from mice through a retro-orbital procedure, and flow cytometry and/or ddPCR is used to observe engineered T cell expansion over time.
  • spleen, blood, tumor and/or other tissue is analyzed via flow cytometry, ddPCR, and/or immunohistochemistry for the presence of engineered T cells.
  • the results demonstrate that T cells engineered with cassette integration at one of the defined genomic loci lead to tumor regression and clearance in injected mice as compared to T cells without cassette integration, and that engineered T cells are detectable in the peripheral blood and tissues of injected mice.
  • sgRNA_ summarized start_ sgRNA Integra- from 2 sgRNA coor Target tion donors, 2 ID sgRNA Sequence GRCH38 Loci Site primersets sgRNA_ GCACCTGAATACCACGCCTG chr16: APRT APRT 79.28 1 (SEQ ID NO: 1) 88811818 sgRNA_ CGCCTGCGATGTAGTCGATG chr16: APRT APRT 78.60 2 (SEQ ID NO: 2) 88811551 sgRNA_ CAGGACGGGCGAGATGTCCC chr16: APRT APRT 85.25 3 (SEQ ID NO: 3) 88811640 sgRNA_ CTGAATCTTTGGAGTACCTG chr15: B2M B2M 78.51 4 (SEQ ID NO: 4) 44715425 sgRNA_

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein are safe harbor loci and methods for identifying and using safe harbor loci to engineer cells to express transgenes. The safe harbor loci exhibit increased transgene knock-in efficiency and allow for increased, stable expression of transgenes in engineered cells. Guide ribonucleic acids (gRNAs) may be used for insertion of transgenes in the safe harbor loci.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 17/716,816 filed Apr. 8, 2022, allowed, which is a divisional of U.S. application Ser. No. 17/239,484 filed Apr. 23, 2021, allowed, which claims priority to and the benefit of U.S. Provisional Patent Application No. 63/141,926, filed on Jan. 26, 2021, and U.S. Provisional Patent Application No. 63/105,834, filed on Oct. 26, 2020, the entire contents of which are incorporated by reference herein for all purposes.
  • SEQUENCE LISTING
  • The instant application contains a Sequence Listing which will be submitted via Patent Center and is hereby incorporated by reference in its entirety. Said XML copy, created on Aug. 29, 2023, is named ANB-203D2_SL.xml and is 845,305 bytes in size.
  • BACKGROUND
  • Cancer continues to present a significant clinical burdSen despite the substantial research efforts and scientific advances in cancer therapies. Blood and bone marrow cancers are frequently diagnosed cancer types, including multiple myelomas, leukemia, and lymphomas. Current treatment options for these cancers are not effective for all patients and/or can have substantial adverse side effects. Other types of cancer also remain challenging to treat using existing therapeutic options. Cancer immunotherapies are a promising solution because they can be highly specific, allowing for increased therapeutic effectiveness and the mitigation of side effects.
  • Genetically engineered immune cell therapy is a growing field with promising applications for the treatment of diseases including, but not limited to, cancer. Through the alteration of coding and/or non-coding genomic regions, researchers are identifying transgenes and insertion sites within cells that facilitate, for example, enhanced cell function, arrest cell growth, induced cell death, and tumor size/volume reduction. The identification of safe harbor sites (SHS) has improved outcomes of genome-engineering therapies. Well known SHS include the AAVS1 adeno-associated virus insertion site on chromosome 19, the human homolog of the murine Rosa26 locus, and the CCR5 chemokine receptor gene—the absence of which confers HIV resistance. (See, for example, Pellenz et al., 2018, the relevant disclosures of which are herein incorporated by reference). However, there is still a need for improved guidelines for gene editing therapies and additional SHS to address challenges such as poor knock-in (KI) efficiency, insertional oncogenesis, unstable and/or anomalous expression of transgenes and/or adjacent genes, etc.
  • SUMMARY
  • The present disclosure is directed, inter alia, to safe harbor loci that exhibit high knock-in efficiency and stable expression of their transgenes. These safe harbor loci can be used to alter T cells for immunotherapy. These safe harbor loci are useful for the treatment of various diseases, including cancer.
  • In one aspect, the present disclosure provides an engineered cell, comprising at least one sequence encoding a transgene, wherein the at least one sequence is inserted within a safe harbor locus, the safe harbor locus is at any one or more of the sgRNA target loci provided in Table 4; and wherein expression of the at least one sequence encoding the transgene is operatively linked to an endogenous promoter. In another aspect, the present disclosure provides an engineered cell, comprising at least one sequence encoding a transgene, wherein the at least one sequence is inserted within a safe harbor locus, the safe harbor locus is at any one or more of the sgRNA target loci provided in Table 4; and wherein expression of the at least one sequence encoding the transgene is operatively linked to an exogenous promoter.
  • In some embodiments, the target locus is selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, and chr9:7970000-7980000. In some embodiments, the target locus is selected from: chr10:72290000-72300000, chr11:128340000-128350000, chr15:92830000-92840000, and chr16:11220000-11230000. In some embodiments, the target locus is chr11:128340000-128350000. In some embodiments, the target locus is chr15:92830000-92840000. In some embodiments, the target locus is a gene selected from: APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.
  • In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, GS120. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, and GS93.
  • In some embodiments, the exogenous promoter is an EF1a promoter. In some embodiments, the engineered cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or a T cell progenitor. In some embodiments, the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR).
  • In another aspect, the present disclosure provides a composition comprising the engineered cell as described herein and a pharmaceutical excipient.
  • In another aspect, the present disclosure provides a guide ribonucleic acids (gRNA) for editing a cell at a safe harbor locus, wherein gRNA comprises any one of the sgRNA sequences in Table 4.
  • In some embodiments, the gRNA comprises any one of SEQ ID NOS:1-120. In some embodiments, the gRNA comprises any one of SEQ ID NOS: 91-96 and 100-105. In some embodiments, the gRNA comprises SEQ ID NO:94 or SEQ ID NO:102. In some embodiments, the gRNA comprises SEQ ID NO:94. In some embodiments, the gRNA comprises SEQ ID NO:102. In some embodiments, the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or a T cell progenitor.
  • In another aspect, the present disclosure provides a method of editing a cell having chromosomal DNA, comprising inserting at least one sequence encoding a transgene within a safe harbor locus in the chromosomal DNA of the cell, wherein the safe harbor locus is any one or more of the sgRNA target loci provided in Table 4.
  • In some embodiments, the target locus is selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, and chr9:7970000-7980000. In some embodiments, the target locus is selected from: chr10:72290000-72300000, chr11:128340000-128350000, chr15:92830000-92840000, and chr16:11220000-11230000. In some embodiments, the target locus is chr11:128340000-128350000. In some embodiments, the target locus is chr15:92830000-92840000. In some embodiments, the target locus is a gene selected from: APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.
  • In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, GS120. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, and GS93.
  • In some embodiments, the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR). In some embodiments, the at least one sequence comprises an exogenous promoter and the exogenous promoter is operably linked to the transgene. In some embodiments, the exogenous promoter is an EF1a promoter. In some embodiments, the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or T cell progenitor. In some embodiments, the at least one sequence is inserted using a homology-directed repair. In some embodiments, the at least one sequence is inserted using a homology independent targeted insertion. In some embodiments, the at least one sequence is inserted using one or more guide ribonucleic acids (gRNAs) and one or more Cas9 endonucleases.
  • In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 1-120. In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 91-96 and 100-105. In some embodiments, the gRNA comprises SEQ ID NO:94 or SEQ ID NO:102. In some embodiments, the gRNA comprises SEQ ID NO:94. In some embodiments, the gRNA comprises SEQ ID NO:102.
  • In another aspect, the present disclosure provides a method of editing a T cell, comprising contacting a T cell with one or more guide ribonucleic acids (gRNAs), at least one sequence encoding a transgene, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of the at least one sequence into chromosomal DNA within a safe harbor locus, wherein the safe harbor locus is selected from any one or more of the sgRNA target loci in Table 4.
  • In some embodiments, the one or more gRNAs comprises a sequence selected from any one of the sgRNA sequences in Table 4. In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 1-120. In some embodiments, the one or more gRNAs comprises any one of SEQ ID NOS: 91-96 and 100-105. In some embodiments, the gRNA comprises SEQ ID NO:94 or SEQ ID NO:102. In some embodiments, the gRNA comprises SEQ ID NO:94. In some embodiments, the gRNA comprises SEQ ID NO:102.
  • In some embodiments, the target locus is selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, and chr9:7970000-7980000. In some embodiments, the target locus is selected from: chr10:72290000-72300000, chr11:128340000-128350000, chr15:92830000-92840000, and chr16:11220000-11230000. In some embodiments, the target locus is chr11:128340000-128350000. In some embodiments, the target locus is chr15:92830000-92840000. In some embodiments, the target locus is a gene selected from: APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.
  • In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, GS120. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4 designated: GS91, GS92, and GS93
  • In another aspect, the present disclosure provides an ex vivo method of obtaining an engineered cell or population thereof, comprising (a) obtaining a cell; and (b) genetically modifying the cell by inserting at least one sequence encoding a transgene within a safe harbor locus, wherein the safe harbor locus is selected from any one of the sgRNA target loci in Table 4.
  • In some embodiments, obtaining the cell comprises: (i) collecting a tissue sample from a subject, (ii) isolating the cells from the tissue samples, and (iii) culturing the cells in vitro. In some embodiments, the tissue sample is a blood sample. In some embodiments, the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or T cell precursor. In some embodiments, the at least one sequence is inserted using a homology-directed repair. In some embodiments, the at least one sequence is inserted using a homology independent targeted insertion.
  • In some embodiments, the genetically modifying in step (b) comprises contacting the cell with one or more guide ribonucleic acids (gRNAs), the at least one sequence, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of the at least one sequence into chromosomal DNA within the safe harbor locus. In some embodiments, the one or more gRNAs comprises a sequence selected from any one of the sgRNA sequences in Table 4.
  • In some embodiments, the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR). In some embodiments, the at least one sequence comprises an exogenous promoter and the exogenous promoter is operably linked to the transgene. In some embodiments, the exogenous promoter is an EF1a promoter.
  • In yet another aspect, the present disclosure provides a method of treating a subject having or at risk of having a disease, comprising administering to the subject an effective amount of an engineered cell as described herein, a population thereof, or a composition as described herein. In some embodiments, the cell, the population thereof, or the composition is administered to the subject by infusion.
  • In yet another aspect, the present disclosure provides a method of treating a subject having or at risk of having a disease, comprising (a) conducting any one of the methods described supra; and (b) administering to the subject an effective amount of a composition comprising the cell or a population thereof. In some embodiments, the composition is administered to the subject by infusion. In some embodiments, the disease is cancer. In some embodiments, the disease is blood cancer.
  • In another aspect, the present disclosure provides a method of identifying a safe harbor locus, comprising: (a) identifying genes or non-coding regions in a chromosome that are above a threshold level for expression across developmental cell states and/or a threshold level for accessibility of chromatin; (b) generating a linear model that correlates the gene or non-coding region from step (a) with knock-in (KI) efficiency and estimates the KI efficiency of any gene or coding region on the chromosome; and (c) selecting the safe harbor locus based on threshold parameters; wherein the safe harbor locus is selected for insertion of at least one sequence encoding a transgene within a cell.
  • In some embodiments, the threshold parameters include one or more of: stable expression of a transgene, knockout of the gene confers benefit to the function of the cell, no known function within the cell, stable transgene expression in vitro with or without CD3/CD28 stimulation, negligible off-target cleavage as detected by iGuide-Seq or CRISPR-Seq, less off-target cleavage relative to other loci as detected by iGuide-Seq or CRISPR-Seq, negligible transgene-independent cytotoxicity, negligible transgene-independent cytokine expression, negligible transgene-independent chimeric antigen receptor expression, negligible deregulation or silencing of nearby genes, and positioned outside of a cancer-related gene. In some embodiments, the stable expression of a transgene at the safe harbor locus is less than or equal to 2-fold expression change over the course of at least 1, 2, 3, 4, 5, 6, or 7 days, and wherein expression change is measured by mean fluorescence intensity of a reporter gene encoded by the at least one sequence. In some embodiments, the accessibility of chromatin is measured using an assay for transposase-accessible chromatin using sequencing (ATAC-seq). In some embodiments, the level of expression across developmental cell states is measured using RNA sequencing (RNA-seq).
  • In some embodiments, the cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or T cell precursor. In some embodiments, the linear model has a coefficient of determination (R2 value) of at least 30%.
  • In yet another aspect, the present disclosure provides an engineered cell, composition, gRNA or method as described herein, wherein insertion within the safe harbor locus increase cell cytotoxicity of diseased cells.
  • In yet another aspect, the present disclosure provides an engineered cell, composition, gRNA or method as described herein, wherein knock-in efficiency at the safe harbor locus is increased relative to other locations along the chromosome.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawings, where:
  • FIG. 1 includes a schematic depicting the methodology used to identify safe harbor loci in the present disclosure, in some embodiments.
  • FIGS. 2A-2C include schematic depicting 3 top safe harbor loci known in the art: AAVS1 (FIG. 2A), CCR5 (FIG. 2B), and Rosa26 (FIG. 2C). The figures were retrieved from Sadelain, M., et al. (2012). Safe harbours for the integration of new DNA in the human genome. Nature reviews Cancer, 12(1), 51-58, the relevant disclosures of which are herein incorporated by reference in their entirety.
  • FIG. 3 includes a schematic outlining the data provided in Roth, T. L., et al. 2019. Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561, the relevant disclosures of which are herein incorporated by reference in their entirety.
  • FIGS. 4A-4B include heatmaps with samples clustered based on activation status and cell type, generated with processed RNA-seq data. FIG. 4A includes a heatmap of samples generated with processed RNA-seq data. FIG. 4B includes a heatmap sample generated with processed RNA-seq data, showing the clustering of ˜20 k genes.
  • FIGS. 5A-5B include plots generated using processed RNA-seq data. FIG. 5A includes a plot showing direct correlation between transcript expression data from Roth, T. L., et al. 2019 and transcript expression data generated by the inventors of the present disclosure. FIG. 5B includes a heatmap showing clusters of the top 10% expressed genes.
  • FIG. 6 includes a heatmap of samples generated with processed ATAC-seq data.
  • FIGS. 7A-7B includes plots depicting the signal enrichment at transcription start sites (TSS) (FIG. 7A) and peak size distribution (FIG. 7B), generated with processed ATAC-seq data for coding regions.
  • FIG. 8 includes a plot depicting the open chromatin regions around the TRAC locus.
  • FIG. 9 includes a plot depicting KI (knock-in) efficiency for coding regions/genes with GFP as a reporter.
  • FIG. 10 includes a plot depicting KI efficiency for coding regions/genes with tNGFR as a reporter.
  • FIG. 11 includes plots showing scaled KI efficiency for 90 genes vs d2 (day-2) RNA-seq data, d4 (day-4) RNA-seq data and ATAC-seq data, utilized for the predictive linear model.
  • FIG. 12 includes a plot showing chromatin accessibility for a top candidate non-coding region, measured using ATAQ sequencing.
  • FIG. 13A includes plots showing the cell counts for GFP controls used for the evaluation of candidate KI loci. FIG. 13B includes pmax (GFP_high) readings for GFP controls used for the evaluation of candidate KI loci.
  • FIG. 14A includes plots showing the maximum episomal GFP expression (GFP_high) readings for non-targeting controls. FIG. 14B includes the cell count for non-targeting controls from donors 1, 2, and 3.
  • FIG. 15 includes the cell count and maximum GFP expression (GFP_high) readings for WT controls.
  • FIG. 16 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA5, which targets a B2M safe harbor locus, and the construct expression was driven by an endogenous promoter.
  • FIG. 17 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA5, which targets a B2M safe harbor locus, and the construct expression was driven by an EF1a promoter.
  • FIG. 18 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA79 to target a TRAC safe harbor locus, and the construct expression was driven by an endogenous promoter.
  • FIG. 19 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA79, which targets a TRAC safe harbor locus, and the construct expression was driven by an exogenous promoter.
  • FIG. 20 includes plots showing TCR (T cell receptor) vs. GFP among all donors and time points when using sgRNA79, and the construct is driven by an endogenous promoter.
  • FIG. 21 includes plots showing TCR vs. GFP among all donors and time points when using sgRNA79 and the construct is driven by an exogenous promoter.
  • FIG. 22 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA83, which targets a TRAC safe harbor locus, and the construct expression was driven by an endogenous promoter.
  • FIG. 23 includes plots showing the cell count and maximum GFP expression (GFP_high) readings when using sgRNA83, which targets a TRAC safe harbor locus, and the construct expression was driven by an exogenous promoter.
  • FIG. 24 includes plots showing TCR vs. GFP among all donors and time points when using sgRNA83 and the construct is driven by an endogenous promoter.
  • FIG. 25 includes plots showing TCR vs. GFP among all donors and time points when using sgRNA83 and the construct is driven by an exogenous promoter.
  • FIG. 26 includes plots illustrating potential sources of variation (e.g., edge effects and electroporation errors) observed between replicates and donors.
  • FIG. 27 includes plots illustrating potential sources of variation observed between replicates and donors, e.g., relating to inherent differences between donors.
  • FIG. 28 includes plots illustrating potential sources of variation observed between replicates and donors, e.g., relating to gating errors.
  • FIG. 29 includes plots showing the GFP mean fluorescence intensity (GFP MFI) and KI efficiency for top KI loci evaluated with endogenous promoters.
  • FIG. 30 includes plots showing the GFP mean fluorescence intensity (GFP MFI) and KI efficiency for top KI loci evaluated with the EF1a promoter.
  • FIGS. 31A-31C include plots showing all the significant KI loci (top KI loci) as evaluated with endogenous and EF1a promoters. FIG. 31A includes a plot showing that the expression from the EF1a promoter was approximately 10 times higher than expression from an endogenous promoter. FIG. 31B shows the top KI loci ranked by GFP MFI at week 3. FIG. 31C shows the top integration loci ranked by GFP MFI (at weeks 3 and 4; donors 1-3).
  • FIG. 32A includes a plot showing some target loci and their measured transgene expression levels. FIG. 32B includes plots showing the transgene (Prime Receptor (PrimeR)) and TCR expression for the control and insertion at GS94, GS102 and TRAC loci.
  • FIG. 33A includes a plot showing the PrimeR levels measured for the indicated integration sites. FIG. 33B includes a schematic showing the GS94 integration site on Chromosome 11.
  • FIG. 34A includes plots showing CAR induction and primeR expression of engineered T cells after 48 hours of coculturing with K562-CD19 cells. FIG. 34B includes plots showing the cytotoxity and cytokine secretion levels for engineered T cells 48 hours of coculturing with K562-CD19/MSLN cells.
  • FIG. 35A includes a schematic showing the experimental overview for evaluating the effect of integration site on cytotoxicity. FIG. 35B includes plots showing the measured cytotoxicity for engineered T cells cocultured for 48 hours with the K562 CD19+/MSLN+ or K562 CD19−/MSLN+ cells.
  • FIG. 36A includes a schematic showing the experimental overview for evaluating the effect of integration site on cytokine secretion. FIG. 36B includes plots showing the measured cytokine levels for engineered T cells cocultured for 48 hours with K562 CD19+/MSLN+ cells.
  • FIG. 37 includes a schematic showing the in vitro experiment conducted to determin the effect of integration site on primeR-independent CAR expression. “Flow” refers to flow cytometry and “restim” refers to repetitive CD3/CD28 stimulation of the engineered T cells. “EP” refers to electroporation.
  • FIGS. 38A and 38B include plots showing the stability of PrimeR expression over time when using the indicated integration sites. “Flow” refers to flow cytometry and “restim” refers to repetitive CD3/CD28 stimualation of the engineered T cells. “EP” refers to electroporation. In FIG. 38B, the PrimeR expression is normalized to the expression from using the TRAC integration site.
  • FIG. 39A includes a schematic showing the iGuide-Seq assay technique. FIG. 39B includes a plot showing the on-target efficiency, using iGuide Seq assay, for the indicated integration sites. FIG. 39C includes schematics from the iGuide-Seq analysis showing that GS94 had no reproducible putatitve off-targets across two donors FIG. 39C discloses SEQ ID NOS 312-322, 312-313, and 323-331, respectively, in order of appearance.
  • FIG. 40 includes a schematic showing the iGuide-Seq workflow and data.
  • FIG. 41 includes a plot showing rhAmp-seg™ analysis of putative off-target sites identified by iGUIDE-seq and Elevation prediction.
  • FIG. 42 includes plots showing RNA-seq analysis of cells with GS94, GS102 and TRAC knock-in of CD19/MSLN circuits. Scatterplot of gene expression in cells with integration at the GS94 locus (y-axis) vs cells with integration at either the TRAC or the GS102 locus (x-axis) in two donors. The yellow dots correspond to ETS1 and FLI1. In blue are the genes that were found to be differentially expressed using edgeR (fold-change >0, FDR-corrected p-value <0.01, average counts-per-million across compared conditions at least 2).
  • FIG. 43 includes plots showing the absence of cytokine-independent growth in cells with CD19/MSLN circuit KI at GS94.
  • DETAILED DESCRIPTION
  • The present disclosure provides safe harbor loci and methods for identifying safe harbor loci that exhibit high integration efficiency (e.g., high knock-in (KI) efficiency), high and constant levels of transgene expression, and such benefits independent of T cell activation/differentiation state. In some embodiments, the safe harbor loci also exhibit minimal to no disruption to T cell function and/or capacity for product manufacturing. In some embodiments, these loci are useful for effective and safe integration and expression of transgenes in T cells (e.g. in CAR T therapies). In some embodiments, the methods described herein can be used for the identification of safe harbor loci for insertion of transgenes in other types of cells.
  • FIG. 1 illustrates the overall approach that the inventors of the present disclosure used to identify safe harbor loci. In some embodiments, the present disclosure provides a method comprising the identification of genes within a genome and non-coding regions with sustained expression in a treatment cell (e.g. T cell) and using a predictive model of KI efficiency as a function of T cell chromatic state and computational analysis to predict candidate integration sites. The method further comprises evaluating the candidate integration sites for actual KI efficiency, sustained levels of transgene expression of a transgene, and minimal disruption to the treatment cell phenotype (e.g., T cell function and/or capacity for treatment product expansion and manufacturing). In some embodiments, the safe harbor loci allow for integration of a transgene driven by an endogenous promoter. In some embodiments, the safe harbor loci allow for integration of a transgene driven by an exogenous promoter (e.g. EF1a promoter).
  • To facilitate an understanding of the present disclosure, a number of terms and phrases are defined below. Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of pharmacology, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, genetics and protein and nucleic acid chemistry, described herein, are those well-known and commonly used in the art. In case of conflict, the present specification, including definitions, will control.
  • Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 4th ed. (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.
  • As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise. The terms “include,” “such as,” and the like are intended to convey inclusion without limitation, unless otherwise specifically indicated.
  • As used herein, the term “comprising” also specifically includes embodiments “consisting of” and “consisting essentially of” the recited elements, unless specifically indicated otherwise.
  • The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ±10%, ±5%, or ±1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s) ±one standard deviation of that value(s).
  • As used herein, the term “gene” refers to the basic unit of heredity, consisting of a segment of DNA arranged along a chromosome, which codes for a specific protein or segment of protein. A gene typically includes a promoter, a 5′ untranslated region, one or more coding sequences (exons), optionally introns, a 3′ untranslated region. The gene may further comprise a terminator, enhancers and/or silencers.
  • As used herein, the term “locus” refers to a specific, fixed physical location on a chromosome where a gene or genetic marker is located.
  • As used herein, the term “target locus” refers to a locus on a chromosome within which a safe harbor locus can be used for the insertion of a sequence. A target locus can consist of multiple potential safe harbor loci (integration sites). Examples of target loci are provided in Table 4, as sgRNA target loci. The notation used for the sgRNA target loci in Table 4 refers to the genomic region of the target locus, defined by the chromosome of the target locus and the coordinate range for that target locus. For example, chr10:33130000-33140000 refers to a target locus on Chr10 (chromosome 10) starting from coordinate 33130000 and ending with coordinate 33140000.
  • The term “safe harbor locus” refers to a locus at which genes or genetic elements can be incorporated without disruption to expression or regulation of adjacent genes. These safe harbor loci are also referred to as safe harbor sites (SHS). As used herein, a safe harbor locus refers to an “integration site” or “knock-in site” at which a sequence encoding a transgene, as defined herein, can be inserted. In some embodiments the insertion occurs with replacement of a sequence that is located at the integration site. In some embodiments, the insertion occurs without replacement of a sequence at the integration site. Examples of integration sites contemplated are provided in Table 4.
  • As used herein, the term “insert” refers to a nucleotide sequence that is integrated (inserted) at a safe harbor site. The insert can be used to refer to the genes or genetic elements that are incorporated at the safe harbor site using, for example, homology-directed repair (HDR) CRISPR/Cas9 genome-editing or other methods for inserting nucleotide sequences into a genomic region known to those of ordinary skill in the art.
  • The “CRISPR/Cas” system refers to a widespread class of bacterial systems for defense against foreign nucleic acid. CRISPR/Cas systems are found in a wide range of eubacterial and archaeal organisms. CRISPR/Cas systems include type I, II, and III sub-types. Wild-type type II CRISPR/Cas systems utilize an RNA-mediated nuclease, Cas9 in complex with guide and activating RNA to recognize and cleave foreign nucleic acid. Guide RNAs having the activity of both a guide RNA and an activating RNA are also known in the art. In some cases, such dual activity guide RNAs are referred to as a small guide RNA (sgRNA).
  • Cas9 homologs are found in a wide variety of eubacteria, including, but not limited to bacteria of the following taxonomic groups: Actinobacteria, Aquificae, Bacteroidetes-Chlorobi, Chlamydiae-Verrucomicrobia, Chlroflexi, Cyanobacteria, Firmicutes, Proteobacteria, Spirochaetes, and Thermotogae. An exemplary Cas9 protein is the Streptococcus pyogenes Cas9 protein. Additional Cas9 proteins and homologs thereof are described in, e.g., Chylinksi, et al., RNA Biol. 2013 May 1; 10(5): 726-737; Nat. Rev. Microbiol. 2011 June; 9(6): 467-477; Hou, et al., Proc Natl Acad Sci USA. 2013 Sep. 24; 110(39):15644-9; Sampson et al., Nature. 2013 May 9; 497(7448):254-7; and Jinek, et al., Science. 2012 Aug. 17; 337(6096):816-21. The Cas9 nuclease domain can be optimized for efficient activity or enhanced stability in the host cell.
  • As used herein, the term “Cas9” refers to an RNA-mediated nuclease (e.g., of bacterial or archeal orgin, or derived therefrom). Exemplary RNA-mediated nuclases include the foregoing Cas9 proteins and homologs thereof, and include but are not limited to, CPF1 (See, e.g., Zetsche et al., Cell, Volume 163, Issue 3, p 759-771, 22 Oct. 2015). Similarly, as used herein, the term “Cas9 ribonucleoprotein” complex and the like refers to a complex between the Cas9 protein, and a crRNA (e.g., guide RNA or small guide RNA), the Cas9 protein and a trans-activating crRNA (tracrRNA), the Cas9 protein and a small guide RNA, or a combination thereof (e.g., a complex containing the Cas9 protein, a tracrRNA, and a crRNA guide RNA).
  • As used herein, the terms “T lymphocyte” and “T cell” are used interchangeably and refer to cells that have completed maturation in the thymus, and identify certain foreign antigens in the body. The terms also refer to the major leukocyte types that have various roles in the immune system, including activation and deactivation of other immune cells. The T cell can be any T cell such as a cultured T cell, e.g., a primary T cell, or a T cell derived from a cultured T cell line, e.g., a Jurkat, SupT1, etc., or a T cell obtained from a mammal. The T cell can be a CD3+ cell. The T cell can be any type of T cell, CD4+/CD8+ double positive T cells, CD4+ helper T cells (e.g. Th1 and Th2 cells), CD8+ T cells (e.g. cytotoxic T cells), peripheral Including but not limited to blood mononuclear cells (PBMC), peripheral blood leukocytes (PBL), tumor infiltrating lymphocytes (TIL), memory T cells, naive T cells, regulatory T cells, γδ T cells, etc. It can be any T cell at any stage of development. Additional types of helper T cells include Th3 (Treg) cells, Th17 cells, Th9 cells, or Tfh cells. Additional types of memory T cells include cells such as central memory T cells (Tcm cells), effector memory T cells (Tem cells and TEMRA cells). A T cell can also refer to a genetically modified T cell, such as a T cell that has been modified to express a T cell receptor (TCR) or a chimeric antigen receptor (CAR). T cells can also be differentiated from stem cells or progenitor cells.
  • “CD4+ T cells” refers to a subset of T cells that express CD4 on their surface and are associated with a cellular immune response. CD4+ T cells are characterized by a post-stimulation secretion profile that can include secretion of cytokines such as IFN-γ, TNF-α, IL-2, IL-4 and IL-10. “CD4” is a 55 kD glycoprotein originally defined as a differentiation antigen on T lymphocytes, but was also found on other cells including monocytes/macrophages. The CD4 antigen is a member of the immunoglobulin superfamily and has been implicated as an associative recognition element in MHC (major histocompatibility complex) class II restricted immune responses. On T lymphocytes, the CD4 antigen defines a helper/inducer subset.
  • “CD8+ T cells” refers to a subset of T cells that express CD8 on their surface, are MHC class I restricted, and function as cytotoxic T cells. The “CD8” molecule is a differentiation antigen present on thymocytes, as well as on cytotoxic and suppressor T lymphocytes. The CD8 antigen is a member of the immunoglobulin superfamily and is an associative recognition element in major histocompatibility complex class I restriction interactions.
  • As used herein, the term “ex vivo” generally includes experiments or measurements made in or on living tissue, preferably in an artificial environment outside the organism, preferably with minimal differences from natural conditions.
  • As used herein, the term “construct” refers to a complex of molecules, including macromolecules or polynucleotides.
  • As used herein, the term “integration” refers to the process of stably inserting one or more nucleotides of a construct into the cell genome, i.e., covalently linking to a nucleic acid sequence in the chromosomal DNA of the cell. It may also refer to nucleotide deletions at a site of integration. Where there is a deletion at the insertion site, “integration” may further include substitution of the endogenous sequence or nucleotide deleted with one or more inserted nucleotides.
  • As used herein, the term “exogenous” refers to a molecule or activity that has been introduced into a host cell and is not native to that cell. The molecule can be introduced, for example, by introduction of the encoding nucleic acid into host genetic material, such as by integration into a host chromosome, or as non-chromosomal genetic material, such as a plasmid. Thus, the term, when used in connection with expression of an encoding nucleic acid, refers to the introduction of the encoding nucleic acid into a cell in an expressible form. The term “endogenous” refers to a molecule or activity that is present in a host cell under natural, unedited conditions. Similarly, the term, when used in connection with expression of the encoding nucleic acid, refers to expression of the encoding nucleic acid that is contained within the cell and not introduced exogenously.
  • As used herein, a “polynucleotide donor construct” refers to a nucleotide sequence (e.g. DNA sequence) that is genetically inserted into a polynucleotide and is exogenous to that polynucleotide. The polynucleotide donor construct is transcribed into RNA and optionally translated into a polypeptide. The polynucleotide donor construct can include prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and synthetic DNA sequences. For example, the polynucleotide donor construct can be a miRNA, shRNA, natural polypeptide (i.e., a naturally occurring polypeptide) or fragment thereof or a variant polypeptide (e.g. a natural polypeptide having less than 100% sequence identity with the natural polypeptide) or fragments thereof.
  • As used herein, the term “transgene” refers to a polynucleotide that has been transferred naturally, or by any of a number of genetic engineering techniques from one organism to another. It is optionally translated into a polypeptide. It is optionally translated into a recombinant protein. A “recombinant protein” is a protein encoded by a gene—recombinant DNA—that has been cloned in a system that supports expression of the gene and translation of messenger RNA (see expression system). The recombinant protein can be a therapeutic agent, e.g. a protein that treats a disease or disorder disclosed herein. As used, transgene can refer to a polynucleotide that encodes a polypeptide. A transgene can also refer to a non-encoding sequence, such as, but not limited to shRNAs, miRNAs, and miRs.
  • The terms “protein,” “polypeptide,” and “peptide” are used herein interchangeably.
  • As used herein, the term “operably linked” refers to the binding of a nucleic acid sequence to a single nucleic acid fragment such that one function is affected by the other. For example, if a promoter is capable of affecting the expression of a coding sequence or functional RNA (i.e., the coding sequence or functional RNA is under transcriptional control by the promoter), the promoter is operably linked thereto. Coding sequences can be operably linked to control sequences in both sense and antisense orientation.
  • As used herein, the term “developmental cell states” refers to, for example, states when the cell is inactive, actively expressing, differentiating, senescent, etc. developmental cell state may also refer to a cell in a precursor state (e.g., a T cell precursor).
  • As used, the term “encoding” refers to a sequence of nucleic acids which codes for a protein or polypeptide of interest. The nucleic acid sequence may be either a molecule of DNA or RNA. In preferred embodiments, the molecule is a DNA molecule. In other preferred embodiments, the molecule is a RNA molecule. When present as a RNA molecule, it will comprise sequences which direct the ribosomes of the host cell to start translation (e.g., a start codon, ATG) and direct the ribosomes to end translation (e.g., a stop codon). Between the start codon and stop codon is an open reading frame (ORF). Such terms are known to one of ordinary skill in the art.
  • The term “inserting” refers to a manipulation of a nucleotide sequence to introduce a non-native sequence. This is done, for example, via the use of restriction enzymes and ligases whereby the DNA sequence of interest, usually encoding the gene of interest, can be incorporated into another nucleic acid molecule by digesting both molecules with appropriate restriction enzymes in order to create compatible overlaps and then using a ligase to join the molecules together. One skilled in the art is very familiar with such manipulations and examples may be found in Sambrook et al. (Sambrook, Fritsch, & Maniatis, “Molecular Cloning: A Laboratory Manual”, 2nd ed., Cold Spring Harbor Laboratory, 1989), which is hereby incorporated by reference in its entirety including any drawings, figures and tables.
  • As used herein, the term “subject” refers to a mammalian subject. Exemplary subjects include humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, goats, rabbits, pigs and sheep. In certain embodiments, the subject is a human. In some embodiments the subject has a disease or condition that can be treated with an engineered cell provided herein or population thereof. In some aspects, the disease or condition is a cancer.
  • As used herein, the term “promoter” refers to a nucleotide sequence (e.g. DNA sequence) capable of controlling the expression of a coding sequence or functional RNA. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. A promoter can be derived from natural genes in its entirety, can be composed of different elements from different promoters found in nature, and/or may comprise synthetic DNA segments. A promoter, as contemplated herein, can be endogenous to the cell of interest or exogenous to the cell of interest. It is appreciated by those skilled in the art that different promoters can induce gene expression in different tissue or cell types, or at different developmental stages, or in response to different environmental conditions. As is known in the art, a promoter can be selected according to the strength of the promoter and/or the conditions under which the promoter is active, e.g., constitutive promoter, strong promoter, weak promoter, inducible/repressible promoter, tissue specific Or developmentally regulated promoters, cell cycle-dependent promoters, and the like.
  • A promoter can be an inducible promoter (e.g., a heat shock promoter, tetracycline-regulated promoter, steroid-regulated promoter, metal-regulated promoter, estrogen receptor-regulated promoter, etc.). The promoter can be a constitutive promoter (e.g., CMV promoter, UBC promoter). In some embodiments, the promoter can be a spatially restricted and/or temporally restricted promoter (e.g., a tissue specific promoter, a cell type specific promoter, etc.). See for example U.S. application Ser. No. 15/715,068, the disclosures of which are herein incorporated by reference in their entirety.
  • Gene editing, as contemplated herein, may involve a gene (or nucleotide sequence) knock-in or knock-out. As used herein, the term “knock-in” refers to an addition of a DNA sequence, or fragment thereof into a genome. Such DNA sequences to be knocked-in may include an entire gene or genes, may include regulatory sequences associated with a gene or any portion or fragment of the foregoing. For example, a polynucleotide donor construct encoding a recombinant protein may be inserted into the genome of a cell carrying a mutant gene. In some embodiments, a knock-in strategy involves substitution of an existing sequence with the provided sequence, e.g., substitution of a mutant allele with a wild-type copy. On the other hand, the term “knock-out” refers to the elimination of a gene or the expression of a gene. For example, a gene can be knocked out by either a deletion or an addition of a nucleotide sequence that leads to a disruption of the reading frame. As another example, a gene may be knocked out by replacing a part of the gene with an irrelevant (e.g., non-coding) sequence.
  • As used herein, the term “non-homologous end joining” or NHEJ refers to a cellular process in which cut or nicked ends of a DNA strand are directly ligated without the need for a homologous template nucleic acid. NHEJ can lead to the addition, the deletion, substitution, or a combination thereof, of one or more nucleotides at the repair site.
  • As used herein, the term “homology directed repair” or HDR refers to a cellular process in which cut or nicked ends of a DNA strand are repaired by polymerization from a homologous template nucleic acid. Thus, the original sequence is replaced with the sequence of the template. The homologous template nucleic acid can be provided by homologous sequences elsewhere in the genome (sister chromatids, homologous chromosomes, or repeated regions on the same or different chromosomes). Alternatively, an exogenous template nucleic acid can be introduced to obtain a specific HDR-induced change of the sequence at the target site. In this way, specific mutations can be introduced at the cut site.
  • The terms “vector” and “plasmid” are used interchangeably and as used herein refer to polynucleotide vehicles useful to introduce genetic material into a cell. Vectors can be linear or circular. Vectors can integrate into a target genome of a host cell or replicate independently in a host cell. Vectors can comprise, for example, an origin of replication, a multicloning site, and/or a selectable marker. An expression vector typically comprises an expression cassette. Vectors and plasmids include, but are not limited to, integrating vectors, prokaryotic plasmids, eukaryotic plasmids, plant synthetic chromosomes, episomes, viral vectors, cosmids, and artificial chromosomes.
  • As used herein the term “expression cassette” is a polynucleotide construct, generated recombinantly or synthetically, comprising regulatory sequences operably linked to a selected polynucleotide to facilitate expression of the selected polynucleotide in a host cell. For example, the regulatory sequences can facilitate transcription of the selected polynucleotide in a host cell, or transcription and translation of the selected polynucleotide in a host cell. An expression cassette can, for example, be integrated in the genome of a host cell or be present in an expression vector.
  • As used herein, the phrase “subject in need thereof” refers to a subject that exhibits and/or is diagnosed with one or more symptoms or signs of a disease or disorder as described herein.
  • A “chemotherapeutic agent” refers to a chemical compound useful in the treatment of cancer. Chemotherapeutic agents include “anti-hormonal agents” or “endocrine therapeutics” which act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer.
  • The term “composition” refers to a mixture that contains, e.g., an engineered cell or protein contemplated herein. In some embodiments, the composition may contain additional components, such as adjuvants, stabilizers, excipients, and the like. The term “composition” or “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective in treating a subject, and which contains no additional components which are unacceptably toxic to the subject in the amounts provided in the pharmaceutical composition.
  • As used herein, the term “effective amount” refers to the amount of a compound (e.g., a compositions described herein, cells described herein) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
  • The terms “modulate” and “modulation” refer to reducing or inhibiting or, alternatively, activating or increasing, a recited variable.
  • The terms “increase” and “activate” refer to an increase of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 50-fold, 100-fold, or greater in a recited variable.
  • The terms “reduce” and “inhibit” refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 100-fold, or greater in a recited variable.
  • 1. Safe Harbor Loci
  • Gene editing therapies include, for example, viral vector integration and site specific integration. Site-specific integration is a promising alternative to random integration of viral vectors, as it mitigates the risks of insertional mutagenesis or insertional oncogenesis (Kolb et al. Trends Biotechnol. 2005 23:399-406; Porteus et al. Nat Biotechnol. 2005 23:967-973; Paques et al. Curr Gen Ther. 2007 7:49-66). However, site specific integration continues to face challenges such as poor knock-in efficiency, risk of insertional oncogenesis, unstable and/or anomalous expression of adjacent genes or the transgene, low accessibility (e.g. within kB of adjacent genes), etc. These challenges can be addressed, in part, through the identification and use of safe harbor loci or safe harbor sites (SHS), which are sites in which genes or genetic elements can be incorporated without disruption to expression or regulation of adjacent genes.
  • The most widely used of the putative human safe harbor sites is the AAVS1 site on chromosome 19q, which was initially identified as a site for recurrent adenoassociated virus insertion. Other potential SHS have been identified on the basis of homology, with sites first identified in other species (e.g., the human homolog of the permissive murine Rosa26 locus) or among the growing number of human genes that appear non-essential under some circumstances. One putative SHS of this type is the CCR5 chemokine receptor gene, which, when disrupted, confers resistance to human immunodeficiency virus infection. Additional potential genomic SHS have been identified in human and other cell types on the basis of viral integration site mapping or gene-trap analyses, as was the original murine Rosa26 locus. The three top SHS, AAVS1, CCR5, and Rosa26, are in close proximity to many protein coding genes and regulatory elements. (See FIG. 2 from Sadelain, M., et al. (2012). Safe harbours for the integration of new DNA in the human genome. Nature reviews Cancer, 12(1), 51-58, the relevant disclosures of which are herein incorporated by reference in their entirety).
  • The AAVS1 (also known as the PPP 1R12C locus) on human chromosome 19 is a known SHS for hosting transgenes (e.g. DNA transgenes) with expected function. It is at position 19q13.42. It has an open chromatin structure and is transcription-competent. The canonical SHS locus for AAVS1 is chr19: 55,625,241-55,629,351. See Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference. An exemplary AAVS1 target gRNA and target sequence are provided below:
  • AAVS1-gRNA sequence:
    (SEQ ID NO: 121)
    ggggccactagggacaggatGTTTTAGAGCTAGAA
    ATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC
    TTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT
    AAVS1 target sequence:
    (SEQ ID NO: 122)
    ggggccactagggacaggat
  • CCR5, which is located on chromosome 3 at position 3p21.31, encodes the major co-receptor for HIV-1. Disruption at this site in the CCR5 gene has been beneficial in HIV/AIDS therapy and prompted the development of zinc-finger nucleases that target its third exon. The canonical SHS locus for CCR5 is chr3: 46,414,443-46,414,942. See Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference.
  • The mouse Rosa26 locus is particularly useful for genetic modification as it can be targeted with high efficiency and is expressed in most cell types tested. Irion et al. 2007 (“Identification and targeting of the ROSA26 locus in human embryonic stem cells.” Nature biotechnology 25.12 (2007): 1477-1482, the relevant disclosure of which are herein incorporated by reference) identified the human homolog, human ROSA26, in chromosome 3 (position 3p25.3). The canonical SHS locus for human Rosa26 (hRosa26) is chr3: 9,415,082-9,414,043. See Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference.
  • Additional examples of safe harbor sites are provided in Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol. 30,7 (2019): 814-828, the relevant disclosures of which are herein incorporated by reference.
  • The present disclosure is directed to methods for identifying safe harbor loci with benefits including, but not limited to, high knock-in efficiency and high expression of transgene. An example of applications of the presently disclosed methods is the identification of safe harbor loci for insertion of transgenes (e.g., chimeric antigen receptors (CAR)) into T-cells. In some embodiments, the safe harbor loci of the present disclosure are useful for the insertion of a sequence encoding a transgene. In some embodiments, the safe harbor sites allow for high transgene expression (sufficient to allow for transgene functionality or treatment of a disease of interest) and stable expression of the transgene over several days, weeks or months. In some embodiments, knockout of the gene at the safe harbor locus confers benefit to the function of the cell, or the gene at the safe harbor locus has no known function within the cell. In some embodiments the safe harbor locus results in stable transgene expression in vitro with or without CD3/CD28 stimulation, negligible off-target cleavage as detected by iGuide-Seq or CRISPR-Seq, less off-target cleavage relative to other loci as detected by iGuide-Seq or CRISPR-Seq, negligible transgene-independent cytotoxicity, negligible transgene-independent cytokine expression, negligible transgene-independent chimeric antigen receptor expression, negligible deregulation or silencing of nearby genes, and positioned outside of a cancer-related gene.
  • As used, a “nearby gene” can refer to a gene that is within about 100 kB, about 125 kB, about 150 kB, about 175 kB, about 200 kB, about 225 kB, about 250 kB, about 275 kB, about 300 kB, about 325 kB, about 350 kB, about 375 kB, about 400 kB, about 425 kB, about 450 kB, about 475 kB, about 500 kB, about 525 kB, about 550 kB away from the safe harbor locus (integration site).
  • In some embodiments, the present disclosure contemplates inserts that comprise one or more transgenes. The transgene can encode a therapeutic protein, an antibody, a peptide, a suicide gene, an apoptosis gene or any other gene of interest. The safe harbor loci identified using the method described herein allow for transgene integration that results in, for example, enhanced therapeutic properties. These enhanced therapeutic properties, as used herein, refer to an enhanced therapeutic property of a cell when compared to a typical immune cell of the same normal cell type. For example, an NK cell having “enhanced therapeutic properties” has an enhanced, improved, and/or increased treatment outcome when compared to a typical, unmodified and/or naturally occurring NK cell. The therapeutic properties of immune cells can include, but are not limited to, cell transplantation, transport, homing, viability, self-renewal, persistence, immune response control and regulation, survival, and cytotoxicity. The therapeutic properties of immune cells are also manifested by: antigen-targeted receptor expression; HLA presentation or lack thereof; tolerance to the intratumoral microenvironment; induction of bystander immune cells and immune regulation; improved target specificity with reduction; resistance to treatments such as chemotherapy.
  • As used herein, the term “insert size” refers to the length of the nucleotide sequence being integrated (inserted) at the safe harbor site. In some embodiments, the insert size comprises at least about 100, 200, 300, 400 or 500 basepairs. In some embodiments, the insert size comprises about 500 nucleotides or basepairs. In some embodiments, the insert size comprises up to 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 kbp (kilo basepairs) or the sizes in between. In some embodiments, the insert size is greater than 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 kbp or the sizes in between. In some embodiments, the insert size is within the range of 3-15 kbp or is any number in that range. In some embodiments, the insert size is within the range of 1.5-8.3 kbp or is any number in that range. In some embodiments, the insert size is within the range of 1.5-15 kbp or is any number in that range. In some embodiments, the insert size is within the range of 0.5-20 kbp or is any number in that range. In some embodiments, the insert size is 0.5-10, 0.6-10, 0.7-10, 0.8-10, 0.9-10, 1-10, 2-10, 3-10, 4-10, 5-10, 6-10, 7-10, 8-10, 9-10 kbp. In some embodiments, the insert size is 0.5-11, 0.6-11, 0.7-11, 0.8-11, 0.9-11, 1-11, 2-11, 3-11, 4-11, 5-11, 6-11, 7-11, 8-11, 9-11, or 10-11 kbp. In some embodiments, the insert size is 0.5-12, 0.6-12, 0.7-12, 0.8-12, 0.9-12, 1-12, 2-12, 3-12, 4-12, 5-12, 6-12, 7-12, 8-12, 9-12, 10-12, or 11-12 kbp. In some embodiments, the insert size is 0.5-13, 0.6-13, 0.7-13, 0.8-13, 0.9-13, 1-13, 2-13, 3-13, 4-13, 5-13, 6-13, 7-13, 8-13, 9-13, 10-13, 11-13, or 12-13 kbp. In some embodiments, the insert size is 0.5-14, 0.6-14, 0.7-14, 0.8-14, 0.9-14, 1-14, 2-14, 3-14, 4-14, 5-14, 6-14, 7-14, 8-14, 9-14, 10-14, 11-14, 12-14 or 13-14 kbp. In some embodiments, the insert size is 0.5-15, 0.6-15, 0.7-15, 0.8-15, 0.9-15, 2-15, 3-15, 4-15, 5-15, 6-15, 7-15, 8-15, 9-15, 10-15, 11-15, 12-15, 13-15, or 14-15 kbp. In some embodiments, the insert size is 0.5-16, 0.6-16, 0.7-16, 0.8-16, 0.9-16, 1-16, 2-16, 3-16, 4-16, 5-16, 6-16, 7-16, 8-16, 9-16, 10-16, 11-16, 12-16, 13-16, 14-16 or 15-16 kbp. In some embodiments, the insert size is 0.5-17, 0.6-17, 0.7-17, 0.8-17, 0.9-17, 1-17, 2-17, 3-17, 4-17, 5-17, 6-17, 7-17, 8-17, 9-17, 10-17, 11-17, 12-17, 13-17, or 14-17, 15-17 or 16-17 kbp. In some embodiments, the insert size is 0.5-18, 0.6-18, 0.7-18, 0.8-18, 0.9-18, 1-18, 2-18, 3-18, 4-18, 5-18, 6-18, 7-18, 8-18, 9-18, 10-18, 11-18, 12-18, 13-18, 14-18, 15-18, 16-18 or 17-18 kbp. In some embodiments, the insert size is 0.5-19, 0.6-19, 0.7-19, 0.8-19, 0.9-19, 1-19, 2-19, 3-19, 4-19, 5-19, 6-19, 7-19, 8-19, 9-19, 10-19, 11-19, 12-19, 13-19, 14-0.7-20, 19, 15-19, 16-19, 17-19, or 18-19 kbp. In some embodiments, the insert size is 0.5-20, 0.6-20, 0.7-20, 0.8-20, 0.9-20, 1-20, 2-20, 3-20, 4-20, 5-20, 6-20, 7-20, 8-20, 9-20, 10-20, 11-20, 12-20, 13-20, 14-20, 15-20, 16-20, 17-20, 18-20, or 19-20 kbp.
  • The inserts of the present disclosure refer to nucleic acid molecules or polynucleotide inserted at a safe harbor site. In some embodiments, the nucleotide sequence is a DNA molecule, e.g., genomic DNA, or comprises deoxy-ribonucleotides. In some embodiments, the insert comprises a smaller fragment of DNA, such as a plastid DNA, mitochondrial DNA, or DNA isolated in the form of a plasmid, a fosmid, a cosmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), and/or any other sub-genome segment of DNA. In some embodiments, the insert is an RNA molecule or comprises ribonucleotides. The nucleotides in the insert are contemplated as naturally occurring nucleotides, non-naturally occurring, and modified nucleotides. Nucleotides may be modified chemically or biochemically, or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications. The polynucleotides can be in any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular conformations, and other three-dimension conformations contemplated in the art.
  • The inserts can have coding and/or non-coding regions. The insert can comprises a non-coding sequence (e.g., control elements, e.g., a promoter sequence). In some embodiments, the insert encodes transcription factors. In some embodiments, the insert encodes an antigen binding receptors such as single receptors, T-cell receptors (TCRs), syn-notch, CARs, mAbs, etc. In some embodiments, the inserts are RNAi molecules, including, but not limited to, miRNAs, siRNA, shRNAs, etc. In some embodiments, the insert is a human sequence. In some embodiments, the insert is chimeric. In some embodiments, the insert is a multi-gene/multi-module therapeutic cassette. A multi-gene/multi-module therapeutic cassette referst to an insert or cassette having one or more than one receptor (e.g., synthetic receptors), other exogenous protein coding sequences, non-coding RNAs, transcriptional regulatory elements, and/or insulator sequences, etc.
  • Various cell types are contemplated as having the safe harbor sites in the present disclosure. A cell comprising a safe harbor site and/or a cell comprising an insert at a safe harbor site as described in the present disclosure can be referred to as an engineered cell. The cells can include, but are not limited to, eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells and the like. Optionally, the cell is a mammalian cell, for example, a human cell. In some embodiments, that engineered cell is a stem cell, a human cell, a primary cell, an hematopoietic cell, an adaptive immune cell, an innate immune cell, a T cell or a T cell progenitor. Non-limiting examples of immune cells that are contemplated in the present disclosure include T cell, B cell, natural killer (NK) cell, NKT/iNKT cell, macrophage, myeloid cell, and dendritic cells. Non-limiting examples of stem cells that are contemplated in the present disclosure include pluripotent stem cells (PSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), embryo-derived embryonic stem cells obtained by nuclear transfer (ntES; nuclear transfer ES), male germline stem cells (GS cells), embryonic germ cells (EG cells), hematopoietic stem/progenitor stem cells (HSPCs), somatic stem cells (adult stem cells), hemangioblasts, neural stem cells, mesenchymal stem cells and stem cells of other cells (including osteocyte, chondrocyte, myocyte, cardiac myocyte, neuron, tendon cell, adipocyte, pancreocyte, hepatocyte, nephrocyte and follicle cells and so on). In some embodiments, the engineered cells is a T cell, NK cells, iPSC, and HSPC. In some embodiments, the engineered cells used in the present disclosure are human cell lines grown in vitro (e.g. deliberately immortalized cell lines, cancer cell lines, etc.).
  • The methods for integrating the inserts at the safe harbor sites can be viral or non-viral delivery techniques.
  • In some embodiments, the nucleic acid sequence is inserted into the genome of the engineered cell by introducing a vector, for example, a viral vector, comprising the nucleic acid. Examples of viral vectors include, but are not limited to, adeno-associated viral (AAV) vectors, retroviral vectors or lentiviral vectors. In some embodiments, the lentiviral vector is an integrase-deficient lentiviral vector.
  • In some embodiments, the nucleic acid sequence is inserted into the genome of the T cell via non-viral delivery. In non-viral delivery methods, the nucleic acid can be naked DNA, or in a non-viral plasmid or vector. Non-viral delivery techniques can be site-specific integration techniques, as described herein or known to those of ordinary skill in the art. Examples of site-specific techniques for integration into the safe harbor loci include, without limitation, homology-dependent engineering using nucleases and homology independent targeted insertion using Cas9.
  • In some embodiments, the insert is integrated at a safe harbor site by introducing into the engineered cell, (a) a targeted nuclease that cleaves a target region in the safe harbor site to create the insertion site; and (b) the nucleic acid sequence (insert), wherein the insert is incorporated at the insertion site by, e.g., HDR. Examples of non-viral delivery techniques that can be used in the methods of the present disclosure are provided in U.S. application Ser. Nos. 16/568,116 and 16/622,843, the relevant disclosures of which are herein incorporated by reference in their entirety.
  • 2. CAR T Cell Therapy
  • Chimeric antigen receptor (CAR) T cells are T cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy. Chimeric antigen receptors are receptor proteins that have been engineered to confer T cells with the ability to target a specific protein. The genetic modification of lymphocytes (e.g. T cells) by incorporation of, for example, CARs, and administration of the engineered cells to a subject is an example of “adoptive cell therapy”. As used herein, the term “adoptive cell therapy” refers to cell-based immunotherapy for transfusion of autologous or allogeneic lymphocytes, referred to as T cells or B cells. In this CAR therapy approach, cells are expanded and cultured ex vivo and genetically modified, prior to transfusion.
  • The expression of CARs allows the engineered T-cells to target and bind specific proteins, for example, tumor antigens. In CAR therapy, T-cells are harvested from a subject—they can be autologous T-cells from the subject own blood or from a donor that will not be receiving the CAR therapy. Once isolated, the T-cells are genetically modified with a CAR, expanded ex vivo, and administered to the subject (i.e. patient) by, e.g. infusion.
  • The CARs may be introduced into the T-cells using, for example, a viral technique (e.g., retroviral integration) or site-specific technique. With site specific integration of the transgenes (e.g. CARs), the transgenes may be targeted to a safe harbor locus. Examples of site-specific techniques for integration into the safe harbor loci include, without limitation, homology-dependent engineering using nucleases and homology independent targeted insertion using Cas9.
  • The engineered CAR T cells have applications to immune-oncology. The CAR, for example, can be selected to target a specific tumor antigen. Examples of cancers that can be effectively targeted using CAR T cells are blood cancers. In some embodiments, CAR T cell therapy can be used to treat solid tumors.
  • 3. Gene Editing
  • The terms “gene editing” or “genome editing”, as used herein, refer to a type of genetic manipulation in which DNA is inserted, replaced, or removed from the genome using artificially manipulated nucleases or “molecular scissors”. It is a useful tool for elucidating the function and effect of sequence-specific genes or proteins or altering cell behavior (e.g. for therapeutic purposes).
  • Currently available genome editing tools include zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALENs) to incorporate genes at safe harbor loci (e.g. the adeno-associated virus integration site 1 (AAVS1) safe harbor locus). The DICE (dual integrase cassette exchange) system utilizing phiC31 integrase and Bxb1 integrase is a tool for target integration. Additionally, clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) techniques can be used for targeted gene insertion.
  • Site specific gene editing approaches can include homology dependent mechanisms or homology independent mechanisms.
  • All methods known in the art for targeted insertion of gene sequences are contemplated in the methods described herein to insert constructs at safe harbor loci.
  • 4. Crispr-Cas Gene Editing
  • One effective example of gene editing is the Crisp-Cas approach (e.g. Crispr-Cas9). This approach incorporates the use of a guide polynucleotide (e.g. guide ribonucleic acid or gRNA) and a cas endonuclease (e.g. Cas9 endonuclease).
  • As used herein, a polypeptide referred to as a “Cas endonuclease” or having “Cas endonuclease activity” refers to a CRISPR-related (Cas) polypeptide encoded by a Cas gene, wherein a Cas polypeptide is a target DNA sequence that can be cleaved when operably linked to one or more guide polynucleotides (see, e.g., U.S. Pat. No. 8,697,359). Also included in this definition are variants of Cas endonuclease that retain guide polynucleotide-dependent endonuclease activity. The Cas endonuclease used in the donor DNA insertion method detailed herein is an endonuclease that introduces double-strand breaks into DNA at the target site (e.g., within the target locus or at the safe harbor site).
  • As used herein, the term “guide polynucleotide” relates to a polynucleotide sequence capable of complexing with a Cas endonuclease and allowing the Cas endonuclease to recognize and cleave a DNA target site. The guide polynucleotide can be a single molecule or a double molecule. The guide polynucleotide sequence can be an RNA sequence, a DNA sequence, or a combination thereof (RNA-DNA combination sequence). A guide polynucleotide comprising only ribonucleic acid is also referred to as “guide RNA”. In some embodiments, a polynucleotide donor construct is inserted at a safe harbor locus using a guide RNA (gRNA) in combination with a cas endonuclease (e.g. Cas9 endonuclease).
  • The guide polynucleotide includes a first nucleotide sequence domain (also referred to as a variable targeting domain or VT domain) that is complementary to a nucleotide sequence in the target DNA, and a second nucleotide that interacts with a Cas endonuclease polypeptide. It can be a double molecule (also referred to as a double-stranded guide polynucleotide) comprising a sequence domain (referred to as a Cas endonuclease recognition domain or CER domain). The CER domain of this double molecule guide polynucleotide comprises two separate molecules that hybridize along the complementary region. The two separate molecules can be RNA sequences, DNA sequences and/or RNA-DNA combination sequences.
  • Genome editing using CRISPR-Cas approaches relies on the repair of site-specific DNA double-strand breaks (DSBs) induced by the RNA-guided Cas endonuclease (e.g. Cas 9 endonuclease). Homology-directed repair (HDR) of these DSBs enables precise editing of the genome by introducing defined genomic changes, including base substitutions, sequence insertions, and deletions. Conventional HDR-based CRISPR/Cas9 genome-editing involves transfecting cells with Cas9, gRNA and donor DNA containing homologous arms matching the genomic locus of interest.
  • HITI (homology independent targeted insertion) uses a non-homologous end joining (NHEJ)-based homology-independent strategy and the method can be more efficient than HDR. Guide RNAs (gRNAs) target the insertion site. For HITI, donor plasmids lack homology arms and DSB repair does not occur through the HDR pathway. The donor polynucleotide construct can be engineered to include Cas9 cleavage site(s) flanking the gene or sequence to be inserted. This results in Cas9 cleavage at both the donor plasmid and the genomic target sequence. Both target and donor have blunt ends and the linearized donor DNA plasmid is used by the NHEJ pathway resulting integration into the genomic DSB site. (See, for example, Suzuki, K., et al. (2016). In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature, 540(7631), 144-149, the relevant disclosures of which are herein incorporated in their entirety).
  • Methods for conducing gene editing using CRISPR-Cas approaches are known to those of ordinary skill in the art. (See, for example, U.S. application Ser. No. 16/312,676, U.S. Ser. No. 15/303,722, and U.S. Ser. No. 15/628,533, the disclosures of which are herein incorporated by reference in their entirety). Additionally, uses of endonucleases for inserting transgenes into safe harbor loci are described, for example, in U.S. application Ser. No. 13/036,343, the disclosures of which are herein incorporated by reference in their entirety.
  • The guide RNAs and/or mRNA (or DNA) encoding an endonuclease can be chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. Non-limiting examples of such moieties include lipid moieties such as a cholesterol moiety, cholic acid, a thioether, a thiocholesterol, an aliphatic chain (e.g., dodecandiol or undecyl residues), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, adamantane acetic acid, a palmityl moiety and an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety. See for example U.S. application Ser. No. 15/715,068, the disclosures of which are herein incorporated by reference in their entirety.
  • 5. Therapeutic Applications
  • For therapeutic applications, the engineered cells, populations thereof, or compositions thereof are administered to a subject, generally a mammal, generally a human, in an effective amount.
  • The engineered cells may be administered to a subject by infusion (e.g., continuous infusion over a period of time) or other modes of administration known to those of ordinary skill in the art.
  • The engineered cells provided herein can be administered as part of a pharmaceutical compositions. In some embodiments, the present disclosure provides compositions comprising a guide RNA of the present disclosure. The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
  • The engineered cells provided herein not only find use in gene therapy but also in non-pharmaceutical uses such as, e.g., production of animal models and production of recombinant cell lines expressing a protein of interest.
  • The engineered cells of the present disclosure can be any cell, generally a mammalian cell, generally a human cell that has been modified by integrating a transgene at a safe harbor locus described herein. In some embodiments, the engineered cells are immune cells. In some embodiments, the engineered cells are lymphocytes. In some embodiments, the engineered cells are T cells or T cell precursors.
  • The engineered cells, compositions and methods of the present disclosure are useful for therapeutic applications such as CAR T cell therapy and TCR T cell therapy. In some embodiments, the insertion of a sequence encoding a transgene within a safe harbor locus maintains the TCR expression relative to instances when there is no insertion and enables transgene expression while maintaining TCR function.
  • Various diseases treated using the engineered cells, populations thereof, or compositions thereof are provided herein. Non-limiting examples of such diseases include alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, cancer, dermatomyositis, diabetes (type 1), certain juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain Valley Syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, certain myocarditis, multiple sclerosis, pemphigus/pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary bile With cirrhosis, psoriasis, rheumatoid arthritis, scleroderma/systemic sclerosis, Sjogren's syndrome, systemic lupus erythematosus, certain thyroiditis, certain uveitis, vitiligo, multiple vasculitis (Wegener)); autoimmune disorders including, but not limited to, granulomatosis; hematopoietic tumors including but not limited to acute and chronic leukemia, lymphoma, multiple myeloma and myelodysplastic syndrome; tumors of the prostate, breast, lung, colon, uterus, skin, liver, bone, pancreas, ovary, testis, bladder, kidney, head, neck, stomach, cervix, rectum, larynx, or esophagus solid tumors; HIV (human immunodeficiency virus) related disorders, RSV (respiratory syncytial virus) related disorders; EBV (Epstein-Barr virus) related disorders; CMV (cytomegalovirus) related disorders; and infectious diseases including, but not limited to, adenovirus-related disorders and BK polyomavirus-related disorders.
  • Cancers that can be treated with the engineered cells (e.g., CAR T-cells) of the present disclosure, populations thereof, or compositions thereof include blood cancers. In some embodiments, the cancer treated using the engineered cells (e.g., CAR T-cells) described herein, populations thereof, or compositions thereof is a hematologic malignancy or leukemia. In some embodiments, the engineered cells (e.g., CAR T-cells) described herein, populations thereof, or compositions thereof are used for the treatment of acute lymphoblastic leukemia (ALL) or diffuse large B-cell lymphoma (DLBCL). In some embodiments, the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplasia, myelodysplastic syndromes, acute T-lymphoblastic leukemia, or acute promyelocytic leukemia, chronic myelomonocytic leukemia, or myeloid blast crisis of chronic myeloid leukemia. Examples of cancers treatable using the engineered cells (e.g., CAR T-cells) described herein include, without limitation, breast cancer, ovarian cancer, esophageal cancer, bladder or gastric cancer, salivary duct carcinoma, salivary duct carcinomas, adenocarcinoma of the lung or aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma. In some other embodiments, the cancer is brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer. In yet other embodiments, the cancer is a squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, neuroblastoma, sarcoma (e.g., an angiosarcoma or chondrosarcoma), larynx cancer, parotid cancer, biliary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumor, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial gland carcinoma, carcinoid, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, connective tissue cancer, cystadenoma, digestive system cancer, duodenum cancer, endocrine system cancer, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell cancer, ependymal cancer, epithelial cell cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, heart cancer, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, large intestine cancer, leiomyosarcoma, lentigo maligna melanomas, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer, osteosarcoma, papillary serous adenocarcinoma, penile cancer, pharynx cancer, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory system cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, smooth muscle cancer, soft tissue cancer, somatostatin-secreting tumor, spine cancer, squamous cell carcinoma, striated muscle cancer, submesothelial cancer, superficial spreading melanoma, T cell leukemia, tongue cancer, undifferentiated carcinoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary system cancer, uterine cervix cancer, uterine corpus cancer, uveal melanoma, vaginal cancer, verrucous carcinoma, VIPoma, vulva cancer, well-differentiated carcinoma, or Wilms tumor.
  • In some embodiments, the present disclosure provides methods of treating a subject in need of treatment by administering to the subject a composition comprising any of the engineered cells described herein. As used, the terms “treat,” “treatment,” and the like refer generally to obtaining a desired pharmacological and/or physiological effect. That effect is preventive in terms of complete or partial prevention of the disease and/or therapeutic in terms of partial or complete cure of the disease and/or adverse effects resulting from the disease. The term “treatment”, as used herein, encompasses any treatment of a disease in a subject (e.g., mammal, e.g., human). Treatment may also refer to the administration of the engineered cells provided herein to a subject that is susceptible to the disease but has not yet been diagnosed as suffering from it, including preventing the disease from occurring; inhibiting disease progression; or reducing the disease (i.e., causing a regression of the disease). Further, treatment may stabilize or reduce undesirable clinical symptoms in subjects (e.g., patients). The cells provided herein populations thereof, or compositions thereof may be administered before, during or after the occurrence of the disease or injury.
  • In certain embodiments, the subject has a disease, condition, and/or injury that can be treated and/or ameliorated by cell therapy. In some embodiments, the subject in need of cell therapy is a subject having an injury, disease, or condition, thereby causing cell therapy (e.g., therapy in which cellular material is administered to the subject). However, it is contemplated that it is possible to treat, ameliorate and/or reduce the severity of at least one symptom associated with the injury, disease or condition. In certain embodiments, a subject in need of cell therapy includes, but is not limited to, a bone marrow transplant or stem cell transplant candidate, a subject who has received chemotherapy or radiation therapy, a hyperproliferative disease or cancer (e.g., a hematopoietic system), a subject having or at risk of developing a hyperproliferative disease or cancer), a subject having or at risk of developing a tumor (e.g., solid tumor), viral infection or virus. It is also intended to encompass subjects suffering from or at risk of suffering from a disease associated with an infection.
  • In some embodiments, the present disclosure provides a composition of the present disclosure along with instructions for use. The instructions for use can be present in the kits as a package insert, in the labeling of the container of the kit or components thereof, or can be in digital form (e.g. on a CD-ROM, via a link on the internet). A kit can include one or more of a genome-targeting nucleic acid, a polynucleotide encoding a genome-targeting nucleic acid, a site-directed polypeptide, and/or a polynucleotide encoding a site-directed polypeptide. Additional components within the kits are also contemplated, for example, buffer (such as reconstituting buffer, stabilizing buffer, diluting buffer), and/or one or more control vectors.
  • 6. Combination Therapies
  • In some embodiments, an engineered cells of the present disclosure or composition thereof is administered with at least one additional therapeutic agent. Any suitable additional therapeutic agent may be administered with an engineered cell provided herein, populations thereof, or compositions thereof. In some aspects, the additional therapeutic agent is selected from radiation, an ophthalmologic agent, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof.
  • In some embodiments, an engineered cell of the present disclosure or composition thereof is administered with a steroid. The administration of a steroid can prevent or mitigate the risk of a subject receiving the engineered cell(s) or composition thereof having an autoimmune reaction.
  • The additional therapeutic agent may be administered by any suitable means. In some embodiments, the engineered cells described herein, populations thereof, or compositions thereof and the additional therapeutic agent is administered in the same pharmaceutical composition, e.g. by infusion. In some embodiments, the engineered cells described herein and additional therapeutic agent are included in different pharmaceutical compositions.
  • The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
  • Various modes of administering the additional therapeutic agents are contemplated herein. In some embodiments, the additional therapeutic agent is administered by any suitable mode of administration. Generally, modes of administration include, without limitation, intravitreal, subretinal, suprachoroidal, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, topical, pulmonary, and subcutaneous routes.
  • In embodiments where the engineered cells provided herein and the additional therapeutic agent are included in different pharmaceutical compositions, administration of the engineered cells provided herein can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent.
  • EXAMPLES
  • The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided herein.
  • Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.
  • The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990).
  • Example 1: Identification of Knock-In Loci in Coding Regions
  • The objective of the experiments in this set of examples was to identify T-cell knock-in (KI) loci in coding regions outside of the T Cell Receptor Alpha Constant (TRAC) locus. To select candidate loci, the criteria and requirements shown in Table 1 were used.
  • TABLE 1
    Criteria used for identification of candidate knock-in loci
    within coding regions
    Detailed Datasets Considered for
    Criteria Requirements identification of loci
    KI High expression at Knock in efficiency
    efficiency d2 (day 2) data on ~90 genes
    Similar expression derived from
    dynamics as TRAC Roth, T. L., et al. 2019.
    (stable expression (Rapid discovery of synthetic
    upon activation) DNA sequences to rewrite endogenous
    Accessible T cell circuits. bioRxiv, 604561.)
    chromatin Bulk RNA-seq data at do, d2, d3 and d4:
    gRNA editing (i) publicly available data;
    efficiency (ii) data derived from Roth,
    T. L., et al. 2019.
    (Rapid discovery of synthetic
    DNA sequences to rewrite
    endogenous T cell circuits.
    bioRxiv, 604561.); and
    (iii) internally generated data
    Bulk ATAC-seq data
    at do, d2, d3 and d4:
    (i) data derived from Roth,
    T. L., et al. 2019.
    (Rapid discovery of
    synthetic DNA sequences
    to rewrite endogenous T cell
    circuits. bioRxiv, 604561.); and
    (ii) internally generated data
    Safety Does not affect T cell screening data
    proliferation, Achilles' project on cancer cell lines data
    cytolytic activity or Annotated oncogenes and tumor
    signaling of T cells suppressors from TCGA
    Annotated functions in immune cells
    Be careful with
    tumor suppressors
    and oncogenes
  • Generally, the requirements for candidate KI loci within the coding regions was that the coding gene is not essential for T cell function or the knock-out of that gene would be beneficial to chimeric antigen receptor therapy (CAR T) functions.
  • As shown in Table 1, some of the data utilized, for comparison purposes, to identify candidate KI loci was sourced, in part, from Roth, T. L., et al. 2019 (Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561), the relevant disclosures of which are herein incorporated by reference in their entirety. A summary of data in the Roth, T. L. et al. paper is shown in FIG. 3 .
  • FIG. 4A and FIG. 4B show the processed RNA-seq data, showing that samples cluster based on activation status and by cell type. Donor 4 (AKI4) was identified as an outlier, as it clustered differently than the others, and was removed from remaining analysis. The transcript expression data from RNA-seq experiments on the 90 genes cited in the Roth, T. L. et al. paper was correlated to transcript expression data in Roth, T. L. et al. paper. (See FIG. 5A and FIG. 5B).
  • FIG. 6 shows the process ATAC-seq data, which focused on the 10 kb area around the transcription start site (TSS). Again, donor 4 (AK14) was identified as an outlier, based on expression profile in both CD4 and CD8 cells, and was removed from remaining analysis. The results of the remaining ATAC-seq analysis are shown in FIGS. 7A-8 . The data in FIG. 7A for TSS enrichment scores also indicated that all libraries were high quality. The data on open chromatin regions around the TRAC locus revealed the highest signal near exon 3 rather than exon 1 (FIG. 8 ).
  • Determination of Knock-In Efficiency:
  • The K1 efficiency results (obtained using the model described infra) based on the 5 donors, 2 gRNA, and 2 replicates/gRNAs from the Roth, T. L. et al. paper are shown in FIG. 9 and FIG. 10 .
  • A linear model was built to estimate KI efficiency of approximately 90 genes using RNA-seq and ATAC-seq data. The linear model captured 33% of the variation in the data (i.e. R2=0.33). FIG. 11 shows KI efficiency versus day 2 (d2) RNA-seq data, day 4 (d4) RNA seq data, and d2 ATAC data. The linear model was applied to remaining candidate genes to estimate their KI efficiency.
  • The candidate coding loci were selected by first ranking all genes in the pooled data sets by predicted KI efficiency, using RNA-seq expression data from d2 (day 2). Candidate coding loci were required to be stably expressed during T cell activation (e.g., <=2-fold expression change relative to day 0 (d0). The candidate loci also had to be accessible based on ATAC-seq data. Using that selection process/requirements, 16 well-characterized coding genes (with known functions) were selected as candidate genes. The knockout of these 16 would confer a benefit to the function of CART cells (e.g. B2M, CD5, SMAD2, PTPRC, CD3E). An additional 12 coding genes with high predicted KI efficiency and no apparent essential function (inert coding genes) were selected as candidate genes. (See Table 2).
  • TABLE 2
    KI Candidate Loci selected
    Genes with Known Functions Inert Coding Genes
    B2M (~70%) CD2 SUB1
    CD3E (~50%) SMAD2 EDF1
    PTPRC (~50%) SLC38A1 CAPNS1
    CD3G (~30%) TIGIT SRP14
    Figure US20230416747A1-20231228-P00001
    SOCS1 PTPN2 RTRAF APRT
    Tested in Roth, T.L. et al CBLB PTPRCAP
    paper (reported editing PTEN SRSF9
    efficiency from Roth, PTPN6 FTL
    T.L. et al paper) CD5 TRIM28
    TET2 SERF2
    TRAC RPS23
  • Example 2: Identification of Knock-In Loci in Gene Deserts
  • The criteria for selection of candidate loci in non-coding regions or gene deserts is summarized in Table 3.
  • TABLE 3
    Criteria used for identification of candidate knock-in loci within
    non-coding regions
    Datasets Considered for
    Criteria Detailed Requirements identification of loci
    KI Accessible chromatin Bulk ATAC-seq data
    efficiency at d0, d2, d3 and d4:
    (i) data derived from
    Roth, T. L., et al. 2019.
    (Rapid discovery of synthetic
    DNA sequences to rewrite
    endogenous T cell circuits.
    bioRxiv, 604561.); and
    (ii) internally generated data
    Safety >10 kb from cancer-related Ensembl genes
    genes or TADS Annotated oncogenes and tumor
    >10 kb from any suppressors from TCGA
    miRNA/functional small Annotated enhancers
    RNAs from Encode and papers
    >10 kb from any 5' gene
    end
    >10 kb from any regulatory
    regions (ultra-conserved
    elements, enhancers)
  • To select candidate regions within the non-coding regions, the inventors here started by looking in highly accessible regions of the genome (10 kb windows). The most accessible region overlapped with (i) annotated protein coding genes (>50% accessible regions), (ii) pseudogenes and noncoding RNAs (˜20% accessible regions), and (iii) enhancer/regulatory regions (˜20% accessible regions). The candidate genes were required to be <10 kb from the coding regions. A few regions that overlapped with long intergenic noncoding RNAs (lincRNAs) but did not have apparent function in T cells were also considered.
  • Examples of other criteria that have been used in the art for selection of SHS are described, for example in Pellenz, S., et al. (2019). New human chromosomal sites with “safe harbor” potential for targeted transgene insertion. Human gene therapy, 30(7), 814-828, the relevant disclosures of which are herein incorporated by reference in their entirety.
  • FIG. 12 is a plot showing the normalized ATAQ SEQ data for a top candidate non-coding region.
  • Using the above-described selection process/requirement, 11 candidate regions in gene deserts were selected. In total, there were 39 KI candidate loci, including those in coding and non-coding regions that would be evaluated as safe harbor loci (predicted loci).
  • Example 3: Experimental Evaluation of Predicted Loci
  • Materials
      • 120 sgRNAs were ordered from Synthego, 3 sgRNAs per region, and editing efficiency was assessed by next generation sequencings (NGS).
        • 87 targeted coding genes
        • 33 targeted gene deserts
      • 189 constructs were synthesized by Genscript
        • Homology arm: 450 bp each
        • eGFP was used as the reporter
        • Vector backbone: pUC57-Kan backbone
        • 78 with endogenous promoters
        • 111 with EF1a-HTLV promoter
      • Constructs were sequence verified by Genscript and majority were internally verified by sequencing. The sgRNA sequences are provided in Table 4 and the construct sequences are provided in Table 5.
  • Methods
  • To evaluate the effectiveness of the predicted loci, the following were used:
      • (87 endogenous constructs+120 exogenous construct)*2=414 wells+Controls=460
      • 3 donors, 2 replicates at 3 time points: wk 1 (d6=day 6), wk 3 (d21=day 21) and wk 4 (d28=day 28)
      • Controls
      • DNA-only (no ribonucleoprotein (RNP)): episomal expression (n=8)
      • DNA+non-targeting guides+RNP: to check if DNA delivery is more efficient with RNP (n=8)
  • pMax GFP was measured to check if transfection is ok (n=3).
  • WT cells with no electroporation
  • WT cells with electroporation
  • Controls were spread out across plates.
  • Cells were electroporated without RNP/HDR to check if cell counting makes sense.
  • 2 more donors were added and changed to 3 replicates at 1 time point: wk 1 (d6)
  • FACS panel: GFP, TCR, Zombie
  • Washed every 3 wells.
  • The secondary data collected included: RNA-seq data: at d0, d2, and d4 (to determine stable expression) and ATAC-seq data: at d2 (to identify activated cells). The methods used for conducting the RNA-seq and ATAC-seq experiments are in Roth, T. L., et al. 2019. (Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561), which is herein incorporated by reference in its entirety.
  • Automated gating was performed on FACS data, using .fcs files. For constructs with endogenous promoters, all 5 donors and all 3 time points were used. For constructs with EF1a promoter, used 3 donors (donors 1-3) and 2 time points (wk 3 and wk 4).
  • To summarize data, wells with a % K1 efficiency (% GFP_high cells)<=10% (likely a gating error, experimental error or minimal integration) were removed. Loci were then ranked by median expression among donors and median % K1 efficiency among donors.
  • Loci significance was calculated using robust rank aggregation, which was the methodology used for consistent ranking of loci among donors and time points. Methods for conducting robust rank aggregation are known in the art. (See, for example, Kolde, R., et al. (2012). Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics (Oxford, England), 28(4), 573-580, the disclosure of which is herein incorporated by reference in its entirety).
  • Results
  • The results from the analysis of controls and experimental groups is shown in FIGS. 13A-25 .
  • The results of the pmax_GFP control experiments revealed that donor 5 had significantly higher cell count than other donors. Generally, the GFP_high readings decreased over time, as expected. (FIGS. 13A and 13B).
  • Experiments to analyze non-targeting controls for changes in episomal GFP expression, revealed that episomal GFP expression decreased to less than 0.05 over time. (FIGS. 14A and 14B) Some of the outliers were attributed to gating errors, which were most severe in donor 3. WT control experiments also exhibited <0.05 GFP_high readings, as expected (FIG. 15 ).
  • As shown in FIG. 16 and FIG. 17 , there was a more consistent trend among donors when using sgRNAS to target the B2M safe harbor locus.
  • A comparison of GFP expression trends between sgRNA79 and sgRNA83 for TRAC insertion and expression with an endogenous reporter revealed that donor 2 trends were different between sgRNA79 and sgRNA83, while donor 4 trends were the same (FIG. 18 and FIG. 22 ). Some potential reasons for the observed variation between replicates and donors include:
      • (1) manual handling of a large number of plates (e.g., FIG. 26 ):
        • Edge effects
        • Electroporation errors
      • (2) Inherent differences among donors (e.g., FIG. 27 ):
        • There were consistent differences with certain wells throughput the assay (spanning multiple weeks)
        • There were variable cell numbers between donors
      • (3) Gating errors (e.g. FIG. 28 ):
        • 1 peak vs >2 peaks in GFP signals
    Example 4: Ranking Loci by Expression and KI Efficiency
  • The loci were ranked based on mean florescence intensity (MFI) of reporter gene, GFP, and KI efficiency.
  • FIG. 29 shows GFP MFI and KI efficiency for all significant loci having endogenous promoters. The B2M locus reported the highest GFP MFI. The TRAC locus was among the top 10 MFI. The highest GFP MFI readings were reported in week 1 and reduced slightly in weeks 3 and 4. The results also showed most top loci have more than 1 sgRNA. With regard to KI efficiency, the SOCS1 locus reported the highest KI efficiency. Overall, KI efficiency showed greater variation among donors than GFP MFI.
  • FIG. 30 shows GFP MFI and KI efficiency for all significant loci having exogenous promoters (e.g. EF1a promoters). The TRAC locus reported the highest GFP MFI. There was comparable expression between weeks 3 and 4. The results also showed most top loci have more than 1 sgRNA. With regard to KI efficiency, the SOCS1 locus reported the highest KI efficiency. Overall, KI efficiency showed less variation when driven by the exogenous promoters than when driven by endogenous promoters.
  • FIGS. 31A, 31B, and 31C show GFP MFI and KI efficiency for all significant loci having endogenous and exogenous (e.g., EF1a) promoters. The results showed that expression driven by EF1a promoters is about 10× higher than endogenous promoters (FIG. 31A). With regard to KI efficiency, the SOCS1 locus reported the highest KI efficiency. At weeks 3 and 4, KI efficiency was higher when driven by the exogenous promoters than when driven by endogenous promoters.
  • Example 5: Evaluation of TCR Expression in Candidate Noncoding Sites
  • This experiment was conducted to identify target loci and integration sites that enable high transgene expression without disrupting the TCR. Some gene deserts ( e.g. gene deserts 2, 3, 5, and 6) were identified as having high transgene expression (FIG. 32A).
  • To evaluate and identify preferred knock-in sites, TCR expression was measured following circuit cassette knock in of PrimeR (Prime Receptor (Myc)). Myc denotes an N-terminal Myc epitope tag to facilate detection of surface expressed primer receptor. Briefly, CD3-CD28 Dynabead-activated T cells were electroporated with sgRNA/Cas9 RNPs targeting the indicated sites (see FIGS. 32B and 33A), as well as HDRTs with homology arms directing HDR-mediated integration into the indicated sites. At day 6 post-electroporation, cells were stained with anti-TCRalpha/beta and anti-myc antibodies and analyzed on an Attune NxT flow cytometer. As shown in FIG. 32B, the TCR expression was maintained at GS94 and GS102 candidate integration (knock-in) sites. Only ⅔ of the cells that had circuit cassette knock in of PrimeR at GS79 (TRAC) locus maintained TCR expression. These results indicated that the GS94 and GS102 sites showed better potential for TCR stimulation.
  • The percentage of cells showing effective knock-in (based on measurements of PrimeR) was 36%±4% when using the GS94 integration site, as compared to 32%±5% when using the TRAC integration site. These results revealed integration sites, including GS94, that supported reproducibly high circuit cassette knockin rates. See FIG. 33A.
  • Example 6: Evaluation of GS94 Circuit Expression and Function
  • GS94 is a candidate integration site located on chromosome 11's distal q arm. It is within 180-350 kb of the promoters for ETS1 and FLI1 (FIG. 33B), however that is considered low-risk for integration vector gene therapy. The circuit expression and function potential of the GS94 gene was evaluated.
  • T cells underwent circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site. The cells were cocultured with K562 C19 cells for 48 hours and then the PrimeR induced CAR MFI was compared to the PrimeR MFI.
  • Briefly, T cells generated as described in the Example above were cocultured with K562 CD19+/MSLN− cells at day 7 post-electroporation. MSLN (mesothelin) is a gene that is overexpressed in human pancreatic cancer. Cells were then stained with anti-FLAG antibody 48 h post initiation of coculture and analyzed on an Attune NxT flow cytometer. The results revealed that GS94 yields superior CAR induction with high prime R expression following the 48-hour coculture with the K562 C19 cells. See FIG. 34A. GS94 resulted in prime antigen-dependent CAR expression that was approximately two-fold higher than the expression in several other candidate integration sites as well as the TRAC integration site. Additionally, on average, the prime receptor surface expression level was no less than 50% of expression level when using the TRAC integration site.
  • Cytotoxicity and Cytokine Secretion
  • To evaluate the effect of the candidate integration site on cytotoxicity and cytokine secretion, T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site were cocultured with K562 C19/MSLN cells for 48 hours. MSLN is a gene that is overexpressed in human pancreatic cancer. The cells were treated at a 1:1 effector:target cell ratio (1:1 E:T)). Briefly, T cells generated as described above were cocultured with K562 CD19+/MSLN+ cells at day 7 post-electroporation. 48 h post initiation of coculture, supernatants were collected and analyzed via Luminex® for cytokine levels. The cytokines measure were IL-2, INFg, and TNF. Cytotoxicity was analyzed by measuring luciferase activity of remaining target cells after 48 h. Each of the data points in FIG. 34B represent two replicates and the lines represent the range of cytotoxicity for the replicates. As shown in FIG. 34B, the GS94 integration sites resulted in superior cycotoxic ability and cytokine secretion following the 48-hour coculture with K562 C19/MSLN cells.
  • Prime-Independent Cytotoxicity
  • To compare the effect of the candidate integration site on cytotoxicity versus prime-independent cytotoxicity, T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site were cocultured with K562 CD19+/MSLN+ cells or K562 CD19−/MSLN+ cells (“K562 MSLN”) at day 7 post-electroporation for 48 hours. 0.3, 1.0, and 3.0 E:T cell ratios were tested. See FIG. 35A and FIG. 35B. At 48 h post initiation of coculture, cytotoxicity was analyzed by measuring luciferase activity of remaining target cells As shown in FIG. 35B, the GS94 integration site resulted in equivalent cytotoxic potential to the TRAC integration site and there was no prime-independent cytotoxicity.
  • Prime-Independent Cytokine Section
  • To compare the effect of the candidate integration site on cytoxicity versus prime-independent cytotoxicity, T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site and GS94 integration site, generated as described above, were cocultured with K562 CD19+/MSLN+ cells. A group that had target cells only (E:T=0; Targets only) was compared to a group with an E:T cell ratio of 1. Following the 48 h coculture with the K562 CD19+/MSLN+ cells, supernatant was collected and analyzed via Luminex® for cytokine levels to measure secretion of IL-2, INFg and TNF cytokines. See FIG. 36A and FIG. 36B. As shown in FIG. 36B, the GS94 integration site resulted in equivalent cytokine secretion to the TRAC integration site and there was no prime-independent secretion of IL-2, INFg or TNF.
  • Prime-Independent CAR Expression
  • To evaluate the effect of the candidate integration site on prime-independent CAR expression, T cells that had undergone circuit cassette integration with PrimeR at GS79 (TRAC) integration site, GS94 integration site, and GS102 integration site were cultured in vitro for 32 days. The cells were treated with repetitive CD3/CD28 stimulation at days 5, 12, 19 and 28 of the experiment. On Day 16, the cells were evaluated for CAR expression using a flow cytometry assay. As shown in FIG. 37 , T cell activation through TCR did not result in prime R-independent CAR expression from circuit cassette integration at the candidate integration sites.
  • T cells generated as described above were cultured in 96-well plates, with T cell growth medium being exchanged every 2 days. At days 5, 12, 19 and 28, T cells were stimulated with 1:1 CD3/CD28 Dynabeads. Cells were analyzed for PrimeR expression by myc epitope tag staining, and for CAR expression by FLAG epitope tag staining at the indicated time points. Flow analysis was performed on an Attune NxT flow cytometer.
  • Example 7: Evaluating Stability of Prime Receptor Expression Over Several Weeks
  • To evaluate the effect of the candidate integration sites on stable (sustained) expression of PrimeR, T cells that had undergone circuit cassette integration with PrimeR at the integration sites indicated in FIG. 38 were cultured in vitro for 32 days. Briefly, T cells generated as described above were cultured in 96-well plates, with T cell growth medium being exchanged every 2 days. At days 5, 12, 19 and 28, T cells were stimulated with 1:1 CD3/CD28 Dynabeads repetitive stimulation. Flow cytometry assays were run on days 16 and 32 using an Attune NxT flow cytometer. The cells were analyzed for PrimeR expression by myc epitope tag staining. As shown in FIGS. 38A and 38B, the GS94 integration site resulted in stable PrimeR expression over at least a 4-week period.
  • Example 8: Evaluation of On-Target Editing Efficiency
  • To evaluate the on-target editing efficiency of candidate knock-in sites, iGUIDE-Seq assay was used. The methods used for conducting the iGUIDE-Seq assay are illustrated in FIG. 39A and provided in Nobles et al., Genome Biology (2019), which is hereby incorporated by reference in its entirety. As shown in FIG. 39B, the GS94 integration site had the highest on-target editing efficiency of the evaluated candidate integration sites. As shown in FIG. 39C, GS94 resulted in no putative off-target editing as observed with two donors.
  • Example 9: Evaluation of GS94 Knock-In Methods
  • Elevation prediction: Computational predictions of potential off-target sites from (gs94) were performed using Elevation-search (algorithm described in Listgarten et al. 2018. Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nat Biomed Engr 2, 37-48; software obtained from github.com/Microsoft/Elevation). All sites identified by Elevation-search were subjected to analysis using rhAmp-seg™.
  • rhAmpSeg™: 49 candidate off-target sites for GS94 identified by iGUIDE or the Elevation prediction algorithm and the GS94 target site were characterized by rhAmpSeg™ (Integrated DNA Technologies, Inc.). This targeted amplification enables NGS-based quantification of the editing occurring at numerous sites simultaneously. Genomic DNA from T cells from at least 2 donors that had been treated singly with each of the following 7 guides: GS84, GS94, GS95, GS96, GS102, GS108, and GS138 was isolated with the GenFind® V3 DNA purification system (Beckman Coulter). Two separate rhAmpSeg™ amplification pools were used to cover the 50 loci, the procedure was performed as recommended by Integrated DNA Technologies for each of the samples. The rhAmpSeg™ libraries were sequenced on a MiniSeg™ with a Mid Output Kit (300-cycles) (Illumina). The CRISPResso2 algorithm (github.com/pinellolab/CRISPResso2) was used to determine the percentage of insertions and deletions at each of the amplified loci. Statistical significance (FDR-adjusted p-value≤0.001) using a chi-squared test was only observed at the GS94 site.
  • RNA-seq: To evaluate changes induced by GS94 integration at the transcriptional level, a CD19/MSLN circuit was integrated at the GS79 (TRAC), GS94, and GS102 integration sites. On day 6 post-integration, 1e6 edited cells were sorted using a BD FACSAria based on transgene expression. RNA was isolated from sorted T cells with the RNeasy kit (Qiagen). Purified RNA was converted into an NGS library using the TruSeq™ RNA Library Prep Kit v2 (Illumina). Libraries were sequenced on either the NovaSeq™ 6000 or NextSeq™ 550 instruments (Illumina). The STAR 2.7.3a aligner (Dobin A. et al. Bioinformatics. 2013. 29:15-21) was used to align the RNA-seq data against the reference human GRCh38 transcriptome and to obtain gene-level read counts. edgeR (Robinson M D et al. Bioinformatics. 2010. 26: 139-140) was used to compute differential expression, combining data across both donors. The only genes within 300 Kb of the GS94 site, ETS1 and FLI1, were not differentially expressed in cells with integration at the GS94 integration site compared to cells with integration at any of the other two loci. At an FDR-adjusted p-value cutoff of 0.01, the number of differentially expressed genes was minimal (<100 genes genome-wide).
  • Cytokine-independent growth assay: To evaluate the safety of the primary T cells with GS94 locus KI, cytokine-independent growth assay was performed to evaluate the potential for oncogenic transformation. Briefly, primary human T cells that had undergone CD19/MSLN circuit cassette integration at GS94 locus were thawed and recovered overnight. 1×106 cells were then seeded in one well of a 24 well-GRex plate, culturing for 5 days in the medium with or without cytokines. Cell number and viability were recorded at days 0, 3 and 5. As a positive control, 1×106 Jurkat cells were cultured in the medium without cytokines in parallel. As shown in FIG. 43 , while GS94 KI T cells maintained good viability and total cell count when cultured with cytokine, the viability of GS94 KI T cells drastically decreased over the course of 5 days when cultured without cytokine and there was no viable cell left on day 5. The positive control Jurkat cells maintained good viability and expansion without cytokine throughout the assay. Taken together, this data shows that GS94 edited primary human T cells still depend on exogenous cytokine for growth, survival and expansion, therefore, there is no concern for cellular transformation.
  • Results
  • The specificity of CRISPR reagents (e.g. SpCas9 complexed with sgRNA) targeting candidate loci including GS94 was evaluated by iGUIDE-seq (FIG. 40 ). GS94-targeting CRISPR RNP showed the highest percentage of iGUIDE-seq oligo cassette trapping events of all candidates evaluated, and the control sgRNA sequences from the iGUIDE-seq paper showed similar specificities to what was reported in the original publication, suggesting that the assay performed as expected.
  • Putative off-target sites were taken from the iGUIDE-seq output, which already suggested that the putative sites were spurious. Additional target sites were predicted by a computational approach (Elevation software package). rhAmp-seg™ was used to prepare high-throughput sequencing libraries for each of the putative off-target sites, and the method was applied to DNA samples from T cells electroporated with CRISPR RNPs targeting the candidate target sites. The resulting NGS data were processed with CRISPResso2 software, and the frequency of insertions and deletions (indels) was taken as indication of CRISPR cleavage activity, as is common in the field. T cells electroporated with GS94-targeting CRISPR RNP showed no greater frequency of indels at the set of putative off-target sites than T cells treated with CRISPR RNP targeting other sites, consistent with the GS94-targeting CRISPR RNP having no consequential or detectable off-target activity, and therefore being the most specific out of the set evaluated (FIG. 41 ).
  • Potential effects of transgene integration at the GS94 site on the regulation of the T cell transcriptome were evaluated by knocking in a large cassette to the site, growing T cells for several days, sorting cells expressing the transgene within the cassette, and then collecting RNA from the cells. RNA-seq libraries were prepared and sequenced, and analysis of the resulting Illumina sequencing data revealed no biologically or statistically significant differences in expression of any genes within 300 kb of the GS94 site in cells with integrations at GS94 compared to cells with integration at TRAC or the GS102 sites (FIG. 42 ). Furthermore, other gene expression differences that reached statistical significance were minimal in number and in effect size, consistent with them being noise in the comparison.
  • To assess whether transgene integration at GS94 could confer a transformed phenotype, cells with integrations at the GS94 site were cultured with and without cytokines in vitro. Cells remained alive and viable with cytokine addition, but died without cytokine supplementation and lost their viability (FIG. 43 ). The positive control Jurkat cells remained viable and proliferated. Overall, this indicates that integration of a transgene at GS94 does not confer capacity for cytokine-independent growth, which is a hallmark of T cell transformation.
  • Example 10: In Vivo Insertion of a CAR Expressing Cassette
  • In vivo efficacy of T cells with a transgene cassette expressing a CAR recognizing a tumor antigen, or a CAR recognizing a tumor antigen under control of a priming receptor recognizing an antigen in the anatomical vicinity of the tumor, is assessed against human tumor cells such as K562 engineered to express the CAR antigen or to express antigens recognized by both the priming receptor and the CAR. Tumor cells (e.g. 1e6) are subcutaneously injected into the flank of NSG mice (Jackson Laboratories). Tumor growth is assessed by dimensional measurement by calipers every 2-4 days. When the tumor volume reaches ˜100 cubic mm, mice are intravenously injected with 5e6 T cells with a CAR or prime-CAR circuit cassette integrated at a specific site by CRISPR-mediated insertion, or with T cells engineered with CRISPR RNP alone, or with PBS alone as a sham injection. Tumor growth is monitored and mice are euthanized when tumor volume reaches 2000 cubic mm. Peripheral blood is bled from mice through a retro-orbital procedure, and flow cytometry and/or ddPCR is used to observe engineered T cell expansion over time. At time of sacrifice, spleen, blood, tumor and/or other tissue is analyzed via flow cytometry, ddPCR, and/or immunohistochemistry for the presence of engineered T cells. The results demonstrate that T cells engineered with cassette integration at one of the defined genomic loci lead to tumor regression and clearance in injected mice as compared to T cells without cassette integration, and that engineered T cells are detectable in the peripheral blood and tissues of injected mice.
  • REFERENCES
    • Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J Hamieh, M., Cunanan, K. M., . . . & Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 543(7643), 113-117.
    • Sadelain, M., Papapetrou, E. P., & Bushman, F. D. (2012). Safe harbours for the integration of new DNA in the human genome. Nature reviews Cancer, 12(1), 51-58.
    • Irion, S., Luche, H., Gadue, P., Fehling, H. J., Kennedy, M., & Keller, G. (2007). Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nature biotechnology, 25(12), 1477-1482.
    • Pellenz, S., Phelps, M., Tang, W., Hovde, B. T., Sinit, R. B., Fu, W., . . . & Monnat Jr, R. J. (2019). New human chromosomal sites with “safe harbor” potential for targeted transgene insertion. Human gene therapy, 30(7), 814-828.
    • Roth, T. L., Li, P. J., Nies, J. F., Yu, R., Nguyen, M. L., Lee, Y., . . . & Nguyen, D. N. (2019). Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561.
  • TABLE 4
    SGRNA SEQUENCES USED FOR EVALUATION OF PREDICTED LOCI
    Median (%
    Modified),
    sgRNA_ summarized
    start_ sgRNA Integra- from 2
    sgRNA coor Target tion donors, 2
    ID sgRNA Sequence GRCH38 Loci Site primersets
    sgRNA_ GCACCTGAATACCACGCCTG chr16: APRT APRT 79.28
    1 (SEQ ID NO: 1)  88811818
    sgRNA_ CGCCTGCGATGTAGTCGATG chr16: APRT APRT 78.60
    2 (SEQ ID NO: 2)  88811551
    sgRNA_ CAGGACGGGCGAGATGTCCC chr16: APRT APRT 85.25
    3 (SEQ ID NO: 3)  88811640
    sgRNA_ CTGAATCTTTGGAGTACCTG chr15: B2M B2M 78.51
    4 (SEQ ID NO: 4)  44715425
    sgRNA_ GGCCACGGAGCGAGACATCT chr15: B2M B2M 94.75
    5 (SEQ ID NO: 5)  44711550
    sgRNA_ AAGTCAACTTCAATGTCGGA chr15: B2M B2M 70.97
    6 (SEQ ID NO: 6)  44715515
    sgRNA_ GCTTGGAGGCCTGATCAGCG chr19: CAPNS1 CAPNS1 89.34
    7 (SEQ ID NO: 7)  36141111
    sgRNA_ CTTATCTCTTCGCAGCGAGG chr19: CAPNS1 CAPNS1 91.09
    8 (SEQ ID NO: 8)  36142301
    sgRNA_ CACACATTACTCCAACATTG chr19: CAPNS1 CAPNS1 71.98
    9 (SEQ ID NO: 9)  36142676
    sgRNA_ TTCCGCAAAATAGAGCCCCA chr3: CBLB CBLB 91.55
    10 (SEQ ID NO: 10) 105746019
    sgRNA_ TGCACAGAACTATCGTACCA chr3: CBLB CBLB 91.43
    11 (SEQ ID NO: 11) 105751622
    sgRNA_ GCAATAAGACTCTTTAAAGA chr3: CBLB CBLB 76.18
    12 (SEQ ID NO: 12) 105853470
    sgRNA_ CAAAGAGATTACGAATGCCT chr1: CD2 CD2 89.80
    13 (SEQ ID NO: 13) 116754658
    sgRNA_ CAAGGCACCCCAGGTTTCCA chr1: CD2 CD2 92.70
    14 (SEQ ID NO: 14) 116754663
    sgRNA_ TTACGAATGCCTTGGAAACC chr1: CD2 CD2 92.82
    15 (SEQ ID NO: 15) 116754666
    sgRNA_ CAGAGACGCATCTGACCCTC chr11: CD3E CD3E 90.96
    16 (SEQ ID NO: 16) 118315540
    sgRNA_ CATGCAGTTCTCACACACTG chr11: CD3E CD3E 87.47
    17 (SEQ ID NO: 17) 118313715
    sgRNA_ GTGTGAGAACTGCATGGAGA chr11: CD3E CD3E 86.65
    18 (SEQ ID NO: 18) 118313715
    sgRNA_ TCTCATTTCAGGAAACCACT chr11: CD3G CD3G 87.24
    19 (SEQ ID NO: 19) 118349748
    sgRNA_ AGTCATACACCTTAACCAAG chr11: CD3G CD3G 87.99
    20 (SEQ ID NO: 20) 118349754
    sgRNA_ TTCAAGGAAACCAGTTGAGG chr11: CD3G CD3G 86.55
    21 (SEQ ID NO: 21) 118352458
    sgRNA_ GAGCCTTGCCTGGAAATCTG chr11: CD5 CD5 84.03
    22 (SEQ ID NO: 22)  61118177
    sgRNA_ AAGCGTCAAAAGTCTGCCAG chr11: CD5 CD5 89.19
    23 (SEQ ID NO: 23)  61118324
    sgRNA_ CGTTCCAACTCGAAGTGCCA chr11: CD5 CD5 83.11
    24 (SEQ ID NO: 24)  61118121
    sgRNA_ GAGCGACTGGGACACGGTGA chr9: EDF1 EDF1 88.84
    25 (SEQ ID NO: 25) 136866246
    sgRNA_ GCTGCGCAAGAAGGGCCCTA chr9: EDF1 EDF1 91.04
    26 (SEQ ID NO: 26) 136866211
    sgRNA_ TTGTTCTGGCCAGCAGCCCC chr9: EDF1 EDF1 85.98
    27 (SEQ ID NO: 27) 136863433
    sgRNA_ CTTCCAGAGCCACATCATCG chr19: FTL FTL 93.10
    28 (SEQ ID NO: 28)  48965791
    sgRNA_ GGGACTCACCAGAGAGAGGT chr19: FTL FTL 88.86
    29 (SEQ ID NO: 29)  48965601
    sgRNA_ CGGTCGAAATAGAAGCCCTA chr19: FTL FTL 93.14
    30 (SEQ ID NO: 30)  48965770
    sgRNA_ AAAAGGATATTGTGCAACTG chr10: PTEN PTEN 92.37
    31 (SEQ ID NO: 31)  87933015
    sgRNA_ TGTGCATATTTATTACATCG chr10: PTEN PTEN 90.64
    32 (SEQ ID NO: 32)  87933183
    sgRNA_ TTTGTGAAGATCTTGACCAA chr10: PTEN PTEN 85.36
    33 (SEQ ID NO: 33)  87933087
    sgRNA_ TGTCATGCTGAACCGCATTG chr18: PTPN2 PTPN2 87.94
    34 (SEQ ID NO: 34)  12830972
    sgRNA_ CCACTCTATGAGGATAGTCA chr18: PTPN2 PTPN2 92.45
    35 (SEQ ID NO: 35)  12859219
    sgRNA_ TTGACATAGAAGAGGCACAA chr18: PTPN2 PTPN2 93.96
    36 (SEQ ID NO: 36)  12836828
    sgRNA_ GAGTACTACACTCAGCAGCA chr12: PTPN6 PTPN6 89.61
    37 (SEQ ID NO: 37)   6952098
    sgRNA_ TCACGCACAAGAAACGTCCA chr12: PTPN6 PTPN6 82.74
    38 (SEQ ID NO: 38)   6954872
    sgRNA_ AGGTCTCGGTGAAACCACCT chr12: PTPN6 PTPN6 91.27
    39 (SEQ ID NO: 39)   6951610
    sgRNA_ AGCATTATCCAAAGAGTCCG chr1: PTPRC PTPRC 88.88
    40 (SEQ ID NO: 40) 198696873
    sgRNA_ ATATTAATTCTTACCAGTGG chr1: PTPRC PTPRC 88.95
    41 (SEQ ID NO: 41) 198692370
    sgRNA_ AGCTTTAAATCAAGGTTCAT chr1: PTPRC PTPRC 96.89
    42 (SEQ ID NO: 42) 198756176
    sgRNA_ ATCCCGAGCCCTAAGGTGCA chr11: PTPRCAP PTPRCA 84.08
    43 (SEQ ID NO: 43)  67436325 P
    sgRNA_ GGCAGCGCGGAGGACAGCGT chr11: PTPRCAP PTPRCA 97.74
    44 (SEQ ID NO: 44)  67436285 P
    sgRNA_ CTCAGGGGGCTACTACCACC chr11: PTPRCAP PTPRCA 91.50
    45 (SEQ ID NO: 45)  67436170 P
    sgRNA_ GTCACCGACGAGACCAGAAG chr5: RPS23 RPS23 79.40
    46 (SEQ ID NO: 46)  82277810
    sgRNA_ GTCGTGGACTTCGTACTGCT chr5: RPS23 RPS23 83.07
    47 (SEQ ID NO: 47)  82277843
    sgRNA_ TAATTTTTAGGCAAGTGTCG chr5: RPS23 RPS23 61.94
    48 (SEQ ID NO: 48)  82277860
    sgRNA_ TTAGCTGTTAGACTTGAATA chr14: RTRAF RTRAF 85.50
    49 (SEQ ID NO: 49)  51993810
    sgRNA_ CGAGAGCCGTCAACTTGCGT chr14: RTRAF RTRAF 85.64
    50 (SEQ ID NO: 50)  51989652
    sgRNA_ CGGCTTCAACTGCAAAGGTG chr14: RTRAF RTRAF 88.77
    51 (SEQ ID NO: 51)  51989700
    sgRNA_ TATGAAAAAGCAGAGCGACT chr15: SERF2 SERF2 89.61
    52 (SEQ ID NO: 52)  43793025
    sgRNA_ TCTGGCGGGCGAGCTCACGC chr15: SERF2 SERF2 86.73
    53 (SEQ ID NO: 53)  43792989
    sgRNA_ CTCACGCTGGTTACCGCCTA chr15: SERF2 SERF2 80.57
    54 (SEQ ID NO: 54)  43792977
    sgRNA_ AAAGATTACGAACTTCCCTG chr12: SLC38A1 SLC38A1 92.24
    55 (SEQ ID NO: 55)  46207559
    sgRNA_ GTTAAAAACAGACATGCCTA chr12: SLC38A1 SLC38A1 91.51
    56 (SEQ ID NO: 56)  46229232
    sgRNA_ ATGCCTAAGGAGGTTGTACC chr12: SLC38A1 SLC38A1 79.48
    57 (SEQ ID NO: 57)  46229246
    sgRNA_ CTCCAGGTATCCCATCGAAA chr18: SMAD2 SMAD2 79.53
    58 (SEQ ID NO: 58)  47869418
    sgRNA_ CACCAAATACGATAGATCAG chr18: SMAD2 SMAD2 86.61
    59 (SEQ ID NO: 59)  47870532
    sgRNA_ TGGCGGCGTGAATGGCAAGA chr18: SMAD2 SMAD2 82.91
    60 (SEQ ID NO: 60)  47896729
    sgRNA_ TAGGATGGTAGCACACAACC chr16: SOCS1 SOCS1 92.25
    61 (SEQ ID NO: 61)  11255478
    sgRNA_ CAGCAGCAGAGCCCCGACGG chr16: SOCS1 SOCS1 83.79
    62 (SEQ ID NO: 62)  11255432
    sgRNA_ CGGCGTGCGAACGGAATGTG chr16: SOCS1 SOCS1 84.24
    63 (SEQ ID NO: 63)  11255296
    sgRNA_ TATAGACGCTGCCCGACGTC chr15: SRP14 SRP14 95.12
    64 (SEQ ID NO: 64)  40038895
    sgRNA_ TCCAAAGAAGGGTACTGTGG chr15: SRP14 SRP14 92.14
    65 (SEQ ID NO: 65)  40038368
    sgRNA_ ACAGTACCCTTCTTTGGAAT chr15: SRP14 SRP14 65.82
    66 (SEQ ID NO: 66)  40038358
    sgRNA_ GCGACGGGCGCATCTACGTG chr12: SRSF9 SRSF9 83.68
    67 (SEQ ID NO: 67) 120469572
    sgRNA_ CCCGACCTCCATAAGTCCTG chr12: SRSF9 SRSF9 92.56
    68 (SEQ ID NO: 68) 120465700
    sgRNA_ GGGGTCCTCGAAGCGCACGA chr12: SRSF9 SRSF9 89.94
    69 (SEQ ID NO: 69) 120469426
    sgRNA_ TGCTCTGTTTAGAAGATGAC chr5: SUB1 SUB1 79.36
    70 (SEQ ID NO: 70)  32591641
    sgRNA_ ATATTCTTTTCTAGTTAAAG chr5: SUB1 SUB1 70.93
    71 (SEQ ID NO: 71)  32591566
    sgRNA_ CCTGTAAAGAAACAAAAGAC chr5: SUB1 SUB1 93.66
    72 (SEQ ID NO: 72)  32591614
    sgRNA_ TGGAGAAAGACGTAACTTCG chr4: TET2 TET2 83.53
    73 (SEQ ID NO: 73) 105234315
    sgRNA_ TCTGCCCTGAGGTATGCGAT chr4: TET2 TET2 90.97
    74 (SEQ ID NO: 74) 105234747
    sgRNA_ ATTCCGCTTGGTGAAAACGA chr4: TET2 TET2 89.62
    75 (SEQ ID NO: 75) 105235656
    sgRNA_ CAGGCACAATAGAAACAACG chr3: TIGIT TIGIT 92.65
    76 (SEQ ID NO: 76) 114295571
    sgRNA_ CCATTTGTAATGCTGACTTG chr3: TIGIT TIGIT 60.75
    77 (SEQ ID NO: 77) 114295700
    sgRNA_ CTGGGTCACTTGTGCCGTGG chr3: TIGIT TIGIT 87.99
    78 (SEQ ID NO: 78) 114295634
    sgRNA_ GTCAGGGTTCTGGATATCTG chr14: TRAC TRAC 98.20
    79 (SEQ ID NO: 79)  22547508
    sgRNA_ TGGATTTAGAGTCTCTCAGC chr14: TRAC TRAC 88.15
    80 (SEQ ID NO: 80)  22547541
    sgRNA_ CTGCGGCTGTGGTCCAGCTG chr14: TRAC TRAC 94.77
    81 (SEQ ID NO: 81)  22550661
    sgRNA_ ACAAAACTGTGCTAGACATG chr14: TRAC TRAC 87.86
    82 (SEQ ID NO: 82)  22547658
    sgRNA_ TTCTTCCCCAGCCCAGGTAA chr14: TRAC TRAC 89.85
    83 (SEQ ID NO: 83)  22547778
    sgRNA_ CGTCATGAGCAGATTAAACC chr14: TRAC TRAC 95.81
    84 (SEQ ID NO: 84)  22550625
    sgRNA_ GAGAGCGCCTGCGACCCGAG chr19: TRIM28 TRIM28 89.44
    85 (SEQ ID NO: 85)  58544980
    sgRNA_ CCAGCGGGTGAAGTACACCA chr19: TRIM28 TRIM28 94.79
    86 (SEQ ID NO: 86)  58544869
    sgRNA_ GGAGCGCTTTTCGCCGCCAG chr19: TRIM28 TRIM28 91.81
    87 (SEQ ID NO: 87)  58544839
    sgRNA_ TGAGGCCTGGACCTTATGCA chr10: chr10: desert_ 69.44
    88 (SEQ ID NO: 88)  33134193  33130000- 1
     33140000 (GS88)
    sgRNA_ CCTGGTGGAGTGAACCATGA chr10: chr10: desert_ 95.25
    89 (SEQ ID NO: 89)  33132917  33130000- 1
     33140000 (GS89)
    sgRNA_ CAAGCACTTAGGTTCCCCTG chr10: chr10: desert_ 91.13
    90 (SEQ ID NO: 90)  33134633  33130000- 1
     33140000 (GS90)
    sgRNA_ GGTCTCCCTACAATTCAGCG chr10: chr10: desert_ 92.02
    91 (SEQ ID NO: 91)  72294568  72290000- 2
     72300000 (GS91)
    sgRNA_ CACAGCGCGTGACTGCAATG chr10: chr10: desert_ 90.22
    92 (SEQ ID NO: 92)  72298268  72290000- 2
     72300000 (GS92)
    sgRNA_ TCTGGGGCACCAATTCTAGG chr10: chr10: desert_ 86.35
    93 (SEQ ID NO: 93)  72292786  72290000- 2
     72300000 (GS93)
    sgRNA_ GAGCCATGCTTGGCTTACGA chr11: chr11: desert_ 91.24
    94 (SEQ ID NO: 94) 128342576 128340000- 3
    128350000 (GS94)
    sgRNA_ GTACAAGTACTTATCTCATG chr11: chr11: desert_ 89.02
    95 (SEQ ID NO: 95) 128343592 128340000- 3
    128350000 (GS95)
    sgRNA_ GAGATAACAACATAACAACA chr11: chr11: desert_ 96.47
    96 (SEQ ID NO: 96) 128347170 128340000- 3
    128350000 (GS96)
    sgRNA_ CATATTCCATAGTCTTTGGG chr11: chr11: desert_ 88.54
    97 (SEQ ID NO: 97)  65425000  65425000- 4
     65427000 (GS97)
    (NEAT1)
    sgRNA_ CTGCCCCTTAGCAACTTAGG chr11: chr11: desert_ 92.76
    98 (SEQ ID NO: 98)  65425507  65425000- 4
     65427000 (GS98)
    (NEAT1)
    sgRNA_ TGTTTAAAAATATGTTGACA chr11: chr11: desert_ 90.76
    99 (SEQ ID NO: 99)  65426264  65425000- 4
     65427000 (GS99)
    (NEAT1)
    sgRNA_ CCAGGAATGGAAACTCACGC chr15: chr15: desert_ 87.84
    100 (SEQ ID NO: 100)  92830315  92830000- 5
     92840000 (GS100)
    sgRNA_ GAGGCCGCTGAATTAACCCG chr15: chr15: desert_ 85.32
    101 (SEQ ID NO: 101)  92831850  92830000- 5
     92840000 (GS101)
    sgRNA_ ATACACGCACACTTGCAGAA chr15: chr15: desert_ 99.92
    102 (SEQ ID NO: 102)  92831131  92830000- 5
     92840000 (GS102)
    sgRNA_ GAGCAGACAGAAACCCAGGG chr16: chr16: desert_ 87.92
    103 (SEQ ID NO: 103)  11225670  11220000- 6
     11230000 (GS103)
    sgRNA_ TGAGTCTCCAAACAGAACAG chr16: chr16: desert_ 88.53
    104 (SEQ ID NO: 104)  11226284  11220000- 6
     11230000 (GS104)
    sgRNA_ TAATATCACTGACTTCACGG chr16: chr16: desert_ 87.65
    105 (SEQ ID NO: 105)  11225029  11220000- 6
     11230000 (GS105)
    sgRNA_ TACACACAATGTAAGCAGCA chr2: chr2: desert_ 71.79
    106 (SEQ ID NO: 106)  87467461  87460000- 7
     87470000 (GS106)
    sgRNA_ GGGAGCTCAATTCGAAACCA chr2: chr2: desert_ 65.89
    107 (SEQ ID NO: 107)  87468809  87460000- 7
     87470000 (GS107)
    sgRNA_ TTGGACAGGTGAGACAGTCG chr2: chr2: desert_ 72.64
    108 (SEQ ID NO: 108)  87467001  87460000- 7
     87470000 (GS108)
    sgRNA_ AAGCTCACTCAGATAGTGTG chr3: chr3: desert_ 76.89
    109 (SEQ ID NO: 109) 186511316 186510000- 8
    186520000 (GS109)
    sgRNA_ CAGGAGAACCACCTTACACG chr3: chr3: desert_ 86.31
    110 (SEQ ID NO: 110) 186515260 186510000- 8
    186520000 (GS110)
    sgRNA_ GGACAGACCCTGATTCACAA chr3: chr3: desert_ 85.47
    111 (SEQ ID NO: 111) 186519655 186510000- 8
    186520000 (GS111)
    sgRNA_ ACATGGCAGTCTATGAACAG chr3: chr3: desert_ 87.77
    112 (SEQ ID NO: 112)  59451154  59450000- 9
     59460000 (GS112)
    sgRNA_ CCTATAGAGAGTACTACTTG chr3: chr3: desert_ 79.33
    113 (SEQ ID NO: 113)  59456416  59450000- 9
     59460000 (GS113)
    sgRNA_ CCAACCGGGTCTTCATTACG chr3: chr3: desert_ 92.21
    114 (SEQ ID NO: 114)  59457029  59450000- 9
     59460000 (GS114)
    sgRNA_ TCAAGCGTAGAGTTCCGAGT chr8: chr8: desert_ 93.07
    115 (SEQ ID NO: 115) 127993006 127980000- 10
    128000000 (GS115)
    sgRNA_ TCATGCAATTATGGACCCAG chr8: chr8: desert_ 89.40
    116 (SEQ ID NO: 116) 127994663 127980000- 10
    128000000 (GS116)
    sgRNA_ CGGGAAAGTGACTGGCCATG chr8: chr8: desert_ 87.45
    117 (SEQ ID NO: 117) 127996766 127980000- 10
    128000000 (GS117)
    sgRNA_ TGAGATTGAAATCAAATCGG chr9: chr9: desert_ 84.84
    118 (SEQ ID NO: 118)   7974159   7970000- 11
      7980000 (GS118)
    sgRNA_ TATGCAATATTCATCACGCG chr9: chr9: desert_ 85.44
    119 (SEQ ID NO: 119)   7977914   7970000- 11
      7980000 (GS119)
    sgRNA_ AATGTGTTAAATCAAATGCA chr9: chr9: desert_ 83.48
    120 (SEQ ID NO: 120)   7976895   7970000- 11
      7980000 (GS120)
  • TABLE 5
    CONSTRUCTS USED FOR EVALUATION OF PREDICTED LOCI
    Construct name Sequence Length
    pARBI-903: ATCTCGGCCAATAAAGGAGAAAGGGCGCGGCCCGTACGCGCGCCAGGTGC 1806
    APRT_1_ GTGGGCGAGACCAGCTCACGCCCCTCCTCCAGCCGCCAAGGCCCCGGCCC
    Endogenous_1 ACAGCTGCCTGGCTGCAGTCAGAAGCGTAGCCCGAGACAAGGAAGGGCGC
    CTTGACTCGCACTTTTGTCCGGTTCGAACGTTCTGctcagtggtgcgtgg
    aatgcgagcgcgtcttaaaatcgatggcgcctaggagtccatgaaatacg
    gTACAGGCTTCCGGCGACGGATGCCCCGCCCCTCACCCACGCTCCGCCCT
    CCGGGGATGCCCCACCCCTCGTGGCGGTCCCGCCCGTCCCCGCGCAGGCG
    CGCTCGGGCTGCCGCTGGCTCTTCGCACGCGGCCATGGCCGACTCCGAGC
    TGCAGCTGGTTGAGCAGCGGATCCGCAGCTTCCCCGACTTCCCCACCCCA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGCGTGGTATTCAGGTGCACGCACAGGCCGCCCTCGTGGCGCCC
    CGACCTGCGGGCCTACGGATGGGAGCGCGTGGCCCGCGACCTCCGGGCGG
    GCGGGGGGGGAACCCTCGTCTTTCGCCCCCGGGGCCCTGCCCTCCTTCGG
    CCCCGGCGTCACCAGGCCTGTCCTTGGGTCCAGGGACATCTCGCCCGTCC
    TGAAGGACCCCGCCTCCTTCCGCGCCGCCATCGGCCTCCTGGCGCGACAC
    CTGAAGGCGACCCACGGGGGCCGCATCGACTACATCGCAGGCGAGTGCCC
    AGTGGCCGCATCTAGGGCGCTTCCGCCTCTGCGCGCGCCGAGGGCAGCAC
    GTGGGCTCTGCGCGTCTGCTTGGGGGAGGGCCTTTGGGGTGCTTCAGGGG
    GCGCCGGGACGGGCGCCGTGCTTGGGTCGCCCGGGAAGGGTTGTGAGATT
    GAGCCC
    (SEQ ID NO: 123)
    pARBI-904: TGCCCCGCCCCTCACCCACGCTCCGCCCTCCGGGGATGCCCCACCCCTCG 1806
    APRT_2_ TGGCGGTCCCGCCCGTCCCCGCGCAGGCGCGCTCGGGCTGCCGCTGGCTC
    Endogenous_2 TTCGCACGCGGCCATGGCCGACTCCGAGCTGCAGCTGGTTGAGCAGCGGA
    TCCGCAGCTTCCCCGACTTCCCCACCCCAGGCGTGGTATTCAGGTGCACG
    CACAGGCCGCCCTCGTGGCGCCCCGACCTGCGGGCCTACGGATGGGAGCG
    CGTGGCCCGCGACCTCCGGGGGGGGGGGGCGGGAACCCTCGTCTTTCGCC
    CCCGGGGCCCTGCCCTCCTTCGGCCCCGGCGTCACCAGGCCTGTCCTTGG
    GTCCAGGGACATCTCGCCCGTCCTGAAGGACCCCGCCTCCTTCCGCGCCG
    CCATCGGCCTCCTGGCGCGACACCTGAAGGCGACCCACGGGGGCCGCATC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGACTACATCGCAGGCGAGTGCCCAGTGGCCGCATCTAGGGCGCT
    TCCGCCTCTGCGCGCGCCGAGGGCAGCACGTGGGCTCTGCGCGTCTGCTT
    GGGGGAGGGCCTTTGGGGTGCTTCAGGGGGCGCCGGGACGGGCGCCGTGC
    TTGGGTCGCCCGGGAAGGGTTGTGAGATTGAGCCCCCGAGGCCGCCGCGC
    TGTGCAGGCGTCCTTCCCGCAGGTTCCGGGTCCCCAGCCCAGGACAGGCG
    TGACCGAGTTGCCGGGTCAGTTGGTCTCCCTGGAGTGCCCAAGCTGAATC
    CACAGGGCCCAGCTGCCTTGCTTCTTGTTCCTTCTGCGAGCTGGTATTGA
    GCGCCTGCCACGAGCCAGGCCTTCCCTGGTGAAGATCACGGAATGCCCAC
    CCAGGGAAGGGAGGCCTGGAGGCCTCCGGGAGAGCCCAAGAGGTGGCCCA
    GGGAGA
    (SEQ ID NO: 124)
    pARBI-905: CGTTCTGctcagtggtgcgtggaatgcgagcgcgtcttaaaatcgatggc 1806
    APRT_3_ gcctaggagtccatgaaatacggTACAGGCTTCCGGCGACGGATGCCCCG
    Endogenous_3 CCCCTCACCCACGCTCCGCCCTCCGGGGATGCCCCACCCCTCGTGGCGGT
    CCCGCCCGTCCCCGCGCAGGCGCGCTCGGGCTGCCGCTGGCTCTTCGCAC
    GCGGCCATGGCCGACTCCGAGCTGCAGCTGGTTGAGCAGCGGATCCGCAG
    CTTCCCCGACTTCCCCACCCCAGGCGTGGTATTCAGGTGCACGCACAGGC
    CGCCCTCGTGGCGCCCCGACCTGCGGGCCTACGGATGGGAGCGCGTGGCC
    CGCGACCTCCGGGCGGGCGGGGGGGGAACCCTCGTCTTTCGCCCCCGGGG
    CCCTGCCCTCCTTCGGCCCCGGCGTCACCAGGCCTGTCCTTGGGTCCAGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGACATCTCGCCCGTCCTGAAGGACCCCGCCTCCTTCCGCGCCGC
    CATCGGCCTCCTGGCGCGACACCTGAAGGCGACCCACGGGGGCCGCATCG
    ACTACATCGCAGGCGAGTGCCCAGTGGCCGCATCTAGGGCGCTTCCGCCT
    CTGCGCGCGCCGAGGGCAGCACGTGGGCTCTGCGCGTCTGCTTGGGGGAG
    GGCCTTTGGGGTGCTTCAGGGGGCGCCGGGACGGGCGCCGTGCTTGGGTC
    GCCCGGGAAGGGTTGTGAGATTGAGCCCCCGAGGCCGCCGCGCTGTGCAG
    GCGTCCTTCCCGCAGGTTCCGGGTCCCCAGCCCAGGACAGGCGTGACCGA
    GTTGCCGGGTCAGTTGGTCTCCCTGGAGTGCCCAAGCTGAATCCACAGGG
    CCCAGCTGCCTTGCTTCTTGTTCCTTCTGCGAGCTGGTATTGAGCGCCTG
    CCACGA
    (SEQ ID NO: 125)
    pARBI-906: AGTAATTTGATGGGGGCTATTATGAACTGAGAAATGAACTTTGAAAAGTA 1806
    B2M_1_ TCTTGGGGCCAAATCATGTAGACTCTTGAGTGATGTGTTAAGGAATGCTA
    Endogenous_4 TGAGTGCTGAGAGGGCATCAGAAGTCCTTGAGAGCCTCCAGAGAAAGGCT
    CTTAAAAATGCAGCGCAATCTCCAGTGACAGAAGATACTGCTAGAAATCT
    GCTAGAAAAAAAACAAAAAAGGCATGTATAGAGGAATTATGAGGGAAAGA
    TACCAAGTCACGGTTTATTCTTCAAAATGGAGGTGGCTTGTTGGGAAGGT
    GGAAGCTCATTTGGCCAGAGTGGAAATGGAATTGGGAGAAATCGATGACC
    AAATGTAAACACTTGGTGCCTGATATAGCTTGACACCAAGTTAGCCCCAA
    GTGAAATACCCTGGCAATATTAATGTGTCTTTTCCCGATATTCCTCAGGT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACTCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGG
    AAAGTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATCCATCCGACA
    TTGAAGTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCAT
    TCAGACTTGTCTTTCAGCAAGGACTGGTCTTTCTATCTCTTGTACTACAC
    TGAATTCACCCCCACTGAAAAAGATGAGTATGCCTGCCGTGTGAACCATG
    TGACTTTGTCACAGCCCAAGATAGTTAAGTGGGGTAAGTCTTACATTCTT
    TTGTAAGCTGCTGAAAGTTGTGTATGAGTAGTCATATCATAAAGCTGCTT
    TGATATAAAAAAGGTCTATGGCCATACTACCCTGAATGAGTCCCATCCCA
    TCTGATATAAACAATCTGCATATTGGGATTGTCAGGGAATGTTCTTAAAG
    ATCAGA
    (SEQ ID NO: 126)
    pARBI-907: AAGATCTTAATCTTCTGGGTTTCCGTTTTCTCGAATGAAAAATGCAGGTC 1806
    B2M_2_ CGAGCAGTTAACTGGCTGGGGCACCATTAGCAAGTCACTTAGCATCTCTG
    Endogenous_5 GGGCCAGTCTGCAAAGCGAGGGGGCAGCCTTAATGTGCCTCCAGCCTGAA
    GTCCTAGAATGAGCGCCCGGTGTCCCAAGCTGGGGCGCGCACCCCAGATC
    GGAGGGCGCCGATGTACAGACAGCAAACTCACCCAGTCTAGTGCATGCCT
    TCTTAAACATCACGAGACTCTAAGAAAAGGAAACTGAAAACGGGAAAGTC
    CCTCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGACAGGTGACGGTC
    CCTGCGGGCCTTGTCCTGATTGGCTGGGCACGCGTTTAATATAAGTGGAG
    GCGTCGCGCTGGCGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTC
    TGGCCTGGAGGCTATCCAGCGTGAGTCTCTCCTACCCTCCCGCTCTGGTC
    CTTCCTCTCCCGCTCTGCACCCTCTGTGGCCCTCGCTGTGCTCTCTCGCT
    CCGTGACTTCCCTTCTCCAAGTTCTCCTTGGTGGCCCGCCGTGGGGCTAG
    TCCAGGGCTGGATCTCGGGGAAGCGGGGGGTGGCCTGGGAGTGGGGAAGG
    GGGTGCGCACCCGGGACGCGCGCTACTTGCCCCTTTCGGCGGGGAGCAGG
    GGAGACCTTTGGCCTACGGCGACGGGAGGGTCGGGACAAAGTTTAGGGCG
    TCGATAAGCGTCAGAGCGCCGAGGTTGGGGGAGGGTTTCTCTTCCGCTCT
    TTCGCGGGGCCTCTGGCTCCCCCAGCGCAGCTGGAGTGGGGGACGGGTAG
    GCTCG
    (SEQ ID NO: 127)
    pARBI-908: AGGAATGCTATGAGTGCTGAGAGGGCATCAGAAGTCCTTGAGAGCCTCCA 1806
    B2M_3_ GAGAAAGGCTCTTAAAAATGCAGCGCAATCTCCAGTGACAGAAGATACTG
    Endogenous_6 CTAGAAATCTGCTAGAAAAAAAACAAAAAAGGCATGTATAGAGGAATTAT
    GAGGGAAAGATACCAAGTCACGGTTTATTCTTCAAAATGGAGGTGGCTTG
    TTGGGAAGGTGGAAGCTCATTTGGCCAGAGTGGAAATGGAATTGGGAGAA
    ATCGATGACCAAATGTAAACACTTGGTGCCTGATATAGCTTGACACCAAG
    TTAGCCCCAAGTGAAATACCCTGGCAATATTAATGTGTCTTTTCCCGATA
    TTCCTCAGGTACTCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGA
    ATGGAAAGTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATCCATCC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGAATTGAAAA
    AGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTTTCTATCTCT
    TGTACTACACTGAATTCACCCCCACTGAAAAAGATGAGTATGCCTGCCGT
    GTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGGGGTAAGTC
    TTACATTCTTTTGTAAGCTGCTGAAAGTTGTGTATGAGTAGTCATATCAT
    AAAGCTGCTTTGATATAAAAAAGGTCTATGGCCATACTACCCTGAATGAG
    TCCCATCCCATCTGATATAAACAATCTGCATATTGGGATTGTCAGGGAAT
    GTTCTTAAAGATCAGATTAGTGGCACCTGCTGAGATACTGATGCACAGCA
    TGGTTTCTGAACCAGTAGTTTCCCTGCAGTTGAGCAGGGAGCAGCAGCAG
    CACTTG
    (SEQ ID NO: 128)
    pARBI-909: GATCTCACATTCTAGCGCCCAGACATGTCGGGAACGCCTTACGCCAACTT 1806
    CAPNS1_1_ GGGGTCCCCACCAAGAGAACCCCCACCAGATCTGCACCCTCCCCTTCACG
    Endogenous_7 CGTGCACCCAGTCCAGGCTCCCTCAAGCCCCACGGGTGCCTTTTAGACCT
    GAGGAGGTTGCAAACCTGATCCCCCATACCTGCCCCACCCATCCGCGGAC
    AACCCGCCCTCGCAAACTCAGACCCCCACCCGGAGGCTTCAGATTCCTCC
    CAGGTCCAGCTGCCGGAAATGCGTGTTTGAAGGGAGGGTGTGGGCTCAGG
    GGCGAAGCACCCACTGGTCCCCTTTTTTCCCCCCAGCAGTGAGTCGCAGC
    CATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGGG
    GAGGCGGGGGCCTGGGTGGGGGCCTGGGAAATGTGCTTGGAGGCCTGATC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAGCGGGGCCGGGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG
    TGGTGGAGGCGGCGGTGGCGGTGGAACGGCCATGCGCATCCTAGGCGGAG
    TCATCAGCGCCATCAGGTAAGGCGGAGACTATCAGAGGGGGGGGCCTGGG
    AATGGGAGGAGCCTCAGTGAGGCGTGGTCTGGGAGGGGCGTGGTCTAAAA
    ATAGAATAGGATTAACCTGGAGGCTAACCTGGGTACATGAATTAGGCCGG
    GGAGGCCTGGTTTGAGAGTTCTGCTGTAAGGGGGTGGACCCCAGTGAGGC
    GGATATCAGTCATTGGGGGCGGTGCTTGATATGGGAGTAGTCTGATTGTG
    TGGGACCAGGACAATGTGGTCCTGAGGGGACTGATGTGGAGTTTTGGCGG
    GTGGGGCTTATGGGTCTGGGCTCAGCCTGCATTGGCTAACCTGGAGATGA
    ACGTT
    (SEQ ID NO: 129)
    pARBI-910: CGGGCATTTAGGAAGCGGGCCATGGAGTAGGGTCTTGGGCAGATGGCACC 1806
    CAPNS1_2_ TGAGGAGGATAAGGCCTTGGGAAGCTGGGGCAGAGCCTCTATGAAGTGAG
    Endogenous_8 CCCTCCAAGGGGCGGGGTCTTTTGATTCTACGTGGGATTTTTTAGGTTTA
    GGGTGGCCAAGATGACTGAAATCTGCCACTGGGTAGGTGTGCCTGGCAGG
    AGGGGAGCCTCCCAGGGGACCGGTCTCTGGGTTTCCTCGAGGGTGGGGTT
    GGCCTGAGGAAGGGAGAAGAGGGGCACGACCAGGGCAGTGTGGATTGGGA
    CAGATGAGGACAAGAACAAATGAAAGGCACAGCAACCAAGTAAGGAAGAT
    AACGGCTGGGGTCTGGAGCGTTGGGGCTGATGGTTCTGTAGTGCTGCCCG
    TTGGAGGCCCCGCCCCTGGCACTAACCCCTCCCCCTTATCTCTTCGCAGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGAGGCGGCTGCGCAGTACAACCCGGAGCCCCCGGTAAGCCCCCT
    CTGCAACCAGACCCCCTTCTCCTGCCAAGGCCTCTTCGAGGTCCCATCCC
    TGTTCCTGTAGAGAAGCCCCACCTTCCTCCCCTTCTTGTGAAATTCCTCT
    GCCAGTTCCTCCCATGCCGTGTCTGCAGCTTCGCCATGGGTCTTAGCCAT
    GCCCCACATACGTGCACCCCATTCACTACCACCCCTCATTCTTTTCCTCA
    TCAAGCTGCCCAGCCCACTCTGACTTCCCCACCCAGGGTACCTGGGTTTG
    GGGAGCCGTCCTGGCCGGGTTCCCCTCCCCCTGCTCTGAGCTCTCCTCCC
    TTTGCAGCCCCCACGCACACATTACTCCAACATTGAGGCCAACGAGAGTG
    AGGAGGTCCGGCAGTTCCGGAGACTCTTTGCCCAGCTGGCTGGAGATGTA
    AGTAAC
    (SEQ ID NO: 130)
    pARBI-911: GCTGATGGTTCTGTAGTGCTGCCCGTTGGAGGCCCCGCCCCTGGCACTAA 1806
    CAPNS1_3_ CCCCTCCCCCTTATCTCTTCGCAGCGAGGCGGCTGCGCAGTACAACCCGG
    Endogenous_9 AGCCCCCGGTAAGCCCCCTCTGCAACCAGACCCCCTTCTCCTGCCAAGGC
    CTCTTCGAGGTCCCATCCCTGTTCCTGTAGAGAAGCCCCACCTTCCTCCC
    CTTCTTGTGAAATTCCTCTGCCAGTTCCTCCCATGCCGTGTCTGCAGCTT
    CGCCATGGGTCTTAGCCATGCCCCACATACGTGCACCCCATTCACTACCA
    CCCCTCATTCTTTTCCTCATCAAGCTGCCCAGCCCACTCTGACTTCCCCA
    CCCAGGGTACCTGGGTTTGGGGAGCCGTCCTGGCCGGGTTCCCCTCCCCC
    TGCTCTGAGCTCTCCTCCCTTTGCAGCCCCCACGCACACATTACTCCAAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatATTGAGGCCAACGAGAGTGAGGAGGTCCGGCAGTTCCGGAGACT
    CTTTGCCCAGCTGGCTGGAGATGTAAGTAACCTGGGGTCCCTGGCCCCGT
    CCTAACCGTTCCATCCCTTCCCTTGTGGCTGCCCTTGCACACACACCCTT
    GACCATGACAATCCCAGTGTTCCCATTCTCCATGACATTCTCAGACCCCT
    TTCAGTCACCCCTGACCTGCCCCTAACTTCCGCCCGCAGGACATGGAGGT
    CAGCGCCACAGAACTCATGAACATTCTCAATAAGGTTGTGACACGACGTA
    AGTGACCGGGGTTAAGGAATAGGGTAGATTCAGAGGCAGAGGGGTCAGAG
    AGGATTTGACCTCTGGCCTCTGACTTTCAACCTGTTACCCACAGACCCTG
    ATCTGAAGACTGATGGTTTTGGCATTGACACATGTCGCAGCATGGTGGCC
    GTGATG
    (SEQ ID NO: 131)
    pARBI-912: ggagagttatagcagatggagacaaaaaagggaactgctggggatcaaac 1806
    CBLB_1_ cttgtaaagtccttctaagtgatatatgaggactttgacttttattcaaa
    Endogenous_10 gttagaaggctttgaacaaaagaattatttcatttgtgttttacaatggt
    cacaagtgccgtagcgagaataggctgTGTAGAGAAGAGATTTTGTGGTT
    TTCTTTTTTGTTCTCTGTATTCTCTTCCTGAAAAATCTGTTTTCTGCCTA
    ATCATATTTCTGTAAAGAACAATAGACTTGAACGTCTGCTGTTAAGTAAC
    AAAGGTTGACCTAAACCACATAAGGTCAGATTAACTTTTAAAATATCCAA
    GATAATGTTAAGTGTATTAAATATGGTTCAGTATGTAATCAAAATATTTG
    ATATTCTCTAGATACTAATCTCttttaatttttttattttttAGCCTTGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGCTCTATTTTGCGGAATTGGAATTTCTTAGCTGTGACACATCC
    AGGTTACATGGCATTTCTCACATATGATGAAGTTAAAGCACGACTACAGA
    AATATAGCACCAAACCCGGAAGGTAAGACTTTTTAGCAGTAATATTATGT
    GATATATCCAAAGATGAAAAATTCTCCATGGTTTGTTCCTAAGTAAGTCA
    GCAATACCCGCTGATGGCATGCTTGGGAGGGGGCTAGAAAAGGTAAAAGA
    CCAAAATGGTGCTTCTTAACATAATGTTTTAAATTGATACATTGTGCTTA
    CTCTGAAACTTGGTATTCATAAAGTGAAAGGGGATATGGTCTCCTTTCTG
    TTTTCATGATATCCGTGTTTATGTGCAAAATTGAATGTATATATTTGAAT
    ACTTGAATACTGTGCTAAAGAACAAATAAATAGAACAGTCTTATGTTCAT
    TACTTT
    (SEQ ID NO: 132)
    pARBI-913: CATATTACTCATTTGTGCAATGAATAAAGGATTTCTATTATTATATGGAC 1806
    CBLB_2_ CCATCATCTTATGACTGTTTTTAGAAAATGAGAATTAAATCTTGATTCAT
    Endogenous_11 TATTAAATAACCTTGTATACACACATGAAGAGGTCATGACACATAAGACT
    TTGACCTAATACCTTTTTTCAGATATGTTTCTATAGCTATCTTGATAGCC
    TAGGACTGTTTGAGAGAAAATTAATTTAAATTTTTGTCATATTCTTAGCA
    AATGCAAAATAATTGAGTTAAACAGAACCCACTACATTTGTTCTGAAATA
    TGAACAATATTCTCAAATATTTGTCTGGTAGTACAAATACAATTATATTA
    ATTTTATTATTGAATTTTGCTGCTTCAAAGGGAGGTATTTCTTAAATGAT
    ACTTGATTCAATTATTTCCCTTTTTTTCCACCTTGCACAGAACTATCGTA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCCATGGAAAGTATTCAGACAGTGCCTTCATGAGGTCCACCAGAT
    TAGCTCTGGCCTGGAAGCAATGGCTCTAAAATCAACAATTGATTTAACTT
    GCAATGATTACATTTCAGTTTTTGAATTTGATATTTTTACCAGGCTGTTT
    CAGGTAAGTTTATACTTGCTTAGTCTATCCATTCCCTtcttctctctccc
    tgtcttttctctctgtttctctctctctctgtctctctctcacacacaca
    cacaTAAACAAACATATGGAAAATAGTGTCATTCCTATTAGTCTGTAATT
    TTATTGGTATGTTTGGTCATTGTTAAAAGTTTAGAGTGAGCCATTTGGCT
    TAAGTTTGGAGTTATCAGATGCTGTGAGCCTGGTGGCTGCTTGTTAGCTT
    TGAGAGGATCCATCCAAAAGAGCTTTGTTTTAAACTCTCTACTTAGTTTC
    TTACTT
    (SEQ ID NO: 133)
    pARBI-914: TTAAACTTTAGAGGTTCAAAATAAGGATATGATATAGAAAAGATTGAATG 1806
    CBLB_3_ GTAGGAGAACAGAATAGGATTTATTTATATTATGACAAACGTGACTATCA
    Endogenous_12 GTTAATAAATTGGAGATAGTAAGTTAAGATCATTATTTATATTATGGAAA
    AATGAAGAAATAGGACATGGTTCTCTAACTTTTTAATTTTTCTGTGAAAT
    AAAATATTATGACTTATTTTATTTTTATCTTTGTTTTTAGGTAAGACTGT
    GCCAAAATCCCAAACTTCAGTTGAAAAATAGCCCACCATATATACTTGAT
    ATTTTGCCTGATACATATCAGCATTTACGACTTATATTGAGTAAATATGA
    TGACAACCAGAAACTTGCCCAACTCAGTGAGAATGAGTACTTTAAAATCT
    ACATTGATAGCCTTATGAAAAAGTCAAAACGGGCAATAAGACTCTTTAAA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGAAGGCAAGGAGAGAATGTATGAAGAACAGTCACAGGACAGGTA
    AGAAGAATATTTCAGATGTTTTGGTGTAAAGGTCATTTATGTTGCTTTTT
    ACTTAATAGTTAACCTAAACGTCACCATGTAATTGTTTTGGGGTAAATGT
    GAGTCGCTTTGTATATagtcatgtggtacttaacgatggggatactttac
    aagaaatgcatttttagacaatttcattgttgtgtggacatgatagagtg
    tacttacacagagctagatggtattacctaccgcacacctaggctgtatg
    atgtagcctattgctcctaggctgcaaatctatacagtatgttactgtac
    tgaatactgtgggcagttgtaacacaatggtaagtatgtgtgtatctaaa
    tatacctaaacatagaaaaggtatggtaaaaatactgtataaaaggccgg
    gcgtgg
    (SEQ ID NO: 134)
    pARBI-915: AGATGAGAAAACCTATCCTTCCCAATTTTTTTGTGTGAGAATTAAAATGC 1806
    CD2_1_ AGCAAGAAAACACACACTCATAAACACATCTGCTTTGGCAAAGGAGCACA
    Endogenous_13_ TCAGAAGGGCTGGCTTGTGCGCGCTCTTGCTCTCTGTGTATGTGTATTAT
    14_15 GTTTTATGTTACTGTAAAAGATGTAAAGAGAGGCACGTGGTTAAGCTCTC
    GGGGTGTGGACTCCACCAGTCTCACTTCAGTTCCTTTTGCATGAAGAGCT
    CAGAATCAAAAGAGGAAACCAACCCCTAAGATGAGCTTTCCATGTAAATT
    TGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAAGGTAAGCATA
    AGAGTCAAAGAAGTCCCAACCCAGCTTTCCCTGAAAGTGACTCTCAGTAA
    CTCTTTTGCTTTTTATAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGACATTCC
    TAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTT
    CAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAG
    GAAAAAGATACATATAAGCTATTTAAAAATGGAACTCTGAAAATTAAGCA
    TCTGAAGACCGATGATCAGGATATCTACAAGGTATCAATATATGATACAA
    AAGGAAAAAATGTGTTGGAAAAAATATTTGATTTGAAGATTCAAGGTAAG
    TGTTCATTCCCTTAATTGCTTTATTTCAGTGTGGGTGCTATTTGGCAAGT
    TGGAAAATAGCATTTCTAATATTCCCCAGCGCTGACCTCTGCCTCCAGGG
    GGGCTATACAGGAAACCAGATGCATGTCTCCTGCCCCAGTGGAGACTGTG
    GTCCAA
    (SEQ ID NO: 135)
    pARBI-916: AGGATTGTTCTAGTTGATTGGTATGTGTGCACTCCTAGTTGTTAAATATT 1806
    CD3E_1_ TTCACTATCACACCTGGATATACTCAACAAATATTTGTTGAGCCAAATAC
    Endogenous_16 TCAACACCAGCCAAACACGTAGTATTTACTTTAGCTTAAGCGAATTATTT
    AGCCCTGACAGAAGCCCTGGAATGTGGGTCTTTAAGTTCCTATTTTTGAG
    ATGGGAAAGCTGAGGCTCACGGAAGGAGGTGACCAGCTCAAGTCTCCTAC
    CGTCCATGCCAAATTAGAATTCCAGCCTGCCTCCTGACTTCAAGTCCAAA
    GTTCTTCCCACGCACTAAAGCTAGCTCTTCAGTGTCCTTTCTTAGGAGGT
    ACTTCCTCCCGCACCACTGACCGCCCCCTCTCTATTTCACCCCCAGCCCA
    TCCGGAAAGGCCAGCGGGACCTGTATTCTGGCCTGAATCAGAGACGCATC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTGACCCTCTGGAGAACACTGCCTCCCGCTGGCCCAGGTCTCCTC
    TCCAGTCCCCCTGCGACTCCCTGTTTCCTGGGCTAGTCTTGGACCCCACG
    AGAGAGAATCGTTCCTCAGCCTCATGGTGAACTCGCGCCCTCCAGCCTGA
    TCCCCCGCTCCCTCCTCCCTGCCTTCTCTGCTGGTACCCAGTCCTAAAAT
    ATTGCTGCTTCCTCTTCCTTTGAAGCATCATCAGTAGTCACACCCTCACA
    GCTGGCCTGCCCTCTTGCCAGGATATTTATTTGTGCTATTCACTCCCTTC
    CCTTTGGATGTAACTTCTCCGTTCAGTTCCCTCCTTTTCTTGCATGTAAG
    TTGTCCCCCATCCCAAAGTATTCCATCTACTTTTCTATCGCCGTCCCCTT
    TTGCAGCCCTCTCTGGGGATGGACTGGGTAAATGTTGACAGAGGCCCTGC
    CCCGTT
    (SEQ ID NO: 136)
    pARBI-917: AATAATAAAATAATAACAATACTTAACATTTATTGAGTGCTTATTAAGTC 1806
    CD3E_2_ TCAAGCACTGTCTGTACCCAACACTTATCAAGGATTCTTTTTCATGTAAT
    Endogenous_17_18 CCTCTCAACAACTATATGGGTTAAGTATCATTTTATTCCCATGAGTAAAG
    GGATGAGGAAACAGAGGGTTTGTGAGTTGAAAACACATTTCACGCTTCTC
    ACAGCTAGTGAGTAATAAAGCTGGGACTCAAACCCAGGGCTGTTTGACTC
    CAGTGCCTCTACCCACGGCCACCACTCTTTGCTTGTCAATGTTGTTCTAA
    ACATATTGAAGGGGGGGCTCTGACCGTGGCAAGCGTGTGAGTAGTAAGGG
    GAGAATGGCCTTCATGCACTCCCTCCTCACCTCCAGCGCCTTGTGTTTTC
    CTTGCTTAGTGATTTCCCCTCTCCCCACCCCACCCCCCACAGTGTGTGAG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAACTGCATGGAGATGGATGTGATGTCGGTGGCCACAATTGTCAT
    AGTGGACATCTGCATCACTGGGGGCTTGCTGCTGCTGGTTTACTACTGGA
    GCAAGAATAGAAAGGCCAAGGCCAAGCCTGTGACACGAGGAGCGGGTGCT
    GGCGGCAGGCAAAGGGGTAAGGCTGTGGAGTCCAGTCAGAGGAGATTCCT
    GCCAAGGGGGACGACCAGCCTGGGCCAGGGTGGGTGGCAAGTCCACAGCT
    AGGTCAGAACAGCTTCTCTAGAGCTTCTATGCACAGCTTCTATTACTGTG
    ATGACAAGATCTCAACAGACGGTTTCAAATCTCACATCACTCCCCTCCTT
    CCCATCCTAGAAAAGTGCAAAAAAGTTTATGAAAGTGATGGGCTTCCTCA
    CATACCTGTCAATGCCTGCAGTCATCCGATTCCGCCCCTAAGCTGTGGGA
    AGAGAG
    (SEQ ID NO: 137)
    pARBI-918: ACTGTGACCCATGAACCAGTAGGTATTGGCGTCACCTGGGATCCTGACGT 1806
    CD3G_1_ TAGTCTCTGTCAATCCTTCTCTTTAGTTCATCTATTCTACCCAAAGTGAT
    Endogenous_19_20 CTCATCATCTGGTATGCTGTTAGCAGTTTCTTACCTGTATAGTATCTTCC
    AAATAACATGCCCCAAAATCCCAAAGTTTTACCCCTACTAATTACAGCAA
    TGTCTCTTTTATTCTTCACCCCCTGACGCAGATATTGGCGTCACCCGAGA
    GCATGTTAGTAATGCAGAATCTCCCCTCCCCAGAACTACTAAATAGCACC
    TGAAATTTTAACAAGATCCCCATGTGATTCATGTGCACATCAAAGTTTGA
    GAAACACTACTCTAATGATCTCCTGGTATGCAGAAGCAGGGAGAATTTCA
    GAGGCAAGATCCTTAATAGAACCACGGCTTTTCTCATTTCAGGAAACCAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTGGTTAAGGTGTATGACTATCAAGAAGATGGTTCGGTACTTCT
    GACTTGTGATGCAGAAGCCAAAAATATCACATGGTTTAAAGATGGGAAGA
    TGATCGGCTTCCTAACTGAAGATaaaaaaaaaTGGAATCTGGGAAGTAAT
    GCCAAGGACCCTCGAGGGATGTATCAGTGTAAAGGATCACAGAACAAGTC
    AAAACCACTCCAAGTGTATTACAGAAGTATGTAATCCCCTTTGGTCTGTT
    TGTTGTGAAATTAATCAGTATTTGCTGTTCTGGTGAGCTTTTTATCTGGG
    GTGAAAGTGGAAATAGATCCTCAACAGTAATATTATCGCCTGTTCTCTTA
    ATTTCAGCTTGCCTCTTTTAAAATACTGTAAGATACTTCCCTCACCCTAT
    TGAAAAACTACAGCCAGTCCTGTAAAATTTTGTTTACCTTTGGGTGGGCT
    CCATGG
    (SEQ ID NO: 138)
    pARBI-919: TTCGAGACAAGCCTGGCCAACATGATGAAACTCTGTCTCTACTAAAAATA 1806
    CD3G_3_ CAAAAAAAATTAACCAGGCGTGGAGGCGCGCGCCTGTAGTCCCAGCTACT
    Endogenous_21 CAGGAGGCTGAGGCAGGAGGACCACTTGAACCCAGGAGGTCGAGGTTGCA
    GTGAGCTGCGATTGTGCCACTGCACTCCAGCCTGGGCAACAGAGAAAGAC
    TCCGTCTCAAAAAAAAAAAAGAGAGAGAGAGAAAAAGAAAAAAGACAGAG
    CCTCCATCTCCTTGTCCTCTTTCCATCCTCAGGACCATGAAGTACCCACT
    CCAAATTCTCACATATAAAAAACATTCAATAAACATGCATCAAATTAATT
    AATAGAGGATGGAAAAAATGACTTATGACTGTGCTGTCCTTTCCAGCCCC
    TCAAGGATCGAGAAGATGACCAGTACAGCCACCTTCAAGGAAACCAGTTG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAGGAGGAATTGAACTCAGGACTCAGAGTAGGTGGGTTCTTCAAT
    GCCAATTCTAATAAAGGACCCTTGCATCAACTGCCCTCGCAATTGCTTCT
    AAGTCTAGCTCCCTTCCCTAAGCGGCTATAAGCATCAGACTCTGGGGATC
    AGGGATTGGGACGTGGTTTGGGGTACTCTTTTCTAAAAATTCTGGGGCCA
    TACTGATTGTCTTGGCCTAGGTAAATATGAATTTTATGTATCTGTAAATC
    CTGTCAGAGCAGGGCCTCAAGCCATAGAGATGCTGAATATTAATCTTAAC
    CTACATTTGAATTTCTCATTATCTACACTATTAACATTTTGGGCTAATTA
    ATTATTTGTGATGAGGGGCTAGCCTGTGCATTGTAGGAGTTATGGAAGCA
    TCCCTGGCCTCTCTCCACCAGATGCTGGTAGATTGTCCAGTGTGACAATC
    AAAAAT
    (SEQ ID NO: 139)
    pARBI-920: GACCTCAGGTGATCTGCCCGCCTCAGCTTCCCAAAGTGCTGGGATTACAG 1806
    CD5_1_ GCATGAGCCACCACACCTGGCCTAAAATTAATTTTTAAAGATCTCTTAAA
    Endogenous_22 AAGCAGACACCAGCCCCAATCTCAGACCCCTTGAGACAGAATTTCCAGGA
    CAGGGGCCATCCTGCTGGACAGTGGGTGCCGAGAACACCTTGCCCATTTA
    TCTGAGCTCCCTTCTGACTCTGAAATCTGGAGCCCCACCCTCCTGGGTCT
    AGCTTCGGGGCTGCCTGGGTCAGGGTCCTCTGGGAAGCCCCTGCAGTGCC
    CCAGAAGGGACGAAGCTCACAAGGGGCAAGGCAGGCAGCCCACGGGGCAG
    GAGGGAGCTCAACTGGGCGTCCTAGGGAGAGGGCAGTGAGGGGTGCCAGT
    GGGGAACCCCTCCCAGCCTGACCCCCACCACACCTTTCTGACCCCCAGAT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTCCAGGCAAGGCTCACCCGTTCCAACTCGAAGTGCCAGGGCCA
    GCTGGAGGTCTACCTCAAGGACGGATGGCACATGGTTTGCAGCCAGAGCT
    GGGGCCGGAGCTCCAAGCAGTGGGAGGACCCCAGTCAAGCGTCAAAAGTC
    TGCCAGCGGCTGAACTGTGGGGTGCCCTTAAGCCTTGGCCCCTTCCTTGT
    CACCTACACACCTCAGAGCTCAATCATCTGCTACGGACAACTGGGCTCCT
    TCTCCAACTGCAGCCACAGCAGAAATGACATGTGTCACTCTCTGGGCCTG
    ACCTGCTTAGGTGGGTAACTAGCCAGCCACACGGGCACCCTGGGCCTGGG
    CGCCAGCCCCGAGGAGACTGCCCGAGGCCTGTGATCTAGGGTCTGAGCAG
    GCTGGTGGAAGGGGTGGGGGGACCCCAGTTTATAACCACTCCCCAAGACA
    CATACC
    (SEQ ID NO: 140)
    pARBI-921: GGACAGGGGCCATCCTGCTGGACAGTGGGTGCCGAGAACACCTTGCCCAT 1806
    CD5_2_ TTATCTGAGCTCCCTTCTGACTCTGAAATCTGGAGCCCCACCCTCCTGGG
    Endogenous_23 TCTAGCTTCGGGGCTGCCTGGGTCAGGGTCCTCTGGGAAGCCCCTGCAGT
    GCCCCAGAAGGGACGAAGCTCACAAGGGGCAAGGCAGGCAGCCCACGGGG
    CAGGAGGGAGCTCAACTGGGCGTCCTAGGGAGAGGGCAGTGAGGGGTGCC
    AGTGGGGAACCCCTCCCAGCCTGACCCCCACCACACCTTTCTGACCCCCA
    GATTTCCAGGCAAGGCTCACCCGTTCCAACTCGAAGTGCCAGGGCCAGCT
    GGAGGTCTACCTCAAGGACGGATGGCACATGGTTTGCAGCCAGAGCTGGG
    GCCGGAGCTCCAAGCAGTGGGAGGACCCCAGTCAAGCGTCAAAAGTCTGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAGCGGCTGAACTGTGGGGTGCCCTTAAGCCTTGGCCCCTTCCT
    TGTCACCTACACACCTCAGAGCTCAATCATCTGCTACGGACAACTGGGCT
    CCTTCTCCAACTGCAGCCACAGCAGAAATGACATGTGTCACTCTCTGGGC
    CTGACCTGCTTAGGTGGGTAACTAGCCAGCCACACGGGCACCCTGGGCCT
    GGGCGCCAGCCCCGAGGAGACTGCCCGAGGCCTGTGATCTAGGGTCTGAG
    CAGGCTGGTGGAAGGGGTGGGGGGACCCCAGTTTATAACCACTCCCCAAG
    ACACATACCCAGGAGGGGGACTGGAAGGGGCCAGCACCCATCTGTAGGAT
    GGCAATGGAGGACCTAGTTCTGCCAATCACTGACTTCATCGTCGCCTCTG
    AACCTCCATTCTCCCATCTGTGAAGTGGGGTGGTACTTCCCGCCTCGCAG
    GAGGCT
    (SEQ ID NO: 141)
    pARBI-922: tgctgggattacaggcatgagccaccacacctggcctaaaattaattttt 1806
    CD5_3_ aaagaTCTCTTAAAAAGCAGACACCAGCCCCAATCTCAGACCCCTTGAGA
    Endogenous_24 CAGAATTTCCAGGACAGGGGCCATCCTGCTGGACAGTGGGTGCCGAGAAC
    ACCTTGCCCATTTATCTGAGCTCCCTTCTGACTCTGAAATCTGGAGCCCC
    ACCCTCCTGGGTCTAGCTTCGGGGCTGCCTGGGTCAGGGTCCTCTGGGAA
    GCCCCTGCAGTGCCCCAGAAGGGACGAAGCTCACAAGGGGCAAGGCAGGC
    AGCCCACGGGGCAGGAGGGAGCTCAACTGGGCGTCCTAGGGAGAGGGCAG
    TGAGGGGTGCCAGTGGGGAACCCCTCCCAGCCTGACCCCCACCACACCTT
    TCTGACCCCCAGATTTCCAGGCAAGGCTCACCCGTTCCAACTCGAAGTGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAGGGCCAGCTGGAGGTCTACCTCAAGGACGGATGGCACATGGT
    TTGCAGCCAGAGCTGGGGCCGGAGCTCCAAGCAGTGGGAGGACCCCAGTC
    AAGCGTCAAAAGTCTGCCAGCGGCTGAACTGTGGGGTGCCCTTAAGCCTT
    GGCCCCTTCCTTGTCACCTACACACCTCAGAGCTCAATCATCTGCTACGG
    ACAACTGGGCTCCTTCTCCAACTGCAGCCACAGCAGAAATGACATGTGTC
    ACTCTCTGGGCCTGACCTGCTTAGGTGGGTAACTAGCCAGCCACACGGGC
    ACCCTGGGCCTGGGCGCCAGCCCCGAGGAGACTGCCCGAGGCCTGTGATC
    TAGGGTCTGAGCAGGCTGGTGGAAGGGGTGGGGGGACCCCAGTTTATAAC
    CACTCCCCAAGACACATACCCAGGAGGGGGACTGGAAGGGGCCAGCACCC
    ATCTGT
    (SEQ ID NO: 142)
    pARBI-923: GGGGGCGGCCGCACGGCTAGAGCGGAGACCCCGCGCCCCCTCCGCCCGCG 1806
    EDF1_1_ TGGCCCGGCCGGGGTGCGGGGCCCGGGGAGGCACGGGGGCTGCGCGTCGG
    Endogenous_25 GGCGCAGCCGCCGCCCGCGTGTGCTCGGAGGCCGCGGGGCCCGGGCTCCG
    GGGTCCTCCCGACCTGCAGCCCCAGCGGCTACCGCGCCTCGCCAGGCCAG
    GCCAGGCCCCGACGTCGCCTTCCCTACGTCGCCGGCGCCCGGCCACGACG
    TCCCTCAGACGAGCCGAACGCCGAATGGCCCCGAGCACGGGAAGTGCCCG
    CCCCCCGCGTGCAGCCAGCCAATGGGACGCCGAAAGCGGGGAGGTGCCGA
    GGGGACGTAGCGTCGCCGCGCCAGGTCTCTAGCAGCTGCCGCTGAGCCGC
    CGGACGGACGCTCGTCTTCGCCCGCCATGGCCGAGAGCGACTGGGACACG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGTGACGGTGCTGCGCAAGAAGGGCCCTACGGCCGCCCAGGCCAA
    ATCCAAGCAGGTGCTTTGCTGACTGAGGAGCGGCCGGGCCGGGCGGGGCG
    GACGCTgggccggggccacggaccgtggggcagggggctcggggaagggc
    aggcggggcctgggacagggcgcaggggacggggacaaggctggGGTGCC
    GGGGGCAGGACGGGGTTCGAAGGGCGGGGCGAATCGCAGGGGTAGGAGGA
    CCGGGCCAGGACaggggtgggaaggtggggggcggacccaggaggggatg
    gacggacccaggaggcagggggCGGGCGACTGGAGGAGGAGAGGAGCAGG
    GAACCGGACGGGGCAAGGGGCAGGCGATAGGGCCGGGACCAGTGCCAGGG
    TGGGGCGGGGAGGGGATAGGGGCAGGGACTGTTGGTGGGGACAGGTGTGA
    GGACAG
    (SEQ ID NO: 143)
    pARBI-924: ACGGCTAGAGCGGAGACCCCGCGCCCCCTCCGCCCGCGTGGCCCGGCCGG 1806
    EDF1_2_ GGTGCGGGGCCCGGGGAGGCACGGGGGCTGCGCGTCGGGGCGCAGCCGCC
    Endogenous_26 GCCCGCGTGTGCTCGGAGGCCGCGGGGCCCGGGCTCCGGGGTCCTCCCGA
    CCTGCAGCCCCAGCGGCTACCGCGCCTCGCCAGGCCAGGCCAGGCCCCGA
    CGTCGCCTTCCCTACGTCGCCGGCGCCCGGCCACGACGTCCCTCAGACGA
    GCCGAACGCCGAATGGCCCCGAGCACGGGAAGTGCCCGCCCCCCGCGTGC
    AGCCAGCCAATGGGACGCCGAAAGCGGGGAGGTGCCGAGGGGACGTAGCG
    TCGCCGCGCCAGGTCTCTAGCAGCTGCCGCTGAGCCGCCGGACGGACGCT
    CGTCTTCGCCCGCCATGGCCGAGAGCGACTGGGACACGGTGACGGTGCTG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCGCAAGAAGGGCCCTACGGCCGCCCAGGCCAAATCCAAGCAGGT
    GCTTTGCTGACTGAGGAGCGGCCGGGCCGGGGGGGGCGGACGCTgggccg
    gggccacggaccgtggggcagggggctcggggaagggcaggcggggcctg
    ggacagggcgcaggggacggggacaaggctggGGTGCCGGGGGCAGGACG
    GGGTTCGAAGGGCGGGGCGAATCGCAGGGGTAGGAGGACCGGGCCAGGAC
    aggggtgggaaggtggggggcggacccaggaggggatggacggacccagg
    aggcagggggCGGGCGACTGGAGGAGGAGAGGAGCAGGGAACCGGACGGG
    GCAAGGGGCAGGCGATAGGGCCGGGACCAGTGCCAGGGTGGGGCGGGGAG
    GGGATAGGGGCAGGGACTGTTGGTGGGGACAGGTGTGAGGACAGAGGCAG
    GAGGTG
    (SEQ ID NO: 144)
    pARBI-925: CCCTGGAGTCGGTGTGAGGCAAAAGCAGAGGAGAGGATTTGGAATTAACC 1806
    EDF1_3_ TGAAGAAAAACCATTTCAAAGCGGTAACCAGACCCCAGAGGCTGCCTGAA
    Endogenous_27 CTCAAGGGGACATGGGAACCCAGGCTGTCCCAAGTTCACACACCTCAGGT
    CGTGGACTTCCAGAGTTTTCTCTCAGTTATGAGGACAGGCAGCTGTACTC
    ATGCCAACCAGAGCTGCTCTGGGAAGATGGCTGCCTCCCAGGGCTCCGGC
    CAGCACCGGTGCAGGCAGGCACTCAGCTGACAACGTCCCCGGGGGCGCCG
    CACACACCACACCCACCAGCACATGGACCCCACAGCACAGCCTCATGTTG
    CAAGCGGAAACACAAGTACCTACATTTCTTGGAAGTCTCCACATCTTCTC
    CTCGTCTCTGTGCCGCTAAGATAGCCTAGAAAATTAGAAAACATCAGTGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTTCTAAAGAGAAGATGTGCTTTATACACATCAGCTCCACTAGG
    ACTGCTGCAAAACCAGGCGCGAAGCGTCGCCTGAGAACAGCAGCTTCTAG
    GGCCCCTGGGGTACGCACCCACACGCAGCTGGGTTTTGTGCGAGAGGCAG
    TGAGAGCCGGGCTGACCTGGCTTCCCGAGGCATTCCCTGCAGGGGAACCA
    GGGGGGTGGAGCCCACCCTCCCCGTGCTATCTGAACACCGGCCATCCCCC
    TCCCCAAACCCACAACCCCAGGAGTGAGAGCCCCGGCGCAGCCTCACCGT
    GGCCAGGTCCTTCTGCGTAAGCCCCTTGCTCTGCCGACCTTGCTGGATCA
    CCTTGCCCACCTCCAGGGTCACCCTGTCATGGTGCAGCTCCTCTGTCTCC
    CGGTCCAGCTTGGCCGTGTTCTTGGTAATAGAATGTTGTTTGTTCTGGCC
    AGCAGC
    (SEQ ID NO: 145)
    pARBI-926: CTCTTGCTTCAACAGTGTTTGGACGGAACAGATCCGGGGACTCTCTTCCA 1806
    FTL_1_ GCCTCCGACCGCCCTCCGATTTCCTCTCCGCTTGCAACCTCCGGGACCAT
    Endogenous_2830 CTTCTCGGCCATCTCCTGCTTCTGGGACCTGCCAGCACCGTTTTTGTGGT
    TAGCTCCTTCTTGCCAACCAACCATGAGCTCCCAGATTCGTCAGAATTAT
    TCCACCGACGTGGAGGCAGCCGTCAACAGCCTGGTCAATTTGTACCTGCA
    GGCCTCCTACACCTACCTCTCTCTGGTGAGTCCCCAGGACGCCCCTGGCC
    CTAATTTCCTCCAGCTGCGCACCTCCGGCCCTCACTGCACGCGCCAGCCT
    TCTTTGTGCGGTCGGGTAAACAGAGGGCGGAGTCCCCTTGGCCTCGCCTC
    CCGCTAACCATTGTTGCCTCCATCTCTTCCCGTAGGGCTTCTATTTCGAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCGCGATGATGTGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCGA
    ATTGGCCGAGGAGAAGCGCGAGGGCTACGAGCGTCTCCTGAAGATGCAAA
    ACCAGCGTGGCGGCCGCGCTCTCTTCCAGGACATCAAGGTAACTAGTGTG
    TGGGTAATGGACTACATCTCCCAGCAGGCCGTGCGCGCGAGGAGCCTTGA
    TTTGAGGGCGTAGGTGTCGCGTGGGCTTCTGGGAGATTGAGTTCGGTCTT
    GTGAGCCCTCTTAACCGCTGGAAATAGAGGCGCACCTCGTGCAGTGCCCA
    CAACACGCGGCAGTCCACACCGCTGCGTGGTCTTAGGGACGTATAGCTGT
    AAGAGCTAGGACAGGGTGCGGAGAGTGATAAATACAAGCTGTCACATGTC
    TTTGTGGCCTGGGCCTCTGACCCCCAACGACTCTTGGGAAATGTAGGTTT
    AGTTCT
    (SEQ ID NO: 146)
    pARBI-927: TGGGGCGGGGGGCTGAGACTCCTATGTGCTCCGGATTGGTCAGGCACGGC 1806
    FTL_2_ CTTCGGCCCCGCCTCCTGCCACCGCAGATTGGCCGCTAGCCCTCCCCGAG
    Endogenous_29 CGCCCTGCCTCCGAGGGCCGGCGCACCATAAAAGAAGCCGCCCTAGCCAC
    GTCCCCTCGCAGTTCGGCGGTCCCGCGGGTCTGTCTCTTGCTTCAACAGT
    GTTTGGACGGAACAGATCCGGGGACTCTCTTCCAGCCTCCGACCGCCCTC
    CGATTTCCTCTCCGCTTGCAACCTCCGGGACCATCTTCTCGGCCATCTCC
    TGCTTCTGGGACCTGCCAGCACCGTTTTTGTGGTTAGCTCCTTCTTGCCA
    ACCAACCATGAGCTCCCAGATTCGTCAGAATTATTCCACCGACGTGGAGG
    CAGCCGTCAACAGCCTGGTCAATTTGTACCTGCAGGCCTCCTACACCTAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCTCTCTCTGGTGAGTCCCCAGGACGCCCCTGGCCCTAATTTCCT
    CCAGCTGCGCACCTCCGGCCCTCACTGCACGCGCCAGCCTTCTTTGTGCG
    GTCGGGTAAACAGAGGGCGGAGTCCCCTTGGCCTCGCCTCCCGCTAACCA
    TTGTTGCCTCCATCTCTTCCCGTAGGGCTTCTATTTCGACCGCGATGATG
    TGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAG
    CGCGAGGGCTACGAGCGTCTCCTGAAGATGCAAAACCAGCGTGGCGGCCG
    CGCTCTCTTCCAGGACATCAAGGTAACTAGTGTGTGGGTAATGGACTACA
    TCTCCCAGCAGGCCGTGCGCGCGAGGAGCCTTGATTTGAGGGCGTAGGTG
    TCGCGTGGGCTTCTGGGAGATTGAGTTCGGTCTTGTGAGCCCTCTTAACC
    GCTGGA
    (SEQ ID NO: 147)
    pARBI-928: CTTTGCATAGTTTATCCTATTAGTAATCTATTCTGTCTTTGGAATATGTT 1806
    PTEN_1_ TTGTGATGATGAAATAAATACTATAAATAGTATTATTCCTTTTGCATTGA
    Endogenous_31 GAGTCCTGACGAAATGTCCATGTGACAGTTCATTTTGGGTTTAGCTCTAC
    CTCTAATATGTGACCTATGCTACCAGTCCGTATAGCGTAAATTCCCAGAA
    TATATCCTCCTGAATAAAATGGGGGAAAATAATACCTGGCTTCCTTAATG
    ATTATATTTAAGACTTATCAAGAGACTATTTTCTATTTAACAATTAGAAA
    GTTAAGCAATACATTATTTTTCTCTGGAATCCAGTGTTTCTTTTAAATAC
    CTGTTAAGTTTGTATGCAACATTTCTAAAGTTACCTACTTGTTAATTAAA
    AATTCAAGAGTTTTTTTTTCTTATTCTGAGGTTATCTTTTTACCACAGTT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACT
    TATCAAACCCTTTTGTGAAGATCTTGACCAATGGCTAAGTGAAGATGACA
    ATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTA
    ATGATATGTGCATATTTATTACATCGGGGCAAATTTTTAAAGGCACAAGA
    GGCCCTAGATTTCTATGGGGAAGTAAGGACCAGAGACAAAAAGGTAAGTT
    ATTTTTTGATGTTTTTCCTTTCCTCTTCCTGGATCTGAGAATTTATTGGA
    AAACAGATTTTGGGTTTCTTTTTTTCCTTCAGTTTTATTGAGGTGTAATT
    GACAAGTAAAAATTATATATAAATACAATGTATAATATGATGTTTTGATG
    TATGTGTATATACATTGTGAAATGATTACTACAGTCAAACTACTTAACAT
    ATTCAT
    (SEQ ID NO: 148)
    pARBI-929: GCTACCAGTCCGTATAGCGTAAATTCCCAGAATATATCCTCCTGAATAAA 1806
    PTEN_2_ ATGGGGGAAAATAATACCTGGCTTCCTTAATGATTATATTTAAGACTTAT
    Endogenous_32 CAAGAGACTATTTTCTATTTAACAATTAGAAAGTTAAGCAATACATTATT
    TTTCTCTGGAATCCAGTGTTTCTTTTAAATACCTGTTAAGTTTGTATGCA
    ACATTTCTAAAGTTACCTACTTGTTAATTAAAAATTCAAGAGTTTTTTTT
    TCTTATTCTGAGGTTATCTTTTTACCACAGTTGCACAATATCCTTTTGAA
    GACCATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCT
    TGACCAATGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTA
    AAGCTGGAAAGGGACGAACTGGTGTAATGATATGTGCATATTTATTACAT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCGGGGCAAATTTTTAAAGGCACAAGAGGCCCTAGATTTCTATGG
    GGAAGTAAGGACCAGAGACAAAAAGGTAAGTTATTTTTTGATGTTTTTCC
    TTTCCTCTTCCTGGATCTGAGAATTTATTGGAAAACAGATTTTGGGTTTC
    TTTTTTTCCTTCAGTTTTATTGAGGTGTAATTGACAAGTAAAAATTATAT
    ATAAATACAATGTATAATATGATGTTTTGATGTATGTGTATATACATTGT
    GAAATGATTACTACAGTCAAACTACTTAACATATTCATCACCTCACATAA
    TTATTATTCTCCCCCCAGGGTGAAAGCATTTAAGATCTACAAGCTACAAT
    TTTCAATTATACAATGTTATTATTAACTATAGTCACTATGCTGTCCAGTA
    GAGCTTCAGATCTTGTTCATCTTGTGTTCCTCCCTCCCCACCCTCAGTCC
    CTGGAA
    (SEQ ID NO: 149)
    pARBI-930: ATAAATAGTATTATTCCTTTTGCATTGAGAGTCCTGACGAAATGTCCATG 1806
    PTEN_3_ TGACAGTTCATTTTGGGTTTAGCTCTACCTCTAATATGTGACCTATGCTA
    Endogenous_33 CCAGTCCGTATAGCGTAAATTCCCAGAATATATCCTCCTGAATAAAATGG
    GGGAAAATAATACCTGGCTTCCTTAATGATTATATTTAAGACTTATCAAG
    AGACTATTTTCTATTTAACAATTAGAAAGTTAAGCAATACATTATTTTTC
    TCTGGAATCCAGTGTTTCTTTTAAATACCTGTTAAGTTTGTATGCAACAT
    TTCTAAAGTTACCTACTTGTTAATTAAAAATTCAAGAGTTTTTTTTTCTT
    ATTCTGAGGTTATCTTTTTACCACAGTTGCACAATATCCTTTTGAAGACC
    ATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCTTGAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAATGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTG
    TAAAGCTGGAAAGGGACGAACTGGTGTAATGATATGTGCATATTTATTAC
    ATCGGGGCAAATTTTTAAAGGCACAAGAGGCCCTAGATTTCTATGGGGAA
    GTAAGGACCAGAGACAAAAAGGTAAGTTATTTTTTGATGTTTTTCCTTTC
    CTCTTCCTGGATCTGAGAATTTATTGGAAAACAGATTTTGGGTTTCTTTT
    TTTCCTTCAGTTTTATTGAGGTGTAATTGACAAGTAAAAATTATATATAA
    ATACAATGTATAATATGATGTTTTGATGTATGTGTATATACATTGTGAAA
    TGATTACTACAGTCAAACTACTTAACATATTCATCACCTCACATAATTAT
    TATTCTCCCCCCAGGGTGAAAGCATTTAAGATCTACAAGCTACAATTTTC
    AATTAT
    (SEQ ID NO: 150)
    pARBI-931: TAGTGACGGTATCAAGAGCAGCATCCCAGGTTGACTTTCTTTGGGGCAGG 1806
    PTPN2_1_ ACCTTGCTTGTGTCTTAACCCTTGGTTCCTACccaagtttgtctctctag
    Endogenous_34 tcctcaactctgaaagccacttgatatcttacacaattccttttttgcct
    gagaaaataaaagtcagttttgatcatttacaaccaaaaatcctaactaa
    cacaGACCTGTTTTTGAAATCAGGTAGATTGGAAGTCTTGGTTTACTTCT
    TATAAGCCCGTCCGCTGTCTGTCTTGTAACATCCCAGGAGCAGACTTAAC
    AAGGCCTTCCTGGAGCCTTGCTCTTTCTGTCTGCTTCCCTCATCTGctct
    ctctcctctctctTCACAGGGTCCACTTCCTAACACATGCTGCCATTTCT
    GGCTTATGGTTTGGCAGCAGAAGACCAAAGCAGTTGTCATGCTGAACCGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatATTGTGGAGAAAGAATCGGTGAGTAATATTTAATATTTACAACT
    TAGTATACTGTATGTGATCATTAGCATATAAAGATTTTCATTTTGGGGCC
    AATATTCATTCCTTAGTTTTGGCCTTTAATTGCTAAAGGCTAGCGGTCAA
    AGTGTTTCTGTCCGGAAAAACTCATGTATCCTTTTCCTTTCTTAAGTATT
    TTTATAACAATTGCAGACCTTTCATCTCCAAGATAGAAATACAATGGAAT
    AAATATGGACTAGCAGTGACATATAGATCTTTGGAATCCCTAGGAATCCT
    TATTGACCTATTGTCAATAAGTCCTCTTCCAGCTTTAAGATCTTGTACTG
    TTCTACTTCAGATTTCTTACTTTATTCTACATTTCATAATTGCTGGTTTT
    TAATGATGATGAAAATTTCCTAATCCACTTCTAATTAGATGTGGCAATGA
    CATGCC
    (SEQ ID NO: 151)
    pARBI-932: CAGAATTTGAATATGATGTGGCTGACCATAGATACCTCCATTGCATTAAT 1806
    PTPN2_2_ TCTGCTTCATAAAGTGTTTGATGCTTGCTTGTAGGTGTTGAATAGAGCCT
    Endogenous_35 AATTAGCAGTAAGTAAACAGATCTagagcacagactttggcatctgaagg
    accttggttcaatgctgggactgccacttactagctatgggatctttggt
    ggatttttaacctttgaaagcctttcatccctcacagatataatggggaa
    gaaaatcgtttccattagtattgtgaggattaaatgattaattgatgtaa
    acaatgtgctttccatagtacttggcatatcataagtgcttcatGTTATT
    TTACGCTGGCTGGGAAGATAAGTTTTGCTGTGGAGAATTTAAGAGGGATA
    TTAAAATATATTTTTGTTATTTTAAGGAAATTCGAAATGAGTCCCATGAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTATCCTCATAGAGTGGCCAAGTTTCCAGAAAACAGAAATCGAAA
    CAGATACAGAGATGTAAGCCCATGTAAGTACTTGTGGGTTTGTGTGCATG
    TGTATTTTTTGGTTTGTTTTAGGAGGCAGGATGTAGTGAAAAGGAGGGCT
    TGGGGTCAGTGTTGATAAATACAGTAATTTTTTTCCTATTTACGTAAGAC
    ACGTTCTTTAAGAATTTAAAGGTGTAGAATAGTGGAAGGAAAAATAATTA
    CCCATAATTATTTCATCCTTCAAACATAGGCACCATTATTTTGGTGTATT
    TCCCACAACCTGTTTTTCTTATGCACAGTTTTCCTTTCTTTAAAATAATT
    GTAATTATAGATGTCTATATAATATCCATATGTATTTCCTTTTCATATCA
    TTCCATCCCCTTTGTAAGTTTTGCTTAAAATAGTTATTGGTGTAGTTTGG
    TTTTTT
    (SEQ ID NO: 152)
    pARBI-933: ACCAGTTATCGTTTTGTAGGTAGACCAATCAATTCTTAGGTACCAAGAAT 1806
    PTPN_3_ CTGAATGATCCTTTTACTTTTAGGAAGGTAAGTACTTTATTCATTTAACT
    Endogenous_36 ATGTTTACTCCTGGTCGATTTTTCAAGTCACAATGGCTAATGTGCTACAA
    ACAGAAGTGCTTCCTTTCCAGCACTATAGTAATAAACAAGATTGCATTTT
    ATACTCCTTACAAAAAAAGTAGAGAATAGTTTAGGATTTGTCTCAACTCT
    ATTATGATGCTAATTCATTTTTCTTATTTCTTCTGTCTTTTTATAAATAC
    CTAGAATATTAATATGAAGATAAAAACAGTAATTTTGAAATGACAGTTGT
    GGTTTATCATTCTCTATTTTCAGATGATCACAGTCGTGTTAAACTGCAAA
    ATGCTGAGAATGATTATATTAATGCCAGTTTAGTTGACATAGAAGAGGCA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAAAGGAGTTACATCTTAACACAGGCAAGTAATACGATACCACG
    CAAATGTCTGAAAATGATGTGTTTGTGCTTGTTCTGCTTTAAATCATAGG
    TAAAAGTATATCTTGACTTCTTTTGGAAATGAAATGGTATTTCAGTTTTT
    TTCTGACGATGTAATGAATTATGGACATTATAAGGTTTTGAAGCTTTGAG
    TATTTAAGATAAAAGGCAAGTTATTTTTGATATTACACGTTCTGTGAAGG
    AAAATTCTTAGGAAATGGCTTAGGCCAGTTCTTTGGCAGATTGTGTTCCT
    TACATTATATCTGACACAGAGTGCTGCTTATGCTTCTTAGTGTCTTCTTT
    TCTCTTCCCATACCCTGTGGCAAAACCAGAGGCCCTGGACAGCTCTTCTG
    TAGCTCCCCCTGCCTCGCATATATCTTCAGAGAGTACACCAAGCCCTGGA
    TGGTGT
    (SEQ ID NO: 153)
    pARBI-934: CCTGCTCAAGGGCCGAGGTGTCCACGGTAGCTTCCTGGCTCGGCCCAGTC 1806
    PTPN6_1_ GCAAGAACCAGGGTGACTTCTCGCTCTCCGTCAGGTAGGTGGGCCCCCCG
    Endogenous_37 CAACCCCGGGCATTTTGGCCACTCTCTTGTGCCATCCAGGCCCTGAACCA
    CTCATTCCTGGTTCCCCGTGGCAGTGCTGACTCCCCGTCTGTTCCCTTGC
    CCCCAACCCCCACACTCCCCATCCCTGTCTGTGCCCACCCATGCCCATGT
    GTGCCCCCACCCAGGACCTCAGCCGATCCCTGCCCTCCTGCCTCTACTCC
    TGCACCGACTGGCCTCACCGCCTGGTGCCCTGCAGGGTGGGGGATCAGGT
    GACCCATATTCGGATCCAGAACTCAGGGGATTTCTATGACCTGTATGGAG
    GGGAGAAGTTTGCGACTCTGACAGAGCTGGTGGAGTACTACACTCAGCAG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAGGGTGTCCTGCAGGACCGCGACGGCACCATCATCCACCTCAA
    GTACCCGCTGAACTGCTCCGATCCCACTAGTGAGAGGTGAGGGCTCCGCA
    CCCCCGCCATTCCCAAGCAGGGATGAGCCGGCTCCCACCCTGAACAGCCA
    GGGAGGCAGGGAGACTGGCAGCCGGCGCTGCCTACCCTCCATCCCCTCCC
    CTCCCTGCACCAGCTGGGGCTCTCAATGTCCCTCCTCCCTGCTGTCCTGG
    GACCTGGTGTCTCAGAGCCTAACCTACCACCCTTTCCACCTAACCCCGAG
    GAAGCCACAGAAAGCTGCCTCGCCCTACTCCGGGAGCCCTGGCCGCTGCA
    ACCCAGGTCCCACTGGAGACAGGGAGGCCACTGCTGGTGGCCAGCATGTC
    GTGCAGGCCAGCTCTGTTGTTAGAAAGCTCTTCTTCCTCTGGAATCGAGC
    CTGCCT
    (SEQ ID NO: 154)
    pARBI-935: CTGGGTTCGAAGCCCGGTTAGAACTCTGGAGGCTAGGATGGCTTGAACCT 1806
    PTPN6_2_ GGGAGGTCGAGGCTGCAGAGAGCTGTAACCGCGCCACTGCACTCCAGCCT
    Endogenous_38 GGGCAACAGAGCTCTGGAAGCTTGCCCTAGAGTCAGTCAAGGGCCCTAGG
    CCAGTGAGTAACAGCTCAGCGTCAGTTTCCTCATCTATAAAATGGGGGTA
    ATATCATACCTAGCTCTCAGCATGTTTGTGAGAGACCTAAATGAGGTGGT
    GGATTTGGAAGCATGTAGCGCAGTGCCTGGCACACAGTAGGTGCTTGATT
    TCCGGCCCCTCTCTGTGAATGTCTCTGCTCAGCGCCTTCCCCTGTGGCCT
    GGGTCTTACCTTCCCTGACGCTGCCTTCTCTAGGTGGTACCATGGCCACA
    TGTCTGGCGGGCAGGCAGAGACGCTGCTGCAGGCCAAGGGCGAGCCCTGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACGTTTCTTGTGCGTGAGAGCCTCAGCCAGCCTGGAGACTTCGT
    GCTTTCTGTGCTCAGTGACCAGCCCAAGGCTGGCCCAGGCTCCCCGCTCA
    GGGTCACCCACATCAAGGTCATGTGCGAGGTAAGGCAGCCAGGCGGCGGG
    GGAGCCTCTGCTGAGGCTCCTGTCTGTGACCACAGTGTGGGTGGCAGGGA
    GGGTCTGCCTGGGCTTGAATTCAAGGCTGGGGACCCAGGGAGGGAGACTC
    AAGTCCTGTGAATGGCCTAATTTGGCTCCCCCCAGGGTGGACGCTACACA
    GTGGGTGGTTTGGAGACCTTCGACAGCCTCACGGACCTGGTGGAGCATTT
    CAAGAAGACGGGGATTGAGGAGGCCTCAGGCGCCTTTGTCTACCTGCGGC
    AGGTCAGGGGTGGGCCCAGCTGCCTCCCCACTTCCCCTGAGCTGTCCCCC
    AGATGT
    (SEQ ID NO: 155)
    pARBI-936: TGTCACATATGTGCAATGCCATGCTCCTGAGCCTTTGATTGCAGACGTGT 1806
    PTPN6_3_ GGGAAGTGGGCCCCGTCCCCACCCCCAGTGCCACCCTGCTCTGCTTCTCT
    Endogenous_39 TCCCTTGCTGTGCTCTAAAACGAGAAGTACAAGTGAGTTCCCCCAAGGGG
    TCGGCCGCGCCTCTTCCTGTCCCCGCCCTGCCGGCTGCCCCAGGCCAGTG
    GAGTGGCAGCCCCAGAACTGGGACCACCGGGGGTGGTGAGGCGGCCCGGC
    ACTGGGAGCTGCATCTGAGGCTTAGTCCCTGAGCTCTCTGCCTGCCCAGA
    CTAGCTGCACCTCCTCATTCCCTGCGCCCCCTTCCTCTCCGGAAGCCCCC
    AGGATGGTGAGGTAAGGGCCTGCCACCCACGGTAGACAGGAGGCAAGGGT
    GCCTGGTGCCCACGGGACCCCTCCTCACTGCCCTGCCTGGGCCGCCCAGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTGGTTTCACCGAGACCTCAGTGGGCTGGATGCAGAGACCCTGCT
    CAAGGGCCGAGGTGTCCACGGTAGCTTCCTGGCTCGGCCCAGTCGCAAGA
    ACCAGGGTGACTTCTCGCTCTCCGTCAGGTAGGTGGGCCCCCCGCAACCC
    CGGGCATTTTGGCCACTCTCTTGTGCCATCCAGGCCCTGAACCACTCATT
    CCTGGTTCCCCGTGGCAGTGCTGACTCCCCGTCTGTTCCCTTGCCCCCAA
    CCCCCACACTCCCCATCCCTGTCTGTGCCCACCCATGCCCATGTGTGCCC
    CCACCCAGGACCTCAGCCGATCCCTGCCCTCCTGCCTCTACTCCTGCACC
    GACTGGCCTCACCGCCTGGTGCCCTGCAGGGTGGGGGATCAGGTGACCCA
    TATTCGGATCCAGAACTCAGGGGATTTCTATGACCTGTATGGAGGGGAGA
    AGTTTG
    (SEQ ID NO: 156)
    pARBI-937: TCTTTAGCTAATGTTCTGTAGCTTGTTTTAGATCTGTGTCTACATATTAT 1806
    PTPRC_1_ ATGTATCTCTGTATGCATCAATATTTGTATATATGCATGCATATATGTGT
    Endogenous_40 ATGTATATTTATGAATACATATACACACCATATACATACACTTATGTATG
    GTGTGTGCATATGTATGTGTAGATATATGTACATACACACTATAGTGGAC
    TGGGGAGTTAGTATACTGGGAGGAGCATACATTTAGGGTATGATTCACAT
    ATTTATTTTGTCCTTCTCCCATTTTCCATTAATTAACAGGATTGACTACA
    GCAAAGATGCCCAGTGTTCCACTTTCAAGTGACCCCTTACCTACTCACAC
    CACTGCATTCTCACCCGCAAGCACCTTTGAAAGAGAAAATGACTTCTCAG
    AGACCACAACTTCTCTTAGTCCAGACAATACTTCCACCCAAGTATCCCCG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGACTCTTTGGATAATGCTAGTGCTTTTAATACCACAGGTTGGCA
    CACAAAAGTTGTTAACTTAAATATCAGGGAATGTCATTTAGAAAATTCTA
    CAGTTATCAGTACAACTTGTCTTTAAATTATTTGCACAGTTTCTAAGTAT
    GTGATTTTATTCAAGTGCAGAAATTGCAGGAAATTAGTATCTGTGAAATA
    TAGATCGACTGAAGTAATTAATGCATGTTGTTAGGGAGTGGAGAGAGAAA
    AGAAGGGAAGCAAGATCTCCAAGGACAATCAGGAGGGGAAATTTGTTCTA
    GTATCCTCTGATCTATACACACTCGCCATGATTCTCCCGCTTGGCTTCCC
    GCCACCTGGACAGATGAGAATTTCCCTAGTTCAGAGATTATCAGTTCTAC
    TCTCCTTGGAAGGTGTCTTAAATGGGAGTCTTCCCATTTCTTTGTTTCAC
    TCTAGA
    (SEQ ID NO: 157)
    pARBI-938: AGGGAATTTTTATATGTTGGTCATATTATATCCCTAGCATGTGGCATAAT 1806
    PTPRC_2_ GTCTAGCACAAAATAGGTGCTCAATTAATCATCATTATCTAAATAAATAA
    Endogenous_41 TGCATTTGGGAAAAAAAAGTTTCAAAAGTTTTTCAAAAGTCTTTTGCAGG
    CTTGAAATTAATCCCAATAGTGATCCTTTAGTCTGTTATGTTTCTGATTT
    AGCCTGGGGATTCAAAAAATAAATAACATAATTTTGATATATTTGGGCTT
    TGTAAACATGGTACTAAGAGAGGAAATATAGTTTCATTAGGGTAAAAGCT
    ACTGAAAATTGCCACTTGGTGAATGTTCTATCATAGACTTGAGGTACATA
    TAAAAATCTAATATATGTTTACATTAATATGAATGAAATTTGAAATTTTC
    TAAGAGATTTTTGTTTCTTCTTTGCAGGGCAAAGCCCAACACCTTCCCCC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACTGGTAAGAATTAATATTTATATTTTTACTAATTTTATTTTCT
    TGTTGCAAAGTTTATATATTTAACTACAATTTTCTATTATTAACACTGAA
    ATTATTTTTAAGGATAAATTTTATAATCATGAGTGATTCTTGACATTCAC
    TTGTTCTTAAACTTTCTGCTTATACGTTATAGAGTTTAATAACTACCTAA
    ACATGTTATTAAATTTGTATATATATTTTGTGTATAAATAGTAACTTTTC
    CCAAACTTGACAGTAAATCACACAACAGGTTTCTACTCTCTTTTAATATT
    TTAAGACTATAAAAAAATGCATTTAAATTAGATAACAAAATTTTATAGTC
    TGAAAGCAGGTTAACAGCTGTCTATGTATGTTATAGATATGTAGATAACA
    GATTTGCATATGTCTATATTTCTTTAAGAGTATGTTGCTTTTTTCAATGG
    TATGCA
    (SEQ ID NO: 158)
    pARBI-939: CCTTTAGCACCATAAAGAAACTAAATTATTTAGATGTTTTTATGAGAACA 1806
    PTPRC_3_ TATCAAAAAGTACTTTTCTGTCATCCAATACTTCCACAAATAAATCATTA
    Endogenous_42 GTTCTTGCTAATCTTCATCTGGCATAAAAATAATGACATCAACTTTCTTC
    ATGTAATTTCCCACTTAATTCCTTTACTAGGAGCAATATCAATTCCTATA
    TGACGTCATTGCCAGCACCTACCCTGCTCAGAATGGACAAGTAAAGAAAA
    ACAACCATCAAGAAGATAAAATTGAATTTGATAATGAAGTGGACAAAGTA
    AAGCAGGATGCTAATTGTGTTAATCCACTTGGTGCCCCAGAAAAGCTCCC
    TGAAGCAAAGGAACAGGCTGAAGGTTCTGAACCCACGAGTGGCACTGAGG
    GGCCAGAACATTCTGTCAATGGTCCTGCAAGTCCAGCTTTAAATCAAGGT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTCATAGGAAAAGACATAAATGAGGAAACTCCAAACCTCCTGTTA
    GCTGTTATTTCTATTTTTGTAGAAGTAGGAAGTGAAAATAGGTATACAGT
    GGATTAATTAAATGCAGCGAACCAATATTTGTAGAAGGGTTATATTTTAC
    TACTGTGGAAAAATATTTAAGATAGTTTTGCCAGAACAGTTTGTACAGAC
    GTATGCTTATTTTAAAATTTTATCTCTTATTCAGTAAAAAACAACTTCTT
    TGTAATCGTTATGTGTGTATATGTATGTGTGTATGGGTGTGTGTTTGTGT
    GAGAGACAGAGAAAGAGAGAGAATTCTTTCAAGTGAATCTAAAAGCTTTT
    GCTTTTCCTTTGTTTTTATGAAGAAAAAATACATTTTATATTAGAAGTGT
    TAACTTAGCTTGAAGGATCTGTTTTTAAAAATCATAAACTGTGTGCAGAC
    TCAATA
    (SEQ ID NO: 159)
    pARBI-940: aaggaaaaaggcactgagtgctggggggtgctggggtgggctgcagtgat 1806
    PTPRCAP_1_ agacatcagggtagaggttaaggtcaggttcagcctcactggggtgaagt
    Endogenous_43 ttgagcacggtgagcaggccatgcagcccgggggaggggaggatgggagg
    aggtggagctttccgggcagagggaacagccagtgcgaaggccccaggca
    ggtggcttaatgcagctgttgggggaggtgagtggtagggaggaggctgg
    agggatgggggctgatctcacagggccagagcctggttgaccaaataagg
    ccttggccttttctGCTTGGCTGTCCCAAGAGGATCCCAAAGAGAAAAAA
    ACGAAAGTGGTCTTGGTCACCCAGCCTGCCCCACACCAGGCCCCACCCCA
    GGTGCTGAGCCCTCTGAGCCCCTGCCTGTCTCCCACAGGCTCTGCCCTGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACCTTAGGGCTCGGGATGCTGCTGGCCCTGCCAGGGGCCTTGGG
    CTCGGGTGGCAGCGCGGAGGACAGCGTGGGCTCCAGCTCTGTCACCGTTG
    TCctgctgctgctgctgctcctactgctgGCCACTGGCCTAGCACTGGCC
    TGGCGCCGCCTCAGCCGTGACTCAGGGGGCTACTACCACCCGGCCCGCCT
    AGGTGCCGCGCTGTGGGGCCGCACGCGGCGCCTGCTCTGGGCCAGCCCCC
    CAGGTCGCTGGCTGCAGGCCCGAGCTGAGCTGGGGTCCACAGACAATGAC
    CTTGAGCGACAGGAGGATGAGCAGGACACAGACTATGACCACGTCGCGGA
    TGGTGGCCTGCAGGCTGACCCTGGGGAAGGCGAGCAGCAATGTGGAGAGG
    CGTCCAGCCCAGAGCAGGTCCCCGTGCGGGCTGAGGAAGCCAGAGACAGT
    GACACG
    (SEQ ID NO: 160)
    pARBI-941: aaggtcaggttcagcctcactggggtgaagtttgagcacggtgagcaggc 1806
    PTPRCAP_2_ catgcagcccgggggaggggaggatgggaggaggtggagctttccgggca
    Endogenous_44 gagggaacagccagtgcgaaggccccaggcaggtggcttaatgcagctgt
    tgggggaggtgagtggtagggaggaggctggagggatgggggctgatctc
    acagggccagagcctggttgaccaaataaggccttggccttttctGCTTG
    GCTGTCCCAAGAGGATCCCAAAGAGAAAAAAACGAAAGTGGTCTTGGTCA
    CCCAGCCTGCCCCACACCAGGCCCCACCCCAGGTGCTGAGCCCTCTGAGC
    CCCTGCCTGTCTCCCACAGGCTCTGCCCTGCACCTTAGGGCTCGGGATGC
    TGCTGGCCCTGCCAGGGGCCTTGGGCTCGGGTGGCAGCGCGGAGGACAGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGTGGGCTCCAGCTCTGTCACCGTTGTCctgctgctgctgctgct
    cctactgctgGCCACTGGCCTAGCACTGGCCTGGCGCCGCCTCAGCCGTG
    ACTCAGGGGGCTACTACCACCCGGCCCGCCTAGGTGCCGCGCTGTGGGGC
    CGCACGCGGCGCCTGCTCTGGGCCAGCCCCCCAGGTCGCTGGCTGCAGGC
    CCGAGCTGAGCTGGGGTCCACAGACAATGACCTTGAGCGACAGGAGGATG
    AGCAGGACACAGACTATGACCACGTCGCGGATGGTGGCCTGCAGGCTGAC
    CCTGGGGAAGGCGAGCAGCAATGTGGAGAGGCGTCCAGCCCAGAGCAGGT
    CCCCGTGCGGGCTGAGGAAGCCAGAGACAGTGACACGGAGGGCGACCTGG
    TCCTCGGCTCCCCAGGACCAGCGAGCGCAGGGGGCAGTGCTGAGGCCCTG
    CTGAGT
    (SEQ ID NO: 161)
    pARBI-942: cagtgcgaaggccccaggcaggtggcttaatgcagctgttgggggaggtg 1806
    PTPRCAP_3_ agtggtagggaggaggctggagggatgggggctgatctcacagggccaga
    Endogenous 45 gcctggttgaccaaataaggccttggccttttctGCTTGGCTGTCCCAAG
    AGGATCCCAAAGAGAAAAAAACGAAAGTGGTCTTGGTCACCCAGCCTGCC
    CCACACCAGGCCCCACCCCAGGTGCTGAGCCCTCTGAGCCCCTGCCTGTC
    TCCCACAGGCTCTGCCCTGCACCTTAGGGCTCGGGATGCTGCTGGCCCTG
    CCAGGGGCCTTGGGCTCGGGTGGCAGCGCGGAGGACAGCGTGGGCTCCAG
    CTCTGTCACCGTTGTCctgctgctgctgctgctcctactgctgGCCACTG
    GCCTAGCACTGGCCTGGCGCCGCCTCAGCCGTGACTCAGGGGGCTACTAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCACCCGGCCCGCCTAGGTGCCGCGCTGTGGGGCCGCACGCGGCG
    CCTGCTCTGGGCCAGCCCCCCAGGTCGCTGGCTGCAGGCCCGAGCTGAGC
    TGGGGTCCACAGACAATGACCTTGAGCGACAGGAGGATGAGCAGGACACA
    GACTATGACCACGTCGCGGATGGTGGCCTGCAGGCTGACCCTGGGGAAGG
    CGAGCAGCAATGTGGAGAGGCGTCCAGCCCAGAGCAGGTCCCCGTGCGGG
    CTGAGGAAGCCAGAGACAGTGACACGGAGGGCGACCTGGTCCTCGGCTCC
    CCAGGACCAGCGAGCGCAGGGGGCAGTGCTGAGGCCCTGCTGAGTGACCT
    GCACGCCTTTGCTGGCAGCGCAGCCTGGGATGACAGCGCCAGGGCAGCTG
    GGGGCCAGGGCCTCCATGTCACCGCACTGTAGAGGCCGGTCTTGGTGTCC
    CATCCC
    (SEQ ID NO: 162)
    pARBI-943: ATAGAGTAGGGCGGGGGATGCCATGGAGAGGCTCCATGGGGGAGGGCCGG 1806
    RPS23_1_ GGAAGCGCCGCTCCAGGAGGCACGTGGTCCGGCGCGGAAGGGGCCCATGA
    Endogenous_46 GGCGTGGAGGCCGCCGAGGTCGGGGTACCGAGGGACGCAGGGAGGCCAGC
    GCTTCCTCCCGGGCATTCGAGCGGGGCCTCGTCCTTCGGGAGAACACATT
    CTCCGGAGCCCTCTTCGAACGTTTATTAGTCGGTTCAGGGCAACTTGAAG
    GCCAAATGTTTGGCCCACAGGCCAATAAATAGTACGAGAGCCAATCGGCT
    TAAGGGTTTATTCCAGGTGAGGCGAGTGTCTTAGAAGATGGGAAACACGT
    AGATGGCGTGTTTTTACGGAAGAACTAAAATATTTAATTTTTAGGCAAGT
    GTCGTGGACTTCGTACTGCTAGGAAGCTCCGTAGTCACCGACGAGACCAG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAAGTGGCATGATAAACAGTATAAGAAAGCTCATTTGGGCACAGC
    CCTAAAGGCCAACCCTTTTGGAGGTGCTTCTCATGCAAAAGGAATCGTGC
    TGGAAAAAGTGTAAGTCCATTGCTCCCGTCAAGTTTTAGTTTATTATAGG
    AATTCGAGACATGAACTTACGAATTCTTGTTTTGAAAGTAATTGCAGGTT
    TTTGTGTAGTAGTATTCATTTGGGCATTGTGGGGTAAAATTGCAAAGCGT
    TTGTTCTATTTAAAAGTTGGTAAAATTAGTTTTTGGGAATTAGGTAGTTA
    AGGTTTTAATTTAACGTTGGCCTGGAAGGAATTGGAGAAGATACTAGCAA
    TGATGAAGTAAAGGACACAAACACCTTTACTGTGGGAGTTGTTATAAGTA
    AATGGCACGTGTCAGCTATTGAACTTTATCGACTTGATAAAACTAAGGTG
    AAGAGA
    (SEQ ID NO: 163)
    pARBI-944: CAAGCGGGACTTGGGGTCTTGGGGACGGGCGGGCGGATGCGAATAGAGTA 1806
    RPS23_2_ GGGCGGGGGATGCCATGGAGAGGCTCCATGGGGGAGGGCCGGGGAAGCGC
    Endogenous_47_48 CGCTCCAGGAGGCACGTGGTCCGGCGCGGAAGGGGCCCATGAGGCGTGGA
    GGCCGCCGAGGTCGGGGTACCGAGGGACGCAGGGAGGCCAGCGCTTCCTC
    CCGGGCATTCGAGCGGGGCCTCGTCCTTCGGGAGAACACATTCTCCGGAG
    CCCTCTTCGAACGTTTATTAGTCGGTTCAGGGCAACTTGAAGGCCAAATG
    TTTGGCCCACAGGCCAATAAATAGTACGAGAGCCAATCGGCTTAAGGGTT
    TATTCCAGGTGAGGCGAGTGTCTTAGAAGATGGGAAACACGTAGATGGCG
    TGTTTTTACGGAAGAACTAAAATATTTAATTTTTAGGCAAGTGCCGCGGA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCTTCGTACTGCTAGGAAGCTCCGTAGTCACCGACGAGACCAGAA
    GTGGCATGATAAACAGTATAAGAAAGCTCATTTGGGCACAGCCCTAAAGG
    CCAACCCTTTTGGAGGTGCTTCTCATGCAAAAGGAATCGTGCTGGAAAAA
    GTGTAAGTCCATTGCTCCCGTCAAGTTTTAGTTTATTATAGGAATTCGAG
    ACATGAACTTACGAATTCTTGTTTTGAAAGTAATTGCAGGTTTTTGTGTA
    GTAGTATTCATTTGGGCATTGTGGGGTAAAATTGCAAAGCGTTTGTTCTA
    TTTAAAAGTTGGTAAAATTAGTTTTTGGGAATTAGGTAGTTAAGGTTTTA
    ATTTAACGTTGGCCTGGAAGGAATTGGAGAAGATACTAGCAATGATGAAG
    TAAAGGACACAAACACCTTTACTGTGGGAGTTGTTATAAGTAAATGGCAC
    GTGTCA
    (SEQ ID NO: 164)
    pARBI-945: TTGTATATCCTTTTTAAAGTTATTCTTTTTAGTTAATTGCTCTATGTGTA
    1806RTRAF_1_ TTGAGACTAGGAATCAGAAAGCTTAGATTCTAGTCCCAGGTGTAAGTTGT
    Endogenous_49 GTAACCCTTGGCAAGTGTCAATCTCTAGGCCTCAGCTTTCTCATCTATAA
    AATGAGGAAGTTGTCGTATTCTATTTTTTTTCTTAAGATGATACACTTAA
    ATGTTCCCTTCTGTTGGGTTATATAATTGCATCAAAAGTGTAGTAATGTT
    ATTAAAAAATTGTTAGAGATCCAAACTAAGGTCTCTTTCAACTCTCCCAT
    TCTTTTTTCTGTGACTTTATGGTAATAATGAAACTGGTGGTTTTCTTTTC
    TTCCCCCTCACAGTATCTCAGAGATGTTAACTGTCCTTTCAAGATTCAAG
    ATCGACAAGAAGCTATTGACTGGCTTCTTGGTTTAGCTGTTAGACTTGAA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTATGGAGATAATGGTACGTTTTGTGGGGAATGTGTATTTTAAAG
    AGAGAGGAAAGATGGGAAAGGGAGTGTGAAAATGTAGGGAACTTTGCAGT
    TTGTTTTGTCTAGTACTATTTTACCTTTGGTTTATTCTTATCACAAGTTA
    AAAGCACTTTTATTGTCTTTCATTGGTGTTTATATATTTCTGTTAGAATT
    TGGAAATGGTGCCCTCTGGAGAAGGCTAATTGACTGTCTTCTCACAGAGT
    AACACTACTTTGATAATATGGTCTGCACCTTAGCCTTTCAAATTAAATTG
    TTTTTAGTGTCCCAGAATTGATGGGACTTTGAAGTGTTGTTGCAGTAGGT
    AATTTCTCAAAAGACTGAAACATGTCTAATGCCAATATACATTAATACTC
    TATAGGCCAGAATATATTACTTATGTTTACTGTCTTAGCACAGATACTTC
    TATGGT
    (SEQ ID NO: 165)
    pARBI-946: GCACCTGTTATGTAGGAGGAGTAATAAAATGAATGAATGCACTCAAAACA 1806
    RTRAF_2_ CTAAACAGTAATTCTGTAATCCAACGGGAGGTACAGCGAATACCAAAAGC
    Endogenous_50 CTACATATACTATTCTCTGCATGCTATAGCAAGAAAGAAAGGAAAGTGGC
    TTCCCGGTGGTTTTCTGCCTATTGTACAACCAGGAAGCTGACAATAAAGT
    TTATTTGAGCGTCGACGTGCGCCGACGTGGCCCCGCCTCCCCAGCCGGAG
    CCGCGATTGGTGGGCATTTGCCGGCGGCCACCGCTTTTAAGCCACGATTG
    GCGAAGGCCGCCGTCATTTCGGAGCGACTCAGCGCCTGCCCGCCCTCTCG
    CCGCGTCGCCGGTGCCTGCGCCTCCCGCTCCACCTCGCTTCTTCTCTCCC
    GGCCGAGGCCCGGGGGACCAGAGCGAGAAGCGGGGACCATGTTCCGACGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAAGTTGACGGCTCTCGACTACCACAACCCCGCCGGCTTCAACTG
    CAAAGGTGAGGCGGCGGCCTCAGCCCGGCCGCGTGTCCCTGACCTGGGCG
    GAGGTCCCAGCCTCAGTGCCCGCACCCCACCTCCCCGTCGGGACCCTCGG
    CGGCCTGGTTTCCGCCGGCAGCCTCCGGGCCCCTCTCCTCTGGGTCGCCA
    CGTACCTCGGCTCTTCGCCGCCCCTTCCCGCCTTTAAAGCCCTCTCACCT
    ACTCCTGTCTCGGCATGTTACTTTCTGCACTTGCTTAACTCCAAGCATCA
    CGTAACTACCTTCTCTGTACATAAAAGGGAGAGCATTCGTCTTTCTCACT
    CACTATTCAACTCCATGGTTCCCTGGGTAATTAGGCGATACCTTGAGCAC
    CTGCTAATTATGGGCCAGCGCGGTGCTGGATTCTGAGGAAGGTGCTGAGT
    AACTTG
    (SEQ ID NO: 166)
    pARBI-947: CACTAAACAGTAATTCTGTAATCCAACGGGAGGTACAGCGAATACCAAAA 1806
    RTRAF_3_ GCCTACATATACTATTCTCTGCATGCTATAGCAAGAAAGAAAGGAAAGTG
    Endogenous_51 GCTTCCCGGTGGTTTTCTGCCTATTGTACAACCAGGAAGCTGACAATAAA
    GTTTATTTGAGCGTCGACGTGCGCCGACGTGGCCCCGCCTCCCCAGCCGG
    AGCCGCGATTGGTGGGCATTTGCCGGCGGCCACCGCTTTTAAGCCACGAT
    TGGCGAAGGCCGCCGTCATTTCGGAGCGACTCAGCGCCTGCCCGCCCTCT
    CGCCGCGTCGCCGGTGCCTGCGCCTCCCGCTCCACCTCGCTTCTTCTCTC
    CCGGCCGAGGCCCGGGGGACCAGAGCGAGAAGCGGGGACCATGTTCCGAC
    GCAAGTTGACGGCTCTCGACTACCACAACCCCGCCGGCTTCAACTGCAAA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGTGAGGCGGCGGCCTCAGCCCGGCCGCGTGTCCCTGACCTGGG
    CGGAGGTCCCAGCCTCAGTGCCCGCACCCCACCTCCCCGTCGGGACCCTC
    GGCGGCCTGGTTTCCGCCGGCAGCCTCCGGGCCCCTCTCCTCTGGGTCGC
    CACGTACCTCGGCTCTTCGCCGCCCCTTCCCGCCTTTAAAGCCCTCTCAC
    CTACTCCTGTCTCGGCATGTTACTTTCTGCACTTGCTTAACTCCAAGCAT
    CACGTAACTACCTTCTCTGTACATAAAAGGGAGAGCATTCGTCTTTCTCA
    CTCACTATTCAACTCCATGGTTCCCTGGGTAATTAGGCGATACCTTGAGC
    ACCTGCTAATTATGGGCCAGCGCGGTGCTGGATTCTGAGGAAGGTGCTGA
    GTAACTTGAAGACTAGTTCACTGCCTGCCAGGAGCTAAAGGGACGAGGGG
    TGGAAG
    (SEQ ID NO: 167)
    pARBI-948: CCGGGTTAGGCATAGGCCCTCCCGGATCTTCCGCGGTGTAAGGAGAAGGC 1806
    SERF2_1_ CAGCGCCCCTGTGATAGGCCCAGAGCCCCCACTCCACAAGCCAGCCCATC
    Endogenous_52 CCCCACGGAGACCCAAACCGTCCACACACACCTTGCCAGCTGTTTGGGCC
    CCACGCCGCCCCAAAACACGCCTCCAGCTGGCCCCTTGGGACCTCCCTTC
    TCTAGTCCGTATTTTGACCTGGCCCGTGGCAGATTCGCCACTCCCCCCTA
    CCCCAAGCAGCCTGGGCCTCGATGGGCCGTTGTCGGGGCCCGGAGATTGA
    AGTGGTGTTGGATCCTGCTGCTGGCCGCGCTGGGGTAGAAGGGTCGCCGG
    TGTGTGGGCAGAGCGGCCCCCGCGTCTCACCTTTAATTTTCTTTCCTTAG
    GCGGTAACCAGCGTGAGCTCGCCCGCCAGAAGAATATGAAAAAGCAGAGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGACTCGGTTAAGGGAAAGCGCCGAGATGACGGGCTTTCTGCTGC
    CGCCCGCAAGCAGAGGTAGCCCCAGGGAGGGGAGGGAAAGGGACGGTGGA
    GACCTGGGTTAGACCAAGGGTTATAGAAGGAAAGAGAGCTACCTCAGGGC
    TTGAATGTGGACTAGTCGTGAGGAGCAGAGTGCATTGCTTCCTCTAGGGT
    TTTATTTCCTCCCCACCCTCCAAATTGTTAGCTCACAGCCTTACAGGAAA
    GGACGGGGGCGGGCGCCTGCCCTCAGTCTGATTTCTGAGCGTCCCTGGGT
    CTGACCTTAAGGGCAAGGGCAGGGAGCTTCACATTTCAAATACAGTTGTG
    GTTACGGCAGCCCAGTACTTTTGGCCCTCCTTGCTGTTCGGTTCTCCTCC
    CTTCTCCCAACCTCCTCACTGGTGTTGCTGGGTGTGGTCCTCAATACAGA
    ATAGAG
    (SEQ ID NO: 168)
    pARBI-949: AATCGAGCCCTTTGCCCACGGCTACTTCACGGGACCACCCTCCCGGGTTA 1806
    SERF2_2_ GGCATAGGCCCTCCCGGATCTTCCGCGGTGTAAGGAGAAGGCCAGCGCCC
    Endogenous_ CTGTGATAGGCCCAGAGCCCCCACTCCACAAGCCAGCCCATCCCCCACGG
    53_54 AGACCCAAACCGTCCACACACACCTTGCCAGCTGTTTGGGCCCCACGCCG
    CCCCAAAACACGCCTCCAGCTGGCCCCTTGGGACCTCCCTTCTCTAGTCC
    GTATTTTGACCTGGCCCGTGGCAGATTCGCCACTCCCCCCTACCCCAAGC
    AGCCTGGGCCTCGATGGGCCGTTGTCGGGGCCCGGAGATTGAAGTGGTGT
    TGGATCCTGCTGCTGGCCGCGCTGGGGTAGAAGGGTCGCCGGTGTGTGGG
    CAGAGCGGCCCCCGCGTCTCACCTTTAATTTTCTTTCCTTAGGCGGTAAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAGCGCGAGCTTGCCCGCCAGAAGAATATGAAAAAGCAGAGCGA
    CTCGGTTAAGGGAAAGCGCCGAGATGACGGGCTTTCTGCTGCCGCCCGCA
    AGCAGAGGTAGCCCCAGGGAGGGGAGGGAAAGGGACGGTGGAGACCTGGG
    TTAGACCAAGGGTTATAGAAGGAAAGAGAGCTACCTCAGGGCTTGAATGT
    GGACTAGTCGTGAGGAGCAGAGTGCATTGCTTCCTCTAGGGTTTTATTTC
    CTCCCCACCCTCCAAATTGTTAGCTCACAGCCTTACAGGAAAGGACGGGG
    GCGGGCGCCTGCCCTCAGTCTGATTTCTGAGCGTCCCTGGGTCTGACCTT
    AAGGGCAAGGGCAGGGAGCTTCACATTTCAAATACAGTTGTGGTTACGGC
    AGCCCAGTACTTTTGGCCCTCCTTGCTGTTCGGTTCTCCTCCCTTCTCCC
    AACCTC
    (SEQ ID NO: 169)
    pARBI-950: TTCAAAAGGAATCTTTTTGTTTCAACTATTAGGATCTTTTTAAATCAAAT 1806
    SLC38A1_1_ ATGTATTTTAATGGTGTACACCAGACCTGAAGAAAAAGATCACAGAAGGA
    Endogenous_55 ATTTCCCCTTTGTAAGATAGAGGTAGTTAAAAATAAGCCTTATGACCTAA
    TAGGTTAATTGTAATGCTCTGGTAGCCAACTTGAAAAAGGAGAAATGATG
    GTTGCATCTCACATTTTAAAATGTTAAGAATTTGTTTTGTAATGAGGATA
    CCTTAACCCCTGAAGGCCAAAATGACTATTTGTGTGAGTTTGAGAAAGGC
    ACATAGTAACTTGGGGAACAGTCAATAGAATGACAAAATCTTGACTATTT
    TAACTTTCTGAACCCTGTCATTTCTTGTGTTCTCAAATTTGATTTTTAAA
    TAGGCTGCATGGTGTATGAAAAGCTGGGGGAACAAGTCTTTGGCACCACA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGGAAGTTCGTAATCTTTGGAGCCACCTCTCTACAGAACACTGG
    AGGTAAAAAGAACATGCTTTTCTTTACATAACTTGAAACTAATTCTGGTG
    GATGAGCGGCCACATGAATTTTAACATAATTCAAGCAGTTATCATCCTCA
    TTGCTAAAATGGCACAGGGAAAGTAAAGCAGAGACAGCAGTCACTTATTT
    AAAGCCACAAATCCTGCTAGAGTAGCTGAAGTTGCCTTTGTGTCTTACTG
    ACAGTTGGTCTAAGAACGGGCTGATAACTTTTTATGTAGCTTGCAACATA
    AGCCTTCGTATCTTCTTTCTAAAAATGTTCTCATTTTCCTTCAGCAATGC
    TGAGCTACCTCTTCATCGTAAAAAATGAACTACCCTCTGCCATAAAGTTT
    CTAATGGGAAAGGAAGAGACATTTTCGTAAGTTATAGACCATTTTTTTAT
    GATATA
    (SEQ ID NO: 170)
    pARBI-951: TAAAGATGTCAAGCTTCAAATCATTATCATAAGGTTAAATATATTACGCA 1806
    SLC38A1_2_ TGTCTTTACAGCAAGTTTATTTCTGATCGTGAAAGTAGAAGAAGTCTCAC
    Endogenous_56_57 AAACAGCCATTTGGAAAAAAAGAAGTGTGATGAGTATGTAAGTATCATTA
    TAATGAAGTATGCTTATTTTTTTAATCATATAAATTGGGACAAATCTTTT
    TAATTCAAGTAGCATAGTACCAAAAGCATAACTACCTGTATTCACCAGGA
    TATTCCTCATACCTTATGTATTTTCTCTTGAAATCCATTCAAGGAAATAA
    CTAGATAACTAAGAATGGATTTTCTTGAATTTTACTTCCATATTGGTTCC
    TGAGAGTGCATTAAAGGCTTTGGCTTGATGAACTTTCTTGGGGATTATTT
    TGCTTAGTGTCAATGTTTGTTTCTTTGTTCAGATTCCAGGTACAACCTCC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTAGGCATGTCAGTTTTTAACCTAAGCAACGCCATTATGGGCAG
    TGGGATTTTGGGACTCGCCTTTGCCCTGGCAAACACTGGAATCCTACTTT
    TTCTGTGAGTATTGACGTGCCGGTACTTTCCATTTTAAAACTGAACTTTT
    TGTATGTTTCTGTTATTACATAGAAGAAATGTGAAATATTTATAAATAGT
    TTTTTTATTAACTTGGCTAAGTTACAAGTACATACTTTGATATTTATTGC
    TTGAGTGATTTTCCAAACTGTACCTAATGCTTACAACAAAGAGGAAGGAG
    AAAATCTTTTTATTAATCAAAAATACTGAAATAAGCATTTGTGAAAAGGA
    TTAAAACATTTGAAAATAACTTTTTTTGGTATTTTTGGAGTCTACCTGTG
    ACTTTAAATCTCAGTTAAAATATTAAGAGGTGTTTAACCCCAGCCAGTCA
    CCACTT
    (SEQ ID NO: 171)
    pARBI-952: ATCATTCTTCACACTAGTTCCTTTTCTGACTCTTCAGTCACCTCCAGAAT 1806
    SMAD2_1_ TAATATCCTTAGAAGCATCTCTAAAATGAGTTTGATTTACTAAACATAGA
    Endogenous_58 AGTTGACAAAGTTTTTCAAGTATAACTGCATAAACTCTCTTTTTTAAAAA
    ATCAGTTTTTCCCAAGTTGTTAGCCTTTCATTGGCATTTGAGTCATTTAT
    GTGACATATTTATAAGAAACATCTGCTAGTGCTGCTGCATACTTTTATCA
    GATCCATTAAATAGTACATTTTTGTTCTTGATTCTCACTAAAACTAACTA
    AATGGCTGTCATTCTTTTCTTTATGCTTTTATTGTACTAATTTAGCCCAT
    TTGACTGCACttttttttttttttttttAAAGTTCCCTCCTTTCTTTTCC
    CCTTGCTTCCCAACAGGTCTCTTGATGGTCGTCTCCAGGTATCCCATCGA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAAAGGATTGCCACATGTTATATATTGCCGATTATGGCGCTGGCC
    TGATCTTCACAGTCATCATGAACTCAAGGCAATTGAAAACTGCGAATATG
    CTTTTAATCTTAAAAAGGATGAAGTATGTGTAAACCCTTACCACTATCAG
    AGAGTTGAGACACCAGGTAGGAATATTGCAAGTTTTTTTCTTGGTTTTGA
    ATTAAATGCCTGAACTTCAGTATATTTAAGTACTCTTGTGACCCAGGAAA
    ATTTTAGTGTAAATTCTAATAAATTACCTTAAATTGTGCATATTATTTGG
    TGGTAATTAAAAtttttttatttttaaaaatttttAATGAGAAAACATAT
    CTGTTTCTTGGAATAGCATATGATTTGGCATGAAAGTGCATATCCAGGAA
    ATCCTGTAGATTGGCAGTCTGCTCAGCGCTATGCTGATGTGCTTCTACAT
    GTCCCT
    (SEQ ID NO: 172)
    pARBI-953: TTCTATATTAAAAATCAGTTGACATCTGTTTTTAGATAATTTTTTAAAAA 1806
    SMAD2_2_ ACTGGATTATAAAATGAAGCACTTAGTAAAGCTGATGGCAGAGGTTTTAG
    Endogenous_59 ATCTTTTGAATACAGGAAAGTGGTAAGGGCATTATAGGTATGATTCATTG
    AGCTAGAGGGCGTTGGTGTTCACATTTTAAAAACATAATCATGACTTATC
    TGGAGTCACATGTTCCATTTTATTGGCTTCCTTCATATAGAAAATATAGT
    AACCAGCACTACATGCCTGTGAAAAAGTGAAGCAATTGTATATTTTCTGG
    GTGAAGGAAGTATTCTGTACATTCTCCATGTTTTACATCATGGTATTTTG
    AATAACCATGCTTCCATGTTCACATCAATTTTTTGTTTTTCAATTTATGC
    ACAGCACTTGCTCTGAAATTTGGGGACTGAGTACACCAAATACGATAGAT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCAGTGGGATACAACAGGCCTTTACAGCTTCTCTGAACAAACCAG
    GTGAATATTCTGCCCTCTGTCGAATCTTAGAGATCTTGTGGGAGGGGGGT
    ATATTTTGAAAGACCTATATGGGGTTGCTTAGTATAATTTTGCCTAGGAT
    GTTTCCTTAATGTAAAATAAGGCATAGCATTTAAAATATCTGCTTGCCAG
    TATAAAAAATATATTAAATGTTTCAGCTGATGTTTTAATCAATGCAATTC
    TAGTTTGAATCTTCTTTAAATTACTGTATCCCCTAAAGAATAATAATTTT
    GATAACTATATATTTATTTTAGCTTGAGATCAGATTATAATCTGTTGTTG
    GCCTAATTTTTAAGTAGATACATGATGAGTTTTGCTAAATTTCTTGTTAT
    CAGAATCTCATCTTTATACTAATAAATACATACTTAATGAACCCCTTATA
    TCACAA
    (SEQ ID NO: 173)
    pARBI-954: TCAATGTATTTTTGTATAGTCTTTTGAGATTAGAGTGAAGTTCTAAAAAG 1806
    SMAD2_3_ TAAGAGAACCTTTTGTGAAAATATTTTAATTGACACTACTAAGAGTTTAA
    Endogenous_60 AATAGTATTGGTGGTGAAAAATCGTTAAAAGTATCTGATTTTACTTGCAA
    AATTACTGTATTTTCCCACAAGAGGAGTCCTTACAACATTCTTGTTTTTA
    GAAGGGTTTGTTTCCATCATTCATTTAAATTCATAAAGATAACGTTTTCA
    TGGGTGGAGAAGTCTATTGGGAAAGTCATAATTCGAATTTCTATCTTGCT
    TTGCAGTTTGCTTTCTATGATAAGTTGAAATTATTACTTGATGTTCAAGG
    TAGTCTCTACATCATCCTTTCAATATTTCTGCTAGGTTCGATACAAGAGG
    CTGTTTTCCTAGCGTGGCTTGCTGCCTTTGGTAAGAACATGTCGTCCATC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTGCCATTCACGCCGCCAGTIGTGAAGAGACTGCTGGGATGGAA
    GAAGTCAGCTGGTGGGTCTGGAGGAGCAGGCGGAGGAGAGCAGAATGGGC
    AGGAAGAAAAGTGGTGTGAGAAAGCAGTGAAAAGTCTGGTGAAGAAGCTA
    AAGAAAACAGGACGATTAGATGAGCTTGAGAAAGCCATCACCACTCAAAA
    CTGTAATACTAAATGTGTTACCATACCAAGGTAAGTTTTGTTAGATCCCA
    GGTTTGATCAAATTATGTCAAGGAATCTGAAGGAAAGTTACTGAATTTGT
    GTTCCTTTCAAGTTGCCTGTAAAAAGTGATGATTGAAATATGACTGTTTT
    TAACCTTGTATAAATTGTTTTTGCTAGCTGACTTGTTTTATAAATTATTT
    TCTTGAATAGTGAGGTTTAATCAAGCTAAATAAGATACTTAGATTTATTA
    TCTTCA
    (SEQ ID NO: 174)
    pARBI-955: GGGCTCCCGCAGCACAGCCTTTCTCCGGCCCTAGCCCAAATCGCCCAGAC 1806
    SOCS1_1_ CAGGCGCGGATCCCAGCCTGGCCAGCAGGCGGCGGGCGCGGGGGGCGAGC
    Endogenous_61 CGGGGCCGGACGGCTGGAGCCAGAACCGGCTGCTCTCCACGCCCCCCTCT
    CGGTGCTGCCCGGAGGCCGGACTCCGCCTCCACCGAGCCCCCACCCGCCG
    GGAAGAGCTCCGCGGAGTACAGAGCCCATTTTCTAGCTGTGTCCACTGAG
    GCTGAACGGATCCGCGCGGACTTGGTGCTCCGTGCTCGCCCCCTAGGGCC
    GGGTCCGCCGGGAGCGCCGCCCTCCGGAGTTGTCCGGCCGGCGCACACCT
    GCCCGGCCCCGCAGCGCCCCAGCTCACCTCTTTGTCTCTCCCGCAGCGCA
    CCCCCGGACGCTATGGCCCACCCCTCCGGCTGGCCCCTTCTGTAGGATGt
    ccggatccggagagggcaggggatctctccttacttgtggcgacgtggag
    gagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT
    GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCA
    GCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTG
    AAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGT
    GACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
    TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAG
    GAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGA
    GGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCA
    TCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC
    TACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCAT
    CAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC
    TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTG
    CTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCC
    CAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCG
    GGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagct
    tataatggttacaaataaagcaatagcatcacaaatttcacaaataaagc
    atttttttcactgcattctagttgtggtttgtccaaactcatcaatgtat
    cttatGTAGCACACAACCAGGTGGCAGCCGACAATGCAGTCTCCACAGCA
    GCAGAGCCCCGACGGCGGCCAGAACCTTCCTCCTCTTCCTCCTCCTcgcc
    cgcggcccccgcgcgcccgcggccgtgccccgcggtcccggccccggCCC
    CCGGCGACACGCACTTCCGCACATTCCGTTCGCACGCCGATTACCGGCGC
    ATCACGCGCGCCAGCGCGCTCCTGGACGCCTGCGGATTCTACTGGGGGCC
    CCTGAGCGTGCACGGGGCGCACGAGCGGCTGCGCGCCGAGCCCGTGGGCA
    CCTTCCTGGTGCGCGACAGCCGCCAGCGGAACTGCTTTTTCGCCCTTAGC
    GTGAAGATGGCCTCGGGACCCACGAGCATCCGCGTGCACTTTCAGGCCGG
    CCGCTTTCACCTGGATGGCAGCCGCGAGAGCTTCGACTGCCTCTTCGAGC
    TGCTG
    (SEQ ID NO: 175)
    pARBI-956: GGATCCCAGCCTGGCCAGCAGGCGGCGGGCGCGGGGCGGCGAGCCGGGGC 1806
    SOCS1_2_ CGGACGGCTGGAGCCAGAACCGGCTGCTCTCCACGCCCCCCTCTCGGTGC
    Endogenous_62 TGCCCGGAGGCCGGACTCCGCCTCCACCGAGCCCCCACCCGCCGGGAAGA
    GCTCCGCGGAGTACAGAGCCCATTTTCTAGCTGTGTCCACTGAGGCTGAA
    CGGATCCGCGCGGACTTGGTGCTCCGTGCTCGCCCCCTAGGGCCGGGTCC
    GCCGGGAGCGCCGCCCTCCGGAGTTGTCCGGCCGGCGCACACCTGCCCGG
    CCCCGCAGCGCCCCAGCTCACCTCTTTGTCTCTCCCGCAGCGCACCCCCG
    GACGCTATGGCCCACCCCTCCGGCTGGCCCCTTCTGTAGGATGGTAGCAC
    ACAACCAGGTGGCAGCCGACAATGCAGTCTCCACAGCAGCAGAGCCCCGA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCGGCGGCCAGAACCTTCCTCCTCTTCCTCCTCCTcgcccgcggc
    ccccgcgcgcccgcggccgtgccccgcggtcccggccccggCCCCCGGCG
    ACACGCACTTCCGCACATTCCGTTCGCACGCCGATTACCGGCGCATCACG
    CGCGCCAGCGCGCTCCTGGACGCCTGCGGATTCTACTGGGGGCCCCTGAG
    CGTGCACGGGGCGCACGAGCGGCTGCGCGCCGAGCCCGTGGGCACCTTCC
    TGGTGCGCGACAGCCGCCAGCGGAACTGCTTTTTCGCCCTTAGCGTGAAG
    ATGGCCTCGGGACCCACGAGCATCCGCGTGCACTTTCAGGCCGGCCGCTT
    TCACCTGGATGGCAGCCGCGAGAGCTTCGACTGCCTCTTCGAGCTGCTGG
    AGCACTACGTGGCGGCGCCGCGCCGCATGCTGGGGGCCCCGCTGCGCCAG
    CGCCGC
    (SEQ ID NO: 176)
    pARBI-957: CGGACTCCGCCTCCACCGAGCCCCCACCCGCCGGGAAGAGCTCCGCGGAG 1806
    SOCS1_3_ TACAGAGCCCATTTTCTAGCTGTGTCCACTGAGGCTGAACGGATCCGCGC
    Endogenous_63 GGACTTGGTGCTCCGTGCTCGCCCCCTAGGGCCGGGTCCGCCGGGAGCGC
    CGCCCTCCGGAGTTGTCCGGCCGGCGCACACCTGCCCGGCCCCGCAGCGC
    CCCAGCTCACCTCTTTGTCTCTCCCGCAGCGCACCCCCGGACGCTATGGC
    CCACCCCTCCGGCTGGCCCCTTCTGTAGGATGGTAGCACACAACCAGGTG
    GCAGCCGACAATGCAGTCTCCACAGCAGCAGAGCCCCGACGGCGGCCAGA
    ACCTTCCTCCTCTTCCTCCTCCTcgcccgcggcccccgcgcgcccgcggc
    cgtgccccgcggtcccggccccggCCCCCGGCGACACGCACTTCCGCACA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTCCGTTCGCACGCCGATTACCGGCGCATCACGCGCGCCAGCGC
    GCTCCTGGACGCCTGCGGATTCTACTGGGGGCCCCTGAGCGTGCACGGGG
    CGCACGAGCGGCTGCGCGCCGAGCCCGTGGGCACCTTCCTGGTGCGCGAC
    AGCCGCCAGCGGAACTGCTTTTTCGCCCTTAGCGTGAAGATGGCCTCGGG
    ACCCACGAGCATCCGCGTGCACTTTCAGGCCGGCCGCTTTCACCTGGATG
    GCAGCCGCGAGAGCTTCGACTGCCTCTTCGAGCTGCTGGAGCACTACGTG
    GCGGCGCCGCGCCGCATGCTGGGGGCCCCGCTGCGCCAGCGCCGCGTGCG
    GCCGCTGCAGGAGCTGTGCCGCCAGCGCATCGTGGCCACCGTGGGCCGCG
    AGAACCTGGCTCGCATCCCCCTCAACCCCGTCCTCCGCGACTACCTGAGC
    TCCTTC
    (SEQ ID NO: 177)
    pARBI-958: GGCAGACAAACAGTTAAAACAGAGGAGTGGGGTAAGTGATGACCTAACCC 1806
    SRP14_1_ AGCCCCGCTGCTCTAGTTTTGTTAAACACCTCATCTGCTATCACGGTCTG
    Endogenous_64 GCGAAACCCTGGAGAAACTATTATTTCCACGACGGAAACATGTAATATCG
    AAGCACGTTAAATTCCACTCAAAGTGGCGGCGTCTGGGATCCCTGACAAA
    GAGCCCTGGGCTGCTTGGGGCCCATTGTTACCAGAAGCAACCTAGGCGGC
    TCAGTGCTGGGGACTGAGCCAGCTACAATCCCTACTATTTTCCGGGCCCG
    AAGCCCCGAATGTGCTCAGTACAGGGTGGGGAAAGGTAGAGGAAGGCGGC
    GGTCCGCGGCAGACAGACTCCGGTGGCTCCCAGACACCGGGAACCCAGGG
    AGCATCGCCCGGCTCCCCTCCCGCTGCTTACACTTCTTCAAGGTGATATA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGACGCTGCCCGACGTCCGGCACTTCTGGAAAAGTCTGGTCAGCT
    CCGTCAGGAACTGGAAAACAACAGGCCCAGCCCCGTTAGCCAGCCCCAAA
    TCCTCGTCCTGCCGCGTCAAGGCCCTGGTCCTCCTGCAGGAGGCACAGGT
    CTCGAGTAACGCCTGAGCCGCCCCCTTCCCTCGGCCGGCCAGGCCTAGCC
    ATACCTGCTCGCTCTCCAACAACACCATCGCGGCGACGCTGGCTCGACTC
    CCTCCGCTTAAGCCCCTAGCAGTGAGAGCCGGAAGTTCGGCCTAGGCTGG
    GGGGACTTCCGCTACTAGACTTCCATTGTCTTCCACCAATCTCTTCTCTT
    CCACCAATCCCGGCCTGCGCCCTCCCCCCTCCCCGCCCGCCTAGCGCCCG
    CGCCCTGGGACGTCCGGGGGCCTGTGACCCGGAGGCGCTGGGGCTGTCCT
    GGGTC
    (SEQ ID NO: 178)
    pARBI-959: GTCTGTCTGCCGCGGACCGCCGCCTTCCTCTACCTTTCCCCACCCTGTAC 1806
    SRP14_2_ TGAGCACATTCGGGGCTTCGGGCCCGGAAAATAGTAGGGATTGTAGCTGG
    Endogenous_ CTCAGTCCCCAGCACTGAGCCGCCTAGGTTGCTTCTGGTAACAATGGGCC
    65_66 CCAAGCAGCCCAGGGCTCTTTGTCAGGGATCCCAGACGCCGCCACTTTGA
    GTGGAATTTAACGTGCTTCGATATTACATGTTTCCGTCGTGGAAATAATA
    GTTTCTCCAGGGTTTCGCCAGACCGTGATAGCAGATGAGGTGTTTAACAA
    AACTAGAGCAGCGGGGCTGGGTTAGGTCATCACTTACCCCACTCCTCTGT
    TTTAACTGTTTGTCTGCCGCTCAGCCACGTACGCGGCCGTGTTCACCAGG
    ATGCATTTTTTCCTTCAGATGACGGTCGAACCAAACCCATTCCAAAGAAG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGTACTGTGGAGGGCTTTGAGCCCGCAGACAACAAGTGTCTGTT
    AAGAGCTACCGATGGGAAGAAGAAGATCAGCACTGTGGTGAGCTTAATTT
    CTAAGGCTGTCTTTTGAAATGTAAAGACTTGAACTTAACAGAGGATGGGG
    CGTTTCTGAACCAGGCTTTTATTTGTTTTTCCCTTTTGCCCTGTGTGGCT
    ATTTTTGAGACCAGGACCTTCCTATACTTTAGTAGTGGAAACCTCAAGAA
    TAAAATAAGAAGGTAGAGGTCAGACAGTCGTTAGTTCTGCTAAAGCTCTT
    GTGGAAATGAAAGTAGCATATTGGTCCTTATTCGTAGTACTGTAAGGAGC
    AGCTGGCATAAATATTTGATTCCTTAGCCCCTTACTGTGCTGGGCCTTCA
    ATAAGCAGTTTCTTGGTACCAGGTGATGCTATTATTTCCTTATCTTTGTG
    GTTCAC
    (SEQ ID NO: 179)
    pARBI-960: CCCACGTCAGTGAGTGCTCACAAGTCTGTGAGGTAGGCGGCGCCACAGAG 1806
    SRSF9_1_ AGAAACTGAGGCGCGGGAGCCCAAGCCACTTGTCCAGCGCCTCAGCCGAG
    Endogenous_67 CGCGAACCGCGCTCGGGGATGGCATCCACACGGCCCGGCCCCAGGCTCTC
    CCTGTCAGCGCCCGAAGGCCCTTCGCACCTCCAGGGGGCGCCGGCCTGCG
    CGCACGCGCAATGGTCGCAGCCGCGTTCTCTTTAAGAGGACTCCTTTTGC
    CTCCGCCGACCCCTTCGCTTCCGCTCCGCGTTCCCACAATGCAGTGCGGC
    TGAGCGCCTCGGAGCCCGCGGGGACGCTGCGGGGGGACCCGTGCTGAggc
    ggcggcggcgacgtgggctgcggcgggcccgcggcgtcgggcggtgcgga
    tgtcgggctgggcggacgagcgcggcggcgAGGGCGACGGGCGCATCTAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGTGGGGAACCTTCCGACCGACGTGCGCGAGAAGGACTTGGAGGA
    CCTGTTCTACAAGTACGGCCGCATCCGCGAGATCGAGCTCAAGAACCGGC
    ACGGCCTCGTGCCCTTCGCCTTCGTGCGCTTCGAGGACCCCCGGTGAGGc
    ccccgcgcccctgccctctcctcctcggtgcctgaggcccccgccttccc
    tgctgtcccctcccccagggctcccctccccccggcctcccctccccccg
    cctccgcgcagacccctcaCGGCGCCCCCTCACGGGTGGAGGATGAGGCA
    GCCTCTCCTCGCAGGCCCGGGCCGTCCTTCGCGCCGTCGTCACTTCCTTT
    ATTTTTATTATTCCAATATTTTACTTAGAAACCCAAAAGCTGAGCCTTTG
    GAGGGCCCAAGCCCGCCTGCACCGGCCTCGGGGGGTCCAAATGAGCCTTG
    TCCGCC
    (SEQ ID NO: 180)
    pARBI-961: TGTGGTGTGCTTTTCGAGAAAATGCTCACGAAGATTAGAAAAACACTGAT 1806
    SRSF9_2_ GGTTTATTGGCAAAATCAATAATCTGTCAGCAGTTGATTCttttttttCT
    Endogenous_68 CTGAATTAGCCCTCTTATGAGTAATCTGTTTGCTCATTCATTATAATTTC
    ATACCTCTAAAACTGCGTGTGACAGCTGTAAAGGTTAATTCCAGTATCAT
    GAAACGTCTCCAAACCAAAGCAGAAGTGCTTCAGGATCCTGATTTGTGTG
    TTTTTTTCTTCACTCTAGGTTTCCCTTTTATGCTTACTACTCATGCCCCT
    CACTTGGAAAGTCACTTGGCCTCCTGAACAGCACTAACTCCAAACGtttt
    ttttgttgttgttgttttttttAGAGATGCAGAGGATGCTATTTATGGAA
    GAAATGGTTATGATTATGGCCAGTGTCGGCTTCGTGTGGAGTTCCCCAGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACTTATGGAGGTCGGGGTGGGTGGCCCCGTGGTGGGAGGAATGG
    GCCTCCTACAAGAAGATCTGATTTCCGAGTTCTTGTTTCAGGTATGTTCC
    TTTCAAACAGaatgagatgatacatgtaaaatacttaacacagagtctgt
    cttccaagaaatgatagctgttattcttCAGTGCATGGGACACGGGGGCT
    TTCTTTTCAATAGCCTGTGTGAAGCCTTGCCCTGGATTGCCAATGAGGAA
    AGTATCCTGCAAATGAAATTGCGCTGGGAGTGCAGCCTTGGAAGAACATA
    ACCATATTTCTTGTAAAGGAGTTTTCTAGTGGTGAGAAGGAAAGATGATG
    GGAAAACTTGAGCTACAATTCTAAAGATGCTTCTTTTGGAATATACTTGG
    CATCAGACATGGTAGAAAGGCATTCAAGGAGCCAGATTTGAACAACTTAC
    CCAGCC
    (SEQ ID NO: 181)
    pARBI-962: GATGGCATCCACACGGCCCGGCCCCAGGCTCTCCCTGTCAGCGCCCGAAG 1806
    SRSF9_3_ GCCCTTCGCACCTCCAGGGGGCGCCGGCCTGCGCGCACGCGCAATGGTCG
    Endogenous_69 CAGCCGCGTTCTCTTTAAGAGGACTCCTTTTGCCTCCGCCGACCCCTTCG
    CTTCCGCTCCGCGTTCCCACAATGCAGTGCGGCTGAGCGCCTCGGAGCCC
    GCGGGGACGCTGCGGGGGGACCCGTGCTGAggcggcggcggcgacgtggg
    ctgcggcgggcccgcggcgtcgggcggtgcggatgtcgggctgggcggac
    gagcgcggcggcgAGGGCGACGGGCGCATCTACGTGGGGAACCTTCCGAC
    CGACGTGCGCGAGAAGGACTTGGAGGACCTGTTCTACAAGTACGGCCGCA
    TCCGCGAGATCGAGCTCAAGAACCGGCACGGCCTCGTGCCCTTCGCCTTC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGTGCGCTTCGAGGACCCCCGGTGAGGcccccgcgcccctgccct
    ctcctcctcggtgcctgaggcccccgccttccctgctgtcccctccccca
    gggctcccctccccccggcctcccctccccccgcctcegcgcagacccct
    caCGGCGCCCCCTCACGGGTGGAGGATGAGGCAGCCTCTCCTCGCAGGCC
    CGGGCCGTCCTTCGCGCCGTCGTCACTTCCTTTATTTTTATTATTCCAAT
    ATTTTACTTAGAAACCCAAAAGCTGAGCCTTTGGAGGGCCCAAGCCCGCC
    TGCACCGGCCTCGGGGGGTCCAAATGAGCCTTGTCCGCCTCCTGCCTGGG
    GCAGCACCGTAGGGGGAAGCGGCCGCGGGGCAGCGCGGGGGTCGCCGTTC
    GCCCTTCCCGCTCGCCTCTCCCCCGGCCCGTGCTCGCCGTGGCTGGAGAG
    CAAGCT
    (SEQ ID NO: 182)
    pARBI-963: GTAACTGACTAGCCTTAGTAGACTGTGGTTTCCAGGTTTATTCAGAAGTA 1806
    SUB1_1_ GCAAGATCCCTCCAtttttttttCTACCAAAGAAATCGTATGTGGGATCC
    Endogenous_70 CAAACCACAAAATAACCGTTCCTGTGGTTAATACTACTATAATGCCTGAA
    GTGTCTTTTGGGATCCTGAGAACAGAGTTTGAAAACATTACTAGACAGAA
    GGATTGGTTAGATTCATAGTTTTGTTGTTGAGTGAAACTTGCTTATGTAT
    ATATTTATGATATTTTGGATGTAGTCTTTTGATTGTTTAAATCTTAAAAA
    GTAATGGGATCTTTTGACACTGGGGTATGTTTTATTTTTATGTGTGCAAA
    TTTTAACCATATTCTTTTCTAGTTAAAGAGGAAAAAGCAAGTTGCTCCAG
    AAAAACCTGTAAAGAAACAAAAGACAGGTGAGACTTCGAGAGCCCTGTCA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTCTTCTAAACAGAGCAGCAGCAGCAGAGATGATAACATGTTTCA
    GGTAAAGTTGGCTAttttttttttttttttttttgacatggagtcatgct
    ctgtcacccaggctggagtgcagtggcgccatctcggctcactgcaacct
    cagcctcctgagttcaagcagttctctgcctcagcctcccgagtagctag
    gattacaggcatccgccaccagacctggctaatttttgtatttttagtag
    agatggggtttcaccatcttggccaggctggtcttgaactcctgaccttg
    tgatccaactgcctcagcctccaaaagtgctgggtttacaggtgtgagcc
    accatgccttgccAAAGTTGGCTGTTTCTTTAGATTCAGAGGAATTATTA
    TCTGGCTTGATCTGAAGAATGTTAAAAGTACTATGATCTGATAATTGCCT
    AATATG
    (SEQ ID NO: 183)
    pARBI-964: ATAAATAAACATATCCTGGAAATGGAATAAGTTGGTTATATTCTTTTTAA 1806
    SUB1_2_ TTAGTATATCTGCTTCGTAAAATAAGTAACTGACTAGCCTTAGTAGACTG
    Endogenous_71 TGGTTTCCAGGTTTATTCAGAAGTAGCAAGATCCCTCCATTTTTTTTTCT
    ACCAAAGAAATCGTATGTGGGATCCCAAACCACAAAATAACCGTTCCTGT
    GGTTAATACTACTATAATGCCTGAAGTGTCTTTTGGGATCCTGAGAACAG
    AGTTTGAAAACATTACTAGACAGAAGGATTGGTTAGATTCATAGTTTTGT
    TGTTGAGTGAAACTTGCTTATGTATATATTTATGATATTTTGGATGTAGT
    CTTTTGATTGTTTAAATCTTAAAAAGTAATGGGATCTTTTGACACTGGGG
    TATGTTTTATTTTTATGTGTGCAAATTTTAACCATATTCTTTTCTAGTTA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAAGAGGAAAAAGCAAGTTGCTCCAGAAAAACCTGTAAAGAAACA
    AAAGACAGGTGAGACTTCGAGAGCCCTGTCATCTTCTAAACAGAGCAGCA
    GCAGCAGAGATGATAACATGTTTCAGGTAAAGTTGGCTATTTTTTTTTTT
    TTTTTTTTTGACATGGAGTCATGCTCTGTCACCCAGGCTGGAGTGCAGTG
    GCGCCATCTCGGCTCACTGCAACCTCAGCCTCCTGAGTTCAAGCAGTTCT
    CTGCCTCAGCCTCCCGAGTAGCTAGGATTACAGGCATCCGCCACCAGACC
    TGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATCTTGGCCA
    GGCTGGTCTTGAACTCCTGACCTTGTGATCCAACTGCCTCAGCCTCCAAA
    AGTGCTGGGTTTACAGGTGTGAGCCACCATGCCTTGCCAAAGTTGGCTGT
    TTCTTT
    (SEQ ID NO: 184)
    pARBI-965: AATTAGTATATCTGCTTCGTAAAATAAGTAACTGACTAGCCTTAGTAGAC 1806
    SUB1_3_ TGTGGTTTCCAGGTTTATTCAGAAGTAGCAAGATCCCTCCATTTTTTTTT
    Endogenous_72 CTACCAAAGAAATCGTATGTGGGATCCCAAACCACAAAATAACCGTTCCT
    GTGGTTAATACTACTATAATGCCTGAAGTGTCTTTTGGGATCCTGAGAAC
    AGAGTTTGAAAACATTACTAGACAGAAGGATTGGTTAGATTCATAGTTTT
    GTTGTTGAGTGAAACTTGCTTATGTATATATTTATGATATTTTGGATGTA
    GTCTTTTGATTGTTTAAATCTTAAAAAGTAATGGGATCTTTTGACACTGG
    GGTATGTTTTATTTTTATGTGTGCAAATTTTAACCATATTCTTTTCTAGT
    TAAAGAGGAAAAAGCAAGTTGCTCCAGAAAAACCTGTAAAGAAACAAAAG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACAGGTGAGACTTCGAGAGCCCTGTCATCTTCTAAACAGAGCAG
    CAGCAGCAGAGATGATAACATGTTTCAGGTAAAGTTGGCTATTTTTTTTT
    TTTTTTTTTTTGACATGGAGTCATGCTCTGTCACCCAGGCTGGAGTGCAG
    TGGCGCCATCTCGGCTCACTGCAACCTCAGCCTCCTGAGTTCAAGCAGTT
    CTCTGCCTCAGCCTCCCGAGTAGCTAGGATTACAGGCATCCGCCACCAGA
    CCTGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATCTTGGC
    CAGGCTGGTCTTGAACTCCTGACCTTGTGATCCAACTGCCTCAGCCTCCA
    AAAGTGCTGGGTTTACAGGTGTGAGCCACCATGCCTTGCCAAAGTTGGCT
    GTTTCTTTAGATTCAGAGGAATTATTATCTGGCTTGATCTGAAGAATGTT
    AAAAGT
    (SEQ ID NO: 185)
    pARBI-966: CACATTTTAATTTTTGTTTCCATGCTCTTTAGAATTCAACTAGAGGGCAG 1806
    TET2_1_ CCTTGTGGATGGCCCCGAAGCAAGCCTGATGGAACAGGATAGAACCAACC
    Endogenous_73 ATGTTGAGGGCAACAGACTAAGTCCATTCCTGATACCATCACCTCCCATT
    TGCCAGACAGAACCTCTGGCTACAAAGCTCCAGAATGGAAGCCCACTGCC
    TGAGAGAGCTCATCCAGAAGTAAATGGAGACACCAAGTGGCACTCTTTCA
    AAAGTTATTATGGAATACCCTGTATGAAGGGAAGCCAGAATAGTCGTGTG
    AGTCCTGACTTTACACAAGAAAGTAGAGGGTATTCCAAGTGTTTGCAAAA
    TGGAGGAATAAAACGCACAGTTAGTGAACCTTCTCTCTCTGGGCTCCTTC
    AGATCAAGAAATTGAAACAAGACCAAAAGGCTAATGGAGAAAGACGTAAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTCGGGGTAAGCCAAGAAAGAAATCCAGGTGAAAGCAGTCAACC
    AAATGTCTCCGATTTGAGTGATAAGAAAGAATCTGTGAGTTCTGTAGCCC
    AAGAAAATGCAGTTAAAGATTTCACCAGTTTTTCAACACATAACTGCAGT
    GGGCCTGAAAATCCAGAGCTTCAGATTCTGAATGAGCAGGAGGGGAAAAG
    TGCTAATTACCATGACAAGAACATTGTATTACTTAAAAACAAGGCAGTGC
    TAATGCCTAATGGTGCTACAGTTTCTGCCTCTTCCGTGGAACACACACAT
    GGTGAACTCCTGGAAAAAACACTGTCTCAATATTATCCAGATTGTGTTTC
    CATTGCGGTGCAGAAAACCACATCTCACATAAATGCCATTAACAGTCAGG
    CTACTAATGAGTTGTCCTGTGAGATCACTCACCCATCGCATACCTCAGGG
    CAGATC
    (SEQ ID NO: 186)
    pARBI-967: AATGGAGAAAGACGTAACTTCGGGGTAAGCCAAGAAAGAAATCCAGGTGA 1806
    TET2_2_ AAGCAGTCAACCAAATGTCTCCGATTTGAGTGATAAGAAAGAATCTGTGA
    Endogenous_74 GTTCTGTAGCCCAAGAAAATGCAGTTAAAGATTTCACCAGTTTTTCAACA
    CATAACTGCAGTGGGCCTGAAAATCCAGAGCTTCAGATTCTGAATGAGCA
    GGAGGGGAAAAGTGCTAATTACCATGACAAGAACATTGTATTACTTAAAA
    ACAAGGCAGTGCTAATGCCTAATGGTGCTACAGTTTCTGCCTCTTCCGTG
    GAACACACACATGGTGAACTCCTGGAAAAAACACTGTCTCAATATTATCC
    AGATTGTGTTTCCATTGCGGTGCAGAAAACCACATCTCACATAAATGCCA
    TTAACAGTCAGGCTACTAATGAGTTGTCCTGTGAGATCACTCACCCATCG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCATACCTCAGGGCAGATCAATTCCGCACAGACCTCTAACTCTGA
    GCTGCCTCCAAAGCCAGCTGCAGTGGTGAGTGAGGCCTGTGATGCTGATG
    ATGCTGATAATGCCAGTAAACTAGCTGCAATGCTAAATACCTGTTCCTTT
    CAGAAACCAGAACAACTACAACAACAAAAATCAGTTTTTGAGATATGCCC
    ATCTCCTGCAGAAAATAACATCCAGGGAACCACAAAGCTAGCGTCTGGTG
    AAGAATTCTGTTCAGGTTCCAGCAGCAATTTGCAAGCTCCTGGTGGCAGC
    TCTGAACGGTATTTAAAACAAAATGAAATGAATGGTGCTTACTTCAAGCA
    AAGCTCAGTGTTCACTAAGGATTCCTTTTCTGCCACTACCACACCACCAC
    CACCATCACAATTGCTTCTTTCTCCCCCTCCTCCTCTTCCACAGGTTCCT
    CAGCTT
    (SEQ ID NO: 187)
    pARBI-968: GGAAAAAGCACTCTGAATGGTGGAGTTTTAGAAGAACACCACCACTACCC 1806
    TET2_3_ CAACCAAAGTAACACAACACTTTTAAGGGAAGTGAAAATAGAGGGTAAAC
    Endogenous_75 CTGAGGCACCACCTTCCCAGAGTCCTAATCCATCTACACATGTATGCAGC
    CCTTCTCCGATGCTTTCTGAAAGGCCTCAGAATAATTGTGTGAACAGGAA
    TGACATACAGACTGCAGGGACAATGACTGTTCCATTGTGTTCTGAGAAAA
    CAAGACCAATGTCAGAACACCTCAAGCATAACCCACCAATTTTTGGTAGC
    AGTGGAGAGCTACAGGACAACTGCCAGCAGTTGATGAGAAACAAAGAGCA
    AGAGATTCTGAAGGGTCGAGACAAGGAGCAAACACGAGATCTTGTGCCCC
    CAACACAGCACTATCTGAAACCAGGATGGATTGAATTGAAGGCCCCTCGT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTTCACCAAGCGGAATCCCATCTAAAACGTAATGAGGCATCACT
    GCCATCAATTCTTCAGTATCAACCCAATCTCTCCAATCAAATGACCTCCA
    AACAATACACTGGAAATTCCAACATGCCTGGGGGGCTCCCAAGGCAAGCT
    TACACCCAGAAAACAACACAGCTGGAGCACAAGTCACAAATGTACCAAGT
    TGAAATGAATCAAGGGCAGTCCCAAGGTACAGTGGACCAACATCTCCAGT
    TCCAAAAACCCTCACACCAGGTGCACTTCTCCAAAACAGACCATTTACCA
    AAAGCTCATGTGCAGTCACTGTGTGGCACTAGATTTCATTTTCAACAAAG
    AGCAGATTCCCAAACTGAAAAACTTATGTCCCCAGTGTTGAAACAGCACT
    TGAATCAACAGGCTTCAGAGACTGAGCCATTTTCAAACTCACACCTTTTG
    CAACAT
    (SEQ ID NO: 188)
    pARBI-969: AAAGGGAGGTTGAGATGGGCTGAGGTCTTCTAGGAGGCGGGGAGGGAGTG 1806
    TIGIT_1_ CAGCCTTGACAAGCCTCCCTGTGGGCGAGGTGTAAAGAGGGGCAGAAGTC
    Endogenous_76 AGCTCTGGAAGCATAGGGCAGTGGGTGGGGAGGAGATGGGCTGGGCTGGG
    CTGGAGTAGAGATGTGTGGAGAAGGGTGAGAAGACTGGAAAGACAACCTG
    AATGGGGGACTGGGAGCCTTGAATAACAGGCATGGAGAGGAGCGTCTCTT
    GAAATGGAAGAAACAGGAAATAATTACAGCCTCTATGGAGGAGCAACAGG
    ATGGACTGGAGAAACTATCATTCCAAAATCCAGTTGGGGCCTCAAAGGCC
    CTTAGAATTTTTCTAGGAAGGTTGAAGGCCAGCTGCTGACCCAGGACTCA
    CATGTGCTTCGTCCTCTTCCCTAGGAATGATGACAGGCACAATAGAAACA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACGGGGAACATTTCTGCAGAGAAAGGTGGCTCTATCATCTTACA
    ATGTCACCTCTCCTCCACCACGGCACAAGTGACCCAGGTCAACTGGGAGC
    AGCAGGACCAGCTTCTGGCCATTTGTAATGCTGACTTGGGGTGGCACATC
    TCCCCATCCTTCAAGGATCGAGTGGCCCCAGGTCCCGGCCTGGGCCTCAC
    CCTCCAGTCGCTGACCGTGAACGATACAGGGGAGTACTTCTGCATCTATC
    ACACCTACCCTGATGGGACGTACACTGGGAGAATCTTCCTGGAGGTCCTA
    GAAAGCTCAGGTATTCCTGCTGGAGCAAGTTGGTGGATAAACCTCTCCCT
    CTAGCATAGAAAATGCAATCCTGAAACACTGCACAGCAGGGCTTCTCAAT
    TCGGGATCACATTTGAATCACCTGAGGAGATTTTAAATCATACTGATGCC
    GAGGCC
    (SEQ ID NO: 189)
    pARBI-970: GAGGAGATGGGCTGGGCTGGGCTGGAGTAGAGATGTGTGGAGAAGGGTGA 1806
    TIGIT_2_ GAAGACTGGAAAGACAACCTGAATGGGGGACTGGGAGCCTTGAATAACAG
    Endogenous_77 GCATGGAGAGGAGCGTCTCTTGAAATGGAAGAAACAGGAAATAATTACAG
    CCTCTATGGAGGAGCAACAGGATGGACTGGAGAAACTATCATTCCAAAAT
    CCAGTTGGGGCCTCAAAGGCCCTTAGAATTTTTCTAGGAAGGTTGAAGGC
    CAGCTGCTGACCCAGGACTCACATGTGCTTCGTCCTCTTCCCTAGGAATG
    ATGACAGGCACAATAGAAACAACGGGGAACATTTCTGCAGAGAAAGGTGG
    CTCTATCATCTTACAATGTCACCTCTCCTCCACCACGGCACAAGTGACCC
    AGGTCAACTGGGAGCAGCAGGACCAGCTTCTGGCCATTTGTAATGCTGAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTGGGGTGGCACATCTCCCCATCCTTCAAGGATCGAGTGGCCCC
    AGGTCCCGGCCTGGGCCTCACCCTCCAGTCGCTGACCGTGAACGATACAG
    GGGAGTACTTCTGCATCTATCACACCTACCCTGATGGGACGTACACTGGG
    AGAATCTTCCTGGAGGTCCTAGAAAGCTCAGGTATTCCTGCTGGAGCAAG
    TTGGTGGATAAACCTCTCCCTCTAGCATAGAAAATGCAATCCTGAAACAC
    TGCACAGCAGGGCTTCTCAATTCGGGATCACATTTGAATCACCTGAGGAG
    ATTTTAAATCATACTGATGCCGAGGCCTCACCCAGACCAATTCAATCAGA
    ATCCCTAATAGCAGAGCTAAACAAGGGTAAGGTCTAAAAGCATTTCCAGG
    TGATTCTAATGGGCAGCCAATACTGAGAACCACTGTTCTTATGTAAGAAG
    CACATC
    (SEQ ID NO: 190)
    pARBI-971: CCTCCCTGTGGGCGAGGTGTAAAGAGGGGCAGAAGTCAGCTCTGGAAGCA 1806
    TIGIT_3_ TAGGGCAGTGGGTGGGGAGGAGATGGGCTGGGCTGGGCTGGAGTAGAGAT
    Endogenous_78 GTGTGGAGAAGGGTGAGAAGACTGGAAAGACAACCTGAATGGGGGACTGG
    GAGCCTTGAATAACAGGCATGGAGAGGAGCGTCTCTTGAAATGGAAGAAA
    CAGGAAATAATTACAGCCTCTATGGAGGAGCAACAGGATGGACTGGAGAA
    ACTATCATTCCAAAATCCAGTTGGGGCCTCAAAGGCCCTTAGAATTTTTC
    TAGGAAGGTTGAAGGCCAGCTGCTGACCCAGGACTCACATGTGCTTCGTC
    CTCTTCCCTAGGAATGATGACAGGCACAATAGAAACAACGGGGAACATTT
    CTGCAGAGAAAGGTGGCTCTATCATCTTACAATGTCACCTCTCCTCCACC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACGGCACAAGTGACCCAGGTCAACTGGGAGCAGCAGGACCAGCT
    TCTGGCCATTTGTAATGCTGACTTGGGGTGGCACATCTCCCCATCCTTCA
    AGGATCGAGTGGCCCCAGGTCCCGGCCTGGGCCTCACCCTCCAGTCGCTG
    ACCGTGAACGATACAGGGGAGTACTTCTGCATCTATCACACCTACCCTGA
    TGGGACGTACACTGGGAGAATCTTCCTGGAGGTCCTAGAAAGCTCAGGTA
    TTCCTGCTGGAGCAAGTTGGTGGATAAACCTCTCCCTCTAGCATAGAAAA
    TGCAATCCTGAAACACTGCACAGCAGGGCTTCTCAATTCGGGATCACATT
    TGAATCACCTGAGGAGATTTTAAATCATACTGATGCCGAGGCCTCACCCA
    GACCAATTCAATCAGAATCCCTAATAGCAGAGCTAAACAAGGGTAAGGTC
    TAAAAG
    (SEQ ID NO: 191)
    pARBI-972: TAATGCCCAGCCTAAGTTGGGGAGACCACTCCAGATTCCAAGATGTACAG 1806
    TRAC_1_ TTTGCTTTGCTGGGCCTTTTTCCCATGCCTGCCTTTACTCTGCCAGAGTT
    Endogenous_79 ATATTGCTGGGGTTTTGAAGAAGATCCTATTAAATAAAAGAATAAGCAGT
    ATTATTAAGTAGCCCTGCATTTCAGGTTTCCTTGAGTGGCAGGCCAGGCC
    TGGCCGTGAACGTTCACTGAAATCATGGCCTCTTGGCCAAGATTGATAGC
    TTGTGCCTGTCCCTGAGTCCCAGTCCATCACGAGCAGCTGGTTTCTAAGA
    TGCTATTTCCCGTATAAAGCATGAGACCGTGACTTGCCAGCCCCACAGAG
    CCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGGCA
    AAGAGGGAAATGAGATCATGTCCTAACCCTGATCCTCTTGTCCCACAGAT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatATCCAGAACCCTGACCCTGCCGTGTACCAGCTGAGAGACTCTAA
    ATCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAA
    ATGTGTCACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTG
    CTAGACATGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAG
    CAACAAATCTGACTTTGCATGTGCAAACGCCTTCAACAACAGCATTATTC
    CAGAAGACACCTTCTTCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCTTC
    GCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTCTG
    GTCAATGATGTCTAAAACTCCTCTGATTGGTGGTCTCGGCCTTATCCATT
    GCCACCAAAACCCTCTTTTTACTAAGAAACAGTGAGCCTTGTTCTGGCAG
    TCCAGA
    (SEQ ID NO: 192)
    pARBI-973: GATTCCAAGATGTACAGTTTGCTTTGCTGGGCCTTTTTCCCATGCCTGCC 1806
    TRAC_2_ TTTACTCTGCCAGAGTTATATTGCTGGGGTTTTGAAGAAGATCCTATTAA
    Endogenous_80 ATAAAAGAATAAGCAGTATTATTAAGTAGCCCTGCATTTCAGGTTTCCTT
    GAGTGGCAGGCCAGGCCTGGCCGTGAACGTTCACTGAAATCATGGCCTCT
    TGGCCAAGATTGATAGCTTGTGCCTGTCCCTGAGTCCCAGTCCATCACGA
    GCAGCTGGTTTCTAAGATGCTATTTCCCGTATAAAGCATGAGACCGTGAC
    TTGCCAGCCCCACAGAGCCCCGCCCTTGTCCATCACTGGCATCTGGACTC
    CAGCCTGGGTTGGGGCAAAGAGGGAAATGAGATCATGTCCTAACCCTGAT
    CCTCTTGTCCCACAGATATCCAGAACCCTGACCCTGCCGTGTACCAGCTG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTCACCGA
    TTTTGATTCTCAAACAAATGTGTCACAAAGTAAGGATTCTGATGTGTATA
    TCACAGACAAAACTGTGCTAGACATGAGGTCTATGGACTTCAAGAGCAAC
    AGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAAACGCCTT
    CAACAACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCAGGTAAGG
    GCAGCTTTGGTGCCTTCGCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGG
    TTCTGCCCAGAGCTCTGGTCAATGATGTCTAAAACTCCTCTGATTGGTGG
    TCTCGGCCTTATCCATTGCCACCAAAACCCTCTTTTTACTAAGAAACAGT
    GAGCCTTGTTCTGGCAGTCCAGAGAATGACACGGGAAAAAAGCAGATGAA
    GAGAAG
    (SEQ ID NO: 193)
    pARBI-974: TTCCTGTGGTAGCGGAACTCACTAAGGGGCCCATCTGGACCCGAGGTATT 1806
    TRAC_3_ GTGATGATAAATTCTGAGCACCTACCCCATCCCCAGAAGGGCTCAGAAAT
    Endogenous_81 AAAATAAGAGCCAAGTCTAGTCGGTGTTTCCTGTCTTGAAACACAATACT
    GTTGGCCCTGGAAGAATGCACAGAATCTGTTTGTAAGGGGATATGCACAG
    AAGCTGCAAGGGACAGGAGGTGCAGGAGCTGCAGGCCTCCCCCACCCAGC
    CTGCTCTGCCTTGGGGAAAACCGTGGGTGTGTCCTGCAGGCCATGCAGGC
    CTGGGACATGCAAGCCCATAACCGCTGTGGCCTCTTGGTTTTACAGATAC
    GAACCTAAACTTTCAAAACCTGTCAGTGATTGGGTTCCGAATCCTCCTCC
    TGAAAGTGGCCGGGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTGAGGTGAGGGGCCTTGAAGCTGGGAGTGGGGTTTAGGGACGCG
    GGTCTCTGGGTGCATCCTAAGCTCTGAGAGCAAACCTCCCTGCAGGGTCT
    TGCTTTTAAGTCCAAAGCCTGAGCCCACCAAACTCTCCTACTTCTTCCTG
    TTACAAATTCCTCTTGTGCAATAATAATGGCCTGAAACGCTGTAAAATAT
    CCTCATTTCAGCCGCCTCAGTTGCACTTCTCCCCTATGAGGTAGGAAGAA
    CAGTTGTTTAGAAACGAAGAAACTGAGGCCCCACAGCTAATGAGTGGAGG
    AAGAGAGACACTTGTGTACACCACATGCCTTGTGTTGTACTTCTCTCACC
    GTGTAACCTCCTCATGTCCTCTCTCCCCAGTACGGCTCTCTTAGCTCAGT
    AGAAAGAAGACATTACACTCATATTACACCCCAATCCTGGCTAGAGTCTC
    CGCACC
    (SEQ ID NO: 194)
    pARBI-975: ATTATTAAGTAGCCCTGCATTTCAGGTTTCCTTGAGTGGCAGGCCAGGCC 1806
    TRAC_4_ TGGCCGTGAACGTTCACTGAAATCATGGCCTCTTGGCCAAGATTGATAGC
    Endogenous_82 TTGTGCCTGTCCCTGAGTCCCAGTCCATCACGAGCAGCTGGTTTCTAAGA
    TGCTATTTCCCGTATAAAGCATGAGACCGTGACTTGCCAGCCCCACAGAG
    CCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGGCA
    AAGAGGGAAATGAGATCATGTCCTAACCCTGATCCTCTTGTCCCACAGAT
    ATCCAGAACCCTGACCCTGCCGTGTACCAGCTGAGAGACTCTAAATCCAG
    TGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAAATGTGT
    CACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatATGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAG
    CAACAAATCTGACTTTGCATGTGCAAACGCCTTCAACAACAGCATTATTC
    CAGAAGACACCTTCTTCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCTTC
    GCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTCTG
    GTCAATGATGTCTAAAACTCCTCTGATTGGTGGTCTCGGCCTTATCCATT
    GCCACCAAAACCCTCTTTTTACTAAGAAACAGTGAGCCTTGTTCTGGCAG
    TCCAGAGAATGACACGGGAAAAAAGCAGATGAAGAGAAGGTGGCAGGAGA
    GGGCACGTGGCCCAGCCTCAGTCTCTCCAACTGAGTTCCTGCCTGCCTGC
    CTTTGCTCAGACTGTTTGCCCCTTACTGCTCTTCTAGGCCTCATTCTAAG
    CCCCTT
    (SEQ ID NO: 195)
    pARBI-976: TTCATTTCCATTTGAGTTGTTCTTATTGAGTCATCCTTCCTGTGGTAGCG 1806
    TRAC_6_ GAACTCACTAAGGGGCCCATCTGGACCCGAGGTATTGTGATGATAAATTC
    Endogenous_84 TGAGCACCTACCCCATCCCCAGAAGGGCTCAGAAATAAAATAAGAGCCAA
    GTCTAGTCGGTGTTTCCTGTCTTGAAACACAATACTGTTGGCCCTGGAAG
    AATGCACAGAATCTGTTTGTAAGGGGATATGCACAGAAGCTGCAAGGGAC
    AGGAGGTGCAGGAGCTGCAGGCCTCCCCCACCCAGCCTGCTCTGCCTTGG
    GGAAAACCGTGGGTGTGTCCTGCAGGCCATGCAGGCCTGGGACATGCAAG
    CCCATAACCGCTGTGGCCTCTTGGTTTTACAGATACGAACCTAAACTTTC
    AAAACCTGTCAGTGATTGGGTTCCGAATCCTCCTCCTGAAAGTGGCCGGG
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGCTGAGGTGA
    GGGGCCTTGAAGCTGGGAGTGGGGTTTAGGGACGCGGGTCTCTGGGTGCA
    TCCTAAGCTCTGAGAGCAAACCTCCCTGCAGGGTCTTGCTTTTAAGTCCA
    AAGCCTGAGCCCACCAAACTCTCCTACTTCTTCCTGTTACAAATTCCTCT
    TGTGCAATAATAATGGCCTGAAACGCTGTAAAATATCCTCATTTCAGCCG
    CCTCAGTTGCACTTCTCCCCTATGAGGTAGGAAGAACAGTTGTTTAGAAA
    CGAAGAAACTGAGGCCCCACAGCTAATGAGTGGAGGAAGAGAGACACTTG
    TGTACACCACATGCCTTGTGTTGTACTTCTCTCACCGTGTAACCTCCTCA
    TGTCCTCTCTCCCCAGTACGGCTCTCTTAGCTCAGTAGAAAGAAGACATT
    ACACTC
    (SEQ ID NO: 196)
    pARBI-977: CAGTCCATCACGAGCAGCTGGTTTCTAAGATGCTATTTCCCGTATAAAGC 1806
    TRAC_ ATGAGACCGTGACTTGCCAGCCCCACAGAGCCCCGCCCTTGTCCATCACT
    Endogenous_83 GGCATCTGGACTCCAGCCTGGGTTGGGGCAAAGAGGGAAATGAGATCATG
    TCCTAACCCTGATCCTCTTGTCCCACAGATATCCAGAACCCTGACCCTGC
    CGTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTAT
    TCACCGATTTTGATTCTCAAACAAATGTGTCACAAAGTAAGGATTCTGAT
    GTGTATATCACAGACAAAACTGTGCTAGACATGAGGTCTATGGACTTCAA
    GAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAA
    ACGCCTTCAACAACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCA
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGTAAGGGCAGCTTTGGTGCCTTCGCAGGCTGTTTCCTTGCTTC
    AGGAATGGCCAGGTTCTGCCCAGAGCTCTGGTCAATGATGTCTAAAACTC
    CTCTGATTGGTGGTCTCGGCCTTATCCATTGCCACCAAAACCCTCTTTTT
    ACTAAGAAACAGTGAGCCTTGTTCTGGCAGTCCAGAGAATGACACGGGAA
    AAAAGCAGATGAAGAGAAGGTGGCAGGAGAGGGCACGTGGCCCAGCCTCA
    GTCTCTCCAACTGAGTTCCTGCCTGCCTGCCTTTGCTCAGACTGTTTGCC
    CCTTACTGCTCTTCTAGGCCTCATTCTAAGCCCCTTCTCCAAGTTGCCTC
    TCCTTATTTCTCCCTGTCTGCCAAAAAATCTTTCCCAGCTCACTAAGTCA
    GTCTCACGCAGTCACTCATTAACCCACCAATCACTGATTGTGCCGGCACA
    TGAATG
    (SEQ ID NO: 197)
    pARBI-978: TGAGGAAGAAGCGCGGGCGGCGCCTTCGGGAGGCGAGCAGGCAGCAGTTG 1806
    TRIM28_1_ GCCGTGCCGTAGCAGCGTCCCGCGCGCGGCGGGCAGCGGCCCAGGAGGCG
    Endogenous_85 CGTGGCGGCGCTCGGCCTCGCGGCGGCGGCGGCGGCAGCGGCCCAGCAGT
    TGGCGGCGAGCGCGTCTGCGCCTGCGCGGCGGGCCCCGCGCCCCTCCTCC
    CCCCCTGGGCGCCCCCGGCGGCGTGTGAATGGCGGCCTCCGCGGCGGCAG
    CCTCGGCAGCAGCGGCCTCGGCCGCCTCTGGCAGCCCGGGCCCGGGCGAG
    GGCTCCGCTGGCGGCGAAAAGCGCTCCACCGCCCCTTCGGCCGCAGCCTC
    GGCCTCTGCCTCAGCCGCGGCGTCGTCGCCCGCGGGGGGCGGCGCCGAGG
    CGCTGGAGCTGCTGGAGCACTGCGGCGTGTGCAGAGAGCGCCTGCGACCC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGAGAGGGAGCCCCGCCTGCTGCCCTGTTTGCACTCGGCCTGTAG
    TGCCTGCTTAGGGCCCGCGGCCCCCGCCGCCGCCAACAGCTCGGGGGACG
    GCGGGGCGGCGGGCGACGGCACCGGTAAGTACGAAGTGATCGGTGCCACC
    CCTCCCCCTACTCTCTGCCTTTGATTCCGACTGGGTGCAGAGATGAGGAT
    GCCACCTGGGCGAGAGGATGGGGGCCCGGACAGGGCACGGGAAATACTTT
    CTGGGTCCTGCATACGAACGTGGGTTTGTGCTGGCCGCTGAGATGGGACA
    TCTGACTAAAGTTGGAGAAAAGAAGGCTCGGGGAGGGGAGGGGCTGGTTC
    GCTGCGGGATAATGGTCGGGGGCCCACCCAGCAGGGGAATGGTGGGGGCC
    ATAACCTGGGTGGGAACTTGTAACAGTCTCCCACATCCCTGCTTCTCGAA
    GTGGTG
    (SEQ ID NO: 198)
    pARBI-979: TCGAAGTGGTGGACTGTCCCGTGTGCAAGCAACAGTGCTTCTCCAAAGAC 1806
    TRIM28_2_ ATCGTGGAGAATTATTTCATGCGTGATAGTGGCAGCAAGGCTGCCACCGA
    Endogenous_86 CGCCCAGGATGCGAACCAGGTGCGTCCTATCTCAGCAACCACAAGGAGGT
    TTCTGGGGAGGGGGCATCTGCGCAGGAGGAGCTTGGCACCAGCTCCAGGC
    TGTTACTCCACTTTCCCAAGGCTCTGGGTGGGCTGCCTAGGTTGGGTCAA
    GGGACCAATCTTAAATCTCCGGTTGTATTTTCTGGGATGTAAACGTGGAT
    CTATCAAGTIGTCTTGCCTTCTCTGACCCTGCCTTTGTCTGGCAGTGCTG
    CACTAGCTGTGAGGATAATGCCCCAGCCACCAGCTACTGTGTGGAGTGCT
    CGGAGCCTCTGTGTGAGACCTGTGTAGAGGCGCACCAGCGGGTGAAGTAC
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatACCAAGGACCATACTGTGCGCTCTACTGGTACATGAGGCTGAGG
    GGGGCTGTTGGAGTTGTTCTCCCATGTGTGCCCTCAGTTGCTTTTATGAT
    GTTGGTTGCATCTGGTGGATGGGTCCTAGAGTTCTCTAGGGGGTGCCGCC
    CGAAGGGCCCGAGGGCAGAACTCCAGAAGCAGAAAAACTGGGGTTGTGGT
    GTGTAGTCTCTAGGGCCTAGGTGGGAGAGGGTGGGAAGGGGAAATAAGGG
    AGACCTTAATGTGCTGCAGGGAGGTACAAAGGGTTTGAGAAGGCTTATCA
    GGGAGTTGTCAGACCTGGTGGTGAAGGGCTCAGCATATGCAAACAGGGAA
    AGGCATGGTGTGAAGGGCTTTCTGGGTTTGTGGTTCCCTGGCACACATCT
    GGTATAAGATGCTGCTAGGGAAAGTAGACTGTGGGTCCATGGATTATAAG
    TGATGA
    (SEQ ID NO: 199)
    pARBI-980: GGCGCCCAATGCGCGTGCGCGGCGGCGTCGGCGCCAGTTATTTCTGTCCC 1806
    TRIM28_3_ GCCCCCCGGCCTCGGCTCTTTCTGCGAGCGGGCGCGCGGGCGAGCGGTTG
    EndogenouS_87 TGCTTGTGCTTGTGGCGCGTGGTGCGGGTTTCGGCGGCGGCTGAGGAAGA
    AGCGCGGGCGGCGCCTTCGGGAGGCGAGCAGGCAGCAGTTGGCCGTGCCG
    TAGCAGCGTCCCGCGCGCGGCGGGCAGCGGCCCAGGAGGCGCGTGGCGGC
    GCTCGGCCTCGCGGCGGCGGCGGCGGCAGCGGCCCAGCAGTTGGCGGCGA
    GCGCGTCTGCGCCTGCGCGGCGGGCCCCGCGCCCCTCCTCCCCCCCTGGG
    CGCCCCCGGCGGCGTGTGAATGGCGGCCTCCGCGGCGGCAGCCTCGGCAG
    CAGCGGCCTCGGCCGCCTCTGGCAGCCCGGGCCCGGGCGAGGGCTCCGCT
    tccggatccggagagggcaggggatctctccttacttgtggcgacgtgga
    ggagaaccccggccccATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
    TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTC
    AGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCT
    GAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG
    TGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatGGCGGCGAAAAGCGCTCCACCGCCCCTTCGGCCGCAGCCTCGGC
    CTCTGCCTCAGCCGCGGCGTCGTCGCCCGCGGGGGGCGGCGCCGAGGCGC
    TGGAGCTGCTGGAGCACTGCGGCGTGTGCAGAGAGCGCCTGCGACCCGAG
    AGGGAGCCCCGCCTGCTGCCCTGTTTGCACTCGGCCTGTAGTGCCTGCTT
    AGGGCCCGCGGCCCCCGCCGCCGCCAACAGCTCGGGGGACGGCGGGGCGG
    CGGGCGACGGCACCGGTAAGTACGAAGTGATCGGTGCCACCCCTCCCCCT
    ACTCTCTGCCTTTGATTCCGACTGGGTGCAGAGATGAGGATGCCACCTGG
    GCGAGAGGATGGGGGCCCGGACAGGGCACGGGAAATACTTTCTGGGTCCT
    GCATACGAACGTGGGTTTGTGCTGGCCGCTGAGATGGGACATCTGACTAA
    AGTTGG
    (SEQ ID NO: 200)
    pARBI-596: ATCTCGGCCAATAAAGGAGAAAGGGCGCGGCCCGTACGCGCGCCAGGTGC 2541
    APRT_1_ GTGGGCGAGACCAGCTCACGCCCCTCCTCCAGCCGCCAAGGCCCCGGCCC
    Exogenous_1 ACAGCTGCCTGGCTGCAGTCAGAAGCGTAGCCCGAGACAAGGAAGGGCGC
    CTTGACTCGCACTTTTGTCCGGTTCGAACGTTCTGctcagtggtgcgtgg
    aatgcgagcgcgtcttaaaatcgatggcgcctaggagtccatgaaatacg
    gTACAGGCTTCCGGCGACGGATGCCCCGCCCCTCACCCACGCTCCGCCCT
    CCGGGGATGCCCCACCCCTCGTGGCGGTCCCGCCCGTCCCCGCGCAGGCG
    CGCTCGGGCTGCCGCTGGCTCTTCGCACGCGGCCATGGCCGACTCCGAGC
    TGCAGCTGGTTGAGCAGCGGATCCGCAGCTTCCCCGACTTCCCCACCCCA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGGCGTGGTAT
    TCAGGTGCACGCACAGGCCGCCCTCGTGGCGCCCCGACCTGCGGGCCTAC
    GGATGGGAGCGCGTGGCCCGCGACCTCCGGGGGGCGGGGCGGGAACCCTC
    GTCTTTCGCCCCCGGGGCCCTGCCCTCCTTCGGCCCCGGCGTCACCAGGC
    CTGTCCTTGGGTCCAGGGACATCTCGCCCGTCCTGAAGGACCCCGCCTCC
    TTCCGCGCCGCCATCGGCCTCCTGGCGCGACACCTGAAGGCGACCCACGG
    GGGCCGCATCGACTACATCGCAGGCGAGTGCCCAGTGGCCGCATCTAGGG
    CGCTTCCGCCTCTGCGCGCGCCGAGGGCAGCACGTGGGCTCTGCGCGTCT
    GCTTGGGGGAGGGCCTTTGGGGTGCTTCAGGGGGCGCCGGGACGGGCGCC
    GTGCTTGGGTCGCCCGGGAAGGGTTGTGAGATTGAGCCC
    (SEQ ID NO: 201)
    pARBI-597: TGCCCCGCCCCTCACCCACGCTCCGCCCTCCGGGGATGCCCCACCCCTCG 2541
    APRT_2_ TGGCGGTCCCGCCCGTCCCCGCGCAGGCGCGCTCGGGCTGCCGCTGGCTC
    Exogenous_2 TTCGCACGCGGCCATGGCCGACTCCGAGCTGCAGCTGGTTGAGCAGCGGA
    TCCGCAGCTTCCCCGACTTCCCCACCCCAGGCGTGGTATTCAGGTGCACG
    CACAGGCCGCCCTCGTGGCGCCCCGACCTGCGGGCCTACGGATGGGAGCG
    CGTGGCCCGCGACCTCCGGGGGGGGGGGGCGGGAACCCTCGTCTTTCGCC
    CCCGGGGCCCTGCCCTCCTTCGGCCCCGGCGTCACCAGGCCTGTCCTTGG
    GTCCAGGGACATCTCGCCCGTCCTGAAGGACCCCGCCTCCTTCCGCGCCG
    CCATCGGCCTCCTGGCGCGACACCTGAAGGCGACCCACGGGGGCCGCATC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGACTACATC
    GCAGGCGAGTGCCCAGTGGCCGCATCTAGGGCGCTTCCGCCTCTGCGCGC
    GCCGAGGGCAGCACGTGGGCTCTGCGCGTCTGCTTGGGGGAGGGCCTTTG
    GGGTGCTTCAGGGGGCGCCGGGACGGGCGCCGTGCTTGGGTCGCCCGGGA
    AGGGTTGTGAGATTGAGCCCCCGAGGCCGCCGCGCTGTGCAGGCGTCCTT
    CCCGCAGGTTCCGGGTCCCCAGCCCAGGACAGGCGTGACCGAGTTGCCGG
    GTCAGTTGGTCTCCCTGGAGTGCCCAAGCTGAATCCACAGGGCCCAGCTG
    CCTTGCTTCTTGTTCCTTCTGCGAGCTGGTATTGAGCGCCTGCCACGAGC
    CAGGCCTTCCCTGGTGAAGATCACGGAATGCCCACCCAGGGAAGGGAGGC
    CTGGAGGCCTCCGGGAGAGCCCAAGAGGTGGCCCAGGGAGA
    (SEQ ID NO: 202)
    pARBI-598: CGTTCTGctcagtggtgcgtggaatgcgagcgcgtcttaaaatcgatggc 2541
    APRT_3_ gcctaggagtccatgaaatacggTACAGGCTTCCGGCGACGGATGCCCCG
    Exogenous_3 CCCCTCACCCACGCTCCGCCCTCCGGGGATGCCCCACCCCTCGTGGCGGT
    CCCGCCCGTCCCCGCGCAGGCGCGCTCGGGCTGCCGCTGGCTCTTCGCAC
    GCGGCCATGGCCGACTCCGAGCTGCAGCTGGTTGAGCAGCGGATCCGCAG
    CTTCCCCGACTTCCCCACCCCAGGCGTGGTATTCAGGTGCACGCACAGGC
    CGCCCTCGTGGCGCCCCGACCTGCGGGCCTACGGATGGGAGCGCGTGGCC
    CGCGACCTCCGGGCGGGCGGGGGGGGAACCCTCGTCTTTCGCCCCCGGGG
    CCCTGCCCTCCTTCGGCCCCGGCGTCACCAGGCCTGTCCTTGGGTCCAGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGACATCTCGC
    CCGTCCTGAAGGACCCCGCCTCCTTCCGCGCCGCCATCGGCCTCCTGGCG
    CGACACCTGAAGGCGACCCACGGGGGCCGCATCGACTACATCGCAGGCGA
    GTGCCCAGTGGCCGCATCTAGGGCGCTTCCGCCTCTGCGCGCGCCGAGGG
    CAGCACGTGGGCTCTGCGCGTCTGCTTGGGGGAGGGCCTTTGGGGTGCTT
    CAGGGGGCGCCGGGACGGGCGCCGTGCTTGGGTCGCCCGGGAAGGGTTGT
    GAGATTGAGCCCCCGAGGCCGCCGCGCTGTGCAGGCGTCCTTCCCGCAGG
    TTCCGGGTCCCCAGCCCAGGACAGGCGTGACCGAGTTGCCGGGTCAGTTG
    GTCTCCCTGGAGTGCCCAAGCTGAATCCACAGGGCCCAGCTGCCTTGCTT
    CTTGTTCCTTCTGCGAGCTGGTATTGAGCGCCTGCCACGA
    (SEQ ID NO: 203)
    pARBI-599: AGTAATTTGATGGGGGCTATTATGAACTGAGAAATGAACTTTGAAAAGTA 2541
    B2M_1_ TCTTGGGGCCAAATCATGTAGACTCTTGAGTGATGTGTTAAGGAATGCTA
    Exogenous_4 TGAGTGCTGAGAGGGCATCAGAAGTCCTTGAGAGCCTCCAGAGAAAGGCT
    CTTAAAAATGCAGCGCAATCTCCAGTGACAGAAGATACTGCTAGAAATCT
    GCTAGAAAAAAAACAAAAAAGGCATGTATAGAGGAATTATGAGGGAAAGA
    TACCAAGTCACGGTTTATTCTTCAAAATGGAGGTGGCTTGTTGGGAAGGT
    GGAAGCTCATTTGGCCAGAGTGGAAATGGAATTGGGAGAAATCGATGACC
    AAATGTAAACACTTGGTGCCTGATATAGCTTGACACCAAGTTAGCCCCAA
    GTGAAATACCCTGGCAATATTAATGTGTCTTTTCCCGATATTCCTCAGGT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACTCCAAAG
    ATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGTCAAATTTCCT
    GAATTGCTATGTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTAC
    TGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTC
    AGCAAGGACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCAC
    TGAAAAAGATGAGTATGCCTGCCGTGTGAACCATGTGACTTTGTCACAGC
    CCAAGATAGTTAAGTGGGGTAAGTCTTACATTCTTTTGTAAGCTGCTGAA
    AGTTGTGTATGAGTAGTCATATCATAAAGCTGCTTTGATATAAAAAAGGT
    CTATGGCCATACTACCCTGAATGAGTCCCATCCCATCTGATATAAACAAT
    CTGCATATTGGGATTGTCAGGGAATGTTCTTAAAGATCAGA
    (SEQ ID NO: 204)
    pARBI-600: AAGATCTTAATCTTCTGGGTTTCCGTTTTCTCGAATGAAAAATGCAGGTC 2541
    B2M_2_ CGAGCAGTTAACTGGCTGGGGCACCATTAGCAAGTCACTTAGCATCTCTG
    Exogenous_5 GGGCCAGTCTGCAAAGCGAGGGGGCAGCCTTAATGTGCCTCCAGCCTGAA
    GTCCTAGAATGAGCGCCCGGTGTCCCAAGCTGGGGCGCGCACCCCAGATC
    GGAGGGCGCCGATGTACAGACAGCAAACTCACCCAGTCTAGTGCATGCCT
    TCTTAAACATCACGAGACTCTAAGAAAAGGAAACTGAAAACGGGAAAGTC
    CCTCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGACAGGTGACGGTC
    CCTGCGGGCCTTGTCCTGATTGGCTGGGCACGCGTTTAATATAAGTGGAG
    GCGTCGCGCTGGCGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTCTCGCTCCG
    TGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATC
    CAGCGTGAGTCTCTCCTACCCTCCCGCTCTGGTCCTTCCTCTCCCGCTCT
    GCACCCTCTGTGGCCCTCGCTGTGCTCTCTCGCTCCGTGACTTCCCTTCT
    CCAAGTTCTCCTTGGTGGCCCGCCGTGGGGCTAGTCCAGGGCTGGATCTC
    GGGGAAGCGGCGGGGTGGCCTGGGAGTGGGGAAGGGGGTGCGCACCCGGG
    ACGCGCGCTACTTGCCCCTTTCGGCGGGGAGCAGGGGAGACCTTTGGCCT
    ACGGCGACGGGAGGGTCGGGACAAAGTTTAGGGCGTCGATAAGCGTCAGA
    GCGCCGAGGTTGGGGGAGGGTTTCTCTTCCGCTCTTTCGCGGGGCCTCTG
    GCTCCCCCAGCGCAGCTGGAGTGGGGGACGGGTAGGCTCG
    (SEQ ID NO: 205)
    pARBI-601: AGGAATGCTATGAGTGCTGAGAGGGCATCAGAAGTCCTTGAGAGCCTCCA 2541
    B2M_3_ GAGAAAGGCTCTTAAAAATGCAGCGCAATCTCCAGTGACAGAAGATACTG
    Exogenous_6 CTAGAAATCTGCTAGAAAAAAAACAAAAAAGGCATGTATAGAGGAATTAT
    GAGGGAAAGATACCAAGTCACGGTTTATTCTTCAAAATGGAGGTGGCTTG
    TTGGGAAGGTGGAAGCTCATTTGGCCAGAGTGGAAATGGAATTGGGAGAA
    ATCGATGACCAAATGTAAACACTTGGTGCCTGATATAGCTTGACACCAAG
    TTAGCCCCAAGTGAAATACCCTGGCAATATTAATGTGTCTTTTCCCGATA
    TTCCTCAGGTACTCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGA
    ATGGAAAGTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATCCATCC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGACATTGAA
    GTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGA
    CTTGTCTTTCAGCAAGGACTGGTCTTTCTATCTCTTGTACTACACTGAAT
    TCACCCCCACTGAAAAAGATGAGTATGCCTGCCGTGTGAACCATGTGACT
    TTGTCACAGCCCAAGATAGTTAAGTGGGGTAAGTCTTACATTCTTTTGTA
    AGCTGCTGAAAGTTGTGTATGAGTAGTCATATCATAAAGCTGCTTTGATA
    TAAAAAAGGTCTATGGCCATACTACCCTGAATGAGTCCCATCCCATCTGA
    TATAAACAATCTGCATATTGGGATTGTCAGGGAATGTTCTTAAAGATCAG
    ATTAGTGGCACCTGCTGAGATACTGATGCACAGCATGGTTTCTGAACCAG
    TAGTTTCCCTGCAGTTGAGCAGGGAGCAGCAGCAGCACTTG
    (SEQ ID NO: 206)
    pARBI-602: GATCTCACATTCTAGCGCCCAGACATGTCGGGAACGCCTTACGCCAACTT 2541
    CAPNS1_1_ GGGGTCCCCACCAAGAGAACCCCCACCAGATCTGCACCCTCCCCTTCACG
    Exogenous_7 CGTGCACCCAGTCCAGGCTCCCTCAAGCCCCACGGGTGCCTTTTAGACCT
    GAGGAGGTTGCAAACCTGATCCCCCATACCTGCCCCACCCATCCGCGGAC
    AACCCGCCCTCGCAAACTCAGACCCCCACCCGGAGGCTTCAGATTCCTCC
    CAGGTCCAGCTGCCGGAAATGCGTGTTTGAAGGGAGGGTGTGGGCTCAGG
    GGCGAAGCACCCACTGGTCCCCTTTTTTCCCCCCAGCAGTGAGTCGCAGC
    CATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGGG
    GAGGCGGGGGCCTGGGTGGGGGCCTGGGAAATGTGCTTGGAGGCCTGATC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAGCGGGGCC
    GGGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGTGGTGGAGGCGGCGG
    TGGCGGTGGAACGGCCATGCGCATCCTAGGCGGAGTCATCAGCGCCATCA
    GGTAAGGCGGAGACTATCAGAGGGGCGGGGCCTGGGAATGGGAGGAGCCT
    CAGTGAGGCGTGGTCTGGGAGGGGCGTGGTCTAAAAATAGAATAGGATTA
    ACCTGGAGGCTAACCTGGGTACATGAATTAGGCCGGGGAGGCCTGGTTTG
    AGAGTTCTGCTGTAAGGGGGTGGACCCCAGTGAGGCGGATATCAGTCATT
    GGGGGCGGTGCTTGATATGGGAGTAGTCTGATTGTGTGGGACCAGGACAA
    TGTGGTCCTGAGGGGACTGATGTGGAGTTTTGGCGGGTGGGGCTTATGGG
    TCTGGGCTCAGCCTGCATTGGCTAACCTGGAGATGAACGTT
    (SEQ ID NO: 207)
    pARBI-603: CGGGCATTTAGGAAGCGGGCCATGGAGTAGGGTCTTGGGCAGATGGCACC 2541
    CAPNS1_2_ TGAGGAGGATAAGGCCTTGGGAAGCTGGGGCAGAGCCTCTATGAAGTGAG
    Exogenous_8 CCCTCCAAGGGGCGGGGTCTTTTGATTCTACGTGGGATTTTTTAGGTTTA
    GGGTGGCCAAGATGACTGAAATCTGCCACTGGGTAGGTGTGCCTGGCAGG
    AGGGGAGCCTCCCAGGGGACCGGTCTCTGGGTTTCCTCGAGGGTGGGGTT
    GGCCTGAGGAAGGGAGAAGAGGGGCACGACCAGGGCAGTGTGGATTGGGA
    CAGATGAGGACAAGAACAAATGAAAGGCACAGCAACCAAGTAAGGAAGAT
    AACGGCTGGGGTCTGGAGCGTTGGGGCTGATGGTTCTGTAGTGCTGCCCG
    TTGGAGGCCCCGCCCCTGGCACTAACCCCTCCCCCTTATCTCTTCGCAGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACAT
    CGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGT
    GCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTG
    GCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAG
    TCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTG
    AAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTG
    AGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
    GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCG
    AGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCG
    GCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTT
    CGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACT
    CTAGAGCTAGCGAATTgccgccaccATGGTGAGCAAGGGCGAGGAGCTGT
    TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGC
    CACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAA
    GCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGC
    CCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTAC
    CCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGG
    CTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGA
    CCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAG
    CTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCT
    GGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGA
    AGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGC
    AGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGG
    CCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGA
    GCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTG
    ACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtt
    tattgcagcttataatggttacaaataaagcaatagcatcacaaatttca
    caaataaagcatttttttcactgcattctagttgtggtttgtccaaactc
    atcaatgtatcttatGAGGCGGCTGCGCAGTACAACCCGGAGCCCCCGGT
    AAGCCCCCTCTGCAACCAGACCCCCTTCTCCTGCCAAGGCCTCTTCGAGG
    TCCCATCCCTGTTCCTGTAGAGAAGCCCCACCTTCCTCCCCTTCTTGTGA
    AATTCCTCTGCCAGTTCCTCCCATGCCGTGTCTGCAGCTTCGCCATGGGT
    CTTAGCCATGCCCCACATACGTGCACCCCATTCACTACCACCCCTCATTC
    TTTTCCTCATCAAGCTGCCCAGCCCACTCTGACTTCCCCACCCAGGGTAC
    CTGGGTTTGGGGAGCCGTCCTGGCCGGGTTCCCCTCCCCCTGCTCTGAGC
    TCTCCTCCCTTTGCAGCCCCCACGCACACATTACTCCAACATTGAGGCCA
    ACGAGAGTGAGGAGGTCCGGCAGTTCCGGAGACTCTTTGCCCAGCTGGCT
    GGAGATGTAAGTAAC
    (SEQ ID NO: 208)
    pARBI-604: GCTGATGGTTCTGTAGTGCTGCCCGTTGGAGGCCCCGCCCCTGGCACTAA 2541
    CAPNS1_3_ CCCCTCCCCCTTATCTCTTCGCAGCGAGGCGGCTGCGCAGTACAACCCGG
    Exogenous_9 AGCCCCCGGTAAGCCCCCTCTGCAACCAGACCCCCTTCTCCTGCCAAGGC
    CTCTTCGAGGTCCCATCCCTGTTCCTGTAGAGAAGCCCCACCTTCCTCCC
    CTTCTTGTGAAATTCCTCTGCCAGTTCCTCCCATGCCGTGTCTGCAGCTT
    CGCCATGGGTCTTAGCCATGCCCCACATACGTGCACCCCATTCACTACCA
    CCCCTCATTCTTTTCCTCATCAAGCTGCCCAGCCCACTCTGACTTCCCCA
    CCCAGGGTACCTGGGTTTGGGGAGCCGTCCTGGCCGGGTTCCCCTCCCCC
    TGCTCTGAGCTCTCCTCCCTTTGCAGCCCCCACGCACACATTACTCCAAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCC
    GCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCT
    CCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAA
    GCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTA
    GACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTAC
    GTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACC
    GGCGCCTACTCTAGAGCTAGCGAATTgccgccaccATGGTGAGCAAGGGC
    GAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGA
    CGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCA
    CCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCC
    GTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTT
    CAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCA
    TGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGC
    AACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAA
    CCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGG
    GGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCC
    GACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACAT
    CGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCA
    TCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAG
    TCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCT
    GGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACA
    Aatgattgtttattgcagcttataatggttacaaataaagcaatagcatc
    acaaatttcacaaataaagcatttttttcactgcattctagttgtggttt
    gtccaaactcatcaatgtatcttatATTGAGGCCAACGAGAGTGAGGAGG
    TCCGGCAGTTCCGGAGACTCTTTGCCCAGCTGGCTGGAGATGTAAGTAAC
    CTGGGGTCCCTGGCCCCGTCCTAACCGTTCCATCCCTTCCCTTGTGGCTG
    CCCTTGCACACACACCCTTGACCATGACAATCCCAGTGTTCCCATTCTCC
    ATGACATTCTCAGACCCCTTTCAGTCACCCCTGACCTGCCCCTAACTTCC
    GCCCGCAGGACATGGAGGTCAGCGCCACAGAACTCATGAACATTCTCAAT
    AAGGTTGTGACACGACGTAAGTGACCGGGGTTAAGGAATAGGGTAGATTC
    AGAGGCAGAGGGGTCAGAGAGGATTTGACCTCTGGCCTCTGACTTTCAAC
    CTGTTACCCACAGACCCTGATCTGAAGACTGATGGTTTTGGCATTGACAC
    ATGTCGCAGCATGGTGGCCGTGATG
    (SEQ ID NO: 209)
    pARBI-605: ggagagttatagcagatggagacaaaaaagggaactgctggggatcaaac 2541
    CBLB_1_ cttgtaaagtccttctaagtgatatatgaggactttgacttttattcaaa
    Exogenous_10 gttagaaggctttgaacaaaagaattatttcatttgtgttttacaatggt
    cacaagtgccgtagcgagaataggctgTGTAGAGAAGAGATTTTGTGGTT
    TTCTTTTTTGTTCTCTGTATTCTCTTCCTGAAAAATCTGTTTTCTGCCTA
    ATCATATTTCTGTAAAGAACAATAGACTTGAACGTCTGCTGTTAAGTAAC
    AAAGGTTGACCTAAACCACATAAGGTCAGATTAACTTTTAAAATATCCAA
    GATAATGTTAAGTGTATTAAATATGGTTCAGTATGTAATCAAAATATTTG
    ATATTCTCTAGATACTAATCTCttttaatttttttattttttAGCCTTGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGCTCTATT
    TTGCGGAATTGGAATTTCTTAGCTGTGACACATCCAGGTTACATGGCATT
    TCTCACATATGATGAAGTTAAAGCACGACTACAGAAATATAGCACCAAAC
    CCGGAAGGTAAGACTTTTTAGCAGTAATATTATGTGATATATCCAAAGAT
    GAAAAATTCTCCATGGTTTGTTCCTAAGTAAGTCAGCAATACCCGCTGAT
    GGCATGCTTGGGAGGGGGCTAGAAAAGGTAAAAGACCAAAATGGTGCTTC
    TTAACATAATGTTTTAAATTGATACATTGTGCTTACTCTGAAACTTGGTA
    TTCATAAAGTGAAAGGGGATATGGTCTCCTTTCTGTTTTCATGATATCCG
    TGTTTATGTGCAAAATTGAATGTATATATTTGAATACTTGAATACTGTGC
    TAAAGAACAAATAAATAGAACAGTCTTATGTTCATTACTTT
    (SEQ ID NO: 210)
    pARBI-606: CATATTACTCATTTGTGCAATGAATAAAGGATTTCTATTATTATATGGAC 2541
    CBLB_2_ CCATCATCTTATGACTGTTTTTAGAAAATGAGAATTAAATCTTGATTCAT
    Exogenous_11 TATTAAATAACCTTGTATACACACATGAAGAGGTCATGACACATAAGACT
    TTGACCTAATACCTTTTTTCAGATATGTTTCTATAGCTATCTTGATAGCC
    TAGGACTGTTTGAGAGAAAATTAATTTAAATTTTTGTCATATTCTTAGCA
    AATGCAAAATAATTGAGTTAAACAGAACCCACTACATTTGTTCTGAAATA
    TGAACAATATTCTCAAATATTTGTCTGGTAGTACAAATACAATTATATTA
    ATTTTATTATTGAATTTTGCTGCTTCAAAGGGAGGTATTTCTTAAATGAT
    ACTTGATTCAATTATTTCCCTTTTTTTCCACCTTGCACAGAACTATCGTA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
    ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
    GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
    AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGC
    ATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAA
    CTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCA
    TCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAG
    CTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
    GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACC
    CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
    GGGATCACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagc
    ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaag
    catttttttcactgcattctagttgtggtttgtccaaactcatcaatgta
    tcttatCCATGGAAAGTATTCAGACAGTGCCTTCATGAGGTCCACCAGAT
    TAGCTCTGGCCTGGAAGCAATGGCTCTAAAATCAACAATTGATTTAACTT
    GCAATGATTACATTTCAGTTTTTGAATTTGATATTTTTACCAGGCTGTTT
    CAGGTAAGTTTATACTTGCTTAGTCTATCCATTCCCTtcttctctctccc
    tgtcttttctctctgtttctctctctctctgtctctctctcacacacaca
    cacaTAAACAAACATATGGAAAATAGTGTCATTCCTATTAGTCTGTAATT
    TTATTGGTATGTTTGGTCATTGTTAAAAGTTTAGAGTGAGCCATTTGGCT
    TAAGTTTGGAGTTATCAGATGCTGTGAGCCTGGTGGCTGCTTGTTAGCTT
    TGAGAGGATCCATCCAAAAGAGCTTTGTTTTAAACTCTCTACTTAGTTTC
    TTACTT
    (SEQ ID NO: 211)
    pARBI-607: TTAAACTTTAGAGGTTCAAAATAAGGATATGATATAGAAAAGATTGAATG 2541
    CBLB_3_ GTAGGAGAACAGAATAGGATTTATTTATATTATGACAAACGTGACTATCA
    Exogenous_12 GTTAATAAATTGGAGATAGTAAGTTAAGATCATTATTTATATTATGGAAA
    AATGAAGAAATAGGACATGGTTCTCTAACTTTTTAATTTTTCTGTGAAAT
    AAAATATTATGACTTATTTTATTTTTATCTTTGTTTTTAGGTAAGACTGT
    GCCAAAATCCCAAACTTCAGTTGAAAAATAGCCCACCATATATACTTGAT
    ATTTTGCCTGATACATATCAGCATTTACGACTTATATTGAGTAAATATGA
    TGACAACCAGAAACTTGCCCAACTCAGTGAGAATGAGTACTTTAAAATCT
    ACATTGATAGCCTTATGAAAAAGTCAAAACGGGCAATAAGACTCTTTAAA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGAAGGCAAG
    GAGAGAATGTATGAAGAACAGTCACAGGACAGGTAAGAAGAATATTTCAG
    ATGTTTTGGTGTAAAGGTCATTTATGTTGCTTTTTACTTAATAGTTAACC
    TAAACGTCACCATGTAATTGTTTTGGGGTAAATGTGAGTCGCTTTGTATA
    Tagtcatgtggtacttaacgatggggatactttacaagaaatgcattttt
    agacaatttcattgttgtgtggacatgatagagtgtacttacacagagct
    agatggtattacctaccgcacacctaggctgtatgatgtagcctattgct
    cctaggctgcaaatctatacagtatgttactgtactgaatactgtgggca
    gttgtaacacaatggtaagtatgtgtgtatctaaatatacctaaacatag
    aaaaggtatggtaaaaatactgtataaaaggccgggcgtgg
    (SEQ ID NO: 212)
    pARBI-608: AGATGAGAAAACCTATCCTTCCCAATTTTTTTGTGTGAGAATTAAAATGC 2541
    CD2_1_ AGCAAGAAAACACACACTCATAAACACATCTGCTTTGGCAAAGGAGCACA
    Exogenous_13_ TCAGAAGGGCTGGCTTGTGCGCGCTCTTGCTCTCTGTGTATGTGTATTAT
    14_15 GTTTTATGTTACTGTAAAAGATGTAAAGAGAGGCACGTGGTTAAGCTCTC
    GGGGTGTGGACTCCACCAGTCTCACTTCAGTTCCTTTTGCATGAAGAGCT
    CAGAATCAAAAGAGGAAACCAACCCCTAAGATGAGCTTTCCATGTAAATT
    TGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAAGGTAAGCATA
    AGAGTCAAAGAAGTCCCAACCCAGCTTTCCCTGAAAGTGACTCTCAGTAA
    CTCTTTTGCTTTTTATAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGAAACCTGG
    GGTGCCTTGGGTCAGGACATCAACTTGGACATTCCTAGTTTTCAAATGAG
    TGATGATATTGACGATATAAAATGGGAAAAAACTTCAGACAAGAAAAAGA
    TTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATAT
    AAGCTATTTAAAAATGGAACTCTGAAAATTAAGCATCTGAAGACCGATGA
    TCAGGATATCTACAAGGTATCAATATATGATACAAAAGGAAAAAATGTGT
    TGGAAAAAATATTTGATTTGAAGATTCAAGGTAAGTGTTCATTCCCTTAA
    TTGCTTTATTTCAGTGTGGGTGCTATTTGGCAAGTTGGAAAATAGCATTT
    CTAATATTCCCCAGCGCTGACCTCTGCCTCCAGGGGGGCTATACAGGAAA
    CCAGATGCATGTCTCCTGCCCCAGTGGAGACTGTGGTCCAA
    (SEQ ID NO: 213)
    pARBI-609: AGGATTGTTCTAGTTGATTGGTATGTGTGCACTCCTAGTTGTTAAATATT 2541
    CD3_ TTCACTATCACACCTGGATATACTCAACAAATATTTGTTGAGCCAAATAC
    E_1_ TCAACACCAGCCAAACACGTAGTATTTACTTTAGCTTAAGCGAATTATTT
    Exogenous_16 AGCCCTGACAGAAGCCCTGGAATGTGGGTCTTTAAGTTCCTATTTTTGAG
    ATGGGAAAGCTGAGGCTCACGGAAGGAGGTGACCAGCTCAAGTCTCCTAC
    CGTCCATGCCAAATTAGAATTCCAGCCTGCCTCCTGACTTCAAGTCCAAA
    GTTCTTCCCACGCACTAAAGCTAGCTCTTCAGTGTCCTTTCTTAGGAGGT
    ACTTCCTCCCGCACCACTGACCGCCCCCTCTCTATTTCACCCCCAGCCCA
    TCCGGAAAGGCCAGCGGGACCTGTATTCTGGCCTGAATCAGAGACGCATC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTGACCCTCTG
    GAGAACACTGCCTCCCGCTGGCCCAGGTCTCCTCTCCAGTCCCCCTGCGA
    CTCCCTGTTTCCTGGGCTAGTCTTGGACCCCACGAGAGAGAATCGTTCCT
    CAGCCTCATGGTGAACTCGCGCCCTCCAGCCTGATCCCCCGCTCCCTCCT
    CCCTGCCTTCTCTGCTGGTACCCAGTCCTAAAATATTGCTGCTTCCTCTT
    CCTTTGAAGCATCATCAGTAGTCACACCCTCACAGCTGGCCTGCCCTCTT
    GCCAGGATATTTATTTGTGCTATTCACTCCCTTCCCTTTGGATGTAACTT
    CTCCGTTCAGTTCCCTCCTTTTCTTGCATGTAAGTIGTCCCCCATCCCAA
    AGTATTCCATCTACTTTTCTATCGCCGTCCCCTTTTGCAGCCCTCTCTGG
    GGATGGACTGGGTAAATGTTGACAGAGGCCCTGCCCCGTT
    (SEQ ID NO: 214)
    pARBI-610: AATAATAAAATAATAACAATACTTAACATTTATTGAGTGCTTATTAAGTC 2541
    CD3_E_2_ TCAAGCACTGTCTGTACCCAACACTTATCAAGGATTCTTTTTCATGTAAT
    Exogenous_17_18 CCTCTCAACAACTATATGGGTTAAGTATCATTTTATTCCCATGAGTAAAG
    GGATGAGGAAACAGAGGGTTTGTGAGTTGAAAACACATTTCACGCTTCTC
    ACAGCTAGTGAGTAATAAAGCTGGGACTCAAACCCAGGGCTGTTTGACTC
    CAGTGCCTCTACCCACGGCCACCACTCTTTGCTTGTCAATGTTGTTCTAA
    ACATATTGAAGGGGGGGCTCTGACCGTGGCAAGCGTGTGAGTAGTAAGGG
    GAGAATGGCCTTCATGCACTCCCTCCTCACCTCCAGCGCCTTGTGTTTTC
    CTTGCTTAGTGATTTCCCCTCTCCCCACCCCACCCCCCACAGTGTGTGAG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatAACTGCATGG
    AGATGGATGTGATGTCGGTGGCCACAATTGTCATAGTGGACATCTGCATC
    ACTGGGGGCTTGCTGCTGCTGGTTTACTACTGGAGCAAGAATAGAAAGGC
    CAAGGCCAAGCCTGTGACACGAGGAGCGGGTGCTGGCGGCAGGCAAAGGG
    GTAAGGCTGTGGAGTCCAGTCAGAGGAGATTCCTGCCAAGGGGGACGACC
    AGCCTGGGCCAGGGTGGGTGGCAAGTCCACAGCTAGGTCAGAACAGCTTC
    TCTAGAGCTTCTATGCACAGCTTCTATTACTGTGATGACAAGATCTCAAC
    AGACGGTTTCAAATCTCACATCACTCCCCTCCTTCCCATCCTAGAAAAGT
    GCAAAAAAGTTTATGAAAGTGATGGGCTTCCTCACATACCTGTCAATGCC
    TGCAGTCATCCGATTCCGCCCCTAAGCTGTGGGAAGAGAG
    (SEQ ID NO: 215)
    pARBI-611: ACTGTGACCCATGAACCAGTAGGTATTGGCGTCACCTGGGATCCTGACGT 2541
    CD3G_1_ TAGTCTCTGTCAATCCTTCTCTTTAGTTCATCTATTCTACCCAAAGTGAT
    Exogenous_19_20 CTCATCATCTGGTATGCTGTTAGCAGTTTCTTACCTGTATAGTATCTTCC
    AAATAACATGCCCCAAAATCCCAAAGTTTTACCCCTACTAATTACAGCAA
    TGTCTCTTTTATTCTTCACCCCCTGACGCAGATATTGGCGTCACCCGAGA
    GCATGTTAGTAATGCAGAATCTCCCCTCCCCAGAACTACTAAATAGCACC
    TGAAATTTTAACAAGATCCCCATGTGATTCATGTGCACATCAAAGTTTGA
    GAAACACTACTCTAATGATCTCCTGGTATGCAGAAGCAGGGAGAATTTCA
    GAGGCAAGATCCTTAATAGAACCACGGCTTTTCTCATTTCAGGAAACCAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTTGGTTAAGG
    TGTATGACTATCAAGAAGATGGTTCGGTACTTCTGACTTGTGATGCAGAA
    GCCAAAAATATCACATGGTTTAAAGATGGGAAGATGATCGGCTTCCTAAC
    TGAAGATaaaaaaaaaTGGAATCTGGGAAGTAATGCCAAGGACCCTCGAG
    GGATGTATCAGTGTAAAGGATCACAGAACAAGTCAAAACCACTCCAAGTG
    TATTACAGAAGTATGTAATCCCCTTTGGTCTGTTTGTTGTGAAATTAATC
    AGTATTTGCTGTTCTGGTGAGCTTTTTATCTGGGGTGAAAGTGGAAATAG
    ATCCTCAACAGTAATATTATCGCCTGTTCTCTTAATTTCAGCTTGCCTCT
    TTTAAAATACTGTAAGATACTTCCCTCACCCTATTGAAAAACTACAGCCA
    GTCCTGTAAAATTTTGTTTACCTTTGGGTGGGCTCCATGG
    (SEQ ID NO: 216)
    pARBI-612: TTCGAGACAAGCCTGGCCAACATGATGAAACTCTGTCTCTACTAAAAATA 2541
    CD3G_3_ CAAAAAAAATTAACCAGGCGTGGAGGCGCGCGCCTGTAGTCCCAGCTACT
    Exogenous_21 CAGGAGGCTGAGGCAGGAGGACCACTTGAACCCAGGAGGTCGAGGTTGCA
    GTGAGCTGCGATTGTGCCACTGCACTCCAGCCTGGGCAACAGAGAAAGAC
    TCCGTCTCAAAAAAAAAAAAGAGAGAGAGAGAAAAAGAAAAAAGACAGAG
    CCTCCATCTCCTTGTCCTCTTTCCATCCTCAGGACCATGAAGTACCCACT
    CCAAATTCTCACATATAAAAAACATTCAATAAACATGCATCAAATTAATT
    AATAGAGGATGGAAAAAATGACTTATGACTGTGCTGTCCTTTCCAGCCCC
    TCAAGGATCGAGAAGATGACCAGTACAGCCACCTTCAAGGAAACCAGTTG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAGGAGGAAT
    TGAACTCAGGACTCAGAGTAGGTGGGTTCTTCAATGCCAATTCTAATAAA
    GGACCCTTGCATCAACTGCCCTCGCAATTGCTTCTAAGTCTAGCTCCCTT
    CCCTAAGCGGCTATAAGCATCAGACTCTGGGGATCAGGGATTGGGACGTG
    GTTTGGGGTACTCTTTTCTAAAAATTCTGGGGCCATACTGATTGTCTTGG
    CCTAGGTAAATATGAATTTTATGTATCTGTAAATCCTGTCAGAGCAGGGC
    CTCAAGCCATAGAGATGCTGAATATTAATCTTAACCTACATTTGAATTTC
    TCATTATCTACACTATTAACATTTTGGGCTAATTAATTATTTGTGATGAG
    GGGCTAGCCTGTGCATTGTAGGAGTTATGGAAGCATCCCTGGCCTCTCTC
    CACCAGATGCTGGTAGATTGTCCAGTGTGACAATCAAAAAT
    (SEQ ID NO: 217)
    pARBI-613: GACCTCAGGTGATCTGCCCGCCTCAGCTTCCCAAAGTGCTGGGATTACAG 2541
    CD5_1_ GCATGAGCCACCACACCTGGCCTAAAATTAATTTTTAAAGATCTCTTAAA
    Exogenous_22 AAGCAGACACCAGCCCCAATCTCAGACCCCTTGAGACAGAATTTCCAGGA
    CAGGGGCCATCCTGCTGGACAGTGGGTGCCGAGAACACCTTGCCCATTTA
    TCTGAGCTCCCTTCTGACTCTGAAATCTGGAGCCCCACCCTCCTGGGTCT
    AGCTTCGGGGCTGCCTGGGTCAGGGTCCTCTGGGAAGCCCCTGCAGTGCC
    CCAGAAGGGACGAAGCTCACAAGGGGCAAGGCAGGCAGCCCACGGGGCAG
    GAGGGAGCTCAACTGGGCGTCCTAGGGAGAGGGCAGTGAGGGGTGCCAGT
    GGGGAACCCCTCCCAGCCTGACCCCCACCACACCTTTCTGACCCCCAGAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTCCAGGCA
    AGGCTCACCCGTTCCAACTCGAAGTGCCAGGGCCAGCTGGAGGTCTACCT
    CAAGGACGGATGGCACATGGTTTGCAGCCAGAGCTGGGGCCGGAGCTCCA
    AGCAGTGGGAGGACCCCAGTCAAGCGTCAAAAGTCTGCCAGCGGCTGAAC
    TGTGGGGTGCCCTTAAGCCTTGGCCCCTTCCTTGTCACCTACACACCTCA
    GAGCTCAATCATCTGCTACGGACAACTGGGCTCCTTCTCCAACTGCAGCC
    ACAGCAGAAATGACATGTGTCACTCTCTGGGCCTGACCTGCTTAGGTGGG
    TAACTAGCCAGCCACACGGGCACCCTGGGCCTGGGCGCCAGCCCCGAGGA
    GACTGCCCGAGGCCTGTGATCTAGGGTCTGAGCAGGCTGGTGGAAGGGGT
    GGGGGGACCCCAGTTTATAACCACTCCCCAAGACACATACC
    (SEQ ID NO: 218)
    pARBI-614: GGACAGGGGCCATCCTGCTGGACAGTGGGTGCCGAGAACACCTTGCCCAT 2541
    CD5_2_ TTATCTGAGCTCCCTTCTGACTCTGAAATCTGGAGCCCCACCCTCCTGGG
    Exogenous_23 TCTAGCTTCGGGGCTGCCTGGGTCAGGGTCCTCTGGGAAGCCCCTGCAGT
    GCCCCAGAAGGGACGAAGCTCACAAGGGGCAAGGCAGGCAGCCCACGGGG
    CAGGAGGGAGCTCAACTGGGCGTCCTAGGGAGAGGGCAGTGAGGGGTGCC
    AGTGGGGAACCCCTCCCAGCCTGACCCCCACCACACCTTTCTGACCCCCA
    GATTTCCAGGCAAGGCTCACCCGTTCCAACTCGAAGTGCCAGGGCCAGCT
    GGAGGTCTACCTCAAGGACGGATGGCACATGGTTTGCAGCCAGAGCTGGG
    GCCGGAGCTCCAAGCAGTGGGAGGACCCCAGTCAAGCGTCAAAAGTCTGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGCGGCTG
    AACTGTGGGGTGCCCTTAAGCCTTGGCCCCTTCCTTGTCACCTACACACC
    TCAGAGCTCAATCATCTGCTACGGACAACTGGGCTCCTTCTCCAACTGCA
    GCCACAGCAGAAATGACATGTGTCACTCTCTGGGCCTGACCTGCTTAGGT
    GGGTAACTAGCCAGCCACACGGGCACCCTGGGCCTGGGCGCCAGCCCCGA
    GGAGACTGCCCGAGGCCTGTGATCTAGGGTCTGAGCAGGCTGGTGGAAGG
    GGTGGGGGGACCCCAGTTTATAACCACTCCCCAAGACACATACCCAGGAG
    GGGGACTGGAAGGGGCCAGCACCCATCTGTAGGATGGCAATGGAGGACCT
    AGTTCTGCCAATCACTGACTTCATCGTCGCCTCTGAACCTCCATTCTCCC
    ATCTGTGAAGTGGGGTGGTACTTCCCGCCTCGCAGGAGGCT
    (SEQ ID NO: 219)
    pARBI-615: tgctgggattacaggcatgagccaccacacctggcctaaaattaattttt 2541
    CD5_3_ aaagaTCTCTTAAAAAGCAGACACCAGCCCCAATCTCAGACCCCTTGAGA
    Exogenous_24 CAGAATTTCCAGGACAGGGGCCATCCTGCTGGACAGTGGGTGCCGAGAAC
    ACCTTGCCCATTTATCTGAGCTCCCTTCTGACTCTGAAATCTGGAGCCCC
    ACCCTCCTGGGTCTAGCTTCGGGGCTGCCTGGGTCAGGGTCCTCTGGGAA
    GCCCCTGCAGTGCCCCAGAAGGGACGAAGCTCACAAGGGGCAAGGCAGGC
    AGCCCACGGGGCAGGAGGGAGCTCAACTGGGCGTCCTAGGGAGAGGGCAG
    TGAGGGGTGCCAGTGGGGAACCCCTCCCAGCCTGACCCCCACCACACCTT
    TCTGACCCCCAGATTTCCAGGCAAGGCTCACCCGTTCCAACTCGAAGTGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatCAGGGCCAGC
    TGGAGGTCTACCTCAAGGACGGATGGCACATGGTTTGCAGCCAGAGCTGG
    GGCCGGAGCTCCAAGCAGTGGGAGGACCCCAGTCAAGCGTCAAAAGTCTG
    CCAGCGGCTGAACTGTGGGGTGCCCTTAAGCCTTGGCCCCTTCCTTGTCA
    CCTACACACCTCAGAGCTCAATCATCTGCTACGGACAACTGGGCTCCTTC
    TCCAACTGCAGCCACAGCAGAAATGACATGTGTCACTCTCTGGGCCTGAC
    CTGCTTAGGTGGGTAACTAGCCAGCCACACGGGCACCCTGGGCCTGGGCG
    CCAGCCCCGAGGAGACTGCCCGAGGCCTGTGATCTAGGGTCTGAGCAGGC
    TGGTGGAAGGGGTGGGGGGACCCCAGTTTATAACCACTCCCCAAGACACA
    TACCCAGGAGGGGGACTGGAAGGGGCCAGCACCCATCTGT
    (SEQ ID NO: 220)
    pARBI-616: TGTCCAAAGTGTGTGTCACCTGCTCTGTGTTCACCCACTGGGTTCATCAG 2541
    chr2_1_ AGGGGCACTTGAACAAAACAGGAATGTCACTGGAGAGGGGAACAAATGCT
    Exogenous_106 GTCCCCAAGTCCTTCCCTGCCGTTTAGAGTAACGCAGCCCCTGTCCGCAC
    ATCCTCACCCCCATCTGCCCTCTGCTTGCCAGAATTATCAGAATCTCTCA
    ATTCTAATTTCAGCCATTCTCTGTGAAAATGAAAAGTTAGTGGCAGGCAA
    TGGACACCCTATTGAAATAGAAATTGTTCTTCATATGTCAGAAAAGTCCC
    AGAGTAATCTGGGAGTAATCTGAGCAAACTGATTCAAAGGATTATTACAA
    TTTCTTAGTCTTCTACTGCTGCAAAAGTGGCACTCTTTGATTCTCATGTT
    TGAGGTTCTAATTACTACCTCATGCAGGACTTACAAGAGATCAGCCATGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGCTTACAT
    TGTGTGTAGTGAATCAATGTTATTCTGAAGGGCCTCCTGGAAGCAGTAGG
    GATTGGAGAATGTATGTCTTTTAACATGATCATTCCCATCCTATGGGGGT
    TGGGCACTCTTAACTCATGTTGCAGATGAGTAAACTGAGGCTTTTGAGAG
    TTTGAGGGTGCACAGCTTGAGGCAGAGGTGGAATTCCCAGCTTCATCCAA
    GAAATCACGAATCTCCAATGGCTTGCACACATCCAGGTTTGCTGGATCCT
    ATTTGTCAAGACCACATGCAGATTAGGAGCCTTCAAACAAATTATTTCCA
    AGGGAGGGCATCTTTCTCTGTAACCCCTACCCTGGCAATTCTCCATGGCC
    TCAGGGAGTCCAGCCGGAAGCTCTGCAATGAGTCCTGGGGAACTCTCATC
    TGGAAAAAGGCGCTCATGACAGGTGGTGCCAACCTTCCACG
    (SEQ ID NO: 221)
    pARBI-617: CTACAAGCATGCATCACCAGGCCTGGCTAATTTTTCTATTTTTTGTAGGG 2541
    chr2_2_ ACAGGGTTTTGCTGTGTTGCCCAGGCTGGTCTCAATTTCCTGGACACAAG
    Exogenous_107 CAATCTGCCTGCCTCAGCCTCATAATGTTTTTTTTTAATGTTAAACCCCT
    TCTTGTGTTGAGAGGCCTGGCTTGTGTGTTTGAGCGCAGCTGCCTACCTT
    TGCAGCTGTAAATGTCAGGGCTCCAGGAGGGCTGGCTGGGTCTCCCCTCC
    TCCCCTGTTGGGTGGGTGGGGCCCTGAGCTTATCCAGGCATCCCTAGGTG
    GATGGATGGGTGGATGGGTAGGCCCTGGCCTTCAGGGAATGCACTGTGTG
    TGGTCTTCCAGCCCCAGCAAAGTCTCAGGGGGCCCGAGCGGGAAGTCGCC
    ATCCTCAGGGGGTCCGAGTGGGGAGTCACCATCCTCACGGTCAGCCGTGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTTCGAATT
    GAGCTCCCAGGGGCGGAGACTCCATTCCCCCGGGGAACAATCTGATAGCC
    AGAAATGAGAGCAGTGAGTGACTTGGACGCTGTGTGATTCAGGAGGGTCC
    CAGTCCCTCAGAGTCGCCTGGACACCAGATTGTATTTACAAAACAGATGG
    ATGAGGAAATGGAGATTGGGTCTTCAAAAGAATTAACCTCAGATTTTATT
    TATTTATTTTAAAAATTTTAATTTTTCCCAAGGACCCTTTCCAAGTCAAG
    AATTGTTTTAAAAAGAAGCCTGGTGAAGGCAAATGCTGTCTGTGGCCGAA
    GGCACCGTGAGGAGCTGAGGCTGACTTATGTTTCTCCTCTGGGCTATGTG
    CGCCTCTAAGGAGTTCACACACTTTAACCCCCTTAGGAACCCTACATGAT
    CATCCTCGTTTCTTAAAGAGGAAGCAGAGCCAGCAAACAAG
    (SEQ ID NO: 222)
    pARBI-618: TCTTGATGGATACCCATCCTTCTCTGCTGTTCTCTCTTTCCTCCATCCTC 2541
    chr2_3_ AAGCACAGGGAGCTTTTGGCGAGGTTAGCTAACTTCGGGGCAGCTGTGAA
    Exogenous_108 TTAGATACTGGCTGTAAGTTACCTCCAACATCCAGAGCATTTAAACGCTC
    GGCTGTCAATGATTGTCATTTTCATTGTTTACATATAGTCACATCCTCAG
    TTTGTGGGGTGGATGCATTTGATTCAATTCAGATATGCCTTTCAAGCTGG
    CCCTGCTGAGCTGGGCCTGAAAGGCACATGGCTCATCTCATCTGCATGTG
    ACAGTCTCTTTGAAGTCCCCAGAAGTGCCTGCTCAGAGTCATGCTCGGGA
    GGGAAGAGGTAAGGCACAGAATGAGTACAGACTGCCACCCAGCCGCAGGA
    AAGGTGACTGCACACCAGAGGTTCCTGGTAAGGAGGTGACTCACCCGCGA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCTGTCTCAC
    CTGTCCAAAGTGTGTGTCACCTGCTCTGTGTTCACCCACTGGGTTCATCA
    GAGGGGCACTTGAACAAAACAGGAATGTCACTGGAGAGGGGAACAAATGC
    TGTCCCCAAGTCCTTCCCTGCCGTTTAGAGTAACGCAGCCCCTGTCCGCA
    CATCCTCACCCCCATCTGCCCTCTGCTTGCCAGAATTATCAGAATCTCTC
    AATTCTAATTTCAGCCATTCTCTGTGAAAATGAAAAGTTAGTGGCAGGCA
    ATGGACACCCTATTGAAATAGAAATTGTTCTTCATATGTCAGAAAAGTCC
    CAGAGTAATCTGGGAGTAATCTGAGCAAACTGATTCAAAGGATTATTACA
    ATTTCTTAGTCTTCTACTGCTGCAAAAGTGGCACTCTTTGATTCTCATGT
    TTGAGGTTCTAATTACTACCTCATGCAGGACTTACAAGAGA
    (SEQ ID NO: 223)
    pARBI-619: TGAGCAAATAGTTCTATCCTTTTTGACACATTTTCCACAGTTTGTATAAT 2541
    chr3_1_ TTATTCATAGAATCCTTCTTAGACTACTAATAAATTCCTATGGGACATAG
    Exogenous_112 TCCTTTTATATGCGGAGGAATCCACCACCATGAAATGTTCACAAGAAATG
    ACTTTTAAAATTTTATTTGTGGCCATGCTGATTATGAATTTCTGAATTAT
    GTCTGGGCTGCTCTTTTTCTCGGAATATGCAAAGTGGGATACTGGCATCT
    CTGTATCTGGAGAGTTACAGCTTCTGAGTTAAAAGATGAATGGGAAGTAG
    CAGGAGAGGGAGAGATCAGAAATCTCCACTCCCTGAAACACAGACACTTC
    ACATACCCAGGAGGTAAATTCCTGGCATGAATTGTAACAAGTATACACAG
    GCATTTGTACATTGTTTGCTTATGTGCTAGATGACATGGCAGTCTATGAA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGGGGCCC
    CACATCTGCAGGCAGGACATTCAGCCCTGTATCTTGCCACTACCATGAAA
    TCTGAGGTTCTTTCATTTTTGTTTTTCTATTCTGATGAGATTGAGGTACA
    CTGACTCACTGGTAAAGAAGACAATTTATTTGTGAACTTGTAGTCACTCC
    ATTTGACGGCCTCCCTCTACTCACTGAGGCACAGCACGTGTGGAACAGGA
    AAAAGGCCTCTGGAGAGCTTGTGTTCCACTGGTTTCTTTGACTTTTGCCA
    ACCAACTTTGCAAATGTTCTCAAAAGGCATTCATTACCTCTGCAGGTGTG
    AAATAACTCTGCAGTTCAAGGGTTTGTGAAATCACGTGAAACAGCTGAAA
    GCTGTTCTGGCAAAGCGACCAGAGTCAGAGTTAGCTGTCACCAAGCCACA
    TCCTGGCTTAAACGATGTTATTTATATCTAACTGCACTCGA
    (SEQ ID NO: 224)
    pARBI-620: AGATGCCCATTGTACCACCTACCATTGCTTGACCCCCGCCCATGAGCTGT 2541
    chr3_2_ TCCTTCATACTCATAACTAAAATGCCAAATGTGTGACTTGAGTAATTAAC
    Exogenous_113 TAGAGACCTCCAGAAGGCTTTCCTTCTTATTCTGGGTACATTGATATTTA
    CTTTAGTATTTGTTTTGCCTTTAAAGTCATGTTCCCTTTTGATTCTTTAA
    TATCATATCCAAAACGAAGTCCTTTTAACCTATAACAATGCAAATCAAAA
    GTGCTGTCTTTCAGCTACCTCAAGGATTTAGCAAGCGTTCCTGGAAATCT
    AACCAACCTTTTAAAAAGTATTTCTATGGGAATGTATTTCTGAGCCCTAA
    ATTATGGATTTTGAAACTAAAATAGAAGAATACTGTAAGTGCAAAACTTC
    CAGTAGATAACAGAATTTGCAAAATCTCTAATCTCTTGTATGTGCCCCAA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGTAGTACTCT
    CTATAGGCCATTGGAACAGAACATCTGGCTTAAAATAATCTCAGCACCAA
    AAACGGTCTAACTATGGTCTCCACAACATAACCCGATGGTTCTCATATTT
    TAGATGCTTGATGCACAAGTTGAACTGGCTAACAATTCAGACTTCAGGAC
    TTGACTCCCCTGGGAATCTGCAGTTGTTTCCCTCCCCTTGAGTGAGACTG
    ACTGTTGGGAGTAGAATAACCGCATGCTCTGGGTCAGAATGCCTGGCCCT
    TCAGAGTAACGGCAGCCATGATCGCTGAGCTCCTACTGTGAGGCACATAC
    TTCGCCACACTAACACATGGAATCCTTGCAAGCTCCTTACATAATCAGTA
    TTTTATGCACTTTGCAAATGAGAATACTAAGGCTCAGAAGAGGCAAGCTC
    CTCTCCCACTGTTAAACAGCTAGTGATGAACAGAGCTGGG
    (SEQ ID NO: 225)
    pARBI-621: ACTCCCCTGGGAATCTGCAGTTGTTTCCCTCCCCTTGAGTGAGACTGACT 2541
    chr3_3_ GTTGGGAGTAGAATAACCGCATGCTCTGGGTCAGAATGCCTGGCCCTTCA
    Exogenous_114 GAGTAACGGCAGCCATGATCGCTGAGCTCCTACTGTGAGGCACATACTTC
    GCCACACTAACACATGGAATCCTTGCAAGCTCCTTACATAATCAGTATTT
    TATGCACTTTGCAAATGAGAATACTAAGGCTCAGAAGAGGCAAGCTCCTC
    TCCCACTGTTAAACAGCTAGTGATGAACAGAGCTGGGACCTAAACTTGTC
    TGATTTCCCACACTGCTGCTCCATCAGATTGTTTGCCAGGTTAAGGATTC
    ATGCCAGGACCTTAAATCCCTCTGAATCGACAGAGCTAACCTAAAGGGCA
    CCTTGATTTCAGGTTTTGTTCCCAAACCTATGACTGTGGCCTGGCCACGT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAATGAAGAC
    CCGGTTGGTTCTAGCTTCACAATGAGCTCATTGGCATTGTCCCCACAACC
    ACCACCCCCTCTCCACCTCTGATCATCCACTATCATTTCTATATGGCCTT
    TGCCAGGCTTGTCCTCATATCAAAGCTTCTGCCCTCTATGTTTAAATGCA
    TAAGCTTGACAAATGTTTTCATTTGAGAAGGCAAGCTGCCTCCCCGTGCT
    TGGTCTAATGTGAGCTTGGTAGAGTGACACTGCTGGATTCAGTTTTAGTC
    ATCAACACTTCCAGCTGATGCTGATCTGAGTAATTGTCCTATTTAGACTC
    TGACAGGTGAAAGTCATAGATTCAGGAAACGGAGACTCCCCTCACCCTGC
    TATGAAGGGGAGTTTGAGAGGGTTGGGCAGCTCTTCCCGGCAGTGGCAGG
    CAGTGTGGGGACACACGTATGGATAAATTGTTAATGCTCTT
    (SEQ ID NO: 226)
    pARBI-622: CTGCAGGTGGCAGACTTACTCATTCTCATGCTTCAGCTCCAGGGGTTCCC 2541
    chr3: CTGTATGAGTCTTCTCTGCCCGCTCCCACACCCCAGGTAGCATTGCCCCT
    1865_ GCTTGCTTTGTGCCCTCACTGTCTCCACATATATACACATCTCTTACAAT
    Exogenous_109 AATATTAAATACCAGCCAACATTTATATAGTACTTCTTATGTACCAAGTA
    CTGTTGTCTATCTATCTATCATCTATCTATCTATCTATGTACACACACAC
    TCATATTATCTTCACAATGCTATGAAATAGGTATTATTGCTGTCCATTTT
    ACAGATGGGGAAACCAATCTATAATTGGTTTAGTGAGATTTACTGAGCAT
    ATCTACAGGTATTTGTCCTTGGTTATAGGAAACCAATCTGTCACTGGTTT
    CCCCTTCTGTAAAATAAGTTAAATAATTTGCTTAAGCTCACTCAGATAGT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGTGTGGTTGA
    GTCATAATCTGAGCTACTCTCTGGCCCAAACTGCTTATTGTAACCACCAC
    ATCATATGGCCACTTCAGCACCAGTCACACCTCATTTTACTTGTTGATGT
    CTCAGTTTTCCCCTCTATTCTGCGGGCTACTTGAGAAGACTTCTGTCTTC
    TTCCTCTAGGTATCTCTGTGCTTGACTCAGTATCGAGACCATAGGTGTGT
    GGGTGGGGTTAATCCACACTTGCTGAACACATGTGTCCGTGCCCAATGTC
    CCTGTGCATAGTGGCTACTTCCCATGGTTCACACGCATCTTCATGGCTCT
    TGTTTCTTCCATTCACCCATCCCATGTCCCTGGCCCTGTTCTCAGTGCTG
    AGGATGGAACCTCATTGCTGCTGCTTCCAGCCCTGGCCCTGCCCCTGTTT
    GGGGCTCAGTGCTTCATCCCGTGGAGCTCAAGGGGTGCTG
    (SEQ ID NO: 227)
    pARBI-623: CTTCTCATCCTCACACCCATTCATTTCTTAGTTTCCCATACTCTGACTTC 2541
    chr3: TACTACCCCAAGTTCATAAAGACCTCATGAACACAACCTGGAGAACGCCC
    1865_ TCAGCCTCATCTCACCTCCCTGCAACACATGGCTCACTTGTCTGCTTCTT
    Exogenous_110 CCTTCTTAGAGTCCTCTCTCTGGTTGACCTGTCAAAGATGGGATTCTCCT
    GTTAACGACCCTGACTCCTTTGTCTCCTTCTACAAAGATAATGCACTGAC
    TTTCCAAATGTACTAACTAGTATGATCATCACTGTCTACTGTTGCATCGA
    ACCACTACTAACCTCAATAGGGAAGGCACCAGGTTCAAGAGGCCAAAGAA
    GAGACCCAGAGCCAGCAAATGAGACATGGGGTTTTATGAGGGGCTCACAT
    AGAGGGGAGAGAGTCCAGTGGCAGTGGGCTGGGCAGGAGAACCACCTTAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACGTGGTCC
    AGTGGTGGGAGGCTGGAAAAGAGATCTGTCTTGCCTACAGTTCAGTGGTG
    GCGGGTTGGGCAGGAAAACCACAACTGCCTGCAAACATCATGCAGTTTAC
    ATAACATTGTCACTTAGCAGCCTCCCCTAACGACCTCCACCTGGCAATCT
    TCATTTAACCCAAAACTCAAGGCCTCAATCCCCTGTATGGACCATGTTTC
    ATGGGACAGGCCAGGGGCTCAGAAGTTTATCATAGATAAGGAATGAATCT
    CCGGGTTGGCCACTCCTGGATTCCCTAGCTTGGAACACACATTCAAGTGT
    ATCTGCCATTCTGAGTGTATTCTTCAATTATTGCTGTCAGGTGTGTTGAC
    CCTCTATCTACATAAGTATTTCTCAAACCAGGGCCCTACGATCAGCATCA
    GCATCACCTGGGGTATATGTGAAAAATGCAGCTCCTGGACC
    (SEQ ID NO: 228)
    pARBI-624: GGGCCAAGCAAGCTCTGAGACAAGCTGTCTCACCTCCTCATCTCCTGAGC 2541
    chr3: ACAACTCACCCACAGCTCTGCCCTCGCCTCCACCTACATCATGCCTTCCT
    1865_ GCATGCCAACTTCCCTCTGAGGTTCCCTTCACCCACTTACAACCACAGCC
    Exogenous_111 TCCTTCCGGACCTCCCCTACACGATGAACAGTCTGCCAGTTAATATACAT
    CAAGCTGCCACCATGAAACAGCTCGGAAAGCCCCATTTGTTCTCAATAGC
    ATTCCAGCTAGAAAGACCATCCACCACCCATGGCCACTGAAGAAGGTCCT
    CCCCTGAGTGCCAGGCAGTGGGGCTCCTAACTCTGGGCCCCAATTAGCTT
    AGCTTGGGGGAGCAAAGGACAGGAGCACTGTTCACCCAGTTGGACTAACA
    GCTCCACACTGTGCCTAATAGGAACCTCCTTCTCACAGGTGGCACCTTTG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGAATCAGG
    GTCTGTCCTGAGCCACCCTCCCTTGGAGAGATCTGAGCACTGAGAACCAC
    AGAGCCTGGGACACCAGCACAGGGTTTGAAAAACTCCACTCCCAGTCAGC
    TGCGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGT
    GGATCACAAGGTCAGGAGTTCGAGACAGCTTGACCAGCATGGTAAAACCC
    CATCTCTACTAAAAGTACAAAAATTAGCCAGGCATGGTGTTGGGCACCTA
    TAATCCCAGCTACTCGGGAGGCTGAGGCAGGGGAATTGTTTGAACCTGGG
    AGCTGGAGGTTGCAGTGAGCCGAGATCGCACCACTGCACTCCAGCCTGGG
    GGCTGAGCGAGATTCTGTCTCAAAAAAATGGGAAAAACATCATTCCCATG
    TGTGTCCTGGTTGCTTGTCTCTTTCAAAGTACTGCATACT
    (SEQ ID NO: 229)
    pARBI-625: CCACATCATGGACCAGAAGCCACTTGGTCTGGTTGTGAGGATGACGGAAC 2541
    chr8_1_ CTTGCCCGAGGAAATGGGCAATGAACAGGAGCCTGTTTGTTTCTCCTTCC
    Exogenous_115 AGCTCCTGACCTGTCTAGCTCCTGACCCTCTCAGTGTCATTCTTGCTCAC
    CCCTGGCCCTGCTCCCTGGATATGCAGACAGGATGGGCTTCTTCCCTTTA
    GACCTTCACTTTGCTCTTTTGGACTCCTCTTCTGGCCTTGCCTTCCCCTG
    GTGTCATCTGCTGGCTCCCTGCCTGATACTGCCACACTGGTCATGCTGGC
    CTCCTGGCCTTTGGTGACACCGCATCAGCAGGCTCCTGCTTCCCTGTCAA
    GGGATACAAGCCAGCACCGGTCTTTCGCCACAAGGTATGTGTGTAAAGAT
    TGCTTCCTGTACTTGGTGTCCACAGGATTTTAAAGAACTCCTGGCCCACT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCGGAACTCT
    ACGCTTGAAACAGAAACATCTTCTCAAAACACCTCTGGTATTGGCCCATT
    TCTCTATTACTGTTTCTTGTGGTTTCATACTGAGGTTTTTGGTGCATTGC
    AATTGCCCTGGAGTTTATTTTTAGTAATAAAGACAGAGTTCAATTAATGT
    CAAAACATGAGGGTAATTGCAGAGGAAGGATTAGTAAGTCTAGGGGAAAA
    TGTGCCCAACTTTTTTTCTTCTGATAACATCTTTCACTGATCATACACCG
    TCACACCCACAGACACGGAGCTTCCTCCGTGATGTCTGCAATGCACTAGG
    CCCAGTCGGGGAGCAGTGGCTGCGCCACCACCTGAAAACGAAAGCATTTC
    TGAGTCTCTTTCAGTCCAGCTCATCTAGCAGCCAGCCACACAGGTGACCA
    CCCACCGTAGCTGTCACTATGGGTGATGATTATCATTATGG
    (SEQ ID NO: 230)
    pARBI-626: AGGATCTTTCTCTCTACAGTGCCTCTTGTGGGACGGGTTCTGCTGATGGG 2541
    chr8_2_ GGCTGTGTTTGGGATCTCGCCTGGAAACACGATCTCTCCAACTTTCCCTG
    Exogenous_116 GGAGCAGAGCCTTGGGTCTCACTGAACCCACCTCCCCAGCACCTTGTGTG
    GTGACTGGCAGGAGGTAGCCATTCCCTCCTGTCCTCTCTGCCCTTGTCCA
    CTTTCCTGTTATGAGTCAGTTGCTGAGATAGGCTATGAGGAGTTAACAGA
    GTGGATAAAAAAGAGCTTTGTCCTTCTTTAAAGCCTTCAAAATATACAGA
    TGTATTAGTCAGGGCTTTCCAGAGAAACAGGACCAATAGAACATGAAGAT
    AGATGCGTATCCATGTCTATATCAATATCTACCTTGATATTTATATCTAT
    ATCTAGGAGATTTATTTATTATAAGGTATTGGCTCATGCAATTATGGACC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGAGGGGT
    CCTGTGATTTGCCACCTGCAGGCTGGAGACCTAGGAAACAGCTGTCGTGT
    CACAAAGGGCAGAGGGCTGGAGAACCTGTAGTGTAGATTCCAGTCCAGAT
    TCGAAGGCCTGAGGACCAGGAATGCCAAGGGCAGGAGAAGATCGATGTCC
    CAGAACAAGCAATCAGGCAGAGATGAAATTCAACCTTCCTGTGCCTTTCT
    GTTCTATTCAGGCCTTCAGTGGGTTGAATGAGGCCCAACCCACATTGAAG
    AGGACCATCTGCTTTACTCAGTCTCCTGGTTGAAGTGATAATCTCATCTG
    GACATACTCAGAAATGCTGTTTAACCAGCTCTCTGGAAATCCTGTGGCCC
    AGTCAAGTTGACACACAAAATTAACCATCACACTGCAGAGACACAGTCTA
    TCCCAATACCTGTATTTACTGGGTAACGTGCATCTCAGCTC
    (SEQ ID NO: 231)
    pARBI-627: TAATAATGACTCTGCTGGTAATTTGTGTCCTTCTGCTTGGAACTGTTTCC 2541
    chr8_3_ TTTTTAGTTTGGTCACCCTCCCAGAGCTGGTTTCAATGGGGGCATACCCA
    Exogenous_117 TTATGGGATGCAGGGCATCCTGCATCCTGAGGAATTTTTTTTCCTCCAAA
    AATGAAACCTTGAAATGAGGACATTGTCCTGTCCACGGACTGCACAACAA
    CACTGAGCCTCAAGGACTCATACTGGCATTTTTCTTCTTTTGCAGAGTGT
    GGGCACCCTGGCTTCAAGCTCACGAGAAACCAGGTCGGGATTTAAACAAT
    GTTGGGTTAAAGCAAAGTTTCATAAAGACAGAATCAAGAAAAAAAGAAAG
    AGAAACCAATCTAAGTGCCATCCTCCCTGAGTTGCATCTTACCTGAGTCT
    TCAGCCGCCGCCCCCTGCTGCTGTGGGAGGAAACGGGAAAGTGACTGGCC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatATGGGGACA
    GGGGTCGGGGGTGTGAGGGTTAGTGGTAGCAGGGAGGTAGCACTTCTGTG
    AAGCCGGAAAGGAGACCTGAACCTGGCTCTCTGCTTTGCTGCTTGCCAGC
    CCTCTGGCTGGGAAGAAGGCTCTTGGCTCTTGTGAGCCTCGGTTTCCTCT
    GCAGAGTGGCCTGTTCTGAGGACAGGCTGACATTGCTGTCCATCAGTCTT
    CCAGGACCCTGAGGATTTCAGCTCTACCCATGGGCACTGAACTGGAACAT
    TCACTGGTCATTTGCTTTCGTTTTTTTTTTTTGTTTGTTTGTTTTTTGAT
    ACAGAGTTTCACTCTTGTTGCCTAGGGTGGAGTACAATGGCGTGATCTCA
    GCTCACCACAAGCTCTGCCTCCCGGGGTCAAGCGATTCTCCCCAGTAGCT
    GAGATTACAGGCATGCGCCACCACGTCCGGCTAATTTTGTA
    (SEQ ID NO: 232)
    pARBI-628: AAGTCAACAACAGGCTCCAGAAAAAAATGGAAATATAAATGGTCCCCAAT 2541
    chr9_1_ TTGGCATTTTGGAATTTGAGGCTTATATAGTATGAGCAAAATAAACTCCT
    Exogenous_118 CCTGCTTCTATGAATTCTTTGCACTTTTTCTCTATAATTCCTTATCAAGC
    AATGGGTTTGTCTGTTAACCAAGACTATACATAAAATGTATTCCCGTAGT
    TCCTTTTATTACATTTTTTCTTTGTTGTTACTAGTGGAGAAGCTAACAAG
    AGCAGAATTTCCTGCCCAACCGTAGCAAATACAGAAAATCAAAAAGAGAA
    GCTTTGATACAGCCAGTGTAGATACAGCTAGGACGTCATGAATCAGAGCT
    CCCACACACGATGATAATGGAAACATCTTATCCATATCTGATTTGCTCAC
    ATATAGTTATTTAGACAACAAATTTTACATTCCTGGATAGGGAGCCTCCG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatATTTGATTTC
    AATCTCATAGTCCAGGTAGGTGTAAAATGACTGCCAAGCCAGCAGACATA
    AATCTGTATTATCTCATTTTCATCACAGTCTCTGCATTGGGAAAAAAATG
    TGAGTGAAAAGACATTTTCTCCCACCTTGTTAAGTACACAATTACATAGT
    TTAAAGAAGATAAGAATTTCAAATTGTTAGAATGATATCATTATTCAAAT
    GATTCCCTGAGAACTTCAAGTATTCCCCTTCCCCCAAATGTAGGCAGGGC
    AAAATAGAACCAGTAGGAATGAAAAATGTTAATTGTTTCAGGTTCTGTAA
    TTTTGGGTTTAATGACTCAGGCTATGTGCTACTGAGTAAAATACTCATCT
    GGAGAAAAAGACTGTTGCATGACATATTTCTGATTAAGGACAATTTAAAC
    TAATTCTAAGAAAACTCTTACATACTGCACATGCCATAAA
    (SEQ ID NO: 233)
    pARBI-629: GATTAGGTCTGGAATAAGATTGCACCATGACTAAAATGACTTCTTTAGCC 2541
    chr9_2_ AATGACATTCCTGAAGATTGGATCAGAGTAAAGTTAAACTAACCTACTCA
    Exogenous_119 AGGAAGACTTTCCTAAATCAGCCCCTTTGCTGTATAATTTAGTATGGAGA
    GCTGATTGTGGGTTTTTCTTGTTTCATTGTTTAATACATAGAGGTTTCAC
    ATTTCATTTTGAAACAGAAAGAGGGACTGGAAGAGATAAGTTAGTATGAG
    TGAGGAAAAGATTAGAAGGTAGAGATAGGATCGCAATGCTGTTATCACCT
    TTGCTTTATTGATAATCTCAGGAAGGACTAGACTGCTAAGAAAGAGGAGC
    CCAGATTGGAATAAAAGAGACGATGCCAGGATCAGCCTGTGAGAGGATGT
    CTCACTTAGTACACCTCAAGGATCATGTCAGCTGAGCATCTATACCCCGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCG
    AGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGC
    GAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCAC
    CGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACG
    GCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTC
    TTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTT
    CAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCG
    ACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGAC
    GGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGT
    CTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGA
    TCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAG
    CAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA
    CCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATC
    ACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATG
    GACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaata
    aagcaatagcatcacaaatttcacaaataaagcatttttttcactgcatt
    ctagttgtggtttgtccaaactcatcaatgtatcttatGTGATGAATATT
    GCATACAGACTCTGCCTTCAAGTCATCCCCCATTCGACAAGCATTTATTT
    AAGGTTCTTACATTCCAGGACTTGTACTAGATGCTAGAAACAAACAGATA
    AGGAAAACGTAGGAAAATGCTTCTCTCAGGAAGCAATATTGTATATGAGT
    GGTGAAGAGCTTCAAATCTGGGGCCAAACTGCTGGGTTTGAAATTTGGCT
    TGGCCACCTACTGGCTGTGAAATCTTGGGCAACTTTCTTAATCACTCTGT
    GCCTCAGTTTCTTCATCTGTAAAATGAAATAGCCATAGTACTTATTACAA
    ATAGGTAATAATTAGTGAGAATTAATTTGAGTCAATACATAAAAATGACT
    CAGAATAAAAGACCAGCTAAGAATATATACACACATACTTAGCTACTTAT
    AATCTAGTAGGAAAGATGGGTATGTTATCAGAGGACTT
    (SEQ ID NO:
    234)
    pARBI-630: CAGATAAAAAAAGCTGAAGCTCAGGGATATTGTCATTTACCCATGAGCTC 2541
    chr9_3_ ACAGGCAGGAAGTGGTGAAACTATCATTAAACTACGGTTGGCCTTGTTCT
    Exogenous_120 TTTGTGGTTTCATTTCACTAAGCCTCTGACACCCTGACCTCAACTTCCTT
    CTGTAGATATGTCACCTGGCCTCCTTCAGTCTAAGACACTACACACTGGC
    CACACACTTTGTCATCCTCATAGACTGACAACCTGCTCTCACATACCCTG
    CTTTCTTACTGTGTAGGCTCTCTTTTCTTGCTCAGAATGTCCTTCCCCAC
    TTCTTCATGTGCCAACTCCTAGTCATCCTACAAGAACCACATTCACTTTA
    AGTTTCTTTTGAAGCCTTTTCAGTGTCCCATACCCTGATCCCATTACCTC
    TTCTATGTATGCAGGGCTTGCTTCATGCTTGTGTAACCCAAGGGCCCTGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatATTTGATTTA
    ACACATTTTAAAATTCTTAACAATTTATGAAAAAGGAAACCCATATGTTC
    ATTCTGCCCTGGACCCTGCAAATTATGCAGCCAATCCTGTGTGTGTTTTT
    TCATGTTGCGTAGACTCTATTACAGTCAGTAACATATTGAGAAAGAGTGT
    GTGTCTCCTCTGATAGTCTATGAGCTCCTTGAAGCAAGAGGCTTGTCTTA
    GTCATTGCTGTATCCTCACACCAGACTCTACGGGATGCTCAGGATTCACC
    TGTTGATCTGTGAGGAAGCCCAAGGCTCAGTTAATGCCCCCCACCCTCCT
    TCCATAACAGTCTCCTGATTAGGAAACAGTGCTTGACCTCTAGACAATCT
    GAGTATCCACTCCAGGAAGTGGAACATTGCCTTCCCAATGTTGAAACTGT
    TAGCACTCAATCATGTTTCAGGAACATATAGAAGGTATGT
    (SEQ ID NO: 235)
    pARBI-631: TGGACCTTATGCAGGGTAATAAAAACCAACACGTGGGGCCTGTGCTGTAA 2541
    chr10_1_ GGTGGCAGAGGGCGATGACTCACCCCACTCATGCAGGTTGAGTCATTTCA
    Exogenous_90 AGGCAGAGTTGTGCCAGTTCAGTACCCAGTAATATTTTCCAGTCGACGAG
    TATCAGTGAACAGGAGATAACCAGTCATTTCTAGATTCTGCTCAGAGTCC
    CAGCTTAGAGGCTCCACCAGCTCAAAGAGACGGGATGGCAAAACAGCCAC
    CTTAATTTCCAGATCATCTGCCAGCTCATCTGCCAGCTGACACACAGCCC
    ATGGCTCCACTATTGCCAGTGCTGTAGCTGCACCAGACCAATCTGGTTCA
    ACTTTTATGTAACAAAGTTGTGATTTGTTTTTCAGTTGCCCGGGACTCCC
    AGGTTGAAGATCATGAGCATGCCCTGATGAGCCAAGGCATGCAACCACAG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGGAACCTA
    AGTGCTTGGACTGAGGAGTGGGGACTGAAATAAGAAGCGGACACTGCAGG
    GCAGGATCAGGATCCAATCAGATCGAGCCCTGGCATCACCTCATGGCAGG
    ATCTAGTCAGATCGTGGCTTTTGACATCACTTCATTGTGAAATCCAATCA
    GATCACACCTTATTACCCTATCCTTATAAAACCGGACCTAGCCCCCAGCT
    CGAGGAGGCACTGCTTTGGGAGTTATCCCAGGTGTTCTTGTTACTAGTTG
    CAAGGAATAAAATCCTCTTGCTAAATCCTCCTTGGTTGTGCAGATGTTGG
    CATGGATGTGGAGAGAAGGGAACACTTACGCTTTGTTGGTGAGGATGTAA
    ATTAGCTCAACTCTGTGATAAACAGTATGGAGAGTTTTCAAAGAACTAAA
    AATAGAACTTCTACTCAACCCAGCAATCCTATGAGTGCATG
    (SEQ ID NO: 236)
    pARBI-632: ACATCTAATCCCACACCATGACTAATAAACATGGCATGCTGCAATGGGCA 2541
    chr10_2_ TTAATTTATGGGTAACAGAAGCAGATCCAAGCCTTTTAGCTAATTAAATA
    Exogenous_88 AAAATGCACCATACAGCAACCATCCTGCCTGCTTGGGTGTAAAATAGAGA
    GGAGAAAGATGGCATGCTGGTCATTGAGAGATAATTACCTGCAATTTCAG
    AGCTGGAATCTAGTGACAACATAAGAAAAATAATAACCTCTCTGGCTGTT
    AGGATTCTCAGTTCTAGCTGCGAGCAAGGAGCAAAGGCACCCACAGACTT
    GCCAAACCTATGTCAGGAATGACGAATAGAAGGCAGAAATCCACATCCCC
    AGGTGGTAAAATTGTTATCCACCTTCGTCACCTCTTTCCTAATGGAGGAA
    GTGAGGACAGGCAGCCTTGGAGTCCTACTTGAATGAGGCCTGGACCTTAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGCAGGGTAA
    TAAAAACCAACACGTGGGGCCTGTGCTGTAAGGTGGCAGAGGGCGATGAC
    TCACCCCACTCATGCAGGTTGAGTCATTTCAAGGCAGAGTTGTGCCAGTT
    CAGTACCCAGTAATATTTTCCAGTCGACGAGTATCAGTGAACAGGAGATA
    ACCAGTCATTTCTAGATTCTGCTCAGAGTCCCAGCTTAGAGGCTCCACCA
    GCTCAAAGAGACGGGATGGCAAAACAGCCACCTTAATTTCCAGATCATCT
    GCCAGCTCATCTGCCAGCTGACACACAGCCCATGGCTCCACTATTGCCAG
    TGCTGTAGCTGCACCAGACCAATCTGGTTCAACTTTTATGTAACAAAGTT
    GTGATTTGTTTTTCAGTTGCCCGGGACTCCCAGGTTGAAGATCATGAGCA
    TGCCCTGATGAGCCAAGGCATGCAACCACAGGGGAACCTAA
    (SEQ ID NO: 237)
    pARBI-633: TGAGGTCTTGGTATGTTGCCCAGGATGGTCTCAAACTCCTGGGCTCAAGC 2541
    chr10_3_ AATCCTCCTGCCTCCACCTCCCAAAGCGCTGAGATTATAGGCATGAGACA
    Exogenous_89 CAGAGCCCAGCCACTGTCCGCATTTCTTTCCTGGCTTCCTTACTGGGTTC
    TCTACTTTCACTCTTGCCTTCTTCCTCTCTTCCACCAGCATAAGTTTTAG
    AAACTGCACTTCTGATCATGCTGCTCTGCTGCTTAAAATCCTTCATGCAG
    ATCATGTAAGACCTTCCTGATCCAGTGCTGCCTTGCCCTCTAGAACCCAG
    GGTGCCTTTCTCCCCTCTGCAGTTCTACTGCGCCACCTGCAGTTTCTCTC
    TCCTGTGTTCATGTGTCTACTCCCTCTGAATGGTAGGCTCACACCCTCCA
    CCTGGCCAACTCTTACTAAATCTTGGGCTTCAACTCAAGGATCACCTTCA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTGGTTCACTC
    CACCAGGCTGGGCTGTGTGTCCTGCCCAGTTCCTATAGTGCCCTAACTCA
    CTTTTTTAAAAAAATACTTTAAGTTCTGGGGTACATGTGCAGAACATGCA
    GGTTTGTTACATAGGTATACACTTGCCATGGTGGTTTGCTGAAGCCATCA
    ATGTCATCTACATTAGGCATTTCTCCTAATGCTGTCCCTCCCCTAGCCTC
    CCACCCCCCAACAGGCCCCAGTGTGTGATGTTCCCCTTCCTGTGTCCATG
    TGTTCTCGTTGTTCAGCTTCCACTTATGAGTGAGAACATGCGGTGTTTGG
    TTTTCTGTTCCTGTGTTAGTTTGCTGAGAATGATGCTTTCCAGCTTCATC
    CATGTCCCTGCAAAGGACATGAACTCATTCTTTTTTATGGCTGTCCATTA
    TTCCATGGTGTATGTGTGCCACATTTTATTTATCCAGTCT
    (SEQ ID NO: 238)
    pARBI-634: CCTTCCACCCCCTTCCTTAATAGTTTTCCTCCTCCGCCTCCTGCACGGCC 2541
    chr10_1_ TCCGCCTCCGCCTGACCGTCCTCGGAAACCTCCCAGCCGCAGCCCGGCCC
    Exogenous_92 TCCCCAGCGGCCTGAGTGGCCTCCTCCCGCGGCGCCCCCCAGCTCCGCAC
    CTCCCCAGCCCCGCCCGAGGCGCGCCCAGCGAGCGTGACCCCGACCCAGG
    GCCACGGCTGCGCCCGTAGGATCGCGGGCGCGCGGGTCTCCATGAGGGAC
    TGGGAGAGATGCGTCACCCGCTAATCCCTCAACTGGGTCGCACCCGGTCT
    GCCTTGGTTGGTCCCTTCTGATGGCGGAGGCGGGACCTCGACTTGGTGGC
    CAATGAGGAGCCTCGTGGGGGTGCTCTCGGCTGCCATGGCAACGGAGGGG
    CCGCCCGCTTCCCCGCGGGGCGAGGCCGGCTCTCCCAGGACTGGCCACAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGCAGTCAC
    GCGCTGTGGCCCCAGTCCTGTTAGCATGAGGTGGGGGTCAGAAGTTGAGG
    AACAACTCGGACCTAAAGCCTTGACAATTGCCAACAGTGTAGACAAGTCC
    CAGCATGCCCAAAATTTATAAGAGAAGGCTGCCTGGAAGAGGGACACGAT
    GAGGAGGGTCTGCTGAAACGGACAAAGAAACCCAGTTCAGTGCAGTGGAG
    TGGACATGGCACGGGCAGGGCACGGAGTGGGGTCGGTGCTTAGTAAGCGG
    ATTAGGGTTTCCAAGCCAAGACCCACCCAGGGCAGGATGGGGAACCAAGG
    TGAGCAGGTGCGCTGAATTGTGGGTCTCACACTGTCCTTCAGTGTCCCGC
    AGGAAGAGAGAGCTAAGGATCACCAGGGTCATTCCCCTGCCTCAGGCAGC
    CTGCACTCCACCTTAGGTACAGTCATGTCCGGTCTTCAGCA
    (SEQ ID NO: 239)
    pARBI-635: TGATCCTCCCACCTCAGTCTCCCAAAGAGCTGGGATTACAGGCATAAGCC 2541
    chr10_2_ ACCTTGCCCCGCCAGTTTTTAGCCTGTCAGCTCTTTGAGGGACACTTGTT
    Exogenous_91 ATGGTCATACCCACAGCTTTGACCCTTACCAGGTGGTCAGGTGGATGAAT
    GAATGAGTAGAAAGAAGGAAGAGAAGGCAGGAGGGAGAAGAGGAAGAATG
    AAGGAAGGGTTGAGTTTGTTCTGGAAGCTCCCAGCTTCCATCCGCACCAC
    ACTCTCCCTCTGTCCCCAGGACACCAGGGAACTGACTCAAGGCTCTCCTC
    TTACCAGGTGCTGTGTGGGGTCCAGGGAGAAGAGCCCATTTGAAATGGGG
    CACTGGTCTAAACTCTGGACCTGCTGCTCACTATTGACTGAACTTAGCCA
    CTTAAATATTCTCCTCTATAAAATGGGAGTGACCATAGCAACTACCTCGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGAATTGTA
    GGGAGACCCAAAAAATGTATATGAATACATTTGTCAACTAAAGAGTGTTA
    GGGATTATCTCAGTGGAGGGATAGGCAGTGCAGGCTCTGGAACCAGACTT
    CTTGTGTTCACATCCCTGCTCCACTGCTTGGAGACCTTTGGCAAGGTCCT
    TAACTCCTCTGGACCTCAGTTTTCTCATCTGTAAAACAGGGATTATACTA
    GTTCCTACCTCACAGAGTTGTGAAGATTAAATGAGATAATGCATGAAAGG
    CTTTTCAATAAGAGCAGGGCACACATTAGGCATGATGTCCATGATCAAGT
    GCCTAATATGTGCCTGCTCTCAGGAAGGATGCTGTGAACTACTTCACACT
    AAAGTGTAAATGAATGATAAGATCTACTATGCTCCACTCATGCCTGTAAT
    CCTAGCACTTTGGGAGGCCGAAGCAAGTGGATCACCTGAGG
    (SEQ ID NO: 240)
    pARBI-636: GGTGAGGTCACCCTGGGTACCTGGAGTTACTCAGAGTGACACTAGTACAC 2541
    chr10_3_ GCCTGGCAGGAGTGATGGATGAGCTAGGCTCCAGGAAAGCAGGTGGGGCT
    Exogenous_93 GGAAACCACCCAAGACAAGGAAATTGTTGGGTTTGAAATTCCAGGTAAGC
    AGAGTATGGCCTGAGAGCAGCGGCAGAGGCTGAAAGTGGGCTTGGTCTCG
    GTATTTTTGAGGCTGAGGTAGCTCCAACTCTCTCCCTCTGAGTCAGCACC
    CCACTTAAGACAGAAATACTGAGATCTGCGACCCCAGCCTCCCCCACAGC
    AACTCCACAGTCCCCAAACCTTTGCTCCGCTGGGTCCTCCCAAGTATGGT
    AGCTGACACAGCCCTGAGCAGCCCACTGTCCTCTGCCCTGCCAAGTCTTC
    TCACTCTTGTCACTTTGTCCTACATCATTTCTTTGTCTGGCACCCCTCCT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAGAATTGGT
    GCCCCAGAGGTGGGAAAAACCTACCCTGCTCACTGCTCTATCTCCTGGGC
    TTAGCTCAGACTCTGGCATACGTGAGTGCTTAGTAGAAACTTGATGGGGT
    ATTAAAATTGAGACCTGGGTGGGTTCTCACATTAAATTTCTAACACTCCT
    TAGGTGGCTTGGGCCCACCCCTCTGAGCCCTGTTTCCACATCTGTAAAGT
    AGCAAACCATCGCCATGAAGAACAGGGAAGAACCAGGTCAGCAGGCAGGG
    CGGATGAAGCATCCAGCCAGTTCTAGGAAGTTTCCGATGGCTAATCCTTC
    AGATGCAGCTTGTAAGCAGGTCAAATACAGAATAGGAAACTGAGGCGCAA
    CGAAGTCATGCTTAGAAGTCTGTCCAGGGAGACCAGTCAAGGCCTCCCCC
    ACACCCTGCAAGCCCTTCTAGGAGCTCTGGTTAAGTCACTC
    (SEQ ID NO: 241)
    pARBI-637: ATCTTCAAATTGTAGTCTTTGTAACAACCAAATAACCTTTTGTGGTCACT 2541
    chr11_1_ GTAAAATTAATATTTGGTAGACAGAATCCATGTACCTTTGCTAAGGTTAG
    Exogenous_99 AATGAATAATTTATTGTATTTTTAATTTGAATGTTTGTGCTTTTTAAATG
    AGCCAAGACTAGAGGGGAAACTATCACCTAAAATCAGTTTGGAAAACAAG
    ACCTAAAAAGGGAAGGGGATGGGGATTGTGGGGAGAGAGTGGGCGAGGTG
    CCTTTACTACATGTGTGATCTGAAAACCCTGCTTGGTTCTGAGCTGCGTC
    TATTGAATTGGTAAAGTAATACCAATGGCTTTTTATCATTTCCTTCTTCC
    CTTTAAGTTTCACTTGAAATTTTAAAAATCATGGTTATTTTTATCGTTGG
    GATCTTTCTGTCTTCTGGGTTCCATTTTTTAAATGTTTAAAAATATGTTG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACATGGTAG
    TTCAGTTCTTAACCAATGACTTGGGGATGATGCAAACAATTACTGTCGTT
    GGGATTTAGAGTGTATTAGTCACGCATGTATGGGGAAGTAGTCTCGGGTA
    TGCTGTTGTGAAATTGAAACTGTAAAAGTAGATGGTTGAAAGTACTGGTA
    TGTTGCTCTGTATGGTAAGAACTAATTCTGTTACGTCATGTACATAATTA
    CTAATCACTTTTCTTCCCCTTTACAGCACAAATAAAGTTTGAGTTCTAAA
    CTCATTAGAATTGTTGTATTGCTATGTTACATTTCTCGACCCCTATCACA
    TTGCCTTCATAACGACTTTGGATGTATCTTCATATTGTAGATTTAGGTCT
    AGATTTGCTAGCTCCAAGTAATTAAGGCCATGTAGGAGAGCATGGTAACC
    ACAGATAGAACTGGTATTATCCCAAGTGGTCTGCAGACTGC
    (SEQ ID NO: 242)
    pARBI-638: TTACAGCACAAATAAAGTTTGAGTTCTAAACTCATTAGAATTGTTGTATT 2541
    chr11_2_ GCTATGTTACATTTCTCGACCCCTATCACATTGCCTTCATAACGACTTTG
    Exogenous_97 GATGTATCTTCATATTGTAGATTTAGGTCTAGATTTGCTAGCTCCAAGTA
    ATTAAGGCCATGTAGGAGAGCATGGTAACCACAGATAGAACTGGTATTAT
    CCCAAGTGGTCTGCAGACTGCTGAGTGGGGATGGGATCTGCTCTCTGTTG
    AGAGTTGGTAATCATTGGTTTGAAATGTGATGAAACCACTCAAGCCAATG
    AAGGTGGGTGTGTAGGTGGGGAGTACTTTGCCATAATATTTTAAAACATT
    ACCTGGTTAGAGTTCTAAGTGGTACTTATTTTTGTTTGGTTAGGGGAAAG
    CCTGAATAAAAACAGAAATGGACACATAATATGCATATTCCATAGTCTTT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGGAGGCTG
    GAATGTGCCTGGGATTTGGGTCTAAGTGTATGCGTAATTCTTACCTCACT
    AAAGAATTTGCCTTGTTTTTTTCCTTTTGGTGAGTGACTAAAACGTCTGG
    GCTTCCCTGTGTGCGTGCTACAGTAAGCAAGCAGAGGCTGTGCAAAGGTG
    TGAGCAGGATCACGTGGAATCTGGAGGATACATCTTGGCTTGCAAACTGC
    CTCTGTCTCCTGGGTGGGACTGTTCTGTCCTTGCACTGCTGTTCTGTGTT
    ACCTCTTGGGGTGTAAGGTTTTGCTTACAGGAGACAAACTTTGGGCGTAG
    AATGGAAGCCACTGCCAGCCTCTGTGCTGAGAAGGAAGGTGCTTGTTTCA
    AAGGGAGCAGCAAGGGAGGCTTGTTCTACTCACCTGGGCCTGTTTGCCTG
    AGAAGGGGAGATAAGGGCTGAACTGGGACTAGCCAGGGGGA
    (SEQ ID NO: 243)
    pARBI-639: TGGGGCTTTGGGGAATTTAGTGCGTGGGTGAGCCAAGAAAATACTAATTA 2541
    chr11_3_ ATAATAGTAAGTTGTTAGTGTTGGTTAAGTTGTTGCTTGGAAGTGAGAAG
    Exogenous_98 TTGCTTAGAAACTTTCCAAAGTGCTTAGAACTTTAAGTGCAAACAGACAA
    ACTAACAAACAAAAATTGTTTTGCTTTGCTACAAGGTGGGGAAGACTGAA
    GAAGTGTTAACTGAAAACAGGTGACACAGAGTCACCAGTTTTCCGAGAAC
    CAAAGGGAGGGGTGTGTGATGCCATCTCACAGGCAGGGGAAATGTCTTTA
    CCAGCTTCCTCCTGGTGGCCAAGACAGCCTGTTTCAGAGGGTTGTTTTGT
    TTGGGGTGTGGGTGTTATCAAGTGAATTAGTCACTTGAAAGATGGGCGTC
    AGACTTGCATACGCAGCAGATCAGCATCCTTCGCTGCCCCTTAGCAACTT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAGGTGGTTG
    ATTTGAAACTGTGAAGGTGTGATTTTTTCAGGAGCTGGAAGTCTTAGAAA
    AGCCTTGTAAATGCCTATATTGTGGGCTTTTAACGTATTTAAGGGACCAC
    TTAAGACGAGATTAGATGGGCTCTTCTGGATTTGTTCCTCATTTGTCACA
    GGTGTCTTGTGATTGAAAATCATGAGCGAAGTGAAATTGCATTGAATTTC
    AAGGGAATTTAGTATGTAAATCGTGCCTTAGAAACACATCTGTTGTCTTT
    TCTGTGTTTGGTCGATATTAATAATGGCAAAATTTTTGCCTATCTAGTAT
    CTTCAAATTGTAGTCTTTGTAACAACCAAATAACCTTTTGTGGTCACTGT
    AAAATTAATATTTGGTAGACAGAATCCATGTACCTTTGCTAAGGTTAGAA
    TGAATAATTTATTGTATTTTTAATTTGAATGTTTGTGCTTT
    (SEQ ID NO: 244)
    pARBI-640: CGACCAACCCATCAAACTCCCCGCCCCCAGCACTTTTATTTCTCCTCTTT 2541
    chr11_1_ AGGAAGTACACTTCAGTATCTTTGGCACAGTGCATGAGCACGACTAAAGT
    Exogenous_94 AAAACATCGCAGAAAACATAGCTTTAGTCTACCCTTCGTGTCCTAAAAGG
    AAAACCAGTAGCTTCCCAGGCCACCGGAAGGGCAACACATGTCCTCTGCA
    GTTTCTGCACACGGGAAGGTAAAGACAGAGAGAGGACCTACTCCTCAACA
    CAGAAACATTTCAAAATCTTTCCTCGCCTGCAACCCAAGCTGAAGTCATT
    CTCCCCAGAAATAACAAAAGTTGGAAGAGAAGCCGGAGACAGGATAGGTG
    CAGGAAGCCCACACTTTGAGGGCAGCACTCAGACACCCTCTCCTGTGTGC
    AGGACGTGCCGAATGTTCAGGTGCAATGAGAATGAGCCATGCTTGGCTTA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCGAGGGCAA
    TCTGGCCCATCAAGTGGCCTTCGCCTCTGGGAGTAACAAAAATGCACTTC
    AAAATAGCTTCTGTAATCAAGCTGCATGGGTGGAGTACTCCCCAGCTGAC
    TCCAGGAAGTTCTCTATCCAAAGCTATTCATTAGGCCAGAGCTGTGCAAA
    TAATTAGTCACCCACTTGCTCCATAACCCTCCATGACAGCCCAGGCATTG
    AGTCCAGGTGGGACCATCAAGCCATGCTCTGGTGGCTCATGCATTATCAT
    AGAAATGGGAGGCTTTATTTATTTTACTAAAAAGAACAAAAACAACAGAC
    TGCTGTCCTTTAGACAATAGGATCACGTCATCTGAGCCCTCTGTGCCCCA
    GGTGACAAGCCCAGCCCCAAGTTCTCTTTCCTCAGCCTCCCCACACATGT
    TCTGGAGGAGATGGGCCCAGCAGGCTGCTCTGAGGCCTGGC
    (SEQ ID NO: 245)
    pARBI-641: TCACAGAATCTTGTTTGAGCTAACAACCAGTTATTCTACCCAAAGTAAAG 2541
    chr11_2_ AGTAACTTAAATTTTCCCATTGTTCTTCCAGGCTGGAAGATGTAAGAAAC
    Exogenous_96 ACACACAGTATAGTGTAGGTTTCCTCCATAGTTAAGTACCCCAGAGCTAG
    GCTGAAATCCAGTGTTGGATTGTTTCCAACTTATAGTAGGGAACCGCCAA
    TGACATGAAAGAGCATTACCTTACCGGACTGATTCATATTCTACTTCCAG
    TCATAGTACAAATGATCACATGTCCACACCCACATGTGCTCTGATAAGTA
    GTCAATTGAGAGGAGTGAGTCAGGGAGCCGTAACTTTGCAGCCAACCTGC
    CAAGAAGAACTGATGCTTTTAGAAATTCAGCAGCTTTCATTGGCATAGAA
    GTTTCAGCCTTATAGGCCCAGGGTTTCTCTGAGGCAGAGGCAAACCCTGT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGTTATGTT
    GTTATCTCAGGATTCTTTTTTTTTTTTTTGAGACAGAGTCTCACTCTGTT
    GCCCAGGCTGGAGTGCAGTGGCACAATCTCGGCTCACTGCAAGCTCCGCC
    TCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACT
    ACAGGCGCCCGCCACCACGCCTTTCTAAATTTTGTATTTTTAGTAGAGAC
    GGGATTTCACCATGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGAT
    CCGCCGCCCTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGC
    GCCCAGCCTATCTCAGGATTCTTAATGTAAAAACAGTTCAGTATGGAAAG
    CGTACTTATGACAGAGCTGTTGCAGAATGTGAAATCACCCATGTGCCTAA
    GTGTCTCCCTACTACCTGGAACACTAGACCACATGCAGCAG
    (SEQ ID NO: 246)
    pARBI-642: CAGCCCTGAACTCAGCCTTCACGGCCCTCCCTAAACACATGGGCCAGCCA 2541
    chr11_3_ CAGGGAAGAAAAAAATGCCCTGTAGCACAGGAATCTAAAACATTGCTGTT
    Exogenous_95 GTTCTAGTTAATAAAAGGACTTAGAGATTGAAAAGAAGTACCATCTGTAT
    GGCTGGCAACAGACAGCATGATTTTGATGACTGACTCTGGGGAGATCTGA
    GAAAACAGTACATAATATGTCCTTACCTCTGCTCCATCATTCATGACCCA
    AGCTCCTGCCCTGTCTTCTCAGGAAGATTCTTACAGTAACTCCAGTTTGG
    AATTCCCCTTTCATATTTGAAATAACAACAGTAATAGTGACCACTAATGC
    TTACCGAGTGTCCACTCTGTGCCAAGCATCGTGTTTTTATCATCTTTTTT
    GTTAGGCACTGTACATGGATTAATACAATTACAACCCACCACAACCCCAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGAGATAAGT
    ACTTGTACTATCCTCATTTTATGGGTGATGATACAAGAAACAGAAAGGTT
    CAGCAACATGCCTAAAGCCACACAGCTACTATGAGGCAAAGTCTAGGTTT
    GAACTCAGAAATTCTGACTTCAGACTCACTTATCTTATTATACTTCACTT
    AGTATCTCCCATTAATTAATTCATTCATTCTTCCTTTTATTTGTTAATTC
    ACCAAATATTCTGGGAAGCTACTTGTCTAGACACTGTATGAAAAATGAGA
    ATGGATACAAAGCAACCTCAGACATGAACTCAAGGTCCTTACAAGCTTAA
    ACGTATATGATACATTTCCAAATAGCAATACTATGAGGACAGCTGATACT
    CACAACATAAGTCTTGGTGGTCACAGGAGATCTATCATAGGATTTCACGA
    AGAACCTGACACTGAAAACCAGAACTTGAGGGAAATAAAAC
    (SEQ ID NO: 247)
    pARBI-643: GTGTCCATCCTGCATGTCTCAAGTCACAATCCTCCAGATATTCAACCAAA 2541
    chr15_1_ GTGCTTGATTCTGTTGGCACAAGGACCATGAAATCTTCAGTAGCTAAGGA
    Exogenous_100 GACTCTTTGACAAATAGATTTATTGCATATGATGTAAAAGGGTCTCATTC
    AGAGAACTACACATTTACTACACATTTACTAGCTGTTAGATGTGAGAAAT
    TGAAGCTTTGAGAATTGTCATTTTGTAAGCACGCTGTAATAATTGTGTTC
    TCTACAAAAATGGAGAAATACTTAATCTTTGCAGGTTTTTATTAGCTTCG
    AAAAAGGGAATACAAATATTTTGATACCTGACTTTATTTTAAAGATACTG
    GCAAGCAAGGAAAGATACTCAGTTTGCTAAATTATAGCATAGATTTGAAA
    GACGGAAATTTTTTTTTGTTATTTTGATTCTTTCTGATTCAGAACCTGCG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGAGTTTCC
    ATTCCTGGGATAGAGAGCCCTGCCAAAGCCAACTCAGTCTCCTGTTATTG
    CAGAAATTTAAAGGTTACTTGAGCTGATTGATACCAATTAAAATAAAAGC
    ATCTACTGCCATTTTATTAAACGCCCTATTTAATCTCCACATCCCAAGTT
    CATTCTCTCTCTCTTTTAAGGCTATACATGGGCCTCAACATTCTCTCTTC
    TTCAGTATCAGCTGTCCTCATCCCTATTCAAAGTCAGAATGACTTGGAAT
    CTATTCAGGGCTGCTACTTAATTGGATGAAGAAAGTACTCTGTTGCATGC
    TAACCTCCCAGATTTGAATTAGAACCAAGGTCCTGAATCTACACAAGACC
    TTTTTCCCTTTCCTTTCTGCATTTATTTCTTTTTTTTCTACATCTTTCTT
    TTTGAATTTTTTTTTTTTTTTTTTTCTGAGATAGAGTCTTG
    (SEQ ID NO: 248)
    pARBI-644: ATCATCAAAATCTTCATTTATACAAATCACGGGTATTAGAAATAAAATCA 2541
    chr15_2_ GGTATTGTGTACAGTCAGATCCCAGGTTTACACAAACTAGAGGTTTCAAT
    Exogenous_101 TAAGTTTCCTTCATTTTATAAAACCATGACACAAGCTGTAAATAAAGGAG
    CTCTGGCTTTAGGCCTTCTTCTGTTTATAGACAGTAAATTTTAATCCTCT
    GTCCCTGCAGACCAACTCAAAGCAGTAACCTTGGCTACCGTTGCCGCAGA
    AGAAACACACCCTGCAGATTTCCAGTTCTATATTCAGTCTTAGAAAATTG
    GTCATGTTGAAAGGGAAAAAACAATTTTACTTTGCCTCAGTTATTGACAC
    CAAGAAGCACTCCTCAGCCTGTTCAGAGGGGAAACAATGAGTCATTCATG
    CTGTCAGCCCAGGTGGTGCATGAATTCCAGACAGAGGCCGCTGAATTAAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCCGTGGAGG
    CGTCTCTCTGAGCAGAGCCCGCAATGCGCCTGCTTGGGGCTCCCTGCAGC
    CTCTGGGGGAGGCAGGGCGGCCCAGAGCAGGCCTGTGCTGGAAAGGAACG
    CGAAGCCCTGTAACCAAGCCTGTACCTCTGCAGTGCTAGTCCCAAGGGGC
    CTCCGAGCTGTTTGTCACCATGTGATTGGCTCAGGAGAGGGGTGGAGAAA
    TGAAAACACTCTGCCCAGGATATATTTAGTTGAAGTGCAGCTGGGGAAGT
    GCTTAAACAAGGGAGCTTTTGTCCTTATGTTGAAGTGTTTTTCTTAACTC
    CTCAAGGGTGAAAAACTTGAGCCACGTACTGATCCCATTCCCCCCCACCA
    CCCCCAATATATTTTCTCTTCTTTAGGAAATGCTCTTATTCTGAAACTTT
    AGAATTTTCTAGGGTTTGTTGCATAAGAGGAAACTGAATAA
    (SEQ ID NO: 249)
    pARBI-645: CTTTCCTTTCTGCATTTATTTCTTTTTTTTCTACATCTTTCTTTTTGAAT 2541
    chr15_3_ TTTTTTTTTTTTTTTTTTCTGAGATAGAGTCTTGCTCTGTCGCCAGGCTG
    Exogenous_102 GAGTGCAGTGGTGTGATCTTGGCTCACTGCAGTCTCCAACTCTGGTTCAA
    GCAATTCTCCTGCCTCAGCCTCCGGGTAGCTGGGACTACAGGCATACACC
    ACCATGCCCAGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCAT
    AGTGGCCAGGATGGTCTCCATCTCTTGACCTCGTGACCTGACCCCCTCGG
    CCTCCCAAAGTGCTGAGATTACAGGCATGAGCCACCGCGCCCGGCCTCTT
    TTTGAATTTTTTTAAAAAAACACCTAAAGTTTAGGAAAGTATAAGAGGCC
    AAAGAAACAAGAGTTCAAAGAAACAAGAGTGTTATACACGCACACTTGCA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGAAAGGTAGT
    AAAATATCTGTATAGTTCTGGCTGTCAAGCTTTTGGACTGAGATATGCGT
    AAGCAAGGCAAAAAGATCCCATAGTCCAGGAATATCAACCAGTCCAGTTT
    CCCAAGGAAACTAAAAGTAACTGAAAATGAGAAGGGTGCCATATAGGAAA
    ATTGAAGGTGGGGCATAATTATTAATACACTGCTTTGGAAATGCTGGTAT
    GGAAGATTCATATATGGACTTCAAAGCATACATGTCTTATACTTAGCTAT
    GGGAAAATTATCATCAAAATCTTCATTTATACAAATCACGGGTATTAGAA
    ATAAAATCAGGTATTGTGTACAGTCAGATCCCAGGTTTACACAAACTAGA
    GGTTTCAATTAAGTTTCCTTCATTTTATAAAACCATGACACAAGCTGTAA
    ATAAAGGAGCTCTGGCTTTAGGCCTTCTTCTGTTTATAGA
    (SEQ ID NO: 250)
    pARBI-646: TGTCTTCACGGCACGGCCCCCGCTTCACCAGCTGCACTGTTTGATGAGCT 2541
    chr16_1_ TTGCAGGTCCCAGATCTTATAAGCTCATGGTGATTGATCCAAATGATGCA
    Exogenous_103 GAGGTCGGCCTAAAGTTAGAAGTGGGCCCCTCTCTGCCCCAAGACAGCCC
    TTCACCCCAATTCCATTCCCACAGTTTGGGCATCCACCCAGGCTGCCAAG
    CCAAGCGGGGGCTGCCCGGGTTAGCAGGGACCTGGCCATGGGCCTCCTCA
    GCTAGGGGCCGCCTCTCTGAGGAGTGGGTGCCCCGCCCCTCCGTGGGCCG
    CCTGGTTTCTCTTATTGGCAGCGTCTGTAGTCCCCTGGCTCTGTCACCCG
    CAGCTATTCTAGGCCTCTGGTTCCTTTCACTTTCTGCTCTGCGTCTTCCT
    GCCTCGGTGGTTCCCCACCATCCAGCCTGAGACCTCCCCGTTGCCCGCCC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggggggcaggacagcaagggggaggattgggaagacaatagcag
    gcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGTG
    CCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG
    GGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAA
    CTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGG
    GAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAAC
    GGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCC
    TTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTC
    GCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTC
    TAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCC
    TTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGC
    TTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGA
    TCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccaccA
    TGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTC
    GAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGG
    CGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA
    CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTAC
    GGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT
    CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT
    TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGC
    GACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGA
    CGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACG
    TCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAG
    ATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA
    GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACT
    ACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGAT
    CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCAT
    GGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaat
    aaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcat
    tctagttgtggtttgtccaaactcatcaatgtatcttatTGGGTTTCTGT
    CTGCTCCTCTCCGTGGTGGCCGGCCCTGGCTCTGCCCCAAAGCCATGGAG
    AAGGCCAAATGCAGGCTGTAGAAAGGTCTGGGATCAGATCCCCCCATCCT
    TCCATGGCCACGTGACCGGGCCCGCCTCTTCCCTCTGAGCCTCACATCCT
    CATCTGAAGAGGGAATGCTGCTCATGCCCACCTTGCGGGGATGTGGGGAG
    GGGGTGCTGCCAGTGGAGACTCCCAGGGGACCCTCCAGGAGTCTCATCCT
    GACTCGAGACTGGGCACCTGGTGGGGGCACAGGCCCCCTCTCCCGCCATG
    GGACCGCCACATCCAGGCTCTCGTGGGTTGAGATGCTGAGGAAAGGAAAG
    AACAAAACCTGCTGGAGGAGCAGCGAACACGGCCCTCAGCTGGGTGACCT
    TGGGCAAGTCACTTCCCCTCTCTGGGCCTCAGTTTCCAT
    (SEQ ID
    NO: 251)
    pARBI-647: CTGAAGAGGGAATGCTGCTCATGCCCACCTTGCGGGGATGTGGGGAGGGG 2541
    chr16_2_ GTGCTGCCAGTGGAGACTCCCAGGGGACCCTCCAGGAGTCTCATCCTGAC
    Exogenous_104 TCGAGACTGGGCACCTGGTGGGGGCACAGGCCCCCTCTCCCGCCATGGGA
    CCGCCACATCCAGGCTCTCGTGGGTTGAGATGCTGAGGAAAGGAAAGAAC
    AAAACCTGCTGGAGGAGCAGCGAACACGGCCCTCAGCTGGGTGACCTTGG
    GCAAGTCACTTCCCCTCTCTGGGCCTCAGTTTCCATATCTGTGAATGAGG
    CAGCTGGACTGAAGAATAGAGAGTCACAAAGCAGAGTGACACAAACTGGG
    CTACAGGAAACCCTGGAGGCCCTCGACCCAGGCTGGGGCCGGGGATGGTT
    CTGCAAAGCCTCTTGGGAGAGGGTTGCCTGAGCTGAGTCTCCAAACAGAA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGTGGCCT
    TAAGTCACGGGAGATGAGCCAGAGCAGTCCAGAGGGCACGGTCAGCACAT
    GCTAAGGTCCTGGGGCACAGAGTACAGGGCTTGAGAAGGGTTCCTCTTGC
    TCCATGTGACTTTCATCATCCAACAGCCTGTGGTGGCACTTGCCTGTATC
    CCAGCTATCTAGGAGGCTGAGGTGGGAGGATTGCTTGAGTCTGAGAGGTC
    GGGCTTGTTCTCCCGGTGTTGGCAGAGTCCAGAGGGAGCAAGTGGAAGCC
    ACAGGTGTCTTGAGGCCTAGGCTGAGATCTAGCACATCACCGCGTCACTT
    CATCCCTTCATTTCATCCTATTGGCCAAAGCAGCCCAATTCTAGGGATGG
    GGATCTAGACTCAACTTCTTGATGGGAGAAGTAGCAAAGTCACACTGCCA
    AGGGCAGGGACACAGGGAGGGATGAAGAGTTAGGAATGGTT
    (SEQ ID NO: 252)
    pARBI-648: AAGCCACCTCCCTGCTCTGTTGCTGGCTCTCCTTGAAGACAAGTGTTTTT 2541
    chr16_3_ CAATTAACCAAAGCGGTGCATGGCAATGTGATAGGGGAATGAAACACAGC
    Exogenous_105 AACAGAATCAATGCCCCACGCTGGGCAATAGCCGACTTTCTGTTCGCTCC
    CATCCCTTCCTTCCCTCCCCGCCTCCTTCCCCTGCTCCTTCCATTCCACA
    AACATTTATTGAGCACCCGCTGTGTGCCAGCCACTGTTCTAGGCCCTGAA
    GACACAGAAGTGAACAAAAAAAAAGAGTCCCTGTGCACATCCTGGAGGGA
    CTTTCCCCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTATACAGTGTA
    TGGAGACAGTGGATAATAAAAGCTGTTTATGAGGCACTTTCTCTGAGCTG
    TTCCATGTGCTTCACTTATACTCATTCAGCTAATCCTCAGGACACCCCCG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGAAGTCAG
    TGATATTAGTCACAGAGGCCCAGAGAAGTGAAGTGACTTGCCCAAGGTCA
    CACAGCCAGCAAGAGGCCAAGCCCGGATTGAACCCCAGCCGCCTGGCTCT
    GGAGCCTGCAGCATAACCACAGCAGGGAACTGCCACCGGAGACAGACATC
    GACAGCCACTAGGAGATGTTAACCAACAGGCTTGTCTTCACGGCACGGCC
    CCCGCTTCACCAGCTGCACTGTTTGATGAGCTTTGCAGGTCCCAGATCTT
    ATAAGCTCATGGTGATTGATCCAAATGATGCAGAGGTCGGCCTAAAGTTA
    GAAGTGGGCCCCTCTCTGCCCCAAGACAGCCCTTCACCCCAATTCCATTC
    CCACAGTTTGGGCATCCACCCAGGCTGCCAAGCCAAGCGGGGGCTGCCCG
    GGTTAGCAGGGACCTGGCCATGGGCCTCCTCAGCTAGGGGC
    (SEQ ID NO: 253)
    pARBI-649: GGGGGCGGCCGCACGGCTAGAGCGGAGACCCCGCGCCCCCTCCGCCCGCG 2541
    EDF1_1_ TGGCCCGGCCGGGGTGCGGGGCCCGGGGAGGCACGGGGGCTGCGCGTCGG
    Exogenous_25 GGCGCAGCCGCCGCCCGCGTGTGCTCGGAGGCCGCGGGGCCCGGGCTCCG
    GGGTCCTCCCGACCTGCAGCCCCAGCGGCTACCGCGCCTCGCCAGGCCAG
    GCCAGGCCCCGACGTCGCCTTCCCTACGTCGCCGGCGCCCGGCCACGACG
    TCCCTCAGACGAGCCGAACGCCGAATGGCCCCGAGCACGGGAAGTGCCCG
    CCCCCCGCGTGCAGCCAGCCAATGGGACGCCGAAAGCGGGGAGGTGCCGA
    GGGGACGTAGCGTCGCCGCGCCAGGTCTCTAGCAGCTGCCGCTGAGCCGC
    CGGACGGACGCTCGTCTTCGCCCGCCATGGCCGAGAGCGACTGGGACACG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGTGACGGTG
    CTGCGCAAGAAGGGCCCTACGGCCGCCCAGGCCAAATCCAAGCAGGTGCT
    TTGCTGACTGAGGAGCGGCCGGGCCGGGCGGGGCGGACGCTgggccgggg
    ccacggaccgtggggcagggggctcggggaagggcaggcggggcctggga
    cagggcgcaggggacggggacaaggctggGGTGCCGGGGGCAGGACGGGG
    TTCGAAGGGCGGGGCGAATCGCAGGGGTAGGAGGACCGGGCCAGGACagg
    ggtgggaaggtggggggcggacccaggaggggatggacggacccaggagg
    cagggggCGGGCGACTGGAGGAGGAGAGGAGCAGGGAACCGGACGGGGCA
    AGGGGCAGGCGATAGGGCCGGGACCAGTGCCAGGGTGGGGGGGGGAGGGG
    ATAGGGGCAGGGACTGTTGGTGGGGACAGGTGTGAGGACAG
    (SEQ ID NO: 254)
    pARBI-650: ACGGCTAGAGCGGAGACCCCGCGCCCCCTCCGCCCGCGTGGCCCGGCCGG 2541
    EDF1_2_ GGTGCGGGGCCCGGGGAGGCACGGGGGCTGCGCGTCGGGGCGCAGCCGCC
    Exogenous_26 GCCCGCGTGTGCTCGGAGGCCGCGGGGCCCGGGCTCCGGGGTCCTCCCGA
    CCTGCAGCCCCAGCGGCTACCGCGCCTCGCCAGGCCAGGCCAGGCCCCGA
    CGTCGCCTTCCCTACGTCGCCGGCGCCCGGCCACGACGTCCCTCAGACGA
    GCCGAACGCCGAATGGCCCCGAGCACGGGAAGTGCCCGCCCCCCGCGTGC
    AGCCAGCCAATGGGACGCCGAAAGCGGGGAGGTGCCGAGGGGACGTAGCG
    TCGCCGCGCCAGGTCTCTAGCAGCTGCCGCTGAGCCGCCGGACGGACGCT
    CGTCTTCGCCCGCCATGGCCGAGAGCGACTGGGACACGGTGACGGTGCTG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatCGCAAGAAGG
    GCCCTACGGCCGCCCAGGCCAAATCCAAGCAGGTGCTTTGCTGACTGAGG
    AGCGGCCGGGCCGGGCGGGGCGGACGCTgggccggggccacggaccgtgg
    ggcagggggctcggggaagggcaggcggggcctgggacagggcgcagggg
    acggggacaaggctggGGTGCCGGGGGCAGGACGGGGTTCGAAGGGCGGG
    GCGAATCGCAGGGGTAGGAGGACCGGGCCAGGACaggggtgggaaggtgg
    ggggcggacccaggaggggatggacggacccaggaggcagggggCGGGCG
    ACTGGAGGAGGAGAGGAGCAGGGAACCGGACGGGGCAAGGGGCAGGCGAT
    AGGGCCGGGACCAGTGCCAGGGTGGGGCGGGGAGGGGATAGGGGCAGGGA
    CTGTTGGTGGGGACAGGTGTGAGGACAGAGGCAGGAGGTG
    (SEQ ID NO: 255)
    pARBI-651: CCCTGGAGTCGGTGTGAGGCAAAAGCAGAGGAGAGGATTTGGAATTAACC 2541
    EDF1_3_ TGAAGAAAAACCATTTCAAAGCGGTAACCAGACCCCAGAGGCTGCCTGAA
    Exogenous_27 CTCAAGGGGACATGGGAACCCAGGCTGTCCCAAGTTCACACACCTCAGGT
    CGTGGACTTCCAGAGTTTTCTCTCAGTTATGAGGACAGGCAGCTGTACTC
    ATGCCAACCAGAGCTGCTCTGGGAAGATGGCTGCCTCCCAGGGCTCCGGC
    CAGCACCGGTGCAGGCAGGCACTCAGCTGACAACGTCCCCGGGGGCGCCG
    CACACACCACACCCACCAGCACATGGACCCCACAGCACAGCCTCATGTTG
    CAAGCGGAAACACAAGTACCTACATTTCTTGGAAGTCTCCACATCTTCTC
    CTCGTCTCTGTGCCGCTAAGATAGCCTAGAAAATTAGAAAACATCAGTGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTTCTAAAG
    AGAAGATGTGCTTTATACACATCAGCTCCACTAGGACTGCTGCAAAACCA
    GGCGCGAAGCGTCGCCTGAGAACAGCAGCTTCTAGGGCCCCTGGGGTACG
    CACCCACACGCAGCTGGGTTTTGTGCGAGAGGCAGTGAGAGCCGGGCTGA
    CCTGGCTTCCCGAGGCATTCCCTGCAGGGGAACCAGGGGGGTGGAGCCCA
    CCCTCCCCGTGCTATCTGAACACCGGCCATCCCCCTCCCCAAACCCACAA
    CCCCAGGAGTGAGAGCCCCGGCGCAGCCTCACCGTGGCCAGGTCCTTCTG
    CGTAAGCCCCTTGCTCTGCCGACCTTGCTGGATCACCTTGCCCACCTCCA
    GGGTCACCCTGTCATGGTGCAGCTCCTCTGTCTCCCGGTCCAGCTTGGCC
    GTGTTCTTGGTAATAGAATGTTGTTTGTTCTGGCCAGCAGC
    (SEQ ID NO: 256)
    pARBI-652: CTCTTGCTTCAACAGTGTTTGGACGGAACAGATCCGGGGACTCTCTTCCA 2541
    FTL_1_ GCCTCCGACCGCCCTCCGATTTCCTCTCCGCTTGCAACCTCCGGGACCAT
    Exogenous_2830 CTTCTCGGCCATCTCCTGCTTCTGGGACCTGCCAGCACCGTTTTTGTGGT
    TAGCTCCTTCTTGCCAACCAACCATGAGCTCCCAGATTCGTCAGAATTAT
    TCCACCGACGTGGAGGCAGCCGTCAACAGCCTGGTCAATTTGTACCTGCA
    GGCCTCCTACACCTACCTCTCTCTGGTGAGTCCCCAGGACGCCCCTGGCC
    CTAATTTCCTCCAGCTGCGCACCTCCGGCCCTCACTGCACGCGCCAGCCT
    TCTTTGTGCGGTCGGGTAAACAGAGGGCGGAGTCCCCTTGGCCTCGCCTC
    CCGCTAACCATTGTTGCCTCCATCTCTTCCCGTAGGGCTTCTATTTCGAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatCGCGATGATG
    TGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAG
    CGCGAGGGCTACGAGCGTCTCCTGAAGATGCAAAACCAGCGTGGCGGCCG
    CGCTCTCTTCCAGGACATCAAGGTAACTAGTGTGTGGGTAATGGACTACA
    TCTCCCAGCAGGCCGTGCGCGCGAGGAGCCTTGATTTGAGGGCGTAGGTG
    TCGCGTGGGCTTCTGGGAGATTGAGTTCGGTCTTGTGAGCCCTCTTAACC
    GCTGGAAATAGAGGCGCACCTCGTGCAGTGCCCACAACACGCGGCAGTCC
    ACACCGCTGCGTGGTCTTAGGGACGTATAGCTGTAAGAGCTAGGACAGGG
    TGCGGAGAGTGATAAATACAAGCTGTCACATGTCTTTGTGGCCTGGGCCT
    CTGACCCCCAACGACTCTTGGGAAATGTAGGTTTAGTTCT
    (SEQ ID NO: 257)
    pARBI-653: TGGGGCGGGGGGCTGAGACTCCTATGTGCTCCGGATTGGTCAGGCACGGC 2541
    FTL_2_ CTTCGGCCCCGCCTCCTGCCACCGCAGATTGGCCGCTAGCCCTCCCCGAG
    Exogenous_29 CGCCCTGCCTCCGAGGGCCGGCGCACCATAAAAGAAGCCGCCCTAGCCAC
    GTCCCCTCGCAGTTCGGCGGTCCCGCGGGTCTGTCTCTTGCTTCAACAGT
    GTTTGGACGGAACAGATCCGGGGACTCTCTTCCAGCCTCCGACCGCCCTC
    CGATTTCCTCTCCGCTTGCAACCTCCGGGACCATCTTCTCGGCCATCTCC
    TGCTTCTGGGACCTGCCAGCACCGTTTTTGTGGTTAGCTCCTTCTTGCCA
    ACCAACCATGAGCTCCCAGATTCGTCAGAATTATTCCACCGACGTGGAGG
    CAGCCGTCAACAGCCTGGTCAATTTGTACCTGCAGGCCTCCTACACCTAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCTCTCTCTG
    GTGAGTCCCCAGGACGCCCCTGGCCCTAATTTCCTCCAGCTGCGCACCTC
    CGGCCCTCACTGCACGCGCCAGCCTTCTTTGTGCGGTCGGGTAAACAGAG
    GGCGGAGTCCCCTTGGCCTCGCCTCCCGCTAACCATTGTTGCCTCCATCT
    CTTCCCGTAGGGCTTCTATTTCGACCGCGATGATGTGGCTCTGGAAGGCG
    TGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAGCGCGAGGGCTACGAG
    CGTCTCCTGAAGATGCAAAACCAGCGTGGCGGCCGCGCTCTCTTCCAGGA
    CATCAAGGTAACTAGTGTGTGGGTAATGGACTACATCTCCCAGCAGGCCG
    TGCGCGCGAGGAGCCTTGATTTGAGGGCGTAGGTGTCGCGTGGGCTTCTG
    GGAGATTGAGTTCGGTCTTGTGAGCCCTCTTAACCGCTGGA
    (SEQ ID NO: 258)
    pARBI-654: CTTTGCATAGTTTATCCTATTAGTAATCTATTCTGTCTTTGGAATATGTT 2541
    PTEN_1_ TTGTGATGATGAAATAAATACTATAAATAGTATTATTCCTTTTGCATTGA
    Exogenous_31 GAGTCCTGACGAAATGTCCATGTGACAGTTCATTTTGGGTTTAGCTCTAC
    CTCTAATATGTGACCTATGCTACCAGTCCGTATAGCGTAAATTCCCAGAA
    TATATCCTCCTGAATAAAATGGGGGAAAATAATACCTGGCTTCCTTAATG
    ATTATATTTAAGACTTATCAAGAGACTATTTTCTATTTAACAATTAGAAA
    GTTAAGCAATACATTATTTTTCTCTGGAATCCAGTGTTTCTTTTAAATAC
    CTGTTAAGTTTGTATGCAACATTTCTAAAGTTACCTACTTGTTAATTAAA
    AATTCAAGAGTTTTTTTTTCTTATTCTGAGGTTATCTTTTTACCACAGTT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCG
    CACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGA
    AGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGAC
    TTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAA
    CAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGG
    TGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC
    GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCC
    CGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACG
    AGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATC
    ACTCTCGGCATGGACGAGCTGTACAAatgattgtttattgcagcttataa
    tggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttt
    tttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttat
    GCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACTTATCAA
    ACCCTTTTGTGAAGATCTTGACCAATGGCTAAGTGAAGATGACAATCATG
    TTGCAGCAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAATGATA
    TGTGCATATTTATTACATCGGGGCAAATTTTTAAAGGCACAAGAGGCCCT
    AGATTTCTATGGGGAAGTAAGGACCAGAGACAAAAAGGTAAGTTATTTTT
    TGATGTTTTTCCTTTCCTCTTCCTGGATCTGAGAATTTATTGGAAAACAG
    ATTTTGGGTTTCTTTTTTTCCTTCAGTTTTATTGAGGTGTAATTGACAAG
    TAAAAATTATATATAAATACAATGTATAATATGATGTTTTGATGTATGTG
    TATATACATTGTGAAATGATTACTACAGTCAAACTACTTAACATATTCAT
    (SEQ ID NO: 259)
    pARBI-655: GCTACCAGTCCGTATAGCGTAAATTCCCAGAATATATCCTCCTGAATAAA 2541
    PTEN_2_ ATGGGGGAAAATAATACCTGGCTTCCTTAATGATTATATTTAAGACTTAT
    Exogenous_32 CAAGAGACTATTTTCTATTTAACAATTAGAAAGTTAAGCAATACATTATT
    TTTCTCTGGAATCCAGTGTTTCTTTTAAATACCTGTTAAGTTTGTATGCA
    ACATTTCTAAAGTTACCTACTTGTTAATTAAAAATTCAAGAGTTTTTTTT
    TCTTATTCTGAGGTTATCTTTTTACCACAGTTGCACAATATCCTTTTGAA
    GACCATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCT
    TGACCAATGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTA
    AAGCTGGAAAGGGACGAACTGGTGTAATGATATGTGCATATTTATTACAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatCGGGGCAAAT
    TTTTAAAGGCACAAGAGGCCCTAGATTTCTATGGGGAAGTAAGGACCAGA
    GACAAAAAGGTAAGTTATTTTTTGATGTTTTTCCTTTCCTCTTCCTGGAT
    CTGAGAATTTATTGGAAAACAGATTTTGGGTTTCTTTTTTTCCTTCAGTT
    TTATTGAGGTGTAATTGACAAGTAAAAATTATATATAAATACAATGTATA
    ATATGATGTTTTGATGTATGTGTATATACATTGTGAAATGATTACTACAG
    TCAAACTACTTAACATATTCATCACCTCACATAATTATTATTCTCCCCCC
    AGGGTGAAAGCATTTAAGATCTACAAGCTACAATTTTCAATTATACAATG
    TTATTATTAACTATAGTCACTATGCTGTCCAGTAGAGCTTCAGATCTTGT
    TCATCTTGTGTTCCTCCCTCCCCACCCTCAGTCCCTGGAA
    (SEQ ID NO: 260)
    pARBI-656: ATAAATAGTATTATTCCTTTTGCATTGAGAGTCCTGACGAAATGTCCATG 2541
    PTEN_3_ TGACAGTTCATTTTGGGTTTAGCTCTACCTCTAATATGTGACCTATGCTA
    Exogenous_33 CCAGTCCGTATAGCGTAAATTCCCAGAATATATCCTCCTGAATAAAATGG
    GGGAAAATAATACCTGGCTTCCTTAATGATTATATTTAAGACTTATCAAG
    AGACTATTTTCTATTTAACAATTAGAAAGTTAAGCAATACATTATTTTTC
    TCTGGAATCCAGTGTTTCTTTTAAATACCTGTTAAGTTTGTATGCAACAT
    TTCTAAAGTTACCTACTTGTTAATTAAAAATTCAAGAGTTTTTTTTTCTT
    ATTCTGAGGTTATCTTTTTACCACAGTTGCACAATATCCTTTTGAAGACC
    ATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCTTGAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAATGGCTA
    AGTGAAGATGACAATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGG
    ACGAACTGGTGTAATGATATGTGCATATTTATTACATCGGGGCAAATTTT
    TAAAGGCACAAGAGGCCCTAGATTTCTATGGGGAAGTAAGGACCAGAGAC
    AAAAAGGTAAGTTATTTTTTGATGTTTTTCCTTTCCTCTTCCTGGATCTG
    AGAATTTATTGGAAAACAGATTTTGGGTTTCTTTTTTTCCTTCAGTTTTA
    TTGAGGTGTAATTGACAAGTAAAAATTATATATAAATACAATGTATAATA
    TGATGTTTTGATGTATGTGTATATACATTGTGAAATGATTACTACAGTCA
    AACTACTTAACATATTCATCACCTCACATAATTATTATTCTCCCCCCAGG
    GTGAAAGCATTTAAGATCTACAAGCTACAATTTTCAATTAT
    (SEQ ID NO: 261)
    pARBI-657: TAGTGACGGTATCAAGAGCAGCATCCCAGGTTGACTTTCTTTGGGGCAGG 2541
    PTPN2_1_ ACCTTGCTTGTGTCTTAACCCTTGGTTCCTACccaagtttgtctctctag
    Exogenous_34 tcctcaactctgaaagccacttgatatcttacacaattccttttttgcct
    gagaaaaaaaagtcagttttgatcatttacaaccaaaaatcctaactaac
    acaGACCTGTTTTTGAAATCAGGTAGATTGGAAGTCTTGGTTTACTTCTT
    ATAAGCCCGTCCGCTGTCTGTCTTGTAACATCCCAGGAGCAGACTTAACA
    AGGCCTTCCTGGAGCCTTGCTCTTTCTGTCTGCTTCCCTCATCTGctctc
    tctcctctctctTCACAGGGTCCACTTCCTAACACATGCTGCCATTTCTG
    GCTTATGGTTTGGCAGCAGAAGACCAAAGCAGTTGTCATGCTGAACCGCt
    gacgactgtgccttctagttgccagccatctgttgtttgcccctcccccg
    tgccttccttgaccctggaaggtgccactcccactgtcctttcctaataa
    aatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggg
    gggtggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatATTGTGGAGA
    AAGAATCGGTGAGTAATATTTAATATTTACAACTTAGTATACTGTATGTG
    ATCATTAGCATATAAAGATTTTCATTTTGGGGCCAATATTCATTCCTTAG
    TTTTGGCCTTTAATTGCTAAAGGCTAGCGGTCAAAGTGTTTCTGTCCGGA
    AAAACTCATGTATCCTTTTCCTTTCTTAAGTATTTTTATAACAATTGCAG
    ACCTTTCATCTCCAAGATAGAAATACAATGGAATAAATATGGACTAGCAG
    TGACATATAGATCTTTGGAATCCCTAGGAATCCTTATTGACCTATTGTCA
    ATAAGTCCTCTTCCAGCTTTAAGATCTTGTACTGTTCTACTTCAGATTTC
    TTACTTTATTCTACATTTCATAATTGCTGGTTTTTAATGATGATGAAAAT
    TTCCTAATCCACTTCTAATTAGATGTGGCAATGACATGCC
    (SEQ ID NO: 262)
    pARBI-658: CAGAATTTGAATATGATGTGGCTGACCATAGATACCTCCATTGCATTAAT 2541
    PTPN2_2_ TCTGCTTCATAAAGTGTTTGATGCTTGCTTGTAGGTGTTGAATAGAGCCT
    Exogenous_35 AATTAGCAGTAAGTAAACAGATCTagagcacagactttggcatctgaagg
    accttggttcaatgctgggactgccacttactagctatgggatctttggt
    ggatttttaacctttgaaagcctttcatccctcacagatataatggggaa
    gaaaatcgtttccattagtattgtgaggattaaatgattaattgatgtaa
    acaatgtgctttccatagtacttggcatatcataagtgcttcatGTTATT
    TTACGCTGGCTGGGAAGATAAGTTTTGCTGTGGAGAATTTAAGAGGGATA
    TTAAAATATATTTTTGTTATTTTAAGGAAATTCGAAATGAGTCCCATGAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTATCCTCATA
    GAGTGGCCAAGTTTCCAGAAAACAGAAATCGAAACAGATACAGAGATGTA
    AGCCCATGTAAGTACTTGTGGGTTTGTGTGCATGTGTATTTTTTGGTTTG
    TTTTAGGAGGCAGGATGTAGTGAAAAGGAGGGCTTGGGGTCAGTGTTGAT
    AAATACAGTAATTTTTTTCCTATTTACGTAAGACACGTTCTTTAAGAATT
    TAAAGGTGTAGAATAGTGGAAGGAAAAATAATTACCCATAATTATTTCAT
    CCTTCAAACATAGGCACCATTATTTTGGTGTATTTCCCACAACCTGTTTT
    TCTTATGCACAGTTTTCCTTTCTTTAAAATAATTGTAATTATAGATGTCT
    ATATAATATCCATATGTATTTCCTTTTCATATCATTCCATCCCCTTTGTA
    AGTTTTGCTTAAAATAGTTATTGGTGTAGTTTGGTTTTTT
    (SEQ ID NO: 263)
    pARBI-659: ACCAGTTATCGTTTTGTAGGTAGACCAATCAATTCTTAGGTACCAAGAAT 2541
    PTPN2_3_ CTGAATGATCCTTTTACTTTTAGGAAGGTAAGTACTTTATTCATTTAACT
    Exogenous_36 ATGTTTACTCCTGGTCGATTTTTCAAGTCACAATGGCTAATGTGCTACAA
    ACAGAAGTGCTTCCTTTCCAGCACTATAGTAATAAACAAGATTGCATTTT
    ATACTCCTTACAAAAAAAGTAGAGAATAGTTTAGGATTTGTCTCAACTCT
    ATTATGATGCTAATTCATTTTTCTTATTTCTTCTGTCTTTTTATAAATAC
    CTAGAATATTAATATGAAGATAAAAACAGTAATTTTGAAATGACAGTTGT
    GGTTTATCATTCTCTATTTTCAGATGATCACAGTCGTGTTAAACTGCAAA
    ATGCTGAGAATGATTATATTAATGCCAGTTTAGTTGACATAGAAGAGGCA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatCAAAGGAGTT
    ACATCTTAACACAGGCAAGTAATACGATACCACGCAAATGTCTGAAAATG
    ATGTGTTTGTGCTTGTTCTGCTTTAAATCATAGGTAAAAGTATATCTTGA
    CTTCTTTTGGAAATGAAATGGTATTTCAGTTTTTTTCTGACGATGTAATG
    AATTATGGACATTATAAGGTTTTGAAGCTTTGAGTATTTAAGATAAAAGG
    CAAGTTATTTTTGATATTACACGTTCTGTGAAGGAAAATTCTTAGGAAAT
    GGCTTAGGCCAGTTCTTTGGCAGATTGTGTTCCTTACATTATATCTGACA
    CAGAGTGCTGCTTATGCTTCTTAGTGTCTTCTTTTCTCTTCCCATACCCT
    GTGGCAAAACCAGAGGCCCTGGACAGCTCTTCTGTAGCTCCCCCTGCCTC
    GCATATATCTTCAGAGAGTACACCAAGCCCTGGATGGTGT
    (SEQ ID NO: 264)
    pARBI-660: CCTGCTCAAGGGCCGAGGTGTCCACGGTAGCTTCCTGGCTCGGCCCAGTC 2541
    PTPN6_1_ GCAAGAACCAGGGTGACTTCTCGCTCTCCGTCAGGTAGGTGGGCCCCCCG
    Exogenous_37 CAACCCCGGGCATTTTGGCCACTCTCTTGTGCCATCCAGGCCCTGAACCA
    CTCATTCCTGGTTCCCCGTGGCAGTGCTGACTCCCCGTCTGTTCCCTTGC
    CCCCAACCCCCACACTCCCCATCCCTGTCTGTGCCCACCCATGCCCATGT
    GTGCCCCCACCCAGGACCTCAGCCGATCCCTGCCCTCCTGCCTCTACTCC
    TGCACCGACTGGCCTCACCGCCTGGTGCCCTGCAGGGTGGGGGATCAGGT
    GACCCATATTCGGATCCAGAACTCAGGGGATTTCTATGACCTGTATGGAG
    GGGAGAAGTTTGCGACTCTGACAGAGCTGGTGGAGTACTACACTCAGCAG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGGGTGTC
    CTGCAGGACCGCGACGGCACCATCATCCACCTCAAGTACCCGCTGAACTG
    CTCCGATCCCACTAGTGAGAGGTGAGGGCTCCGCACCCCCGCCATTCCCA
    AGCAGGGATGAGCCGGCTCCCACCCTGAACAGCCAGGGAGGCAGGGAGAC
    TGGCAGCCGGCGCTGCCTACCCTCCATCCCCTCCCCTCCCTGCACCAGCT
    GGGGCTCTCAATGTCCCTCCTCCCTGCTGTCCTGGGACCTGGTGTCTCAG
    AGCCTAACCTACCACCCTTTCCACCTAACCCCGAGGAAGCCACAGAAAGC
    TGCCTCGCCCTACTCCGGGAGCCCTGGCCGCTGCAACCCAGGTCCCACTG
    GAGACAGGGAGGCCACTGCTGGTGGCCAGCATGTCGTGCAGGCCAGCTCT
    GTTGTTAGAAAGCTCTTCTTCCTCTGGAATCGAGCCTGCCT
    (SEQ ID NO: 265)
    pARBI-661: CTGGGTTCGAAGCCCGGTTAGAACTCTGGAGGCTAGGATGGCTTGAACCT 2541
    PTPN6_2_ GGGAGGTCGAGGCTGCAGAGAGCTGTAACCGCGCCACTGCACTCCAGCCT
    Exogenous_38 GGGCAACAGAGCTCTGGAAGCTTGCCCTAGAGTCAGTCAAGGGCCCTAGG
    CCAGTGAGTAACAGCTCAGCGTCAGTTTCCTCATCTATAAAATGGGGGTA
    ATATCATACCTAGCTCTCAGCATGTTTGTGAGAGACCTAAATGAGGTGGT
    GGATTTGGAAGCATGTAGCGCAGTGCCTGGCACACAGTAGGTGCTTGATT
    TCCGGCCCCTCTCTGTGAATGTCTCTGCTCAGCGCCTTCCCCTGTGGCCT
    GGGTCTTACCTTCCCTGACGCTGCCTTCTCTAGGTGGTACCATGGCCACA
    TGTCTGGCGGGCAGGCAGAGACGCTGCTGCAGGCCAAGGGCGAGCCCTGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACGTTTCTT
    GTGCGTGAGAGCCTCAGCCAGCCTGGAGACTTCGTGCTTTCTGTGCTCAG
    TGACCAGCCCAAGGCTGGCCCAGGCTCCCCGCTCAGGGTCACCCACATCA
    AGGTCATGTGCGAGGTAAGGCAGCCAGGCGGCGGGGGAGCCTCTGCTGAG
    GCTCCTGTCTGTGACCACAGTGTGGGTGGCAGGGAGGGTCTGCCTGGGCT
    TGAATTCAAGGCTGGGGACCCAGGGAGGGAGACTCAAGTCCTGTGAATGG
    CCTAATTTGGCTCCCCCCAGGGTGGACGCTACACAGTGGGTGGTTTGGAG
    ACCTTCGACAGCCTCACGGACCTGGTGGAGCATTTCAAGAAGACGGGGAT
    TGAGGAGGCCTCAGGCGCCTTTGTCTACCTGCGGCAGGTCAGGGGTGGGC
    CCAGCTGCCTCCCCACTTCCCCTGAGCTGTCCCCCAGATGT
    (SEQ ID NO: 266)
    pARBI-662: TGTCACATATGTGCAATGCCATGCTCCTGAGCCTTTGATTGCAGACGTGT 2541
    PTPN6_3_ GGGAAGTGGGCCCCGTCCCCACCCCCAGTGCCACCCTGCTCTGCTTCTCT
    Exogenous_39 TCCCTTGCTGTGCTCTAAAACGAGAAGTACAAGTGAGTTCCCCCAAGGGG
    TCGGCCGCGCCTCTTCCTGTCCCCGCCCTGCCGGCTGCCCCAGGCCAGTG
    GAGTGGCAGCCCCAGAACTGGGACCACCGGGGGTGGTGAGGCGGCCCGGC
    ACTGGGAGCTGCATCTGAGGCTTAGTCCCTGAGCTCTCTGCCTGCCCAGA
    CTAGCTGCACCTCCTCATTCCCTGCGCCCCCTTCCTCTCCGGAAGCCCCC
    AGGATGGTGAGGTAAGGGCCTGCCACCCACGGTAGACAGGAGGCAAGGGT
    GCCTGGTGCCCACGGGACCCCTCCTCACTGCCCTGCCTGGGCCGCCCAGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGGTTTCAC
    CGAGACCTCAGTGGGCTGGATGCAGAGACCCTGCTCAAGGGCCGAGGTGT
    CCACGGTAGCTTCCTGGCTCGGCCCAGTCGCAAGAACCAGGGTGACTTCT
    CGCTCTCCGTCAGGTAGGTGGGCCCCCCGCAACCCCGGGCATTTTGGCCA
    CTCTCTTGTGCCATCCAGGCCCTGAACCACTCATTCCTGGTTCCCCGTGG
    CAGTGCTGACTCCCCGTCTGTTCCCTTGCCCCCAACCCCCACACTCCCCA
    TCCCTGTCTGTGCCCACCCATGCCCATGTGTGCCCCCACCCAGGACCTCA
    GCCGATCCCTGCCCTCCTGCCTCTACTCCTGCACCGACTGGCCTCACCGC
    CTGGTGCCCTGCAGGGTGGGGGATCAGGTGACCCATATTCGGATCCAGAA
    CTCAGGGGATTTCTATGACCTGTATGGAGGGGAGAAGTTTG
    (SEQ ID NO: 267)
    pARBI-663: TCTTTAGCTAATGTTCTGTAGCTTGTTTTAGATCTGTGTCTACATATTAT 2541
    PTPRC_1_ ATGTATCTCTGTATGCATCAATATTTGTATATATGCATGCATATATGTGT
    Exogenous_40 ATGTATATTTATGAATACATATACACACCATATACATACACTTATGTATG
    GTGTGTGCATATGTATGTGTAGATATATGTACATACACACTATAGTGGAC
    TGGGGAGTTAGTATACTGGGAGGAGCATACATTTAGGGTATGATTCACAT
    ATTTATTTTGTCCTTCTCCCATTTTCCATTAATTAACAGGATTGACTACA
    GCAAAGATGCCCAGTGTTCCACTTTCAAGTGACCCCTTACCTACTCACAC
    CACTGCATTCTCACCCGCAAGCACCTTTGAAAGAGAAAATGACTTCTCAG
    AGACCACAACTTCTCTTAGTCCAGACAATACTTCCACCCAAGTATCCCCG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGACTCTTTG
    GATAATGCTAGTGCTTTTAATACCACAGGTTGGCACACAAAAGTTGTTAA
    CTTAAATATCAGGGAATGTCATTTAGAAAATTCTACAGTTATCAGTACAA
    CTTGTCTTTAAATTATTTGCACAGTTTCTAAGTATGTGATTTTATTCAAG
    TGCAGAAATTGCAGGAAATTAGTATCTGTGAAATATAGATCGACTGAAGT
    AATTAATGCATGTTGTTAGGGAGTGGAGAGAGAAAAGAAGGGAAGCAAGA
    TCTCCAAGGACAATCAGGAGGGGAAATTTGTTCTAGTATCCTCTGATCTA
    TACACACTCGCCATGATTCTCCCGCTTGGCTTCCCGCCACCTGGACAGAT
    GAGAATTTCCCTAGTTCAGAGATTATCAGTTCTACTCTCCTTGGAAGGTG
    TCTTAAATGGGAGTCTTCCCATTTCTTTGTTTCACTCTAGA
    (SEQ ID NO: 268)
    pARBI-664: AGGGAATTTTTATATGTTGGTCATATTATATCCCTAGCATGTGGCATAAT 2541
    PTPRC_2_ GTCTAGCACAAAATAGGTGCTCAATTAATCATCATTATCTAAATAAATAA
    Exogenous_41 TGCATTTGGGAAAAAAAAGTTTCAAAAGTTTTTCAAAAGTCTTTTGCAGG
    CTTGAAATTAATCCCAATAGTGATCCTTTAGTCTGTTATGTTTCTGATTT
    AGCCTGGGGATTCAAAAAATAAATAACATAATTTTGATATATTTGGGCTT
    TGTAAACATGGTACTAAGAGAGGAAATATAGTTTCATTAGGGTAAAAGCT
    ACTGAAAATTGCCACTTGGTGAATGTTCTATCATAGACTTGAGGTACATA
    TAAAAATCTAATATATGTTTACATTAATATGAATGAAATTTGAAATTTTC
    TAAGAGATTTTTGTTTCTTCTTTGCAGGGCAAAGCCCAACACCTTCCCCC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACTGGTAAG
    AATTAATATTTATATTTTTACTAATTTTATTTTCTTGTTGCAAAGTTTAT
    ATATTTAACTACAATTTTCTATTATTAACACTGAAATTATTTTTAAGGAT
    AAATTTTATAATCATGAGTGATTCTTGACATTCACTTGTTCTTAAACTTT
    CTGCTTATACGTTATAGAGTTTAATAACTACCTAAACATGTTATTAAATT
    TGTATATATATTTTGTGTATAAATAGTAACTTTTCCCAAACTTGACAGTA
    AATCACACAACAGGTTTCTACTCTCTTTTAATATTTTAAGACTATAAAAA
    AATGCATTTAAATTAGATAACAAAATTTTATAGTCTGAAAGCAGGTTAAC
    AGCTGTCTATGTATGTTATAGATATGTAGATAACAGATTTGCATATGTCT
    ATATTTCTTTAAGAGTATGTTGCTTTTTTCAATGGTATGCA
    (SEQ ID NO: 269)
    pARBI-665: CCTTTAGCACCATAAAGAAACTAAATTATTTAGATGTTTTTATGAGAACA 2541
    PTPRC_3_ TATCAAAAAGTACTTTTCTGTCATCCAATACTTCCACAAATAAATCATTA
    Exogenous_42 GTTCTTGCTAATCTTCATCTGGCATAAAAATAATGACATCAACTTTCTTC
    ATGTAATTTCCCACTTAATTCCTTTACTAGGAGCAATATCAATTCCTATA
    TGACGTCATTGCCAGCACCTACCCTGCTCAGAATGGACAAGTAAAGAAAA
    ACAACCATCAAGAAGATAAAATTGAATTTGATAATGAAGTGGACAAAGTA
    AAGCAGGATGCTAATTGTGTTAATCCACTTGGTGCCCCAGAAAAGCTCCC
    TGAAGCAAAGGAACAGGCTGAAGGTTCTGAACCCACGAGTGGCACTGAGG
    GGCCAGAACATTCTGTCAATGGTCCTGCAAGTCCAGCTTTAAATCAAGGT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTCATAGGAA
    AAGACATAAATGAGGAAACTCCAAACCTCCTGTTAGCTGTTATTTCTATT
    TTTGTAGAAGTAGGAAGTGAAAATAGGTATACAGTGGATTAATTAAATGC
    AGCGAACCAATATTTGTAGAAGGGTTATATTTTACTACTGTGGAAAAATA
    TTTAAGATAGTTTTGCCAGAACAGTTTGTACAGACGTATGCTTATTTTAA
    AATTTTATCTCTTATTCAGTAAAAAACAACTTCTTTGTAATCGTTATGTG
    TGTATATGTATGTGTGTATGGGTGTGTGTTTGTGTGAGAGACAGAGAAAG
    AGAGAGAATTCTTTCAAGTGAATCTAAAAGCTTTTGCTTTTCCTTTGTTT
    TTATGAAGAAAAAATACATTTTATATTAGAAGTGTTAACTTAGCTTGAAG
    GATCTGTTTTTAAAAATCATAAACTGTGTGCAGACTCAATA
    (SEQ ID NO: 270)
    pARBI-666: aaggaaaaaggcactgagtgctggggggtgctggggtgggctgcagtgat
    PTPRCAP_1_ agacatcagggtagaggttaaggtcaggttcagcctcactggggtgaagt
    Exogenous_43 ttgagcacggtgagcaggccatgcagcccgggggaggggaggatgggagg
    aggtggagctttccgggcagagggaacagccagtgcgaaggccccaggca
    ggtggcttaatgcagctgttgggggaggtgagtggtagggaggaggctgg
    agggatgggggctgatctcacagggccagagcctggttgaccaaataagg
    ccttggccttttctGCTTGGCTGTCCCAAGAGGATCCCAAAGAGAAAAAA
    ACGAAAGTGGTCTTGGTCACCCAGCCTGCCCCACACCAGGCCCCACCCCA
    GGTGCTGAGCCCTCTGAGCCCCTGCCTGTCTCCCACAGGCTCTGCCCTGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatACCTTAGGGC
    TCGGGATGCTGCTGGCCCTGCCAGGGGCCTTGGGCTCGGGTGGCAGCGCG
    GAGGACAGCGTGGGCTCCAGCTCTGTCACCGTTGTCctgctgctgctgct
    gctcctactgctgGCCACTGGCCTAGCACTGGCCTGGCGCCGCCTCAGCC
    GTGACTCAGGGGGCTACTACCACCCGGCCCGCCTAGGTGCCGCGCTGTGG
    GGCCGCACGCGGCGCCTGCTCTGGGCCAGCCCCCCAGGTCGCTGGCTGCA
    GGCCCGAGCTGAGCTGGGGTCCACAGACAATGACCTTGAGCGACAGGAGG
    ATGAGCAGGACACAGACTATGACCACGTCGCGGATGGTGGCCTGCAGGCT
    GACCCTGGGGAAGGCGAGCAGCAATGTGGAGAGGCGTCCAGCCCAGAGCA
    GGTCCCCGTGCGGGCTGAGGAAGCCAGAGACAGTGACACG 2541
    (SEQ ID NO: 271)
    pARBI-667: aaggtcaggttcagcctcactggggtgaagtttgagcacggtgagcaggc 2541
    PTPRCAP_2_ catgcagcccgggggaggggaggatgggaggaggtggagctttccgggca
    Exogenous_44 gagggaacagccagtgcgaaggccccaggcaggtggcttaatgcagctgt
    tgggggaggtgagtggtagggaggaggctggagggatgggggctgatctc
    acagggccagagcctggttgaccaaataaggccttggccttttctGCTTG
    GCTGTCCCAAGAGGATCCCAAAGAGAAAAAAACGAAAGTGGTCTTGGTCA
    CCCAGCCTGCCCCACACCAGGCCCCACCCCAGGTGCTGAGCCCTCTGAGC
    CCCTGCCTGTCTCCCACAGGCTCTGCCCTGCACCTTAGGGCTCGGGATGC
    TGCTGGCCCTGCCAGGGGCCTTGGGCTCGGGTGGCAGCGCGGAGGACAGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGTGGGCTCC
    AGCTCTGTCACCGTTGTCctgctgctgctgctgctcctactgctgGCCAC
    TGGCCTAGCACTGGCCTGGCGCCGCCTCAGCCGTGACTCAGGGGGCTACT
    ACCACCCGGCCCGCCTAGGTGCCGCGCTGTGGGGCCGCACGCGGCGCCTG
    CTCTGGGCCAGCCCCCCAGGTCGCTGGCTGCAGGCCCGAGCTGAGCTGGG
    GTCCACAGACAATGACCTTGAGCGACAGGAGGATGAGCAGGACACAGACT
    ATGACCACGTCGCGGATGGTGGCCTGCAGGCTGACCCTGGGGAAGGCGAG
    CAGCAATGTGGAGAGGCGTCCAGCCCAGAGCAGGTCCCCGTGCGGGCTGA
    GGAAGCCAGAGACAGTGACACGGAGGGCGACCTGGTCCTCGGCTCCCCAG
    GACCAGCGAGCGCAGGGGGCAGTGCTGAGGCCCTGCTGAGT
    (SEQ ID NO: 272)
    pARBI-668: cagtgcgaaggccccaggcaggtggcttaatgcagctgttgggggaggtg 2541
    PTPRCAP_3_ agtggtagggaggaggctggagggatgggggctgatctcacagggccaga
    Exogenous_45 gcctggttgaccaaataaggccttggccttttctGCTTGGCTGTCCCAAG
    AGGATCCCAAAGAGAAAAAAACGAAAGTGGTCTTGGTCACCCAGCCTGCC
    CCACACCAGGCCCCACCCCAGGTGCTGAGCCCTCTGAGCCCCTGCCTGTC
    TCCCACAGGCTCTGCCCTGCACCTTAGGGCTCGGGATGCTGCTGGCCCTG
    CCAGGGGCCTTGGGCTCGGGTGGCAGCGCGGAGGACAGCGTGGGCTCCAG
    CTCTGTCACCGTTGTCctgctgctgctgctgctcctactgctgGCCACTG
    GCCTAGCACTGGCCTGGCGCCGCCTCAGCCGTGACTCAGGGGGCTACTAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCACCCGGCC
    CGCCTAGGTGCCGCGCTGTGGGGCCGCACGCGGCGCCTGCTCTGGGCCAG
    CCCCCCAGGTCGCTGGCTGCAGGCCCGAGCTGAGCTGGGGTCCACAGACA
    ATGACCTTGAGCGACAGGAGGATGAGCAGGACACAGACTATGACCACGTC
    GCGGATGGTGGCCTGCAGGCTGACCCTGGGGAAGGCGAGCAGCAATGTGG
    AGAGGCGTCCAGCCCAGAGCAGGTCCCCGTGCGGGCTGAGGAAGCCAGAG
    ACAGTGACACGGAGGGCGACCTGGTCCTCGGCTCCCCAGGACCAGCGAGC
    GCAGGGGGCAGTGCTGAGGCCCTGCTGAGTGACCTGCACGCCTTTGCTGG
    CAGCGCAGCCTGGGATGACAGCGCCAGGGCAGCTGGGGGCCAGGGCCTCC
    ATGTCACCGCACTGTAGAGGCCGGTCTTGGTGTCCCATCCC
    (SEQ ID NO: 273)
    pARBI-669: ATAGAGTAGGGCGGGGGATGCCATGGAGAGGCTCCATGGGGGAGGGCCGG 2541
    RPS23_1_ GGAAGCGCCGCTCCAGGAGGCACGTGGTCCGGCGCGGAAGGGGCCCATGA
    Exogenous_46 GGCGTGGAGGCCGCCGAGGTCGGGGTACCGAGGGACGCAGGGAGGCCAGC
    GCTTCCTCCCGGGCATTCGAGCGGGGCCTCGTCCTTCGGGAGAACACATT
    CTCCGGAGCCCTCTTCGAACGTTTATTAGTCGGTTCAGGGCAACTTGAAG
    GCCAAATGTTTGGCCCACAGGCCAATAAATAGTACGAGAGCCAATCGGCT
    TAAGGGTTTATTCCAGGTGAGGCGAGTGTCTTAGAAGATGGGAAACACGT
    AGATGGCGTGTTTTTACGGAAGAACTAAAATATTTAATTTTTAGGCAAGT
    GTCGTGGACTTCGTACTGCTAGGAAGCTCCGTAGTCACCGACGAGACCAG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAAGTGGCAT
    GATAAACAGTATAAGAAAGCTCATTTGGGCACAGCCCTAAAGGCCAACCC
    TTTTGGAGGTGCTTCTCATGCAAAAGGAATCGTGCTGGAAAAAGTGTAAG
    TCCATTGCTCCCGTCAAGTTTTAGTTTATTATAGGAATTCGAGACATGAA
    CTTACGAATTCTTGTTTTGAAAGTAATTGCAGGTTTTTGTGTAGTAGTAT
    TCATTTGGGCATTGTGGGGTAAAATTGCAAAGCGTTTGTTCTATTTAAAA
    GTTGGTAAAATTAGTTTTTGGGAATTAGGTAGTTAAGGTTTTAATTTAAC
    GTTGGCCTGGAAGGAATTGGAGAAGATACTAGCAATGATGAAGTAAAGGA
    CACAAACACCTTTACTGTGGGAGTTGTTATAAGTAAATGGCACGTGTCAG
    CTATTGAACTTTATCGACTTGATAAAACTAAGGTGAAGAGA
    (SEQ ID NO: 274)
    pARBI-670: CAAGCGGGACTTGGGGTCTTGGGGACGGGCGGGCGGATGCGAATAGAGTA 2541
    RPS23_2_ GGGCGGGGGATGCCATGGAGAGGCTCCATGGGGGAGGGCCGGGGAAGCGC
    Exogenous_ CGCTCCAGGAGGCACGTGGTCCGGCGCGGAAGGGGCCCATGAGGCGTGGA
    47_48 GGCCGCCGAGGTCGGGGTACCGAGGGACGCAGGGAGGCCAGCGCTTCCTC
    CCGGGCATTCGAGCGGGGCCTCGTCCTTCGGGAGAACACATTCTCCGGAG
    CCCTCTTCGAACGTTTATTAGTCGGTTCAGGGCAACTTGAAGGCCAAATG
    TTTGGCCCACAGGCCAATAAATAGTACGAGAGCCAATCGGCTTAAGGGTT
    TATTCCAGGTGAGGCGAGTGTCTTAGAAGATGGGAAACACGTAGATGGCG
    TGTTTTTACGGAAGAACTAAAATATTTAATTTTTAGGCAAGTGCCGCGGA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCTTCGTACT
    GCTAGGAAGCTCCGTAGTCACCGACGAGACCAGAAGTGGCATGATAAACA
    GTATAAGAAAGCTCATTTGGGCACAGCCCTAAAGGCCAACCCTTTTGGAG
    GTGCTTCTCATGCAAAAGGAATCGTGCTGGAAAAAGTGTAAGTCCATTGC
    TCCCGTCAAGTTTTAGTTTATTATAGGAATTCGAGACATGAACTTACGAA
    TTCTTGTTTTGAAAGTAATTGCAGGTTTTTGTGTAGTAGTATTCATTTGG
    GCATTGTGGGGTAAAATTGCAAAGCGTTTGTTCTATTTAAAAGTTGGTAA
    AATTAGTTTTTGGGAATTAGGTAGTTAAGGTTTTAATTTAACGTTGGCCT
    GGAAGGAATTGGAGAAGATACTAGCAATGATGAAGTAAAGGACACAAACA
    CCTTTACTGTGGGAGTTGTTATAAGTAAATGGCACGTGTCA
    (SEQ ID NO: 275)
    pARBI-671: TTGTATATCCTTTTTAAAGTTATTCTTTTTAGTTAATTGCTCTATGTGTA 2541
    RTRAF_1_ TTGAGACTAGGAATCAGAAAGCTTAGATTCTAGTCCCAGGTGTAAGTTGT
    Exogenous_49 GTAACCCTTGGCAAGTGTCAATCTCTAGGCCTCAGCTTTCTCATCTATAA
    AATGAGGAAGTTGTCGTATTCTATTTTTTTTCTTAAGATGATACACTTAA
    ATGTTCCCTTCTGTTGGGTTATATAATTGCATCAAAAGTGTAGTAATGTT
    ATTAAAAAATTGTTAGAGATCCAAACTAAGGTCTCTTTCAACTCTCCCAT
    TCTTTTTTCTGTGACTTTATGGTAATAATGAAACTGGTGGTTTTCTTTTC
    TTCCCCCTCACAGTATCTCAGAGATGTTAACTGTCCTTTCAAGATTCAAG
    ATCGACAAGAAGCTATTGACTGGCTTCTTGGTTTAGCTGTTAGACTTGAA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTATGGAGATA
    ATGGTACGTTTTGTGGGGAATGTGTATTTTAAAGAGAGAGGAAAGATGGG
    AAAGGGAGTGTGAAAATGTAGGGAACTTTGCAGTTTGTTTTGTCTAGTAC
    TATTTTACCTTTGGTTTATTCTTATCACAAGTTAAAAGCACTTTTATTGT
    CTTTCATTGGTGTTTATATATTTCTGTTAGAATTTGGAAATGGTGCCCTC
    TGGAGAAGGCTAATTGACTGTCTTCTCACAGAGTAACACTACTTTGATAA
    TATGGTCTGCACCTTAGCCTTTCAAATTAAATTGTTTTTAGTGTCCCAGA
    ATTGATGGGACTTTGAAGTGTTGTTGCAGTAGGTAATTTCTCAAAAGACT
    GAAACATGTCTAATGCCAATATACATTAATACTCTATAGGCCAGAATATA
    TTACTTATGTTTACTGTCTTAGCACAGATACTTCTATGGT
    (SEQ ID NO: 276)
    pARBI-672: GCACCTGTTATGTAGGAGGAGTAATAAAATGAATGAATGCACTCAAAACA 2541
    RTRAF_2_ CTAAACAGTAATTCTGTAATCCAACGGGAGGTACAGCGAATACCAAAAGC
    Exogenous_50 CTACATATACTATTCTCTGCATGCTATAGCAAGAAAGAAAGGAAAGTGGC
    TTCCCGGTGGTTTTCTGCCTATTGTACAACCAGGAAGCTGACAATAAAGT
    TTATTTGAGCGTCGACGTGCGCCGACGTGGCCCCGCCTCCCCAGCCGGAG
    CCGCGATTGGTGGGCATTTGCCGGCGGCCACCGCTTTTAAGCCACGATTG
    GCGAAGGCCGCCGTCATTTCGGAGCGACTCAGCGCCTGCCCGCCCTCTCG
    CCGCGTCGCCGGTGCCTGCGCCTCCCGCTCCACCTCGCTTCTTCTCTCCC
    GGCCGAGGCCCGGGGGACCAGAGCGAGAAGCGGGGACCATGTTCCGACGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAAGTTGACG
    GCTCTCGACTACCACAACCCCGCCGGCTTCAACTGCAAAGGTGAGGCGGC
    GGCCTCAGCCCGGCCGCGTGTCCCTGACCTGGGCGGAGGTCCCAGCCTCA
    GTGCCCGCACCCCACCTCCCCGTCGGGACCCTCGGCGGCCTGGTTTCCGC
    CGGCAGCCTCCGGGCCCCTCTCCTCTGGGTCGCCACGTACCTCGGCTCTT
    CGCCGCCCCTTCCCGCCTTTAAAGCCCTCTCACCTACTCCTGTCTCGGCA
    TGTTACTTTCTGCACTTGCTTAACTCCAAGCATCACGTAACTACCTTCTC
    TGTACATAAAAGGGAGAGCATTCGTCTTTCTCACTCACTATTCAACTCCA
    TGGTTCCCTGGGTAATTAGGCGATACCTTGAGCACCTGCTAATTATGGGC
    CAGCGCGGTGCTGGATTCTGAGGAAGGTGCTGAGTAACTTG
    (SEQ ID NO: 277)
    pARBI-673: CACTAAACAGTAATTCTGTAATCCAACGGGAGGTACAGCGAATACCAAAA 2541
    RTRAF_3_ GCCTACATATACTATTCTCTGCATGCTATAGCAAGAAAGAAAGGAAAGTG
    Exogenous_51 GCTTCCCGGTGGTTTTCTGCCTATTGTACAACCAGGAAGCTGACAATAAA
    GTTTATTTGAGCGTCGACGTGCGCCGACGTGGCCCCGCCTCCCCAGCCGG
    AGCCGCGATTGGTGGGCATTTGCCGGCGGCCACCGCTTTTAAGCCACGAT
    TGGCGAAGGCCGCCGTCATTTCGGAGCGACTCAGCGCCTGCCCGCCCTCT
    CGCCGCGTCGCCGGTGCCTGCGCCTCCCGCTCCACCTCGCTTCTTCTCTC
    CCGGCCGAGGCCCGGGGGACCAGAGCGAGAAGCGGGGACCATGTTCCGAC
    GCAAGTTGACGGCTCTCGACTACCACAACCCCGCCGGCTTCAACTGCAAA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGTGAGGCG
    GCGGCCTCAGCCCGGCCGCGTGTCCCTGACCTGGGCGGAGGTCCCAGCCT
    CAGTGCCCGCACCCCACCTCCCCGTCGGGACCCTCGGCGGCCTGGTTTCC
    GCCGGCAGCCTCCGGGCCCCTCTCCTCTGGGTCGCCACGTACCTCGGCTC
    TTCGCCGCCCCTTCCCGCCTTTAAAGCCCTCTCACCTACTCCTGTCTCGG
    CATGTTACTTTCTGCACTTGCTTAACTCCAAGCATCACGTAACTACCTTC
    TCTGTACATAAAAGGGAGAGCATTCGTCTTTCTCACTCACTATTCAACTC
    CATGGTTCCCTGGGTAATTAGGCGATACCTTGAGCACCTGCTAATTATGG
    GCCAGCGCGGTGCTGGATTCTGAGGAAGGTGCTGAGTAACTTGAAGACTA
    GTTCACTGCCTGCCAGGAGCTAAAGGGACGAGGGGTGGAAG
    (SEQ ID NO: 278)
    pARBI-674: CCGGGTTAGGCATAGGCCCTCCCGGATCTTCCGCGGTGTAAGGAGAAGGC 2541
    SERF2_1_ CAGCGCCCCTGTGATAGGCCCAGAGCCCCCACTCCACAAGCCAGCCCATC
    Exogenous_52 CCCCACGGAGACCCAAACCGTCCACACACACCTTGCCAGCTGTTTGGGCC
    CCACGCCGCCCCAAAACACGCCTCCAGCTGGCCCCTTGGGACCTCCCTTC
    TCTAGTCCGTATTTTGACCTGGCCCGTGGCAGATTCGCCACTCCCCCCTA
    CCCCAAGCAGCCTGGGCCTCGATGGGCCGTTGTCGGGGCCCGGAGATTGA
    AGTGGTGTTGGATCCTGCTGCTGGCCGCGCTGGGGTAGAAGGGTCGCCGG
    TGTGTGGGCAGAGCGGCCCCCGCGTCTCACCTTTAATTTTCTTTCCTTAG
    GCGGTAACCAGCGTGAGCTCGCCCGCCAGAAGAATATGAAAAAGCAGAGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGACTCGGTT
    AAGGGAAAGCGCCGAGATGACGGGCTTTCTGCTGCCGCCCGCAAGCAGAG
    GTAGCCCCAGGGAGGGGAGGGAAAGGGACGGTGGAGACCTGGGTTAGACC
    AAGGGTTATAGAAGGAAAGAGAGCTACCTCAGGGCTTGAATGTGGACTAG
    TCGTGAGGAGCAGAGTGCATTGCTTCCTCTAGGGTTTTATTTCCTCCCCA
    CCCTCCAAATTGTTAGCTCACAGCCTTACAGGAAAGGACGGGGGCGGGCG
    CCTGCCCTCAGTCTGATTTCTGAGCGTCCCTGGGTCTGACCTTAAGGGCA
    AGGGCAGGGAGCTTCACATTTCAAATACAGTTGTGGTTACGGCAGCCCAG
    TACTTTTGGCCCTCCTTGCTGTTCGGTTCTCCTCCCTTCTCCCAACCTCC
    TCACTGGTGTTGCTGGGTGTGGTCCTCAATACAGAATAGAG
    (SEQ ID NO: 279)
    DARBI-675: AATCGAGCCCTTTGCCCACGGCTACTTCACGGGACCACCCTCCCGGGTTA 2541
    SERF2_2_ GGCATAGGCCCTCCCGGATCTTCCGCGGTGTAAGGAGAAGGCCAGCGCCC
    Exogenous_ CTGTGATAGGCCCAGAGCCCCCACTCCACAAGCCAGCCCATCCCCCACGG
    53_54 AGACCCAAACCGTCCACACACACCTTGCCAGCTGTTTGGGCCCCACGCCG
    CCCCAAAACACGCCTCCAGCTGGCCCCTTGGGACCTCCCTTCTCTAGTCC
    GTATTTTGACCTGGCCCGTGGCAGATTCGCCACTCCCCCCTACCCCAAGC
    AGCCTGGGCCTCGATGGGCCGTTGTCGGGGCCCGGAGATTGAAGTGGTGT
    TGGATCCTGCTGCTGGCCGCGCTGGGGTAGAAGGGTCGCCGGTGTGTGGG
    CAGAGCGGCCCCCGCGTCTCACCTTTAATTTTCTTTCCTTAGGCGGTAAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGCGCGAG
    CTTGCCCGCCAGAAGAATATGAAAAAGCAGAGCGACTCGGTTAAGGGAAA
    GCGCCGAGATGACGGGCTTTCTGCTGCCGCCCGCAAGCAGAGGTAGCCCC
    AGGGAGGGGAGGGAAAGGGACGGTGGAGACCTGGGTTAGACCAAGGGTTA
    TAGAAGGAAAGAGAGCTACCTCAGGGCTTGAATGTGGACTAGTCGTGAGG
    AGCAGAGTGCATTGCTTCCTCTAGGGTTTTATTTCCTCCCCACCCTCCAA
    ATTGTTAGCTCACAGCCTTACAGGAAAGGACGGGGGCGGGCGCCTGCCCT
    CAGTCTGATTTCTGAGCGTCCCTGGGTCTGACCTTAAGGGCAAGGGCAGG
    GAGCTTCACATTTCAAATACAGTTGTGGTTACGGCAGCCCAGTACTTTTG
    GCCCTCCTTGCTGTTCGGTTCTCCTCCCTTCTCCCAACCTC
    (SEQ ID NO: 280)
    pARBI-676: TTCAAAAGGAATCTTTTTGTTTCAACTATTAGGATCTTTTTAAATCAAAT 2541
    SLC38A1_1_ ATGTATTTTAATGGTGTACACCAGACCTGAAGAAAAAGATCACAGAAGGA
    Exogenous_55 ATTTCCCCTTTGTAAGATAGAGGTAGTTAAAAATAAGCCTTATGACCTAA
    TAGGTTAATTGTAATGCTCTGGTAGCCAACTTGAAAAAGGAGAAATGATG
    GTTGCATCTCACATTTTAAAATGTTAAGAATTTGTTTTGTAATGAGGATA
    CCTTAACCCCTGAAGGCCAAAATGACTATTTGTGTGAGTTTGAGAAAGGC
    ACATAGTAACTTGGGGAACAGTCAATAGAATGACAAAATCTTGACTATTT
    TAACTTTCTGAACCCTGTCATTTCTTGTGTTCTCAAATTTGATTTTTAAA
    TAGGCTGCATGGTGTATGAAAAGCTGGGGGAACAAGTCTTTGGCACCACA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGGGAAGTTCG
    TAATCTTTGGAGCCACCTCTCTACAGAACACTGGAGGTAAAAAGAACATG
    CTTTTCTTTACATAACTTGAAACTAATTCTGGTGGATGAGCGGCCACATG
    AATTTTAACATAATTCAAGCAGTTATCATCCTCATTGCTAAAATGGCACA
    GGGAAAGTAAAGCAGAGACAGCAGTCACTTATTTAAAGCCACAAATCCTG
    CTAGAGTAGCTGAAGTTGCCTTTGTGTCTTACTGACAGTTGGTCTAAGAA
    CGGGCTGATAACTTTTTATGTAGCTTGCAACATAAGCCTTCGTATCTTCT
    TTCTAAAAATGTTCTCATTTTCCTTCAGCAATGCTGAGCTACCTCTTCAT
    CGTAAAAAATGAACTACCCTCTGCCATAAAGTTTCTAATGGGAAAGGAAG
    AGACATTTTCGTAAGTTATAGACCATTITTTTATGATATA
    (SEQ ID NO: 281)
    pARBI-677: TAAAGATGTCAAGCTTCAAATCATTATCATAAGGTTAAATATATTACGCA 2541
    SLC38A1_2_ TGTCTTTACAGCAAGTTTATTTCTGATCGTGAAAGTAGAAGAAGTCTCAC
    Exogenous_ AAACAGCCATTTGGAAAAAAAGAAGTGTGATGAGTATGTAAGTATCATTA
    56_57 TAATGAAGTATGCTTATTTTTTTAATCATATAAATTGGGACAAATCTTTT
    TAATTCAAGTAGCATAGTACCAAAAGCATAACTACCTGTATTCACCAGGA
    TATTCCTCATACCTTATGTATTTTCTCTTGAAATCCATTCAAGGAAATAA
    CTAGATAACTAAGAATGGATTTTCTTGAATTTTACTTCCATATTGGTTCC
    TGAGAGTGCATTAAAGGCTTTGGCTTGATGAACTTTCTTGGGGATTATTT
    TGCTTAGTGTCAATGTTTGTTTCTTTGTTCAGATTCCAGGTACAACCTCC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTAGGCATG
    TCAGTTTTTAACCTAAGCAACGCCATTATGGGCAGTGGGATTTTGGGACT
    CGCCTTTGCCCTGGCAAACACTGGAATCCTACTTTTTCTGTGAGTATTGA
    CGTGCCGGTACTTTCCATTTTAAAACTGAACTTTTTGTATGTTTCTGTTA
    TTACATAGAAGAAATGTGAAATATTTATAAATAGTTTTTTTATTAACTTG
    GCTAAGTTACAAGTACATACTTTGATATTTATTGCTTGAGTGATTTTCCA
    AACTGTACCTAATGCTTACAACAAAGAGGAAGGAGAAAATCTTTTTATTA
    ATCAAAAATACTGAAATAAGCATTTGTGAAAAGGATTAAAACATTTGAAA
    ATAACTTTTTTTGGTATTTTTGGAGTCTACCTGTGACTTTAAATCTCAGT
    TAAAATATTAAGAGGTGTTTAACCCCAGCCAGTCACCACTT
    (SEQ ID NO: 282)
    pARBI-678: ATCATTCTTCACACTAGTTCCTTTTCTGACTCTTCAGTCACCTCCAGAAT 2541
    SMAD2_1_ TAATATCCTTAGAAGCATCTCTAAAATGAGTTTGATTTACTAAACATAGA
    Exogenous_58 AGTTGACAAAGTTTTTCAAGTATAACTGCATAAACTCTCTTTTTTAAAAA
    ATCAGTTTTTCCCAAGTTGTTAGCCTTTCATTGGCATTTGAGTCATTTAT
    GTGACATATTTATAAGAAACATCTGCTAGTGCTGCTGCATACTTTTATCA
    GATCCATTAAATAGTACATTTTTGTTCTTGATTCTCACTAAAACTAACTA
    AATGGCTGTCATTCTTTTCTTTATGCTTTTATTGTACTAATTTAGCCCAT
    TTGACTGCACttttttttttttttttttAAAGTTCCCTCCTTTCTTTTCC
    CCTTGCTTCCCAACAGGTCTCTTGATGGTCGTCTCCAGGTATCCCATCGA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatAAAGGATTGC
    CACATGTTATATATTGCCGATTATGGCGCTGGCCTGATCTTCACAGTCAT
    CATGAACTCAAGGCAATTGAAAACTGCGAATATGCTTTTAATCTTAAAAA
    GGATGAAGTATGTGTAAACCCTTACCACTATCAGAGAGTTGAGACACCAG
    GTAGGAATATTGCAAGTTTTTTTCTTGGTTTTGAATTAAATGCCTGAACT
    TCAGTATATTTAAGTACTCTTGTGACCCAGGAAAATTTTAGTGTAAATTC
    TAATAAATTACCTTAAATTGTGCATATTATTTGGTGGTAATTAAAAtttt
    tttatttttaaaaatttttAATGAGAAAACATATCTGTTTCTTGGAATAG
    CATATGATTTGGCATGAAAGTGCATATCCAGGAAATCCTGTAGATTGGCA
    GTCTGCTCAGCGCTATGCTGATGTGCTTCTACATGTCCCT
    (SEQ ID NO: 283)
    pARBI-679: TTCTATATTAAAAATCAGTTGACATCTGTTTTTAGATAATTTTTTAAAAA 2541
    SMAD2_2_ ACTGGATTATAAAATGAAGCACTTAGTAAAGCTGATGGCAGAGGTTTTAG
    Exogenous_59 ATCTTTTGAATACAGGAAAGTGGTAAGGGCATTATAGGTATGATTCATTG
    AGCTAGAGGGCGTTGGTGTTCACATTTTAAAAACATAATCATGACTTATC
    TGGAGTCACATGTTCCATTTTATTGGCTTCCTTCATATAGAAAATATAGT
    AACCAGCACTACATGCCTGTGAAAAAGTGAAGCAATTGTATATTTTCTGG
    GTGAAGGAAGTATTCTGTACATTCTCCATGTTTTACATCATGGTATTTTG
    AATAACCATGCTTCCATGTTCACATCAATTTTTTGTTTTTCAATTTATGC
    ACAGCACTTGCTCTGAAATTTGGGGACTGAGTACACCAAATACGATAGAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCAGTGGGAT
    ACAACAGGCCTTTACAGCTTCTCTGAACAAACCAGGTGAATATTCTGCCC
    TCTGTCGAATCTTAGAGATCTTGTGGGAGGGGGGTATATTTTGAAAGACC
    TATATGGGGTTGCTTAGTATAATTTTGCCTAGGATGTTTCCTTAATGTAA
    AATAAGGCATAGCATTTAAAATATCTGCTTGCCAGTATAAAAAATATATT
    AAATGTTTCAGCTGATGTTTTAATCAATGCAATTCTAGTTTGAATCTTCT
    TTAAATTACTGTATCCCCTAAAGAATAATAATTTTGATAACTATATATTT
    ATTTTAGCTTGAGATCAGATTATAATCTGTTGTTGGCCTAATTTTTAAGT
    AGATACATGATGAGTTTTGCTAAATTTCTTGTTATCAGAATCTCATCTTT
    ATACTAATAAATACATACTTAATGAACCCCTTATATCACAA
    (SEQ ID NO: 284)
    pARBI-680: TCAATGTATTTTTGTATAGTCTTTTGAGATTAGAGTGAAGTTCTAAAAAG 2541
    SMAD2_3_ TAAGAGAACCTTTTGTGAAAATATTTTAATTGACACTACTAAGAGTTTAA
    Exogenous_60 AATAGTATTGGTGGTGAAAAATCGTTAAAAGTATCTGATTTTACTTGCAA
    AATTACTGTATTTTCCCACAAGAGGAGTCCTTACAACATTCTTGTTTTTA
    GAAGGGTTTGTTTCCATCATTCATTTAAATTCATAAAGATAACGTTTTCA
    TGGGTGGAGAAGTCTATTGGGAAAGTCATAATTCGAATTTCTATCTTGCT
    TTGCAGTTTGCTTTCTATGATAAGTTGAAATTATTACTTGATGTTCAAGG
    TAGTCTCTACATCATCCTTTCAATATTTCTGCTAGGTTCGATACAAGAGG
    CTGTTTTCCTAGCGTGGCTTGCTGCCTTTGGTAAGAACATGTCGTCCATC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTTGCCATTCA
    CGCCGCCAGTIGTGAAGAGACTGCTGGGATGGAAGAAGTCAGCTGGTGGG
    TCTGGAGGAGCAGGCGGAGGAGAGCAGAATGGGCAGGAAGAAAAGTGGTG
    TGAGAAAGCAGTGAAAAGTCTGGTGAAGAAGCTAAAGAAAACAGGACGAT
    TAGATGAGCTTGAGAAAGCCATCACCACTCAAAACTGTAATACTAAATGT
    GTTACCATACCAAGGTAAGTTTTGTTAGATCCCAGGTTTGATCAAATTAT
    GTCAAGGAATCTGAAGGAAAGTTACTGAATTTGTGTTCCTTTCAAGTTGC
    CTGTAAAAAGTGATGATTGAAATATGACTGTTTTTAACCTTGTATAAATT
    GTTTTTGCTAGCTGACTTGTTTTATAAATTATTTTCTTGAATAGTGAGGT
    TTAATCAAGCTAAATAAGATACTTAGATTTATTATCTTCA
    (SEQ ID NO: 285)
    pARBI-681: GGGCTCCCGCAGCACAGCCTTTCTCCGGCCCTAGCCCAAATCGCCCAGAC 2541
    SOCS1_1_ CAGGCGCGGATCCCAGCCTGGCCAGCAGGCGGCGGGCGCGGGGCGGCGAG
    Exogenous_61 CCGGGGCCGGACGGCTGGAGCCAGAACCGGCTGCTCTCCACGCCCCCCTC
    TCGGTGCTGCCCGGAGGCCGGACTCCGCCTCCACCGAGCCCCCACCCGCC
    GGGAAGAGCTCCGCGGAGTACAGAGCCCATTTTCTAGCTGTGTCCACTGA
    GGCTGAACGGATCCGCGCGGACTTGGTGCTCCGTGCTCGCCCCCTAGGGC
    CGGGTCCGCCGGGAGCGCCGCCCTCCGGAGTTGTCCGGCCGGCGCACACC
    TGCCCGGCCCCGCAGCGCCCCAGCTCACCTCTTTGTCTCTCCCGCAGCGC
    ACCCCCGGACGCTATGGCCCACCCCTCCGGCTGGCCCCTTCTGTAGGATG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGTAGCACAC
    AACCAGGTGGCAGCCGACAATGCAGTCTCCACAGCAGCAGAGCCCCGACG
    GCGGCCAGAACCTTCCTCCTCTTCCTCCTCCTcgcccgcggcccccgcgc
    gcccgcggccgtgccccgcggtcccggccccggCCCCCGGCGACACGCAC
    TTCCGCACATTCCGTTCGCACGCCGATTACCGGCGCATCACGCGCGCCAG
    CGCGCTCCTGGACGCCTGCGGATTCTACTGGGGGCCCCTGAGCGTGCACG
    GGGCGCACGAGCGGCTGCGCGCCGAGCCCGTGGGCACCTTCCTGGTGCGC
    GACAGCCGCCAGCGGAACTGCTTTTTCGCCCTTAGCGTGAAGATGGCCTC
    GGGACCCACGAGCATCCGCGTGCACTTTCAGGCCGGCCGCTTTCACCTGG
    ATGGCAGCCGCGAGAGCTTCGACTGCCTCTTCGAGCTGCTG
    (SEQ ID NO: 286)
    pARBI-682: GGATCCCAGCCTGGCCAGCAGGCGGCGGGCGCGGGGCGGCGAGCCGGGGC 2541
    SOCS1_2_ CGGACGGCTGGAGCCAGAACCGGCTGCTCTCCACGCCCCCCTCTCGGTGC
    Exogenous_62 TGCCCGGAGGCCGGACTCCGCCTCCACCGAGCCCCCACCCGCCGGGAAGA
    GCTCCGCGGAGTACAGAGCCCATTTTCTAGCTGTGTCCACTGAGGCTGAA
    CGGATCCGCGCGGACTTGGTGCTCCGTGCTCGCCCCCTAGGGCCGGGTCC
    GCCGGGAGCGCCGCCCTCCGGAGTTGTCCGGCCGGCGCACACCTGCCCGG
    CCCCGCAGCGCCCCAGCTCACCTCTTTGTCTCTCCCGCAGCGCACCCCCG
    GACGCTATGGCCCACCCCTCCGGCTGGCCCCTTCTGTAGGATGGTAGCAC
    ACAACCAGGTGGCAGCCGACAATGCAGTCTCCACAGCAGCAGAGCCCCGA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCGGCGGCCA
    GAACCTTCCTCCTCTTCCTCCTCCTcgcccgcggcccccgcgcgcccgcg
    gccgtgccccgcggtcccggccccggCCCCCGGCGACACGCACTTCCGCA
    CATTCCGTTCGCACGCCGATTACCGGCGCATCACGCGCGCCAGCGCGCTC
    CTGGACGCCTGCGGATTCTACTGGGGGCCCCTGAGCGTGCACGGGGCGCA
    CGAGCGGCTGCGCGCCGAGCCCGTGGGCACCTTCCTGGTGCGCGACAGCC
    GCCAGCGGAACTGCTTTTTCGCCCTTAGCGTGAAGATGGCCTCGGGACCC
    ACGAGCATCCGCGTGCACTTTCAGGCCGGCCGCTTTCACCTGGATGGCAG
    CCGCGAGAGCTTCGACTGCCTCTTCGAGCTGCTGGAGCACTACGTGGCGG
    CGCCGCGCCGCATGCTGGGGGCCCCGCTGCGCCAGCGCCGC
    (SEQ ID NO: 287)
    pARBI-683: CGGACTCCGCCTCCACCGAGCCCCCACCCGCCGGGAAGAGCTCCGCGGAG 2541
    SOCS1_3_ TACAGAGCCCATTTTCTAGCTGTGTCCACTGAGGCTGAACGGATCCGCGC
    Exogenous_63 GGACTTGGTGCTCCGTGCTCGCCCCCTAGGGCCGGGTCCGCCGGGAGCGC
    CGCCCTCCGGAGTTGTCCGGCCGGCGCACACCTGCCCGGCCCCGCAGCGC
    CCCAGCTCACCTCTTTGTCTCTCCCGCAGCGCACCCCCGGACGCTATGGC
    CCACCCCTCCGGCTGGCCCCTTCTGTAGGATGGTAGCACACAACCAGGTG
    GCAGCCGACAATGCAGTCTCCACAGCAGCAGAGCCCCGACGGCGGCCAGA
    ACCTTCCTCCTCTTCCTCCTCCTcgcccgcggcccccgcgcgcccgcggc
    cgtgccccgcggtcccggccccggCCCCCGGCGACACGCACTTCCGCACA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTCCGTTCG
    CACGCCGATTACCGGCGCATCACGCGCGCCAGCGCGCTCCTGGACGCCTG
    CGGATTCTACTGGGGGCCCCTGAGCGTGCACGGGGCGCACGAGCGGCTGC
    GCGCCGAGCCCGTGGGCACCTTCCTGGTGCGCGACAGCCGCCAGCGGAAC
    TGCTTTTTCGCCCTTAGCGTGAAGATGGCCTCGGGACCCACGAGCATCCG
    CGTGCACTTTCAGGCCGGCCGCTTTCACCTGGATGGCAGCCGCGAGAGCT
    TCGACTGCCTCTTCGAGCTGCTGGAGCACTACGTGGCGGCGCCGCGCCGC
    ATGCTGGGGGCCCCGCTGCGCCAGCGCCGCGTGCGGCCGCTGCAGGAGCT
    GTGCCGCCAGCGCATCGTGGCCACCGTGGGCCGCGAGAACCTGGCTCGCA
    TCCCCCTCAACCCCGTCCTCCGCGACTACCTGAGCTCCTTC
    (SEQ ID NO: 288)
    pARBI-684: GGCAGACAAACAGTTAAAACAGAGGAGTGGGGTAAGTGATGACCTAACCC 2541
    SRP14_1_ AGCCCCGCTGCTCTAGTTTTGTTAAACACCTCATCTGCTATCACGGTCTG
    Exogenous_64 GCGAAACCCTGGAGAAACTATTATTTCCACGACGGAAACATGTAATATCG
    AAGCACGTTAAATTCCACTCAAAGTGGCGGCGTCTGGGATCCCTGACAAA
    GAGCCCTGGGCTGCTTGGGGCCCATTGTTACCAGAAGCAACCTAGGCGGC
    TCAGTGCTGGGGACTGAGCCAGCTACAATCCCTACTATTTTCCGGGCCCG
    AAGCCCCGAATGTGCTCAGTACAGGGTGGGGAAAGGTAGAGGAAGGCGGC
    GGTCCGCGGCAGACAGACTCCGGTGGCTCCCAGACACCGGGAACCCAGGG
    AGCATCGCCCGGCTCCCCTCCCGCTGCTTACACTTCTTCAAGGTGATATA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGACGCTGCC
    CGACGTCCGGCACTTCTGGAAAAGTCTGGTCAGCTCCGTCAGGAACTGGA
    AAACAACAGGCCCAGCCCCGTTAGCCAGCCCCAAATCCTCGTCCTGCCGC
    GTCAAGGCCCTGGTCCTCCTGCAGGAGGCACAGGTCTCGAGTAACGCCTG
    AGCCGCCCCCTTCCCTCGGCCGGCCAGGCCTAGCCATACCTGCTCGCTCT
    CCAACAACACCATCGCGGCGACGCTGGCTCGACTCCCTCCGCTTAAGCCC
    CTAGCAGTGAGAGCCGGAAGTTCGGCCTAGGCTGGGCGGGACTTCCGCTA
    CTAGACTTCCATTGTCTTCCACCAATCTCTTCTCTTCCACCAATCCCGGC
    CTGCGCCCTCCCCCCTCCCCGCCCGCCTAGCGCCCGCGCCCTGGGACGTC
    CGGGGGCCTGTGACCCGGAGGCGCTGGGGCTGTCCTGGGTC
    (SEQ ID NO: 289)
    pARBI-685: GTCTGTCTGCCGCGGACCGCCGCCTTCCTCTACCTTTCCCCACCCTGTAC 2541
    SRP14_2_ TGAGCACATTCGGGGCTTCGGGCCCGGAAAATAGTAGGGATTGTAGCTGG
    Exogenous_ CTCAGTCCCCAGCACTGAGCCGCCTAGGTTGCTTCTGGTAACAATGGGCC
    65_66 CCAAGCAGCCCAGGGCTCTTTGTCAGGGATCCCAGACGCCGCCACTTTGA
    GTGGAATTTAACGTGCTTCGATATTACATGTTTCCGTCGTGGAAATAATA
    GTTTCTCCAGGGTTTCGCCAGACCGTGATAGCAGATGAGGTGTTTAACAA
    AACTAGAGCAGCGGGGCTGGGTTAGGTCATCACTTACCCCACTCCTCTGT
    TTTAACTGTTTGTCTGCCGCTCAGCCACGTACGCGGCCGTGTTCACCAGG
    ATGCATTTTTTCCTTCAGATGACGGTCGAACCAAACCCATTCCAAAGAAG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGTACTGTG
    GAGGGCTTTGAGCCCGCAGACAACAAGTGTCTGTTAAGAGCTACCGATGG
    GAAGAAGAAGATCAGCACTGTGGTGAGCTTAATTTCTAAGGCTGTCTTTT
    GAAATGTAAAGACTTGAACTTAACAGAGGATGGGGCGTTTCTGAACCAGG
    CTTTTATTTGTTTTTCCCTTTTGCCCTGTGTGGCTATTTTTGAGACCAGG
    ACCTTCCTATACTTTAGTAGTGGAAACCTCAAGAATAAAATAAGAAGGTA
    GAGGTCAGACAGTCGTTAGTTCTGCTAAAGCTCTTGTGGAAATGAAAGTA
    GCATATTGGTCCTTATTCGTAGTACTGTAAGGAGCAGCTGGCATAAATAT
    TTGATTCCTTAGCCCCTTACTGTGCTGGGCCTTCAATAAGCAGTTTCTTG
    GTACCAGGTGATGCTATTATTTCCTTATCTTTGTGGTTCAC
    (SEQ ID NO: 290)
    pARBI-686: CCCACGTCAGTGAGTGCTCACAAGTCTGTGAGGTAGGCGGCGCCACAGAG 2541
    SRSF9_1_ AGAAACTGAGGCGCGGGAGCCCAAGCCACTTGTCCAGCGCCTCAGCCGAG
    Exogenous_67 CGCGAACCGCGCTCGGGGATGGCATCCACACGGCCCGGCCCCAGGCTCTC
    CCTGTCAGCGCCCGAAGGCCCTTCGCACCTCCAGGGGGCGCCGGCCTGCG
    CGCACGCGCAATGGTCGCAGCCGCGTTCTCTTTAAGAGGACTCCTTTTGC
    CTCCGCCGACCCCTTCGCTTCCGCTCCGCGTTCCCACAATGCAGTGCGGC
    TGAGCGCCTCGGAGCCCGCGGGGACGCTGCGGGGGGACCCGTGCTGAggc
    ggcggcggcgacgtgggctgcggcgggcccgcggcgtcgggcggtgcgga
    tgtcgggctgggcggacgagcgcggcggcgAGGGCGACGGGCGCATCTAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatGTGGGGAACC
    TTCCGACCGACGTGCGCGAGAAGGACTTGGAGGACCTGTTCTACAAGTAC
    GGCCGCATCCGCGAGATCGAGCTCAAGAACCGGCACGGCCTCGTGCCCTT
    CGCCTTCGTGCGCTTCGAGGACCCCCGGTGAGGcccccgcgcccctgccc
    tctcctcctcggtgcctgaggcccccgccttccctgctgtcccctccccc
    agggctcccctccccccggcctcccctccccccgcctccgcgcagacccc
    tcaCGGCGCCCCCTCACGGGTGGAGGATGAGGCAGCCTCTCCTCGCAGGC
    CCGGGCCGTCCTTCGCGCCGTCGTCACTTCCTTTATTTTTATTATTCCAA
    TATTTTACTTAGAAACCCAAAAGCTGAGCCTTTGGAGGGCCCAAGCCCGC
    CTGCACCGGCCTCGGGGGGTCCAAATGAGCCTTGTCCGCC
    (SEQ ID NO: 291)
    pARBI-687: TGTGGTGTGCTTTTCGAGAAAATGCTCACGAAGATTAGAAAAACACTGAT 2541
    SRSF9_2_ GGTTTATTGGCAAAATCAATAATCTGTCAGCAGTTGATTCttttttttCT
    Exogenous_68 CTGAATTAGCCCTCTTATGAGTAATCTGTTTGCTCATTCATTATAATTTC
    ATACCTCTAAAACTGCGTGTGACAGCTGTAAAGGTTAATTCCAGTATCAT
    GAAACGTCTCCAAACCAAAGCAGAAGTGCTTCAGGATCCTGATTTGTGTG
    TTTTTTTCTTCACTCTAGGTTTCCCTTTTATGCTTACTACTCATGCCCCT
    CACTTGGAAAGTCACTTGGCCTCCTGAACAGCACTAACTCCAAACGtttt
    ttttgttgttgttgttttttttAGAGATGCAGAGGATGCTATTTATGGAA
    GAAATGGTTATGATTATGGCCAGTGTCGGCTTCGTGTGGAGTTCCCCAGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggggggtggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatACTTATGGAG
    GTCGGGGTGGGTGGCCCCGTGGTGGGAGGAATGGGCCTCCTACAAGAAGA
    TCTGATTTCCGAGTTCTTGTTTCAGGTATGTTCCTTTCAAACAGaatgag
    atgatacatgtaaaatacttaacacagagtctgtcttccaagaaatgata
    gctgttattcttCAGTGCATGGGACACGGGGGCTTTCTTTTCAATAGCCT
    GTGTGAAGCCTTGCCCTGGATTGCCAATGAGGAAAGTATCCTGCAAATGA
    AATTGCGCTGGGAGTGCAGCCTTGGAAGAACATAACCATATTTCTTGTAA
    AGGAGTTTTCTAGTGGTGAGAAGGAAAGATGATGGGAAAACTTGAGCTAC
    AATTCTAAAGATGCTTCTTTTGGAATATACTTGGCATCAGACATGGTAGA
    AAGGCATTCAAGGAGCCAGATTTGAACAACTTACCCAGCC
    (SEQ ID NO: 292)
    pARBI-688: GATGGCATCCACACGGCCCGGCCCCAGGCTCTCCCTGTCAGCGCCCGAAG 2541
    SRSF9_3_ GCCCTTCGCACCTCCAGGGGGCGCCGGCCTGCGCGCACGCGCAATGGTCG
    Exogenous_69 CAGCCGCGTTCTCTTTAAGAGGACTCCTTTTGCCTCCGCCGACCCCTTCG
    CTTCCGCTCCGCGTTCCCACAATGCAGTGCGGCTGAGCGCCTCGGAGCCC
    GCGGGGACGCTGCGGGGGGACCCGTGCTGAggcggcggcggcgacgtggg
    ctgcggcgggcccgcggcgtcgggcggtgcggatgtcgggctgggcggac
    gagcgcggcggcgAGGGCGACGGGCGCATCTACGTGGGGAACCTTCCGAC
    CGACGTGCGCGAGAAGGACTTGGAGGACCTGTTCTACAAGTACGGCCGCA
    TCCGCGAGATCGAGCTCAAGAACCGGCACGGCCTCGTGCCCTTCGCCTTC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGTGCGCTTC
    GAGGACCCCCGGTGAGGcccccgcgcccctgccctctcctcctcggtgcc
    tgaggcccccgccttccctgctgtcccctcccccagggctcccctccccc
    cggcctcccctccccccgcctccgcgcagacccctcaCGGCGCCCCCTCA
    CGGGTGGAGGATGAGGCAGCCTCTCCTCGCAGGCCCGGGCCGTCCTTCGC
    GCCGTCGTCACTTCCTTTATTTTTATTATTCCAATATTTTACTTAGAAAC
    CCAAAAGCTGAGCCTTTGGAGGGCCCAAGCCCGCCTGCACCGGCCTCGGG
    GGGTCCAAATGAGCCTTGTCCGCCTCCTGCCTGGGGCAGCACCGTAGGGG
    GAAGCGGCCGCGGGGCAGCGCGGGGGTCGCCGTTCGCCCTTCCCGCTCGC
    CTCTCCCCCGGCCCGTGCTCGCCGTGGCTGGAGAGCAAGCT
    (SEQ ID NO: 293)
    pARBI-689: GTAACTGACTAGCCTTAGTAGACTGTGGTTTCCAGGTTTATTCAGAAGTA 2541
    SUB1_1_ GCAAGATCCCTCCAtttttttttCTACCAAAGAAATCGTATGTGGGATCC
    Exogenous_70 CAAACCACAAAATAACCGTTCCTGTGGTTAATACTACTATAATGCCTGAA
    GTGTCTTTTGGGATCCTGAGAACAGAGTTTGAAAACATTACTAGACAGAA
    GGATTGGTTAGATTCATAGTTTTGTTGTTGAGTGAAACTTGCTTATGTAT
    ATATTTATGATATTTTGGATGTAGTCTTTTGATTGTTTAAATCTTAAAAA
    GTAATGGGATCTTTTGACACTGGGGTATGTTTTATTTTTATGTGTGCAAA
    TTTTAACCATATTCTTTTCTAGTTAAAGAGGAAAAAGCAAGTTGCTCCAG
    AAAAACCTGTAAAGAAACAAAAGACAGGTGAGACTTCGAGAGCCCTGTCA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTCTTCTAAAC
    AGAGCAGCAGCAGCAGAGATGATAACATGTTTCAGGTAAAGTTGGCTAtt
    ttttttttttttttttttgacatggagtcatgctctgtcacccaggctgg
    agtgcagtggcgccatctcggctcactgcaacctcagcctcctgagttca
    agcagttctctgcctcagcctcccgagtagctaggattacaggcatccgc
    caccagacctggctaatttttgtatttttagtagagatggggtttcacca
    tcttggccaggctggtcttgaactcctgaccttgtgatccaactgcctca
    gcctccaaaagtgctgggtttacaggtgtgagccaccatgccttgccAAA
    GTTGGCTGTTTCTTTAGATTCAGAGGAATTATTATCTGGCTTGATCTGAA
    GAATGTTAAAAGTACTATGATCTGATAATTGCCTAATATG
    (SEQ ID NO: 294)
    pARBI-690: ATAAATAAACATATCCTGGAAATGGAATAAGTTGGTTATATTCTTTTTAA 2541
    SUB1_2_ TTAGTATATCTGCTTCGTAAAATAAGTAACTGACTAGCCTTAGTAGACTG
    Exogenous_71 TGGTTTCCAGGTTTATTCAGAAGTAGCAAGATCCCTCCATTTTTTTTTCT
    ACCAAAGAAATCGTATGTGGGATCCCAAACCACAAAATAACCGTTCCTGT
    GGTTAATACTACTATAATGCCTGAAGTGTCTTTTGGGATCCTGAGAACAG
    AGTTTGAAAACATTACTAGACAGAAGGATTGGTTAGATTCATAGTTTTGT
    TGTTGAGTGAAACTTGCTTATGTATATATTTATGATATTTTGGATGTAGT
    CTTTTGATTGTTTAAATCTTAAAAAGTAATGGGATCTTTTGACACTGGGG
    TATGTTTTATTTTTATGTGTGCAAATTTTAACCATATTCTTTTCTAGTTA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAAGAGGAAA
    AAGCAAGTTGCTCCAGAAAAACCTGTAAAGAAACAAAAGACAGGTGAGAC
    TTCGAGAGCCCTGTCATCTTCTAAACAGAGCAGCAGCAGCAGAGATGATA
    ACATGTTTCAGGTAAAGTTGGCTATTTTTTTTTTTTTTTTTTTTGACATG
    GAGTCATGCTCTGTCACCCAGGCTGGAGTGCAGTGGCGCCATCTCGGCTC
    ACTGCAACCTCAGCCTCCTGAGTTCAAGCAGTTCTCTGCCTCAGCCTCCC
    GAGTAGCTAGGATTACAGGCATCCGCCACCAGACCTGGCTAATTTTTGTA
    TTTTTAGTAGAGATGGGGTTTCACCATCTTGGCCAGGCTGGTCTTGAACT
    CCTGACCTTGTGATCCAACTGCCTCAGCCTCCAAAAGTGCTGGGTTTACA
    GGTGTGAGCCACCATGCCTTGCCAAAGTTGGCTGTTTCTTT
    (SEQ ID NO: 295)
    pARBI-691: AATTAGTATATCTGCTTCGTAAAATAAGTAACTGACTAGCCTTAGTAGAC 2541
    SUB1_3_ TGTGGTTTCCAGGTTTATTCAGAAGTAGCAAGATCCCTCCATTTTTTTTT
    Exogenous_72 CTACCAAAGAAATCGTATGTGGGATCCCAAACCACAAAATAACCGTTCCT
    GTGGTTAATACTACTATAATGCCTGAAGTGTCTTTTGGGATCCTGAGAAC
    AGAGTTTGAAAACATTACTAGACAGAAGGATTGGTTAGATTCATAGTTTT
    GTTGTTGAGTGAAACTTGCTTATGTATATATTTATGATATTTTGGATGTA
    GTCTTTTGATTGTTTAAATCTTAAAAAGTAATGGGATCTTTTGACACTGG
    GGTATGTTTTATTTTTATGTGTGCAAATTTTAACCATATTCTTTTCTAGT
    TAAAGAGGAAAAAGCAAGTTGCTCCAGAAAAACCTGTAAAGAAACAAAAG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACAGGTGAG
    ACTTCGAGAGCCCTGTCATCTTCTAAACAGAGCAGCAGCAGCAGAGATGA
    TAACATGTTTCAGGTAAAGTTGGCTATTTTTTTTTTTTTTTTTTTTGACA
    TGGAGTCATGCTCTGTCACCCAGGCTGGAGTGCAGTGGCGCCATCTCGGC
    TCACTGCAACCTCAGCCTCCTGAGTTCAAGCAGTTCTCTGCCTCAGCCTC
    CCGAGTAGCTAGGATTACAGGCATCCGCCACCAGACCTGGCTAATTTTTG
    TATTTTTAGTAGAGATGGGGTTTCACCATCTTGGCCAGGCTGGTCTTGAA
    CTCCTGACCTTGTGATCCAACTGCCTCAGCCTCCAAAAGTGCTGGGTTTA
    CAGGTGTGAGCCACCATGCCTTGCCAAAGTTGGCTGTTTCTTTAGATTCA
    GAGGAATTATTATCTGGCTTGATCTGAAGAATGTTAAAAGT
    (SEQ ID NO: 296)
    pARBI-692: CACATTTTAATTTTTGTTTCCATGCTCTTTAGAATTCAACTAGAGGGCAG 2541
    TET2_1_ CCTTGTGGATGGCCCCGAAGCAAGCCTGATGGAACAGGATAGAACCAACC
    Exogenous_73 ATGTTGAGGGCAACAGACTAAGTCCATTCCTGATACCATCACCTCCCATT
    TGCCAGACAGAACCTCTGGCTACAAAGCTCCAGAATGGAAGCCCACTGCC
    TGAGAGAGCTCATCCAGAAGTAAATGGAGACACCAAGTGGCACTCTTTCA
    AAAGTTATTATGGAATACCCTGTATGAAGGGAAGCCAGAATAGTCGTGTG
    AGTCCTGACTTTACACAAGAAAGTAGAGGGTATTCCAAGTGTTTGCAAAA
    TGGAGGAATAAAACGCACAGTTAGTGAACCTTCTCTCTCTGGGCTCCTTC
    AGATCAAGAAATTGAAACAAGACCAAAAGGCTAATGGAGAAAGACGTAAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTCGGGGTA
    AGCCAAGAAAGAAATCCAGGTGAAAGCAGTCAACCAAATGTCTCCGATTT
    GAGTGATAAGAAAGAATCTGTGAGTTCTGTAGCCCAAGAAAATGCAGTTA
    AAGATTTCACCAGTTTTTCAACACATAACTGCAGTGGGCCTGAAAATCCA
    GAGCTTCAGATTCTGAATGAGCAGGAGGGGAAAAGTGCTAATTACCATGA
    CAAGAACATTGTATTACTTAAAAACAAGGCAGTGCTAATGCCTAATGGTG
    CTACAGTTTCTGCCTCTTCCGTGGAACACACACATGGTGAACTCCTGGAA
    AAAACACTGTCTCAATATTATCCAGATTGTGTTTCCATTGCGGTGCAGAA
    AACCACATCTCACATAAATGCCATTAACAGTCAGGCTACTAATGAGTTGT
    CCTGTGAGATCACTCACCCATCGCATACCTCAGGGCAGATC
    (SEQ ID NO: 297)
    pARBI-693: AATGGAGAAAGACGTAACTTCGGGGTAAGCCAAGAAAGAAATCCAGGTGA 2541
    TET2_2_ AAGCAGTCAACCAAATGTCTCCGATTTGAGTGATAAGAAAGAATCTGTGA
    Exogenous_74 GTTCTGTAGCCCAAGAAAATGCAGTTAAAGATTTCACCAGTTTTTCAACA
    CATAACTGCAGTGGGCCTGAAAATCCAGAGCTTCAGATTCTGAATGAGCA
    GGAGGGGAAAAGTGCTAATTACCATGACAAGAACATTGTATTACTTAAAA
    ACAAGGCAGTGCTAATGCCTAATGGTGCTACAGTTTCTGCCTCTTCCGTG
    GAACACACACATGGTGAACTCCTGGAAAAAACACTGTCTCAATATTATCC
    AGATTGTGTTTCCATTGCGGTGCAGAAAACCACATCTCACATAAATGCCA
    TTAACAGTCAGGCTACTAATGAGTTGTCCTGTGAGATCACTCACCCATCG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatCATACCTCA
    GGGCAGATCAATTCCGCACAGACCTCTAACTCTGAGCTGCCTCCAAAGCC
    AGCTGCAGTGGTGAGTGAGGCCTGTGATGCTGATGATGCTGATAATGCCA
    GTAAACTAGCTGCAATGCTAAATACCTGTTCCTTTCAGAAACCAGAACAA
    CTACAACAACAAAAATCAGTTTTTGAGATATGCCCATCTCCTGCAGAAAA
    TAACATCCAGGGAACCACAAAGCTAGCGTCTGGTGAAGAATTCTGTTCAG
    GTTCCAGCAGCAATTTGCAAGCTCCTGGTGGCAGCTCTGAACGGTATTTA
    AAACAAAATGAAATGAATGGTGCTTACTTCAAGCAAAGCTCAGTGTTCAC
    TAAGGATTCCTTTTCTGCCACTACCACACCACCACCACCATCACAATTGC
    TTCTTTCTCCCCCTCCTCCTCTTCCACAGGTTCCTCAGCTT
    (SEQ ID NO: 298)
    pARBI-694: GGAAAAAGCACTCTGAATGGTGGAGTTTTAGAAGAACACCACCACTACCC 2541
    TET2_3_ CAACCAAAGTAACACAACACTTTTAAGGGAAGTGAAAATAGAGGGTAAAC
    Exogenous_75 CTGAGGCACCACCTTCCCAGAGTCCTAATCCATCTACACATGTATGCAGC
    CCTTCTCCGATGCTTTCTGAAAGGCCTCAGAATAATTGTGTGAACAGGAA
    TGACATACAGACTGCAGGGACAATGACTGTTCCATTGTGTTCTGAGAAAA
    CAAGACCAATGTCAGAACACCTCAAGCATAACCCACCAATTTTTGGTAGC
    AGTGGAGAGCTACAGGACAACTGCCAGCAGTTGATGAGAAACAAAGAGCA
    AGAGATTCTGAAGGGTCGAGACAAGGAGCAAACACGAGATCTTGTGCCCC
    CAACACAGCACTATCTGAAACCAGGATGGATTGAATTGAAGGCCCCTCGT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatTTTCACCAAG
    CGGAATCCCATCTAAAACGTAATGAGGCATCACTGCCATCAATTCTTCAG
    TATCAACCCAATCTCTCCAATCAAATGACCTCCAAACAATACACTGGAAA
    TTCCAACATGCCTGGGGGGCTCCCAAGGCAAGCTTACACCCAGAAAACAA
    CACAGCTGGAGCACAAGTCACAAATGTACCAAGTTGAAATGAATCAAGGG
    CAGTCCCAAGGTACAGTGGACCAACATCTCCAGTTCCAAAAACCCTCACA
    CCAGGTGCACTTCTCCAAAACAGACCATTTACCAAAAGCTCATGTGCAGT
    CACTGTGTGGCACTAGATTTCATTTTCAACAAAGAGCAGATTCCCAAACT
    GAAAAACTTATGTCCCCAGTGTTGAAACAGCACTTGAATCAACAGGCTTC
    AGAGACTGAGCCATTTTCAAACTCACACCTTTTGCAACAT
    (SEQ ID NO: 299)
    pARBI-695: AAAGGGAGGTTGAGATGGGCTGAGGTCTTCTAGGAGGCGGGGAGGGAGTG 2541
    TIGIT_1_ CAGCCTTGACAAGCCTCCCTGTGGGCGAGGTGTAAAGAGGGGCAGAAGTC
    Exogenous_76 AGCTCTGGAAGCATAGGGCAGTGGGTGGGGAGGAGATGGGCTGGGCTGGG
    CTGGAGTAGAGATGTGTGGAGAAGGGTGAGAAGACTGGAAAGACAACCTG
    AATGGGGGACTGGGAGCCTTGAATAACAGGCATGGAGAGGAGCGTCTCTT
    GAAATGGAAGAAACAGGAAATAATTACAGCCTCTATGGAGGAGCAACAGG
    ATGGACTGGAGAAACTATCATTCCAAAATCCAGTTGGGGCCTCAAAGGCC
    CTTAGAATTTTTCTAGGAAGGTTGAAGGCCAGCTGCTGACCCAGGACTCA
    CATGTGCTTCGTCCTCTTCCCTAGGAATGATGACAGGCACAATAGAAACA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACGGGGAAC
    ATTTCTGCAGAGAAAGGTGGCTCTATCATCTTACAATGTCACCTCTCCTC
    CACCACGGCACAAGTGACCCAGGTCAACTGGGAGCAGCAGGACCAGCTTC
    TGGCCATTTGTAATGCTGACTTGGGGTGGCACATCTCCCCATCCTTCAAG
    GATCGAGTGGCCCCAGGTCCCGGCCTGGGCCTCACCCTCCAGTCGCTGAC
    CGTGAACGATACAGGGGAGTACTTCTGCATCTATCACACCTACCCTGATG
    GGACGTACACTGGGAGAATCTTCCTGGAGGTCCTAGAAAGCTCAGGTATT
    CCTGCTGGAGCAAGTTGGTGGATAAACCTCTCCCTCTAGCATAGAAAATG
    CAATCCTGAAACACTGCACAGCAGGGCTTCTCAATTCGGGATCACATTTG
    AATCACCTGAGGAGATTTTAAATCATACTGATGCCGAGGCC
    (SEQ ID NO: 300)
    pARBI-696: GAGGAGATGGGCTGGGCTGGGCTGGAGTAGAGATGTGTGGAGAAGGGTGA 2541
    TIGIT_2_ GAAGACTGGAAAGACAACCTGAATGGGGGACTGGGAGCCTTGAATAACAG
    Exogenous_77 GCATGGAGAGGAGCGTCTCTTGAAATGGAAGAAACAGGAAATAATTACAG
    CCTCTATGGAGGAGCAACAGGATGGACTGGAGAAACTATCATTCCAAAAT
    CCAGTTGGGGCCTCAAAGGCCCTTAGAATTTTTCTAGGAAGGTTGAAGGC
    CAGCTGCTGACCCAGGACTCACATGTGCTTCGTCCTCTTCCCTAGGAATG
    ATGACAGGCACAATAGAAACAACGGGGAACATTTCTGCAGAGAAAGGTGG
    CTCTATCATCTTACAATGTCACCTCTCCTCCACCACGGCACAAGTGACCC
    AGGTCAACTGGGAGCAGCAGGACCAGCTTCTGGCCATTTGTAATGCTGAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTGGGGTGG
    CACATCTCCCCATCCTTCAAGGATCGAGTGGCCCCAGGTCCCGGCCTGGG
    CCTCACCCTCCAGTCGCTGACCGTGAACGATACAGGGGAGTACTTCTGCA
    TCTATCACACCTACCCTGATGGGACGTACACTGGGAGAATCTTCCTGGAG
    GTCCTAGAAAGCTCAGGTATTCCTGCTGGAGCAAGTTGGTGGATAAACCT
    CTCCCTCTAGCATAGAAAATGCAATCCTGAAACACTGCACAGCAGGGCTT
    CTCAATTCGGGATCACATTTGAATCACCTGAGGAGATTTTAAATCATACT
    GATGCCGAGGCCTCACCCAGACCAATTCAATCAGAATCCCTAATAGCAGA
    GCTAAACAAGGGTAAGGTCTAAAAGCATTTCCAGGTGATTCTAATGGGCA
    GCCAATACTGAGAACCACTGTTCTTATGTAAGAAGCACATC
    (SEQ ID NO: 301)
    pARBI-697: CCTCCCTGTGGGCGAGGTGTAAAGAGGGGCAGAAGTCAGCTCTGGAAGCA 2541
    TIGIT_3_ TAGGGCAGTGGGTGGGGAGGAGATGGGCTGGGCTGGGCTGGAGTAGAGAT
    Exogenous_78 GTGTGGAGAAGGGTGAGAAGACTGGAAAGACAACCTGAATGGGGGACTGG
    GAGCCTTGAATAACAGGCATGGAGAGGAGCGTCTCTTGAAATGGAAGAAA
    CAGGAAATAATTACAGCCTCTATGGAGGAGCAACAGGATGGACTGGAGAA
    ACTATCATTCCAAAATCCAGTTGGGGCCTCAAAGGCCCTTAGAATTTTTC
    TAGGAAGGTTGAAGGCCAGCTGCTGACCCAGGACTCACATGTGCTTCGTC
    CTCTTCCCTAGGAATGATGACAGGCACAATAGAAACAACGGGGAACATTT
    CTGCAGAGAAAGGTGGCTCTATCATCTTACAATGTCACCTCTCCTCCACC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggggggcaggacagcaagggggaggattgggaagacaatagca
    ggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGGT
    GCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGG
    GGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAA
    ACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
    GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
    CGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTC
    CTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGT
    CGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGT
    CTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCC
    CTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTG
    CTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAG
    ATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccacc
    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGT
    CGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGG
    GCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
    ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
    CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACT
    TCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC
    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGG
    CGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG
    ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
    GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
    GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
    AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC
    TACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGA
    TCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA
    TGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaaa
    taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgca
    ttctagttgtggtttgtccaaactcatcaatgtatcttatACGGCACAAG
    TGACCCAGGTCAACTGGGAGCAGCAGGACCAGCTTCTGGCCATTTGTAAT
    GCTGACTTGGGGTGGCACATCTCCCCATCCTTCAAGGATCGAGTGGCCCC
    AGGTCCCGGCCTGGGCCTCACCCTCCAGTCGCTGACCGTGAACGATACAG
    GGGAGTACTTCTGCATCTATCACACCTACCCTGATGGGACGTACACTGGG
    AGAATCTTCCTGGAGGTCCTAGAAAGCTCAGGTATTCCTGCTGGAGCAAG
    TTGGTGGATAAACCTCTCCCTCTAGCATAGAAAATGCAATCCTGAAACAC
    TGCACAGCAGGGCTTCTCAATTCGGGATCACATTTGAATCACCTGAGGAG
    ATTTTAAATCATACTGATGCCGAGGCCTCACCCAGACCAATTCAATCAGA
    ATCCCTAATAGCAGAGCTAAACAAGGGTAAGGTCTAAAAG
    (SEQ ID NO: 302)
    pARBI-698: TAATGCCCAGCCTAAGTTGGGGAGACCACTCCAGATTCCAAGATGTACAG 2541
    TRAC_1_ TTTGCTTTGCTGGGCCTTTTTCCCATGCCTGCCTTTACTCTGCCAGAGTT
    Exogenous_79 ATATTGCTGGGGTTTTGAAGAAGATCCTATTAAATAAAAGAATAAGCAGT
    ATTATTAAGTAGCCCTGCATTTCAGGTTTCCTTGAGTGGCAGGCCAGGCC
    TGGCCGTGAACGTTCACTGAAATCATGGCCTCTTGGCCAAGATTGATAGC
    TTGTGCCTGTCCCTGAGTCCCAGTCCATCACGAGCAGCTGGTTTCTAAGA
    TGCTATTTCCCGTATAAAGCATGAGACCGTGACTTGCCAGCCCCACAGAG
    CCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGGCA
    AAGAGGGAAATGAGATCATGTCCTAACCCTGATCCTCTTGTCCCACAGAT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatATCCAGAAC
    CCTGACCCTGCCGTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTC
    TGTCTGCCTATTCACCGATTTTGATTCTCAAACAAATGTGTCACAAAGTA
    AGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGACATGAGGTCT
    ATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTT
    TGCATGTGCAAACGCCTTCAACAACAGCATTATTCCAGAAGACACCTTCT
    TCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCTTCGCAGGCTGTTTCCTT
    GCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTCTGGTCAATGATGTCTAA
    AACTCCTCTGATTGGTGGTCTCGGCCTTATCCATTGCCACCAAAACCCTC
    TTTTTACTAAGAAACAGTGAGCCTTGTTCTGGCAGTCCAGA
    (SEQ ID NO: 303)
    pARBI-699: GATTCCAAGATGTACAGTTTGCTTTGCTGGGCCTTTTTCCCATGCCTGCC 2541
    TRAC_2_ TTTACTCTGCCAGAGTTATATTGCTGGGGTTTTGAAGAAGATCCTATTAA
    Exogenous_80 ATAAAAGAATAAGCAGTATTATTAAGTAGCCCTGCATTTCAGGTTTCCTT
    GAGTGGCAGGCCAGGCCTGGCCGTGAACGTTCACTGAAATCATGGCCTCT
    TGGCCAAGATTGATAGCTTGTGCCTGTCCCTGAGTCCCAGTCCATCACGA
    GCAGCTGGTTTCTAAGATGCTATTTCCCGTATAAAGCATGAGACCGTGAC
    TTGCCAGCCCCACAGAGCCCCGCCCTTGTCCATCACTGGCATCTGGACTC
    CAGCCTGGGTTGGGGCAAAGAGGGAAATGAGATCATGTCCTAACCCTGAT
    CCTCTTGTCCCACAGATATCCAGAACCCTGACCCTGCCGTGTACCAGCTG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatAGAGACTCT
    AAATCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAAC
    AAATGTGTCACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTG
    TGCTAGACATGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCTGG
    AGCAACAAATCTGACTTTGCATGTGCAAACGCCTTCAACAACAGCATTAT
    TCCAGAAGACACCTTCTTCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCT
    TCGCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTC
    TGGTCAATGATGTCTAAAACTCCTCTGATTGGTGGTCTCGGCCTTATCCA
    TTGCCACCAAAACCCTCTTTTTACTAAGAAACAGTGAGCCTTGTTCTGGC
    AGTCCAGAGAATGACACGGGAAAAAAGCAGATGAAGAGAAG
    (SEQ ID NO: 304)
    pARBI-700: TTCCTGTGGTAGCGGAACTCACTAAGGGGCCCATCTGGACCCGAGGTATT 2541
    TRAC_3_ GTGATGATAAATTCTGAGCACCTACCCCATCCCCAGAAGGGCTCAGAAAT
    Exogenous_81 AAAATAAGAGCCAAGTCTAGTCGGTGTTTCCTGTCTTGAAACACAATACT
    GTTGGCCCTGGAAGAATGCACAGAATCTGTTTGTAAGGGGATATGCACAG
    AAGCTGCAAGGGACAGGAGGTGCAGGAGCTGCAGGCCTCCCCCACCCAGC
    CTGCTCTGCCTTGGGGAAAACCGTGGGTGTGTCCTGCAGGCCATGCAGGC
    CTGGGACATGCAAGCCCATAACCGCTGTGGCCTCTTGGTTTTACAGATAC
    GAACCTAAACTTTCAAAACCTGTCAGTGATTGGGTTCCGAATCCTCCTCC
    TGAAAGTGGCCGGGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTGAGGTGAG
    GGGCCTTGAAGCTGGGAGTGGGGTTTAGGGACGCGGGTCTCTGGGTGCAT
    CCTAAGCTCTGAGAGCAAACCTCCCTGCAGGGTCTTGCTTTTAAGTCCAA
    AGCCTGAGCCCACCAAACTCTCCTACTTCTTCCTGTTACAAATTCCTCTT
    GTGCAATAATAATGGCCTGAAACGCTGTAAAATATCCTCATTTCAGCCGC
    CTCAGTTGCACTTCTCCCCTATGAGGTAGGAAGAACAGTTGTTTAGAAAC
    GAAGAAACTGAGGCCCCACAGCTAATGAGTGGAGGAAGAGAGACACTTGT
    GTACACCACATGCCTTGTGTTGTACTTCTCTCACCGTGTAACCTCCTCAT
    GTCCTCTCTCCCCAGTACGGCTCTCTTAGCTCAGTAGAAAGAAGACATTA
    CACTCATATTACACCCCAATCCTGGCTAGAGTCTCCGCACC
    (SEQ ID NO: 305)
    pARBI-701: ATTATTAAGTAGCCCTGCATTTCAGGTTTCCTTGAGTGGCAGGCCAGGCC 2541
    TRAC_4_ TGGCCGTGAACGTTCACTGAAATCATGGCCTCTTGGCCAAGATTGATAGC
    Exogenous_82 TTGTGCCTGTCCCTGAGTCCCAGTCCATCACGAGCAGCTGGTTTCTAAGA
    TGCTATTTCCCGTATAAAGCATGAGACCGTGACTTGCCAGCCCCACAGAG
    CCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGGCA
    AAGAGGGAAATGAGATCATGTCCTAACCCTGATCCTCTTGTCCCACAGAT
    ATCCAGAACCCTGACCCTGCCGTGTACCAGCTGAGAGACTCTAAATCCAG
    TGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAAATGTGT
    CACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatATGAGGTCT
    ATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTT
    TGCATGTGCAAACGCCTTCAACAACAGCATTATTCCAGAAGACACCTTCT
    TCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCTTCGCAGGCTGTTTCCTT
    GCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTCTGGTCAATGATGTCTAA
    AACTCCTCTGATTGGTGGTCTCGGCCTTATCCATTGCCACCAAAACCCTC
    TTTTTACTAAGAAACAGTGAGCCTTGTTCTGGCAGTCCAGAGAATGACAC
    GGGAAAAAAGCAGATGAAGAGAAGGTGGCAGGAGAGGGCACGTGGCCCAG
    CCTCAGTCTCTCCAACTGAGTTCCTGCCTGCCTGCCTTTGCTCAGACTGT
    TTGCCCCTTACTGCTCTTCTAGGCCTCATTCTAAGCCCCTT
    (SEQ ID NO: 306)
    pARBI-702: TTCATTTCCATTTGAGTTGTTCTTATTGAGTCATCCTTCCTGTGGTAGCG 2541
    TRAC_6_ GAACTCACTAAGGGGCCCATCTGGACCCGAGGTATTGTGATGATAAATTC
    Exogenous_84 TGAGCACCTACCCCATCCCCAGAAGGGCTCAGAAATAAAATAAGAGCCAA
    GTCTAGTCGGTGTTTCCTGTCTTGAAACACAATACTGTTGGCCCTGGAAG
    AATGCACAGAATCTGTTTGTAAGGGGATATGCACAGAAGCTGCAAGGGAC
    AGGAGGTGCAGGAGCTGCAGGCCTCCCCCACCCAGCCTGCTCTGCCTTGG
    GGAAAACCGTGGGTGTGTCCTGCAGGCCATGCAGGCCTGGGACATGCAAG
    CCCATAACCGCTGTGGCCTCTTGGTTTTACAGATACGAACCTAAACTTTC
    AAAACCTGTCAGTGATTGGGTTCCGAATCCTCCTCCTGAAAGTGGCCGGG
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatTTTAATCTG
    CTCATGACGCTGCGGCTGTGGTCCAGCTGAGGTGAGGGGCCTTGAAGCTG
    GGAGTGGGGTTTAGGGACGCGGGTCTCTGGGTGCATCCTAAGCTCTGAGA
    GCAAACCTCCCTGCAGGGTCTTGCTTTTAAGTCCAAAGCCTGAGCCCACC
    AAACTCTCCTACTTCTTCCTGTTACAAATTCCTCTTGTGCAATAATAATG
    GCCTGAAACGCTGTAAAATATCCTCATTTCAGCCGCCTCAGTTGCACTTC
    TCCCCTATGAGGTAGGAAGAACAGTTGTTTAGAAACGAAGAAACTGAGGC
    CCCACAGCTAATGAGTGGAGGAAGAGAGACACTTGTGTACACCACATGCC
    TTGTGTTGTACTTCTCTCACCGTGTAACCTCCTCATGTCCTCTCTCCCCA
    GTACGGCTCTCTTAGCTCAGTAGAAAGAAGACATTACACTC
    (SEQ ID NO: 307)
    pARBI-703: CAGTCCATCACGAGCAGCTGGTTTCTAAGATGCTATTTCCCGTATAAAGC 2541
    TRAC_ ATGAGACCGTGACTTGCCAGCCCCACAGAGCCCCGCCCTTGTCCATCACT
    Exogenous_83 GGCATCTGGACTCCAGCCTGGGTTGGGGCAAAGAGGGAAATGAGATCATG
    TCCTAACCCTGATCCTCTTGTCCCACAGATATCCAGAACCCTGACCCTGC
    CGTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTAT
    TCACCGATTTTGATTCTCAAACAAATGTGTCACAAAGTAAGGATTCTGAT
    GTGTATATCACAGACAAAACTGTGCTAGACATGAGGTCTATGGACTTCAA
    GAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAA
    ACGCCTTCAACAACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCA
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGTAAGGGC
    AGCTTTGGTGCCTTCGCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGGTT
    CTGCCCAGAGCTCTGGTCAATGATGTCTAAAACTCCTCTGATTGGTGGTC
    TCGGCCTTATCCATTGCCACCAAAACCCTCTTTTTACTAAGAAACAGTGA
    GCCTTGTTCTGGCAGTCCAGAGAATGACACGGGAAAAAAGCAGATGAAGA
    GAAGGTGGCAGGAGAGGGCACGTGGCCCAGCCTCAGTCTCTCCAACTGAG
    TTCCTGCCTGCCTGCCTTTGCTCAGACTGTTTGCCCCTTACTGCTCTTCT
    AGGCCTCATTCTAAGCCCCTTCTCCAAGTTGCCTCTCCTTATTTCTCCCT
    GTCTGCCAAAAAATCTTTCCCAGCTCACTAAGTCAGTCTCACGCAGTCAC
    TCATTAACCCACCAATCACTGATTGTGCCGGCACATGAATG
    (SEQ ID NO: 308)
    pARBI-704: TGAGGAAGAAGCGCGGGCGGCGCCTTCGGGAGGCGAGCAGGCAGCAGTTG 2541
    TRIM28_1_ GCCGTGCCGTAGCAGCGTCCCGCGCGCGGCGGGCAGCGGCCCAGGAGGCG
    Exogenous_85 CGTGGCGGCGCTCGGCCTCGCGGCGGCGGCGGCGGCAGCGGCCCAGCAGT
    TGGCGGCGAGCGCGTCTGCGCCTGCGCGGCGGGCCCCGCGCCCCTCCTCC
    CCCCCTGGGCGCCCCCGGCGGCGTGTGAATGGCGGCCTCCGCGGCGGCAG
    CCTCGGCAGCAGCGGCCTCGGCCGCCTCTGGCAGCCCGGGCCCGGGCGAG
    GGCTCCGCTGGCGGCGAAAAGCGCTCCACCGCCCCTTCGGCCGCAGCCTC
    GGCCTCTGCCTCAGCCGCGGCGTCGTCGCCCGCGGGGGGCGGCGCCGAGG
    CGCTGGAGCTGCTGGAGCACTGCGGCGTGTGCAGAGAGCGCCTGCGACCC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGAGAGGGAG
    CCCCGCCTGCTGCCCTGTTTGCACTCGGCCTGTAGTGCCTGCTTAGGGCC
    CGCGGCCCCCGCCGCCGCCAACAGCTCGGGGGACGGCGGGGCGGCGGGCG
    ACGGCACCGGTAAGTACGAAGTGATCGGTGCCACCCCTCCCCCTACTCTC
    TGCCTTTGATTCCGACTGGGTGCAGAGATGAGGATGCCACCTGGGCGAGA
    GGATGGGGGCCCGGACAGGGCACGGGAAATACTTTCTGGGTCCTGCATAC
    GAACGTGGGTTTGTGCTGGCCGCTGAGATGGGACATCTGACTAAAGTTGG
    AGAAAAGAAGGCTCGGGGAGGGGAGGGGCTGGTTCGCTGCGGGATAATGG
    TCGGGGGCCCACCCAGCAGGGGAATGGTGGGGGCCATAACCTGGGTGGGA
    ACTTGTAACAGTCTCCCACATCCCTGCTTCTCGAAGTGGTG
    (SEQ ID NO: 309)
    pARBI-705: TCGAAGTGGTGGACTGTCCCGTGTGCAAGCAACAGTGCTTCTCCAAAGAC 2541
    TRIM28_2_ ATCGTGGAGAATTATTTCATGCGTGATAGTGGCAGCAAGGCTGCCACCGA
    Exogenous_86 CGCCCAGGATGCGAACCAGGTGCGTCCTATCTCAGCAACCACAAGGAGGT
    TTCTGGGGAGGGGGCATCTGCGCAGGAGGAGCTTGGCACCAGCTCCAGGC
    TGTTACTCCACTTTCCCAAGGCTCTGGGTGGGCTGCCTAGGTTGGGTCAA
    GGGACCAATCTTAAATCTCCGGTTGTATTTTCTGGGATGTAAACGTGGAT
    CTATCAAGTIGTCTTGCCTTCTCTGACCCTGCCTTTGTCTGGCAGTGCTG
    CACTAGCTGTGAGGATAATGCCCCAGCCACCAGCTACTGTGTGGAGTGCT
    CGGAGCCTCTGTGTGAGACCTGTGTAGAGGCGCACCAGCGGGTGAAGTAC
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatACCAAGGAC
    CATACTGTGCGCTCTACTGGTACATGAGGCTGAGGGGGGCTGTTGGAGTT
    GTTCTCCCATGTGTGCCCTCAGTTGCTTTTATGATGTTGGTTGCATCTGG
    TGGATGGGTCCTAGAGTTCTCTAGGGGGTGCCGCCCGAAGGGCCCGAGGG
    CAGAACTCCAGAAGCAGAAAAACTGGGGTTGTGGTGTGTAGTCTCTAGGG
    CCTAGGTGGGAGAGGGTGGGAAGGGGAAATAAGGGAGACCTTAATGTGCT
    GCAGGGAGGTACAAAGGGTTTGAGAAGGCTTATCAGGGAGTTGTCAGACC
    TGGTGGTGAAGGGCTCAGCATATGCAAACAGGGAAAGGCATGGTGTGAAG
    GGCTTTCTGGGTTTGTGGTTCCCTGGCACACATCTGGTATAAGATGCTGC
    TAGGGAAAGTAGACTGTGGGTCCATGGATTATAAGTGATGA
    (SEQ ID NO: 310)
    pARBI-706: GGCGCCCAATGCGCGTGCGCGGCGGCGTCGGCGCCAGTTATTTCTGTCCC 2541
    TRIM28_3_ GCCCCCCGGCCTCGGCTCTTTCTGCGAGCGGGCGCGCGGGCGAGCGGTTG
    Exogenous_87 TGCTTGTGCTTGTGGCGCGTGGTGCGGGTTTCGGCGGCGGCTGAGGAAGA
    AGCGCGGGCGGCGCCTTCGGGAGGCGAGCAGGCAGCAGTTGGCCGTGCCG
    TAGCAGCGTCCCGCGCGCGGCGGGCAGCGGCCCAGGAGGCGCGTGGCGGC
    GCTCGGCCTCGCGGCGGCGGCGGCGGCAGCGGCCCAGCAGTTGGCGGCGA
    GCGCGTCTGCGCCTGCGCGGCGGGCCCCGCGCCCCTCCTCCCCCCCTGGG
    CGCCCCCGGCGGCGTGTGAATGGCGGCCTCCGCGGCGGCAGCCTCGGCAG
    CAGCGGCCTCGGCCGCCTCTGGCAGCCCGGGCCCGGGCGAGGGCTCCGCT
    tgacgactgtgccttctagttgccagccatctgttgtttgcccctccccc
    gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaata
    aaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctgg
    ggggtggggtggggcaggacagcaagggggaggattgggaagacaatagc
    aggcatgctggggatgcggtgggctctatggGGATCTGCGATCGCTCCGG
    TGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGG
    GGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTA
    AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG
    GGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCA
    ACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCT
    CCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG
    TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCG
    TCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTC
    CCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCT
    GCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACA
    GATCCAAGCTGTGACCGGCGCCTACTCTAGAGCTAGCGAATTgccgccac
    cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
    TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
    GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
    CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCT
    ACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGAC
    TTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
    CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGG
    GCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
    GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
    CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
    AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC
    CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCA
    CTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCG
    ATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
    ATGGACGAGCTGTACAAatgattgtttattgcagcttataatggttacaa
    ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgc
    attctagttgtggtttgtccaaactcatcaatgtatcttatGGCGGCGAA
    AAGCGCTCCACCGCCCCTTCGGCCGCAGCCTCGGCCTCTGCCTCAGCCGC
    GGCGTCGTCGCCCGCGGGGGGCGGCGCCGAGGCGCTGGAGCTGCTGGAGC
    ACTGCGGCGTGTGCAGAGAGCGCCTGCGACCCGAGAGGGAGCCCCGCCTG
    CTGCCCTGTTTGCACTCGGCCTGTAGTGCCTGCTTAGGGCCCGCGGCCCC
    CGCCGCCGCCAACAGCTCGGGGGACGGCGGGGCGGCGGGCGACGGCACCG
    GTAAGTACGAAGTGATCGGTGCCACCCCTCCCCCTACTCTCTGCCTTTGA
    TTCCGACTGGGTGCAGAGATGAGGATGCCACCTGGGCGAGAGGATGGGGG
    CCCGGACAGGGCACGGGAAATACTTTCTGGGTCCTGCATACGAACGTGGG
    TTTGTGCTGGCCGCTGAGATGGGACATCTGACTAAAGTTGG
    (SEQ ID NO: 311)

Claims (21)

1. A method of editing a cell having chromosomal DNA, comprising inserting at least one sequence comprising a transgene within a safe harbor locus in the chromosomal DNA of the cell, wherein the safe harbor locus is at any one or more of an sgRNA target loci selected from: chr11:128340000-128350000, chr15:92830000-92840000, chr10:33130000-33140000, chr10:72290000-72300000, chr11:65425000-65427000 (NEAT1), chr16: 11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, chr9:7970000-7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, or TRIM28.
2. The method of claim 1, wherein the sgRNA target locus is chr11:128340000-128350000 or chr15:92830000-92840000.
3. The method of claim 1, wherein the sgRNA target locus comprises an integration site comprising a start coordinate of chr11:128342576.
4. The method of claim 1, wherein the sgRNA target locus comprises an integration site comprising a start coordinate of chr15:92831131.
5. The method of claim 1, wherein the at least one sequence is operatively linked to an endogenous promoter.
6. The method of claim 1, wherein the at least one sequence is operatively linked to an exogenous promoter.
7. The method of claim 6, wherein the exogenous promoter is an EF1α promoter.
8. The method of claim 1, wherein the cell is a natural killer (NK) cell, an induced pluripotent stem cell (iPSC), a human pluripotent stem cell (HSPC), a T cell, a CD8+ T cell, or a T cell progenitor cell.
9. The method of claim 8, wherein the cell is a T cell, a CD8+ T cell, or a T cell progenitor cell.
10. The method of claim 8, wherein the cell is a CD8+ T cell.
11. The method of claim 13, wherein the transgene encodes a protein, a therapeutic agent, a cancer-specific therapeutic agent, a T-cell receptor (TCR), a Prime Receptor (primeR), or a chimeric antigen receptor (CAR).
12. The method of claim 1, wherein the transgene encodes a chimeric antigen receptor (CAR).
13. The method of claim 1, wherein the transgene encodes a T-cell receptor (TCR).
14. The method of claim 1, wherein the transgene encodes a Prime Receptor (primeR).
15. The method of claim 1, wherein the transgene encodes an shRNA, an miRNA, or an siRNA.
16. The method of claim 1, wherein the at least one sequence is inserted using a homology-directed repair or a homology independent targeted insertion.
17. The method of claim 1, wherein the at least one sequence is inserted using one or more guide ribonucleic acids (gRNAs) and one or more Cas9 endonucleases, optionally wherein the one or more gRNAs comprises any one of SEQ ID NOS: 1-120.
18. The method of claim 17, wherein the one or more gRNAs comprises SEQ ID NO: 94.
19. The method of claim 17, wherein the one or more gRNAs comprises SEQ ID NO: 102.
20. A guide ribonucleic acid (gRNA) for editing a cell at a safe harbor locus, wherein the gRNA comprises any one of SEQ ID NOS:1-120.
21. An ex vivo method of obtaining an engineered cell or population thereof, comprising:
a. obtaining a cell; and
b. genetically modifying the cell by inserting at least one sequence encoding a transgene within a safe harbor locus, wherein the safe harbor locus is at any one or more of an sgRNA target loci selected from: chr10:33130000-33140000, chr10:72290000-72300000, chr11:128340000-128350000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:186510000-186520000, chr3:59450000-59460000, chr8:127980000-128000000, chr9:7970000-7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, or TRIM28.
US18/453,801 2020-10-26 2023-08-22 Safe harbor loci Pending US20230416747A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/453,801 US20230416747A1 (en) 2020-10-26 2023-08-22 Safe harbor loci

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105834P 2020-10-26 2020-10-26
US202163141926P 2021-01-26 2021-01-26
US17/239,484 US11332744B1 (en) 2020-10-26 2021-04-23 Safe harbor loci
US17/716,816 US11761004B2 (en) 2020-10-26 2022-04-08 Safe harbor loci
US18/453,801 US20230416747A1 (en) 2020-10-26 2023-08-22 Safe harbor loci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/716,816 Division US11761004B2 (en) 2020-10-26 2022-04-08 Safe harbor loci

Publications (1)

Publication Number Publication Date
US20230416747A1 true US20230416747A1 (en) 2023-12-28

Family

ID=81258012

Family Applications (3)

Application Number Title Priority Date Filing Date
US17/239,484 Active US11332744B1 (en) 2020-10-26 2021-04-23 Safe harbor loci
US17/716,816 Active US11761004B2 (en) 2020-10-26 2022-04-08 Safe harbor loci
US18/453,801 Pending US20230416747A1 (en) 2020-10-26 2023-08-22 Safe harbor loci

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US17/239,484 Active US11332744B1 (en) 2020-10-26 2021-04-23 Safe harbor loci
US17/716,816 Active US11761004B2 (en) 2020-10-26 2022-04-08 Safe harbor loci

Country Status (1)

Country Link
US (3) US11332744B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11332744B1 (en) * 2020-10-26 2022-05-17 Arsenal Biosciences, Inc. Safe harbor loci
WO2023064928A2 (en) 2021-10-14 2023-04-20 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20130227715A1 (en) 2010-02-26 2013-08-29 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
AU2013355327A1 (en) 2012-12-05 2015-06-11 Sangamo Therapeutics, Inc. Methods and compositions for regulation of metabolic disorders
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
SG10201809157VA (en) 2014-04-18 2018-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170362635A1 (en) 2016-06-20 2017-12-21 University Of Washington Muscle-specific crispr/cas9 editing of genes
US20190185849A1 (en) 2016-06-29 2019-06-20 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018058064A1 (en) 2016-09-23 2018-03-29 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing
EP3759217A4 (en) 2018-03-02 2022-05-11 Generation Bio Co. Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
US11332744B1 (en) * 2020-10-26 2022-05-17 Arsenal Biosciences, Inc. Safe harbor loci

Also Published As

Publication number Publication date
US20220127616A1 (en) 2022-04-28
US20220315928A1 (en) 2022-10-06
US11332744B1 (en) 2022-05-17
US11761004B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
JP7101419B2 (en) Targeted substitution of endogenous T cell receptors
US20230416747A1 (en) Safe harbor loci
JP6929791B2 (en) Compositions and methods for epigenome editing
JP7385281B2 (en) Method for producing low antigenicity cells
US20210317406A1 (en) Gene targets for t-cell-based immunotherapy
IL297881A (en) Selection by essential-gene knock-in
WO2022093846A1 (en) Safe harbor loci
TW202235617A (en) Compositions and methods for reducing mhc class ii in a cell
WO2021197342A1 (en) Active dna transposon systems and methods for use thereof
JP2020528046A (en) Compositions and Methods for Enhancing the Efficacy of T Cell-Based Immunotherapy
US20240307444A1 (en) Methods and compositions for improved immunotherapies
CN116546993A (en) Safe harbor gene locus
TW202417626A (en) Immune cells having co-expressed tgfbr shrnas
CN118369110A (en) CD38 compositions and methods for immunotherapy
WO2024123235A1 (en) Safe harbour loci for cell engineering

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION